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Abstract
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that causes the most 
common form of dementia, affecting approximately 5% of the population over the age of 65 
years in Europe. Short-term memory impairment, disorientation, aphasia, and a general 
cognitive decline are common symptoms early in disease development. According to the 
World Health Organization, an estimated 37 million people worldwide currently have 
dementia; AD affects about 18 million of them. In spite of tremendous research efforts, there 
is no causal therapy for AD. Histopathological hallmarks of AD are the extracellular plaques 
consisting of the amyloid ?-peptide (A?) and neurofibrillary tangles which are found in the 
brains of the AD patients. A?? is heterogeneously produced by the sequential cleavages of 
amyloid precursor protein (APP) by the two aspartic proteases: ?- and ?-secretase. 
Intramembrane cleavage by ?-secretase occurs with little sequence specificity, resulting in A? 
fragments of different length, predominantly A?40, A?42, and some A?38. A?42 being the most 
aggregatory, and is believed to trigger the amyloid cascade, a pathological series of 
neurotoxic events, which eventually leads to neurodegeneration and finally AD. ?-Secretase 
has been an attractive target in many ways for AD therapeutics since it catalyzes the final step 
in the release of A?.  
The present work describes the design, synthesis and biological evaluation of ?-secretase 
modulators, affinity probes and photoaffinity labels. Epidemiological studies have indicated a 
close association between prolonged use of nonsteroidal anti-inflammaroy drugs (NSAIDs), 
and reduced risk for AD. Therefore, cyclooxygenase (COX) inhibitors such as flurbiprofen, 
sulindac sulfoxide and meclofenamic acid were converted into amides and esters and 
anticipated that the modification of acid functionality would reduce the COX inhibitory 
activity while increasing the ?-secretase modulatory activity. However, the conversion of the 
acid moiety of COX inhibitors into their amides or esters resulted either in inverse modulation 
or inhibition. Further efforts were then focussed on carprofen, a COX-2 inhibitor which is 
approved for the use in dogs and cows. N-substitution of carprofen resulted in potent 
modulators of ?-secretase, and the compounds displayed little or no effect on ?-secretase 
cleavage at the ?-site. Knowing about the relevance of N-substitution of carprofen and the 
necessity of the free acid functionality for ?-secretase modulation, a series of N-substituted 
carbazolyloxy acetic acids was synthesized. As anticipated, they turned out to be effective 
modulators of ?-secretase and displayed little or no effect on ?-secretase cleavage at the ?-site. 
An analogous derivative of the LXR agonist TO-901317 was synthesized, but the 
hexafluorocarbinol moiety was replaced by an oxyacetic acid in order to transform it into a 
modulator of ?-secretase. As expected, the introduction of the acid moiety changed the mode 
of action from an inverse modulation to normal modulation of ?-secretase. Curcumin has 
multiple targets in AD. A series of NSAIDs derived affinity labels was synthesized in order to 
identify and characterize the binding site by immunoprecipitation assay. Flurbiprofen derived 
photoaffinity label captured active ?-secretase complex in a dose dependant manner, but 
others either failed to provide a binding partner or resulted in unspecific binding. Flurbiprofen 
and DAPT derived photoaffnity labels were synthesized in order to investigate the binding 
site via covalent bond formation with the active site on the ?-secretase complex. The 
photaffnity labelling experiment carried out with a flurbiprofen derived photoaffnity probe 
revealed that it binds to the C-terminal fragment of presenilin (PS). Whereas, DAPT derived 
photoaffinity label displayed very weak binding to PS, the active site of ?-secretase.  
Zusamenfassung 
Die Alzheimer-Demenz (AD) ist eine verheerende, neurodegenerative Funktionsstörung, die die 
häufigste Form der Demenz darstellt und etwa 5% der Bevölkerung über 65 in Europa befällt. 
Bekannte Symptome in der frühen Krankheitsphase sind die Beeinträchtigung des 
Kurzzeitgedächtnisses, Orientierungslosigkeit, Aphemie sowie eine generelle Verschlechterung der 
Wahrnehmung. Laut Schätzungen der Weltgesundheitsbehörde leiden 37 Millionen Menschen 
weltweit an einer Demenz: 18 Millionen davon an AD. Trotz gewaltiger Forschungsbemühungen gibt 
es keine Kausaltherapie für die AD. Histopathologische Kennzeichen sind die extrazellulären Plaques, 
die aus amyloiden ?-Peptiden (A?) bestehen sowie die Neurofibrillären Bündel, die in den Gehirnen 
von Alzheimerpatienten gefunden wurden. A? wird durch die sequentielle Spaltung des amyloiden 
Vorläuferproteins (APP)  durch zwei Aspartylproteasen,  ?- and ?-Sekretase, erzeugt. Eine 
Intramembranspaltung durch die ?-Sekretase erfolgt mit geringer Sequenzspezifität und resultiert in 
verschiedenen A?-Fragmenten unterschiedlicher Länge, vorwiegend A?40, A?42 und etwas A?38. A?42 
neigt am stärksten zur Aggregation und man nimmt an, dass es die Amyloidkaskade, eine 
pathologische Abfolge an neurotoxischen  Abläufen, die zur Neurodegeneration und schließlich zur 
AD führt, auslöst. Die ?-Sekretase stellt durch die Freisetzung von A??ein attraktives Zielmolekül für 
eine Kausaltherapie von AD dar.  
Die vorliegende Arbeit beschreibt das Design, die Synthese und die biologische Wirkuntersuchung 
von ?-Sekretasemodulatoren, Affinitätsproben und Photoaffinitätsmarkern. Epidemiologische Studien 
implizieren einen engen Zusammenhang zwischen einem längerfristigen Einsatz von nichtsteroidalen 
Antirheumatika (NSAIDs) und einem verminderten Risiko für AD. Folglich wurden 
Cyclooxygenaseinhibitoren (COX-Inhibitoren) wie Flurbiprofen, Sulindac-Sulfoxid und 
Meclofenaminsäure in Amide und Ester umgewandelt and postuliert, dass die Modifizierung der 
Säurefunktion die COX-inhibierende Aktivität verringert und die ?-Sekretase-modulierende Aktivität 
erhöht. Die Umwandlung der Säurefunktion dieser COX-Inhibitoren in ihre Amide oder Ester 
resultierte entweder in inverser Modulation oder in einer vollständigen Hemmung. Weitere 
Bemühungen wurden schließlich auf Carprofen, einem COX-2-Inhibitor, zugelassen für den Einsatz 
bei Hunden und Kühen, gerichtet. Eine N-Substitution von Carprofen resultierte in potenten 
Modulatoren der ?-Sekretase, und die Verbindungen zeigten nur eine geringe oder keine Wirkung auf 
die ?-Sekretase-Spaltung der ?-Schnittstelle. Mit dem Wissen um die Bedeutung der N-Substitution 
von Carprofen und der Notwendigkeit der freien Säure auf die ?-Sekretase-Modulation wurde eine 
Serie an N-substituierten Carbazolyloxy-Ethansäuren synthetisiert. Wie erwartet stellten sie sich als 
effektive Modulatoren der ?-Sekrase heraus und zeigten keine oder nur eine geringe Wirkung auf die 
?-Sekretase-Spaltung der ?-Schnittstelle. Weiterhin wurde ein analoges Derivat des LXR-Agonisten 
TO-901317 synthetisiert. Die Hexafluormethanol-Funktion wurde jedoch durch eine Oxyethansäure 
ersetzt um einen Modulator der ?-Sekretase zu erhalten. Wie erwartet änderte die Einführung der 
Säurefunktion die Wirkungsweise der ?-Sekretase von inverser zu normaler Modulation. Um die 
Bindungsstelle durch Immunpräzipitationsexperimente  zu bestimmen, wurde eine Serie an von 
NSAIDs abgeleiteten Affinitätslabeln synthetisiert. Ein von Flurbiprofen abgeleiteter 
Photoaffinitätsmarker markierte zwar den aktiven ?-Sekretasekomplex dosisabhänging, jedoch gelang 
wegen unspezifischer Bindung nicht den direkten Bindungspartner zu identifizieren. Flurbiprofen- und 
DAPT-abgeleitete Photoaffinitätslabel wurden hergestellt um die Bindungsstelle in der Nähe des 
aktiven Zentrums des ?-Sekretasekomplexes zu bestimmen Das Photoaffinitätsexperiment mit einer 
von Flurbiprofen abgeleiteten Photoaffinitätsprobe zeigte, dass es an das C-terminale Fragment von 
Presenilin (PS) bindet. Die DAPT-abgeleitete Photoaffinitätsprobe zeigte hingegen eine sehr schwache 
Bindung an PS, der aktive Zentrum der ?-Sekretase.  
 
 
 
 
 
 
Die Übereinstimmung mit der englischen Zusammenfassung wird bestätigt. 
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1. INTRODUCTION 
 
1.1. Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disorder 
characterized by memory loss, unusual behaviour, personality changes and a decline in 
thinking abilities. It is the most common form of dementia and accounts for 50–60% of all 
dementia cases. The prevalence of dementia is below 1% in persons aged 60–64 years.[1] But 
it shows a dramatic increase with age so that in people aged 85 years or older the occurrence 
is between 24% and 33% in developed world. In 2001, more than 24 million people had 
dementia and it is expected to double every 20 years up to 81 million in 2040 because of the 
increase in life expectancy.[2] Ageing is the most obvious risk factor for AD. Epidemiological 
studies have indicated several disputed links apart from ageing. Other risk factors which are 
associated with AD includes: hypercholesterolaemia, hypertension, atherosclerosis, coronary 
heart disease, smoking, obesity, and diabetes.[3] Several evidences suggest that dietetic intake 
of homocysteine associated vitamins (vitamin B12 and folate), antioxidants such as vitamin C 
and E, unsaturated fatty acids and moderate alcohol intake, especially wine, ingredients such 
as curcumin, might lower the risk of AD.[4, 5] The pathological hallmarks of AD are 
extracellular deposits of aggregated ?-amyloid (A?) peptide and intracellular neurofibrillary 
tangles (NFTs). The major proteinaceous component of NFTs are abnormal filaments called 
straight filaments (SFs) or paired helical filaments (PHFs). The basic protein of these 
filaments is the microtubule-associated protein tau. A? is generated by the sequential 
proteolytic processing of ?-APP by ?-secretase and ?-secretase. 
1.1.1. Genetics in AD 
From a genetic point of view, AD is a heterogeneous disorder with both familial and sporadic 
forms. Familial AD is an autosomal dominant disorder with onset before age 65 years. The 
first mutation causing the familial form of the disease was identified in the amyloid precursor 
protein (APP) gene on chromosome 21.[6] Other families with the familial disease, several 
additional APP mutations were also found. Mutations in the presenilin 1 (PS1) and presenilin 
2 (PS2) genes comprise most cases of familial disease.[7] However, the familial form of AD is 
very rare with a prevalence below 0·1%. There is a close association between the 
apolipoprotein E (APOE) ?4 allele and AD.[8] Meta-analysis showed that the APOE ?4 allele 
increases the risk of AD by 3-fold in heterozygotes and by 15-fold in homozygotes. The 
APOE ?4 allele controls mainly by adapting age of onset so that each allele copy lowers the 
age at onset by almost 10 years. APOE is crucial for A? deposition. It promotes A? 
fibrillisation and plaque formation. The APOE ?4 allele has been considered to account for 
most of the genetic risk in sporadic AD.[9] Therefore, the contribution of other competitor 
genes is probably much less. Several studies have reported weak associations with different 
candidate genes, but few of them have been confirmed.[10]  
1.1.2. Clinical Features and Diagnosis 
AD is a slowly progressing disorder, with progressive impairment of memory. The symptoms 
include aphasia, apraxia, and agnosia, accompanied by general cognitive symptoms, such as 
impaired judgment, decision-making, and orientation. There are several factors which serve as 
the basis in the diagnosis of AD such as medical history along with the clinical, neurological, 
and psychiatric examination. Neuropsychological testing can be helpful to get objective signs 
of memory disturbances in very primary stages. Neuroimaging is an important diagnostic tool 
in AD. Computerized tomography (CT) and magnetic resonance imaging (MRI) play a crucial 
role in the diagnosis of AD to rule out other causes of dementia, such as brain tumour and 
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subdural haematoma. Cerebral atrophy, visualised as enlarged ventricles and cortical sulci, is 
also recognized by CT and MRI, but the overlap with typical ageing and other dementias is 
too large to have any diagnostic significance. Nevertheless, neuroimaging is a valuable tool to 
detect cerebrovascular disease, such as cerebral infarcts and white-matter lesions, which is of 
significance to identify AD/vascular dementia. An accurate diagnosis of AD can only be 
made by neuropathology.[11] Large community-based neuropathology studies revealed that a 
substantial proportion (20–40%) of non-demented persons have adequate plaques and tangles 
to warrant a neuropathological diagnosis of AD, yet without symptoms ![12] 
1.1.3. Pathogenesis 
The histopathological hallmarks in AD are senile or neuritic plaques and neurofibrillary 
tangles. At the microscopic level these are found (Figure 1.1) in the medial temporal lobe 
structures and cortical areas of the brain, accompanied by a degeneration of  neurons and 
synapses. Several pathogenic mechanisms that trigger these changes have been studied such 
as: A? aggregation and deposition with plaque development, tau hyperphosphorylation with 
tangle formation, neurovascular dysfunction. Apart from these mechanisms, other 
mechanisms such as cell-cycle abnormalities, inflammatory processes, oxidative stress, and 
mitochondrial dysfunction have also been investigated. The discovery of a close relationship 
between plaque formation and dementia put great focus on the involvement of plaques in the 
pathogenesis of AD.[13] 
 
 
Figure 1.1: Plaques and tangles in the cerebral cortex in AD.  
Plaques are extracellular deposits of A? which are surrounded by dystrophic neurites, reactive 
astrocytes, and microglia. A?42 is the most toxic and fibrilogenic species and forms the central core of 
plaques. Tangles are intracellular aggregates composed of a hyperphosphorylated form of the 
microtubule-associated protein tau.[14] (Reprinted from The Lancet with permission ? copyright 2006 
by Elsevir) 
 
1.1.3.1. Tau and neurofibrillary tangles 
Neurofibrillary tangles (NFTs) are an additional histopathological hallmark of AD. These are 
particularly found in cell bodies, apical dendrites as NFT, in distal dendrites as neuropil 
threads and in the abnormal neurites that are associated with some neuritic plaques. The main 
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components of these neuritic plaques are abnormal filaments such as straight filaments (SFs) 
or paired helical filaments (PHFs). The basic component of these filaments is the 
microtubule-associated protein tau[15] which is widely expressed in the mammalian nervous 
system. Tau, a normal axonal protein which binds to microtubules through its microtubule-
binding domains thus promotes microtubule assembly and stability. Six tau isoforms are 
produced in the adult human brain and are found in neurofibrillary lesions of AD patients.[16] 
Tau phosphorylation is controlled by the delicate balance between multiple kinases (eg, GSK-
3? and CDK5) and phosphatases (eg, PP-1 and PP-2A).[17] Tau hyperphosphorylation in AD 
begins intracellularly and leads to sequestration of normal tau and other microtubule-
associated proteins. This causes disassembly of microtubules and thus impairs axonal 
transport, compromising neuronal and synaptic function (Figure 1.2). Tau becomes prone to 
aggregation into insoluble fibrils in tangles, further compromising neuronal function. Tau 
pathology begins early in the disease process in neurons in the transentorhinal region which 
later expands to the hippocampus and amygdala, and neocortical association areas. It is still 
matter of debate whether tau hyperphosphorylation, and tangle formation are a basis or 
outcome of AD.[18]  
 
Disassembly of 
microtubules
Abnormally hyperphos-
phorylated tau
Sequestration of tau, 
MAP1, and MAP2 by
hyperphosphorylated tau
Disassembly of 
microtubules
Disassembly of 
microtubules
Kinases Phosphatases
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flow/transport
Neuronal / synaptic 
dysfunction
with transmitter deficits
Neuronal death
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Ubiquitinylation
 
Figure 1.2: Schematic representation of tau hyperphosphorylation and tangle formation. 
Tau phosphorylation is controlled by the delicate balance between multiple kinases and phosphatases. 
Sequestration of normal tau and other microtubule-associated proteins by hyperphosphorylated tau 
results in the disassembly of microtubules and disturbed axonal transport. Hyperphosphorylated tau 
becomes prone to aggregation into insoluble PHFs and larger aggregates in tangles.[14] (Modified and 
reprinted from The Lancet with permission ? copyright 2006 by Elsevier) 
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1.1.3.2. A? Plaques 
Identification of the protein composition of plaques was unsuccessful until the mid-1980s due 
to the insolubility of plaques. But, the success in purification of plaque cores and the 
identification of the amino acid sequence of A? which is the major constituents of plaques[19] 
paved the way for the cloning of the APP gene. A? is degraded by the peptidases insulin-
degrading enzyme, neprilysin, and by endothelin-converting enzyme under normal 
conditions.[20] A? is also cleared from the brain in a process balanced by the efflux. The efflux 
is mediated by low-density lipoprotein receptor related protein. Influx is mediated by the 
receptor for advanced glycation end products of A? across the blood–brain barrier.[21] The 
central hypothesis for the cause of AD is the amyloid cascade hypothesis (Figure 1.3), which 
states that an imbalance between the production and clearance of A? in the brain is the 
initiating event and this ultimately leads to neuronal degeneration and dementia.[22] This 
hypothesis is supported by the finding that the mutations implicated in the familial disease are 
present in the genes for both the substrate, APP, and the key enzyme, PS for A? generation. 
Most of the APP mutations are found around the secretase sites, and both the APP and PS 
mutations increase A?42 production. Soluble A? is thought to undergo a conformational 
change to high ?-sheet form, making it prone to aggregate into soluble oligomers and larger 
insoluble fibrils in plaques. In this process, the fibrillogenic A?42 isoform triggers the 
aggregation of other A? species.[23]  
1.1.4. Amyloid Cascade Hypothesis 
It is the most preferred model used to explain the pathogenic events causing AD. The amyloid 
cascade hypothesis (Figure 1.3) states that, an imbalance between the production and 
clearance of A? in the brain is the initiating event which ultimately leads to neuronal 
degeneration and dementia.  
The hypothesis is supported by several evidences and observations.[22]  
1. Persons with the Dawns syndrome have an additional copy of the APP gene and thus 
produce more A?.  
2. Mutations causing hereditary AD in the APP or PS genes increase production of the 
longer and more amyloidogenic A?42 form of the A? peptide. 
3. The levels of the deposited A? associate with cognitive decline and severity of the 
disease in AD patients and in transgenic animals [24] 
4. The A? peptide is neurotoxic to several cell lines. 
5. Transgenic mice that are knocked out for ?-secretase show rescue of memory 
impairments found in the parental strain with an intact ?-secretase gene. This indicates 
that overexpression of APP does not cause memory deficits and that the production of 
A? and or APP C-terminal fragments are required for the demonstration of reduced 
memory function in the mice.[25] 
Tangle formation appears closely linked to A? since tau deposition is increased in transgenic 
mice expressing human mutant tau together with mutant APP as compared to mice expressing 
mutant tau alone. 
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Figure 1.3: Amyloid cascade hypothesis 
According to this hypothesis, the central event in the disease pathogenesis is an imbalance between A? 
production and clearance, with increased A? production in familial disease and decreased A? 
clearance in sporadic disease. A? oligomers could directly inhibit hippocampal long-term potentiation 
and impair synaptic function, in addition to the inflammatory and oxidative stress caused by 
aggregated and deposited A?. These processes impair neuronal and synaptic function with resulting 
neurotransmitter deficits and cognitive symptoms. Tau pathology with tangle formation is regarded as 
a downstream event, but could contribute to neuronal dysfunction and cognitive symptoms.[14] 
(Modified and reprinted from The Lancet with permission ?copyright 2006 by Elsevier) 
 
Moreover, injection of fibrillar A?42 enhances the tangle formation in tau transgenic mice.[26] 
The attention has been focused on in which form (fibrills, protofibrills, oligomers or 
monomers) the amyloid species has the most adverse effects. Several reports blames the 
oligomeric and protofibrillar aggregates as being the most toxic form of A?.[27] Even though 
the amyloid cascade hypothesis is convincing, there are certain issues which are not clarified 
by amyloid cascade theory such as, the role of tangles and /or the inflammatory response.[28] 
1.1.5. ?-Amyloid Precursor Protein 
APP is an evolutionary conserved glycoprotein with ubiquitous expression throughout the 
body and is a type I transmembrane protein. It has a large extracellular N-terminal domain and 
a short C-terminal tail projecting into the cytoplasm. APP is produced in the endoplasmic 
reticulum and trafficked through the secretory pathway to the plasma membrane. APP 
intracellular domain (AICD) was detected in the nucleus and found to interact with the 
nuclear adaptor protein Fe65 and the histone acetyltransferase Tip60. AICD has together with 
these two proteins been reported to activate transcription of a Gal4-receptor gene suggesting a 
gene regulatory role for APP.  
Introduction 
 
 6
1.1.5.1. APP Processing 
Amyloid plaques are deposits composed primarily of insoluble A? of approximately 4 kDa 
generated from APP, which is processed via two different pathways: the amyloidogenic and 
the non-amyloidogenic pathways. 
A 
Extracellular Domain
N-terminalC-terminal
?-Secretase
A?
C-terminalA? AICD
sAPP-?
A? Plaques
?-Secretase
C-99
 
B 
Extracellular Domain
N-terminalC-terminal
?-Secretase
p3
C-terminalp3
sAPP-?
p3 peptide
C-83
?-Secretase
 
Figure 1.4: Schematic outline of APP processing. 
 (A) APP is a type I integral membrane protein with a large extra and a short intracellular domain. 
Cleavage of APP in the endosomal-lysosomal pathway by ?-secretase enables the secretion of sAPP-?. 
Processing of C99 by ?-secretase leads to the release of the A?-peptides. (B) Cleavage by ?-secretase 
within the A? domain leads to secretion of the soluble sAPP-? and prevents the formation of A?-
fragments (non-amyloidogenic pathway). The C-terminal fragment C83 is processed further by ?-
secretase releasing the p3 peptide.  
 
The non-amyloidogenic pathway involves the activity of ?-secretase at membrane level 
(Figure 1.4 A).[29] ?-Secretase belongs to the family of metalloproteases such as, the tumor 
necrosis alpha converting enzyme (TACE) and ADAM10. ?-Secretase activity cuts within the 
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sequence of the A?, at the residue 17.[30] Non-amyloidogenic processing of APP does not 
release intact A? and the generated fragments p3 peptides, do not aggregate and display 
amyloidogenic activity. In AD pathology, the production of A? is the net result of APP 
amyloidogenic processing. This involves the activity first of ?- then of ?-secretase and 
requires the internalization of APP from the membrane to the endosomes and the lysosomes 
(Figure 1.4 B).[31] ?-secretase, recently identified as the ?-site APP-cleaving enzyme (BACE-
1),[32] cuts APP at the beginning of the sequence of the A?, generating an extracellular soluble 
fragment called s?-APP and an intracellular COOH-terminal fragment called C99. 
Subsequently, ?-secretase cuts C99 at residues 38/40/42 of the A? sequence and generates A? 
peptides of various lengths.  
1.1.6. Established Therapies for AD 
In spite of tremendous research efforts, there is no approved causal treatment for AD today. 
Current pharmacological approaches related to AD treatment include antioxidant therapy, 
AChE (acetylcholine esterase) inhibitors, nicotinic and muscarinic agonists, nerve growth 
factor (NGF), low molecular lipophilic compounds that can activate the neurotrophic factor 
signalling pathway, anti-inflammatory drugs such as COX-1 and COX-2 inhibitors, drugs 
which interfere with A? formation and deposition, drugs which attenuate A? toxicity and food 
dietary components and ingredients such as curcumin.[33] Some 500 compounds are in 
development to treat neurodegenerative diseases. At least 10% of these are related to AD. The 
targets derive from a whole range of sometimes well-known receptors and enzymes: GSK-3, 
PDE 4 and muscarinic M1. nACh modulators, AChE inhibitors, NMDA modulators, 5-HT 
agonists and several vaccination projects (e.g. Elan, Cytos Biotechnology) are in advanced 
stages of research or development.[1] Plaques formation was seen as the main reason for the 
formation of AD and their removal was one of the therapy goals until 2001. Now, soluble A? 
and early oligomers have to take the blame for most of the A? associated effects. AChE 
inhibitors produce small improvements in cognitive and global assessments, but 
galanthamine, tacrine, donepezil and rivastigmine do not address the severe mortality in the 
final stages of AD. Memantine hydrochloride protects the neurons against overactivation of 
N-methyl-D-aspartate receptors and was approved for the treatment of moderate to severe AD 
in 2002 as first of its class. Thus, a causal therapy is still in demand, since no existing therapy 
effectively stops or cures AD. 
1.1.7. ?-Secretase 
BACE-1 was identified as the ?-secretase which cleaves APP and regulates the production of 
A? in vitro.[32] In vivo experiments confirmed that this enzyme is mainly responsible for 
initiating the amyloidogenic processing of APP. Particularly, brains of BACE-1 knockout 
mice had no detectable levels of A? and did not show accumulation of APP C-terminal 
fragments (CTF) C99 and C89.[34] Whereas brains of BACE-1 transgenic mice were 
characterized by increased levels of A? and amassing of the CTF.[35] It is a type-1 membrane 
protein characterized by a large extracellular domain and a short intracellular domain. The 
two aspartic residues involved in ?-secretase activity are located in the extracellular domain. 
The short intracellular domain contains a sorting sequence (DISLL), which is involved in the 
trafficking of the protein.[36] Particularly, the LL domain was found to regulate the 
internalization of the protein from the plasma membrane to the endosomal compartment,[32] 
and to the lysosomes where BACE-1 is degraded.[37]  
1.1.8. ?-Secretase 
?-Secretase mediates the critical step in the release of A? from the membrane. ?-Secretase 
cleavage is unusual, as it carries out the proteolysis within the hydrophobic environment. It 
generates A? peptides of different lengths, indicating a lack of sequence specificity. However, 
?-secretase is conformation specific since it selectively cleaves ?-helical substrates.[38] The 
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major forms of A? it generates are A?38, A?40 and A?42.[39] The more aggregating and toxic 
A?42 corresponds to approximately 5–10% of the total amount of A? secreted by cultured 
cells under normal conditions. Other A? peptides of residues 19, 37–39 and 43–48 were also 
identified but these represent only minor species.[40] The longer the peptides, the more 
insoluble they are and hence more prone to aggregate and thus seed amyloid deposition. ?-
Secretase also mediates the release of AICD by cleaving at the ?-site, nine amino acids away 
from the ?40 cleavage site.[41] The relationship between ?- and ?-cleavage has been discovered 
recently, with the isolation of A?49, which is the the N-terminal product of ?-cleavage and thus 
may be a precursor for secreted A?. ?-Secretase processes the APP transmembrane domain 
(TMD) from its C-terminal end by sequential steps and each cleavage occurs on the same side 
of the ?-helix. Biochemical and genetic studies have demonstrated that presenilin (PS), 
nicastrin, anterior pharynx defective-1 (Aph-1) and presenilin enhancer-2 (Pen-2) form the 
enzymatically active core of the ?-secretase complex (Figure 1.5).[42] 
1.1.8.1. Presenilins: PS1 and PS2 
Presenilins (PS1 and PS2) control the activity of ?-secretase and are involved in the 
processing of APP and the production of A?.[43] They account for the majority of the cases of 
inherited familial AD. Levels of A? were dramatically decreased in animal models lacking the 
expression of PS1 but not PS2.[44] This indicates that among the two presenilins, PS1 plays a 
major role regulating the activity of ?-secretase and hence A?. PS1 is an aspartyl protease and 
its topology is characterized by 9 or 10-membrane spanning domains. The sixth and seventh 
domains bear the aspartates residues (D257 and D385) which are vital for the production of 
A?. The mutation on the either of these residues abolishes the A? generation.[45] It is a 
mechanism which results in the formation of N-terminal and C-terminal fragments of PS1. 
These two fragments contain one of the two critical aspartate residues and remain associated 
forming a heterodimer which comprises the active PS.[46] PS1 and ?-secretase activity resides 
in its ability to cleave APP within the plasma membrane at the 38-, 40- and 42- sites of the A? 
sequence. This process is known as Regulated Intra-membrane Proteolysis (RIP). It requires 
the exchange of water molecules, which are excluded from the hydrophobic lipid bilayer of 
the cell membrane.[47] The exact mechanism of this process and how it is affected by inherited 
mutations in PS remains mysterious. Pharmacological ?-secretase activity can be assigned to 
the two critical aspartate residues in PS, but PS1 alone is not able to coordinate all the 
processes that lead to its own activation.[48] It has been reported that overexpression of PS1 
does not lead to increased levels of its N- and C-terminal fragments.[49] Therefore, there must 
be more additional limiting factors which control the endoproteolysis of PS1. Numerous 
studies performed during the last few years have confirmed that, PS especially PS1, is a part 
of a tetrameric complex which constitutes the active ?-secretase. The other members of this 
tetrameric complex are nicastrin, Aph-1 and Pen-2. All of these are membrane inserted 
proteins which are co-factors in the regulation of ?-secretase dependent APP processing and 
A? formation.  
1.1.8.2. Nicastrin 
Nicastrin was the first protein of the ?-secretase complex to be identified.[50] The domain of 
nicastrin involved in the interaction with PS1 has been identified as the N-terminal part of its 
transmembrane domain (TMD).[51] This was further confirmed by the experiments carried out 
with the transitions-state analogues which bind specifically to active PS. These experiments 
showed that nicastrin copurifies with the active form of PS1. This indicates that it is an 
integral part of the active ?-secretase complex.[52] Nicastrin is a large type-1 transmembrane 
protein (~ 130 kDa) and exists as an immature and a mature protein.[53] Studies performed in 
order to understand the role of nicastrin revealed that PS1 and nicastrin require each other to 
become fully mature.[48] These two can be released from the endoplasmic reticulum and be 
sorted to the plasma membrane where the complex PS1-nicastrin is biologically active.[54] 
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Due to the large extracellular domain of nicastrin, it was speculated that the role of nicastrin 
within the ?-secretase complex would be to recognize the substrate by measuring the length of 
the membrane-inserted end.[55] But, recently it has been reported that nicastrin functions as a 
?-secretase substrate receptor and it binds specifically to the N-terminal side of the APP and 
Notch C-terminal fragments.  
 
 
Figure 1.5: Members of the gamma-secretase activity complex.  
The ?-secretase complex comprises four integral membrane proteins. PS is believed to contain nine to 
ten TMDs and two critical aspartate residues in transmembrane domains 6 and 7 that are proposed to 
form the catalytic site of the enzymatic complex. PS becomes proteolytically processed into an NTF 
with six membrane-spanning domains and a CTF with two transmembrane domains, before becoming 
inserted into active complexes of high molecular weight. Nicastrin comprises a single transmembrane 
domain and becomes highly glycosylated during maturation of the ?-secretase complex. Aph-1 is 
predicted to contain seven transmembrane domains. Nicastrin and Aph-1 can associate as a 
subcomplex. Pen-2 contains two transmembrane domains and is required for the endoproteolysis of 
PS. 
 
1.1.8.3. Anterior pharynx-defective phenotype-1 and Presenilin enhancer-2  
Aph-1 (anterior pharynx-defective phenotype) and Pen-2 (presenilin enhancer) were isolated 
as part of the ?-secretase complex in two different experiments carried out in C. elegans.[56, 57] 
Aph-1 and Pen-2 are required for Notch signaling and A? formation. Aph-1 is required along 
with PS for the correct localization of the mature form of nicastrin at the cell surface. Aph-1 
exists in more than one isoform which may be involved in the formation of the ?-secretase 
complex. Aph-1-a being the mostly involved in Notch signaling and the processing of APP.[58] 
Pen-2 is a short two-membrane domain spanning protein and it is formed of approximately 
101 amino acids. Pen-2 knockout affects the activity of the ?-secretase complex by altering 
the Notch-mediated signaling pathway and the processing of APP.[57] The physiological 
significance of Aph-1 and Pen-2 within the ?-secretase complex is to stabilize mature PS and 
nicastrin,[59] and to control the endoproteolysis of PS which is crucial for the creation of the 
active heterodimer.[60] It was revealed that, in absence of PS, Pen-2 is destabilized and 
degraded in the endoplasmic reticulum as ubiquitinylated protein.[61] The C-terminal domain 
of Pen-2 is involved in the maturation of nicastrin and the formation of the PS heterodimer. 
Pen-2 associates with the nicastrin/PS1 complex in the endoplasmic reticulum regulating its 
maturation and sorting to the plasma membrane.  
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Figure 1.6: ?-Secretase complex and binding partners.  
PS, Nicastrin, Aph-1 and Pen-2 are assembled to form the enzymatic core complex. CD147 is an 
integral regulatory subunit of the native complex. TMP21, PLD1 and GSK3 have been found to 
modulate ?-secretase activity and transiently or weakly bind to the complex; transient interactions with 
the complex are depicted by white arrows.[62] (Reprinted from The Journal of Medicinal Chemistry 
with permission ? copyright 2007 by the American Chemical Society) 
 
Purification of endogenous ?-secretase complexes from detergent solubilized HeLa cell 
membranes showed along with the four mandatory components of the enzymatic core it bears 
an additional integral subunit, the membrane protein CD147. CD147 was found to have a 
regulatory effect on ?-secretase activity.[63] Apart from CD147, other transient or weak 
binding partners of the ?-secretase complex, such as glycogen synthase kinase-3 (GSK-3), 
phospholipase D1 (PLD1) and TMP21 also have been reported (Figure 1.6).[62] Although the 
presence of these binding partners is crucial for the activity of ?-secretase, none of these 
proteins have been detected in chromatographically purified samples of the complex. CD147 
in endogenous ?-secretase complexes was found to down-modulate the production of A?-
peptides. But, its effect on the processing of other ?-secretase substrates, such as Notch, 
remains to be investigated.[63] CD147 is a glycosylated type-1 transmembrane protein with a 
molecular weight of about 50 kDa. It is believed that it has a short cytoplasmic domain about 
40 amino acids long, a transmembrane region of approximately 25 amino acids long and a 
large extracellular region consisting primarily of two immunoglobulin-like (Ig-like) domains. 
How these four components (PS1, nicastrin, Aph-1 and Pen-2) coordinate ?-secretase activity 
is still a matter of investigation. Although the catalytic activity of the ?-secretase complex 
resides in the two aspartate residue in PS1, these four proteins certainly contribute in the 
regulation of one another's activation and/or maturation. These four protein altogether 
combine and form the active ?-secretase complex and are obligatory to reconstitute ?-
secretase activity in mammalian cells.[64] In addition to APP, the ?-secretase complex 
processes numerous other type I TM proteins including fragments of Notch, E-cadherin, N-
cadherin, CD44, DCC, ErbB4, LRP and nectin-1, which are involved in many physiological 
and pathological functions.[65] 
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1.2.??-Secretase Inhibitors 
Special features of the ?-secretase complex hinder crystallisation and thus crystallographic 
analysis of the enzyme, which is a major obstacle for structure-based drug design. 
Furthermore, the information available on inhibitor binding sites is still limited. Therefore, all 
selective, non-peptidic ?-secretase inhibitors had to be provided by high throughput screening 
(HTS) efforts. Peptidic PS1 inhibitors, like Merck’s L-685,458 (1, IC50 = 17 nM) are potent 
inhibitors.[66] The semi-peptidic inhibitors have also been comprehensively utilized in a range 
of discoveries from the Elan/Lilly group.[67-69] DAPT 4 (HEK IC50 = 20 nM) was developed 
from a N-dichlorophenylalanine lead and the phenylglycine and the difluoro phenylacetic acid 
are crucial for activity (Scheme 1.1).  
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Scheme 1.1: Semi-peptidic ?-secretase inhibitors. 
 
DAPT is not a prodrug, despite the labile nature of tertiary butyl ester, which may be cleaved 
at the low pH of the gut. It has demonstrated robust efficacy in vivo in the PDAPP and 
Tg2576 mouse models.[70, 71] DAPT has also been shown to cause a phenotype consistent with 
interference in the Notch signaling pathway in both drosophila and zebra fish embryos.[72] 
Modification of these early compounds ended up in benzodiazepine-containing analogs such 
as 5 (IC50 0.3 nM CHO ?-APP cells).[73] Further amplification, taking advantage of the 
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increased activity observed with several metabolites bearing an additional benzylic hydroxyl 
group, resulted in the discovery of mandelate analogs such as 6 and 7 which displayed high 
levels of potency in whole cell assays (e.g. 7; IC50 119 pM – HEK 293 cells overexpressing 
?APP695).[74] 7 was further evaluated in vitro and in vivo as a prototypical, potent, orally 
active ?-secretase inhibitor: upon oral dosing to 3-5 months old Tg2576 mice, 7 (LY- 411575) 
gave a dose-dependent reduction of both A?40 and A?42 in all compartments studied (cortex, 
hippocampus, CSF and plasma; 3 hours post-dose) with a minimum effective dose of 1mg/kg 
(0.3 mg/kg in plasma). Further analyses of the time course of inhibition following a 1 mg/kg 
dose of 7 exhibited a significant reduction in A? levels in cortex, hippocampus and plasma up 
to 24 hours post-dose although CSF levels were only reduced significantly at 3 and 9 hours 
post-dose.[75]  
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In another study, chronic administration of 7 (LY-411575) to PDAPP mice prior to the onset 
of plaque deposition resulted in a considerable lowering of brain A? levels (by ELISA) and 
immunohistochemically-determined A? burden. In addition, markers of neuritic pathology 
and glial inflammation were also significantly reduced following this treatment.  
Apart from the previously described peptidic and semi-peptidic inhibitors, the efficacy of 
lipophilic scaffolds based around a sulfonamide moiety (Scheme 1.2) have been explored in 
the recent discoveries.[65] The Amgen group exploited fenchylamine sulfonamides as 
moderately potent inhibitors. SAR studies revealed that a stereochemical dependence of 
inhibitory potency with 8 giving optimal activity (IC50 1.8 ?M) for the inhibition of A?42 
production in HEK293 cells.[76] The Merck group employed an unusual bicyclo-[4.2.1] 
sulfonamide scaffold characterized by the toluyl sulfonamide 9.[77] Related acyclic sulfamides 
(e.g. 10) and spirofused cyclic sulfamides (e.g. 11) have also been reported. More recent 
disclosures have described a number of more elaborate molecules which bear olefinic 
substituents, heterocyclic groups, alkynyl groups or substituted oxadiazoles on the benzo-
fused moiety. Many of these compounds are claimed to inhibit A? production in whole cells 
showing IC50 <1 ?M. Additionally, the introduction of bridgehead substituents on to the 
[4.2.1] core (e.g. 12) was demonstrated. Wyeth/Arqule groups reported the sulfonamides (13) 
which were prepared from amino alcohols.[78] An alternative series of diaryl sulfonamides 14 
and 15 (IC50 7-13 nM solubilized enzyme assay)[79] has also been disclosed by the BMS 
group.[80]  
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Acetamide derivatives such as 16 also have been reported by the same group. Compound 16 
displayed potent inhibitory activity with an IC50 <50 nM for inhibition of A? secretion in H4 
cells. In a series of closely related disclosures, the Schering group employed a variety of 
sulfonamides, such as piperidine 17, tetrahydroquinoline 18 (IC50 30-535 nM in DKF167 cells 
expressing C99) and 2,6-disubstituted piperidine 19 (IC50 0.2 nM). Removal of the nitrogen 
atom from these sulfonamides resulted in a series of corresponding sulfones. The Merck 
group has reported cyclohexyl sulfones such as 20 (IC50 <100 nM, SH-SY5Y cells) as potent 
?-secretase inhibitors.[81-83] Following to this initial discovery of cyclohexyl sulfones, further 
compounds such as 21 have been claimed by the Bayer AG.[84] Various related sulfone 
analogs were also claimed in a disclosure by Daiichi Pharm Co. (e.g. 22, IC50 <50 nM, H4 
cells). The Elan patent application [85] reported three general synthetic schemes and about 700 
tabulated examples. Selected N-(oxoazepanyl) benzenesulfonamides showed promising 
activities, for example, compound 23 inhibited ?-secretase with an IC50 within the range of 
0.1-25 nM. However, the activities of compound 24 and 25 are unknown (or not reported). 
Roche’s 1,4-benzoxazepin-3-one 26 was prepared by a cyclocondensation of 
(formylaryloxy)alkanoic acid, amine and isonitrile (Scheme 1.3).[86] Compound 26 inhibited 
?-secretase with an IC50 value of 0.18 (no units given). Additionally, Roche presented 
malonamide derivatives, where some compounds display IC50 values of < 1.0 µM.[87] The aryl 
cyclohexyl sulfone (27),[83] developed by Merck, inhibits the processing of APP by ?-
secretase with ED50 values of < 1 µM. Elli Lilly optimized their series of dipeptides to 
challenge the amyloid hypothesis in a clinical setting. A selective ?-secretase modulator (28) 
was reported by MSD,[88] the carboxylic acid seems to be important to achieve the desired 
ratio of A?38/A?40/A?42. This modulation is distinctly different from inhibition as the total A? 
load may be unaffected. 29 (BMS-299897) 2-[(1R)-1-[[(4-chlorophenyl) sulfony](2,5-
difluorophenyl)amino]ethyl]-5-fluorobenzenepropanoic acid is a potent ?-secretase 
inhibitor.[89] It was found to reduce A? in brain, cerebrospinal fluid (CSF) and plasma in 
young transgenic mice in a dose and time dependent manner with a significant correlation 
between brain and CSF A? levels. Transgenic mice were used to examine potential side 
effects due to Notch inhibition which is a crucial issue with ?-secretase inhibitor. 29 (BMS-
299897) was 15-fold more effective and selective at preventing the cleavage of APP than of 
Notch in vitro (APP IC50 of 7.1 nM, Notch IC50 of 105.9 nM). No changes in the maturation 
of CD8+ thymocytes or of intestinal goblet cells were observed in mice treated with 29. 
1.2.1. Additional Cleavage of Substrates by ?-Secretase  
The most crucial issue related to ?-secretase inhibition is the identification of a gradually 
increasing number of additional integral membrane proteins which are processed by the 
enzyme. Little is known about the functional consequences of inhibiting the processing of 
these alternative substrates except Notch.  
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The role of Notch signaling in lymphopoiesis is well known,[90, 91] and most of the reported 
and confirmed ?-secretase inhibitors such as compounds 30 & 31 (Scheme 1.4) impair 
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thymocyte development in a concentration-dependent manner with phenotypes resulting from 
a blockage at earlier, immature stage to later stages.[92, 93] Lilly group observed a 
gastrointestinal toxicity in rats upon dosing the potent ?-secretase inhibitor 23.[94] Moreover, 
the histological analysis showed a reduction in absorptive enterocytes, an increase in goblet 
cells and upregulation of the transcripts for the secreted proteins adipsin, secretin, glucagon-
like peptide, cholecystokinin and somatostatin. These observations are in accordance with a 
disruption of the Hes-1-mediated control of intestinal stem cell fate[95] which sequentially is 
dependent on the Notch pathway. These observations suggest that the ?-secretase inhibitory 
effect of 23 may be directly responsible for the observed toxicity. Notch has also been further 
implicated in maturation in the immune system,[96] memory and learning,[97, 98] and muscular 
regeneration[99] amongst other pathways. 
1.2.2. Interaction of ?-secretase enzyme with different ?-secretase inhibitors 
Clarke et al. demonstrated that the two principal classes of inhibitor, aspartyl protease 
transition state analogues and small molecule non-transition state inhibitors, display 
fundamental differences in the way they interact with the enzyme.[100] Taking advantage of a 
?-secretase enzyme overexpressing cellular system and different radiolabelled ?-secretase 
inhibitors, it was observed that the maximal binding of nontransition state ?-secretase 
inhibitors accounts only for half the number of catalytic sites of the recombinant enzyme 
complex. This characteristic stoichiometry can be best accommodated with a model whereby 
the non-transition state inhibitors bind to a unique site at the interface of a dimeric enzyme 
(Figure 1.7). Subsequent competition studies confirmed that this site appears to be targeted 
by the main classes of small molecule ?-secretase inhibitor.  
 
 
Figure 1.7: Models of the interaction of the ?-secretase enzyme with different types of ?-secretase 
inhibitor. (A) This model is analogous to the dimerization of the G protein-coupled dopamine D2 
receptor. It also accounts for the proximity of the two individual PS1-NTF subunits, which harbor the 
two Asp-257 residues in a dimeric complex. A close alignment of PS1-NTFs in the ?-secretase 
complex was implied by the generation of PS1-NTF dimmers upon photoaffinity labeling. (B) An 
alternative model of the ?-secretase dimer, envisaging the interaction of the enzyme with the different 
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types of inhibitor.[100] (Reprinted from The Journal of Biological Chemistry ? copyright 2006 by The 
American Society for Biochemistry and Molecular Biology) 
 
Transition state analogue inhibitor binding depends on the presence of two transmembrane 
aspartate residues that are required for catalysis. Putative binding of the small molecule-type 
inhibitors to a unique site at the dimer interface could explain the 2:1 stoichiometry observed 
for the enzyme obtained from ?(NRC-F8)-secretase cells. These interactions are exclusive and 
lead to noncompetitive antagonism. Essentially, binding of either type of inhibitor to its 
respective binding site introduces allosteric changes in the enzyme, preventing the binding of 
the alternative type of inhibitor. NSAID-type ?-secretase modulators target none of these two 
binding sites but change their conformation. In contrast, the NSAID and ?-secretase 
modulator, sulindac sulfide displayed noncompetitive antagonism for all types of inhibitor. 
This finding suggested that non-steroidal anti-inflammatory drug-type ?-secretase modulators 
target an alternative site on the enzyme, thereby changing the conformation of the binding 
sites for ?-secretase inhibitors. 
It was predicted that there is the presence of at least three binding sites on the ?-secretase 
enzyme. Each being specifically targeted by a separate class of compounds: transition state 
analogue inhibitors, non-transition state analogue inhibitors and NSAID-type modulators. [100] 
1.2.3. Role of Casin Kinase-1 in Regulation of A? 
Recently, Flajolet et al. demonstrated using an in silico analysis that APP, ?-secretase and ?-
secretase subunits contain, multiple CK1 consensus phosphorylation sites in their intracellular 
regions.[101] Many of them are conserved among human, rat and mouse species. 
Overexpression of constitutively active CK1?, one of the CK1 isoforms expressed in brain, 
leads to an increase in A? peptide production. The human, rat and mouse amino acid 
sequences corresponding to amyloid-? related proteins (APP, BACE, PS1, PS2, Aph-1, Pen-2 
and nicastrin) were screened for the presence of putative CK1 phosphorylation sites by using 
different computational tools (e.g., ELM-motifs; http://elm.eu.org, NetPhos 2.0) The in silico 
analysis of intracellular domains in APP, BACE, PS1, PS2, Aph-1, Pen-2 and nicastrin 
revealed the presence of numerous putative phosphorylation sites, particularly in PS1 and 
PS2. Moreover, the same in silico analysis of the two kinases which have been involved in 
AD (Cdk5/p35 and GSK3-?) also showed the presence of numerous putative phosphorylation 
sites for CK1, conserved in human, rat and mouse sequences. 
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The effect of the three different classes of CK1 inhibitors, IC-261, D4476 and CKI-7 was 
compared on A? peptide production in N2A cells expressing APP-695 (Scheme 1.5). A?40 
peptide production was significantly reduced after 3 h of incubation with IC261 or D4476 and 
A?42 peptide production was significantly reduced after 3 h of incubation with each of the 
three inhibitors. The reduction was shown by using two different methods: sandwich ELISA 
and Western blot analysis after immunoprecipitation. None of the CK1 inhibitors inhibited 
Notch cleavage. Three structurally unrelated CK1 inhibitors significantly decrease A? peptide 
production  indicating that the three inhibitors might be acting through a common target, 
namely CK1. This hypothesis is further supported by the fact that constitutively active CK1? 
leads to increased A? peptide formation. Altogether, these results indicated the involvement 
of CK1? activity in the regulation of the APP ?-secretase cleavage. Notch cleavage was not 
affected by any of the CK1 inhibitors tested and this indicates that CK1 acts directly or 
indirectly on the ?-secretase activity to selectively interfere with the APP ?-cleavage site but 
not at the Notch/APP CK1 ?-cleavage site. 
1.3. Non-Steroidal Anti-Inflammatory Drugs and AD 
Brain of AD patients show a number of pathological abnormalities such as a profound loss of 
synapses, profuse reactive gliosis, microglial proliferation and ultimately indication of 
inflammatory processes.[102] Increasing evidence suggests that a large number of 
inflammatory mediators are elements of the neuropathology linked with brain degeneration in 
AD. There are several factors identified in the brain of AD patients which include activated 
complement proteins, cytokines, chemokines, acute phase reactants, proteases and their 
inhibitors, proteoglycans, growth factors and various other enzymes. Due to these 
observations, different inflammatory hypotheses for AD have been proposed. One of these 
postulates states that, neurodegeneration in AD brain is secondary to an inflammatory 
response to SPs and NFTs rather than to these hallmarks themselves. Moreover, inflammation 
initiates the formation of SPs and NFTs and their progressive accumulation which in sequence 
activates immune reactions that force a self-sustaining “auto destructive” process (Figure 
1.8). Thus, these hypotheses propose that in both circumstances chronic inflammation has a 
fundamental role in AD pathogenesis.  
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Figure 1.8: Role of inflammation in dementia. 
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This hypothesis is further supported by the several genetic studies indicating that 
polymorphisms of some inflammatory genes (i.e., interleukin (IL)-1a; IL-1b; tumor necrosis 
factor (TNF)-?; ?2-macroglobulin, ?1- antichimotrypsin) increase the risk of AD.[103] 
Epidemiological studies demonstrated that use of NSAIDs, may delay or prevent the onset of 
AD. They slow its progression and reduce the severity of cognitive symptoms.[104, 105] The 
duration of the treatment is critical for the outcome as long-term treatment is more beneficial 
compared to the short-term treatment.[104] Moreover, the type of NSAIDs is also crucial for 
the outcome e.g. ibuprofen, sulindac, indomethacin offers the best protection where as 
naproxen does not. All this information and the observations supported the rationale for 
clinical trials of different NSAIDs in AD patients.  
1.3.1. Epidemiological Studies 
Epidemiological studies indicated that, the long term use of anti-inflammatory drugs may 
delay the development of AD. For example, patients with rheumatoid arthritis have a lower 
prevalence rate of AD compared to control patients and this is due to the fact that patients 
with rheumatoid arthritis usually receive long-term treatment with anti-inflammatory agents 
including NSAIDs.[106] The results of a co-twin control study[107] and population based cohort 
studies demonstrated that continuous use of NSAIDs is associated with a delayed onset and 
reduced risk of AD (Figure 1.9).[102] A recent prospective study concluded that long-term 
NSAID use might reduce the risk of AD, only if such use occurs well before the inception of 
dementia.[108] Based on these epidemiological observations, neuropathological observations, 
genetics, in vitro and animal experiments, COX activity has been considered a compelling 
target for therapeutic intervention 
 
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
NO NSAID LESS THAN 1
MONTH
BETWEEN 1 & 23
MONTHS
2 YEARS OR MORE
NSAID Exposure
R
el
at
iv
e 
R
is
k
R
el
at
iv
e 
R
is
k
 
Figure 1.9: Schematic illustration indicating NSAID exposure and the reduced risk of AD. 
 
NSAIDs represent the most widely used therapeutic agents. Conventional NSAIDs reversibly 
inhibit the COX activity of the enzyme prostaglandin H synthase, which converts arachidonic 
acid to prostaglandin H2, the immediate precursor of various prostaglandins and 
thromboxane.[109]  
1.3.2. APP Metabolism by NSAIDs 
It is well documented that NSAIDs can modulate the secretion of s?-APP from different 
neuronal cell lines, astrocytes and neurons via a protein kinase C (PKC)-mediated 
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mechanism.[110] Weggen et al. in their very first study reported three NSAIDs which displayed 
selective A?42-lowering activity in a variety of stable transfected cell lines.[111] Two 
structurally closed compounds, sulindac sulfide and indomethacin lowered A?42 (IC50 = 25–
50 ?M) whereas the ibuprofen, lowered A?42 with an IC50 of around 250 ?M. At maximal 
non-toxic concentrations, 70–80% A?42 inhibition was observed without significant reduction 
of A?40 levels. Interestingly, this activity was not associated with all NSAIDs and negative 
results were observed with other commonly prescribed NSAIDs such as naproxen and aspirin 
as they did not affect either A?40 or A?42 levels.[111] Later Eriksen et al. identified other 
NSAIDs with A?42-lowering activity such as fenoprofen 36, flurbiprofen 32 and 
meclofenamic acid 37.[112]  
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Scheme 1.6: NSAIDs that modulate ?-secretase activity. 
Some COX-2-specific inhibitors, including celecoxib 38 and other structurally related 
compounds such as the peroxisome proliferator-activated receptor-? (PPAR-?) antagonist, 
fenofibrate were found to increase A?42 levels selectively.[113, 114] Furthermore, cell based 
studies with A?42-lowering compounds have revealed that ?-secretase modulators do not 
affect the cleavage of other ?-secretase substrates such as Notch and others.[111, 114-118] Assays 
with APP-transfected cell lines revealed that, A?42-lowering NSAIDs do not change APP 
expression, turnover, internalization or release of the APP ectodomain. Significantly, in 
contrast to the conventional ?-secretase inhibitors NSAIDs do not cause accumulation of APP 
C-terminal fragments.[111, 114, 115] Some NSAIDs display their A?-lowering effect by inhibiting 
the small GTP-binding protein Rho and its effector, Rho associated kinase (Rock).[119] 
Interestingly, some NSAIDs could at least in vitro shift the ?-APP metabolism towards 
shorter and less fibrillogenic forms of the A? peptides (Figure 1.10). Ibuprofen 35, sulindac 
33 and indomethacin 34 modulate APP metabolism to explicitly generate less A?42, the most 
toxic species which is prone to aggregate and more soluble A?38 by interfering directly with 
the activities of ?- and ?-secretases which are the two important enzymes in this metabolic 
pathway.  Furthermore, treatment with sulindac sulfide 32, indomethacin 33 and ibuprofen 35 
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(Scheme 1.6) did neither impair ?-secretase-mediated NOTCH receptor cleavage and NICD 
formation nor the generation of the ICDs of APP and the ErbB-4 receptor.[111, 114, 116, 118]
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Figure 1.10. APP metabolism by NSAIDs.  
Heterogeneous cleavage at the ?-site generates different A? species by cleavage at the ?38, ?40 and 
?42 sites. A subset of NSAIDs increases the cleavage at the ?38 site while reducing cleavage at the ?42 
site.[120] (Reprinted from The Journal of Medicinal Chemistry with permission ? copyright 2007 by 
the American Chemical Society)  
 
This consistently unaffected ICDs generation of several ?-secretase substrates indicate that ?-
secretase modulators and improved compounds following the similar mode of action may 
avoid the toxicity which is associated with ?-secretase inhibitors such as 23. Substantial 
progress has been made to determine the mechanism of action of A?42-lowering compounds.  
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Scheme 1.7: NSAIDs derivatives that modulate ?-secretase. 
 
However, several arguments rule out any involvement of COX in the A?42-lowering activity 
such as: only a few NSAIDs display A?42-lowering activity, whereas all NSAIDs inhibit 
COX,[111] the A?42-lowering activity of sulindac sulfide was not impaired in COX-1/-2-
deficient cells,[111] and NSAID derivatives have been reported which lower A?42 devoid of 
their COX inhibitory activity.[112, 115, 120, 121] Peretto et al. reported novel cyclopropylated 
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flurbiprofen analogues (Scheme 1.7) with potent and selective inhibitory activity on A?42.[121] 
Compared to flurbiprofen, the compounds 39, 40 displayed improved potency on A?42. 
Moreover, introduction of the cyclopropyl substituent at the alpha position caused almost 
complete loss of COX-1 inhibitory activity. In rats, compounds 39, 40 showed good oral 
bioavailability and long elimination half-life. Short-term studies in a transgenic mice showed 
that compounds 39, 40 decreased plasma A?42 concentrations significantly. Carprofen 41, a 
COX-2 inhibitor approved for the use in dogs, cows and horses is a weak inhibitor of ?-
secretase. The geminal dimethyl derivatives of Carprofen and Flurbiprofen (42, 43) displayed 
40% and 67% inhibition of A?42 production respectively in HEK cells at 100 ?M 
concentration [122]. 
1.3.3. Long-Term and Short-Term Treatment Studies with A?42-Lowering Compounds 
Several long-term and short-term treatment studies in APP-transgenic mouse models of AD 
have been performed with A?42-lowering NSAIDs. Even before the A?42-lowering activity of 
certain NSAIDs was reported, Lim et al. demonstrated that chronic treatment with high doses 
of ibuprofen for 6 months strongly reduced both amyloid pathology and inflammatory 
responses in Tg2576 mice.[123] In animals treated with ibuprofen, the total number and area of 
A? plaques was reduced by 50% while the soluble and insoluble A? in the brain was reduced 
by 30–40%. Significant reductions in the number of plaque-associated activated microglia 
cells and lowered levels of pro-inflammatory markers were also observed.[123] Indomethacin 
was found to reduce amyloid pathology in Tg2576 mouse model but celecoxib and 
nimesulide, did not show significant reductions in amyloid pathology.[124, 125] Short-term 
treatment studies have demonstrated that A?42-lowering NSAIDs can lower A?42 levels in the 
brains of young, plaque-free APP-transgenic mice. In the initial experiments, 3-month-old 
Tg2576 mice were orally dosed for 3 days with 50 mg/kg/day of ibuprofen or naproxen.[111] 
Treatment with ibuprofen resulted in a 39% decrease in SDS-soluble A?42 without any 
changes in A?40 levels, whereas naproxen displayed no effect. Further short term studies have 
shown in vivo A?42-lowering activity for additional NSAIDs including sulindac sulfide, 
indomethacin and flurbiprofen.[112] Only a few clinical trials with NSAIDs in AD patients 
have been conducted to date. In the very first trial with indomethacin, a slowing of the 
cognitive decline was observed.[126] Severe side effects caused due to the long-term use of 
NSAIDs hamper the clinical use of NSAIDs, especially in elderly AD patients. Another 
promising strategy may be the application of specific NSAID enantiomers devoid COX 
inhibitory activity. A particular interesting compound is the (R)-enantiomer of flurbiprofen, 
which lacks COX inhibitory activity, but is equipotent in reducing A?42 in vitro and in vivo 
compared to (S)-flurbiprofen.[112, 115] (R)-flurbiprofen is under development for treatment of 
AD. A phase II clinical trial with duration of 12 months has recently been completed. Results 
indicated that the drug was well tolerated and positive results were observed with the highest 
dose (800-mg, twice-daily) in patients with mild AD.  
1.3.4. NSAIDs as Agonist of Peroxisome Proliferator-Activated Receptor- ? (PPAR-?) 
Apart from COX inhibition, another concerned mechanism of NSAIDs by which they exert 
the modulatory activity is the activation of the PPAR-?. PPAR-? is a member of the nuclear 
receptor family of transcription factors. It is expressed in monocytes/macrophage-like cells 
and its activation is related to the decrease in the expression of inflammatory genes,[127] and 
the creation of cytokines with potent inflammatory actions (i.e., IL-1, IL-6, TNF?).[128] A few 
NSAIDs when used at high concentration were found to act as direct PPAR- ? ligands and as 
a result they reduced cytokine production.[129] In vitro studies have demonstrated that 
indomethacin and ibuprofen, both can activate PPAR-? in microglia, reduce the A?-mediated 
secretion of inflammatory cytokines and neurotoxicity.[130] Since PPAR-? is involved in AD 
pathology, it is hypothesized that some of the beneficial effects from the treatment of NSAIDs 
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in AD may be due to their action on PPAR-? and subsequent reduction of brain 
inflammation.[131, 132] But, it is unlikely that this mechanism is involved in the A?-lowering 
effect of NSAIDs, because a direct agonist for PPAR-?, pioglitazone, failed to affect amyloid 
formation and deposition in an animal model of AD-like amyloidosis.[133] 
1.3.5. Prevention of NF-kB Activation 
NF-kB, a transcription factor is involved in the regulation of several cellular target genes.[134] 
It is expressed throughout in the CNS and is present in neurons and glial cells. It could be a 
positive regulator of genes whose products mediate acute-phase response, nitric oxide and a 
full array of inflammatory cytokines. It is well known that NSAIDs prevent the activation of 
nuclear factor-kB (NF-kB).  In vitro studies have revealed that various pathogenetic stimuli 
can activate this factor such as: A? peptides and different NSAIDs which can directly prevent 
this activation with subsequent reduction of the inflammatory responses. NF-kB expression is 
increased in AD brains and at least in vitro this factor can regulate A? formation in a neuronal 
cell line.[135] Recently, it was reported that activated NF-kB is increased in brains of Tg2576 
compared with wild type littermates and this enhancement was associated with the deposition 
of A?. Treatment of indomethacin in Tg2576 for seven days revealed that the activity of NF-
kB was significantly reduced along with a reduction of reactive astrocytosis.  
1.4 Role of Curcumin in AD 
Curcumin is a major component of the yellow spice turmeric.[136] This spice is used in 
traditional diet and as an herbal medicine in India. It is derived from the plant Curcuma longa 
Linn and its preparations have been used to treat various diseases for centuries in Ayurvedic 
medicines. Curcumin and its constituents are currently undergoing scientific evaluation for 
their efficacy as anti-inflammatory agents, in preventing and treating cancer[137, 138] for the 
treatment of human immunodeficiency virus (HIV) infection,[139] and for the treatment of 
cystic fibrosis.[140] It has been demonstrated that curcumin has anti-oxidant, anti-inflammatory 
and cholesterol lowering properties. These three properties are believed to play a crucial role 
in the processes involved in the pathogenesis of AD (Figure 1.11). The frequency of AD in 
India is roughly one-quarter of that in the US in patients between 70 and 79 years and one of 
the lowest prevalence rates of AD in the world since turmeric consumption is widespread 
India.  
Oxidative damage plays a significant role in the pathogenesis of AD. Increased levels of the 
oxidated forms of various organic molecules such as lipids, proteins, DNA and carbohydrates 
have been found in brain, cerebrospinal fluid (CSF), blood and/or urine of AD patients.[141, 142] 
Oxidative stress is the net effect of unregulated production of reactive oxygen species (ROS), 
such as hydrogen peroxide, nitric oxide, superoxide and the extremely reactive hydroxyl 
radicals. Epidemiological studies have indicated an association between dietary antioxidant 
consumption and a reduced risk for the development of AD.[143] A clinical trial suggested a 
probable benefit for the anti-oxidant alpha-tocopherol (vitamin E) in slowing the development 
of established AD.[144] Curcumin displays potent antioxidant activity. Reddy et al. [145] 
demonstrated that curcumin inhibits lipid peroxidation. Rao et al. [146] reproduced this in a 
different in-vitro model and found that curcumin 44, demethoxycurcumin 45 and 
bisdemethoxycurcumin 46 are more potent antioxidants than alpha-tocopherol (Scheme 1.8). 
Curcumin prevents oxidative damage of DNA in mouse fibroblasts.[147] Kim et al.  illustrated 
that the curcuminoids are more potent antioxidants than alpha tocopherol using a 2,2-
diphenyl-1-picrylhydrazyl (DPPH) radical trapping assay.[148]  
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Figure 1.11: Curcumin has multiple targets in AD.  
It reduces the A? load by inhibiting A?42 fibril formation and disaggregating preformed fibrils. 
Curcumin acts as an antioxidant: it reduces oxidative damage, synaptic loss and neuronal dysfunction. 
Curcumin curtails the damage by inhibiting NF-kB induced iNOS, COX-2 and inflammatory 
cytokinin production by reactive glia. Lastly, curcumin can lower plasma and tissue cholesterol, 
potentially lowering A? production. 
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Scheme 1.8: Chemical structures of curcumin, its isomers and curcumin derived radiolabels. 
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Inflammation is presumed to play a crucial role in AD pathogenesis.[149] Curcumin shows 
anti-inflammatory effects therefore may have a role in slowing or halting AD. Curcumin 
inhibits lipoxygenase and COX-2, enzymes which are responsible for the synthesis of the pro-
inflammatory leukotrienes, prostaglandins and thromboxanes.[150] It also inhibits AP-1 
mediated transcription linked to cytokine regulation in vitro,[151] and represses inducible nitric 
oxide synthase (iNOS) in activated macrophages.[152] These processes are responsible for 
promotion of inflammation. 
Epidemiological studies have indicated that high levels of cholesterol may contribute to the 
pathogenesis of AD. Persons with high levels of cholesterol have an increased susceptibility 
to AD apparently influenced by the APOE ?-4 genotype. Moreover, AD patients have 
increased levels of total serum and low density lipoprotein (LDL) cholesterol along with 
reduced levels of high density lipoprotein (HDL) in their plasma as compared to age match 
controls. Cholesterol unusually accumulates in the dense cores of A? plaques in the brain of 
AD patients. Epidemiological studies have revealed that use of 3-hydroxy-3- methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors  have been associated with a reduced risk of 
AD.[153] HMG-CoA is involved in the synthesis of cholesterol and cholesterol has an 
influence on A? deposition. It is believed that cholesterol interacts with the amyloid cascade 
in the pathogenesis of AD. Moreover, generation and clearance of A? is regulated by 
cholesterol. Soni et al. demonstrated that administration of 500 mg of curcuminoids a day for 
7 days reduced levels of serum cholesterol and lipid peroxides in healthy volunteers.[154] 
These observations indicate that there might be an additional mechanism by which curcumin 
might exert beneficial effects in AD. 
It is well documented that toxic effects of A? on normal cellular function and viability 
trigger the pathogenesis of AD. A?42 has been demonstrated to have adverse effects in a 
number of cell culture models. Kim et al. demonstrated that curcuminoids protects PC12 rat 
pheochromocytoma and human umbilical vein endothelial cells from A?42 injury and 
speculated that curcumin’s antioxidant properties might have mediated this effect.[148] 
Aggregation of A? into fibrils and the subsequent formation of A? plaques are speculated to 
be crucial steps in the pathogenesis of AD. Therefore, these processes are potential targets for 
AD therapy. Ono et al. carried out an in vitro study and measured the effects of curcumin on 
the formation of A? fibrils from A?40 and A?42.[155] They found that curcumin inhibits the 
formation and extension of A? fibrils and destabilizes preformed A? fibrils in a dose-
dependent manner at 0.1-1 ?M concentrations. Yang et al. demonstrated that curcumin 
directly binds small A? species to block aggregation and fibril formation, both  in vitro and in 
vivo.[156] Under aggregating conditions in vitro, curcumin inhibited aggregation (IC50 = 0.8 
?M) and disaggregated fibrillar A?40 (IC50 = 1 ?M), indicating favorable stoichiometry for 
inhibition. Curcumin was found to be a better A?40 aggregation inhibitor compared to 
ibuprofen and naproxen and prevented A?42 oligomer formation and toxicity at 0.1 and 1.0 
?M concentration. Therefore, curcumin has primary effects on A? aggregation apart from its 
antioxidant, anti-inflammatory and platelet aggregation inhibiting properties. It has been 
reported that curcumin has favorable brain permeability and satisfactory A? plaque binding 
properties. Those were predicted from the fluorescence staining of A? plaques in brain 
sections from APPsw transgenic mice administered with curcumin by injection or in diet[156]. 
Recently Ryu et al. demonstrated that the fluoropropyl-substituted curcumin 47 shows the 
highest binding affinity (Ki 0.07 nM) whereas curcumin exhibited binding affinity for A? (1-
40) aggregates (Ki 0.20 nM). The attachment of iodine to its phenyl ring 48 significantly 
decreased its binding affinity by 47-fold (Scheme 1.8). The radiolabelled fluoropropyl-
substituted curcumin was evaluated as a potential probe for A? plaque imaging. Partition 
coefficient measurement and biodistribution in normal mice demonstrated that 48 has a 
suitable lipophilicity and reasonable initial brain uptake. Metabolism studies also indicated 
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that [18F] curcumin is metabolically stable in the brain. These results suggested that 47 is a 
suitable radioligand for A? plaque imaging. 
Altogether, these properties collectively make curcumin a potential druglike candidate 
for AD. Widespread use of curcumin as a food additive and relatively small short-term studies 
in humans advocate its safety and tolerability. However, important information regarding 
curcumin bioavailability, safety and tolerability especially in an elderly population is still 
lacking. 
1.5. Photoaffinity Labelling 
In spite of being over forty years old, photoaffinity labelling is still a useful and reliable 
method for the structural investigation of receptor binding sites. It remains a classical research 
area for chemists who design and synthesize new photoactivable reagents. Biochemists and 
biologists then use these reagents to identify and characterize the target receptors. 
Investigation of receptor-ligand interactions remains a never-ending challenge for chemists 
and biologists. Structural exploration of biological receptors is the starting point for a better 
understanding of how they function and how they can be targeted. Photoaffinity labelling is 
widely used as a tool for labelling polypeptides with photoactive ligands. In many cases these 
ligands such as radiolabelled ligands or affinity ligands allow the characterization of 
functional proteins on sodium dodecyl-sulfate (SDS) gels (Figure 1.12). However, only a few 
of these experiments led to the identification of the amino acid residues labeled by the 
photosensitive probes. This ultimate step gives important structural information regarding the 
position of the binding site on the primary structure of a receptor and precise data on the 
ligand-receptor interaction. 
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Figure 1.12: Principle and successive steps for the identification of amino acids utilizing photoaffinity 
labelling technique. 
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1.5.1. Typical Compounds Used as Photoreative Groups 
Commonly used photoreactive groups in photoaffinity labelling are summarized in (Scheme 
1.9).[157] Aryl azide generates nitrene as a very reactive intermediate species. Diazirine and its 
linear isomer, diazo, generate carbenes as highly reactive intermediate. Since the discovery of 
photoaffinity labelling by Westheimer in 1962, many efforts have been devoted to develop 
various photoreactive groups. One must consider several undesirable features before using 
azides as photoreactive groups. Notably shorter wavelengths are usually required for azides to 
achieve effective photodecomposition without significant damage to the bioactive 
macromolecules. Although the chemistry of intermediate carbenes and nitrenes remains to be 
investigated,[158] nitrenes are generally treated to be less reactive than carbenes.[159] 
Furthermore, the short-lived singlet phenylnitrenes rapidly rearrange into more stable 
ketenimines in which the reactivity is limited to nucleophilic groups.[160] If suitable 
nucleophiles are not found within the proximity of the ligand-binding site, ketenimines may 
migrate from the binding pocket to label remote nucleophiles in a nonspecific manner. 
Perfluorophenylazides can eliminate this undesired side reaction by increasing the energy 
barrier required for the ketenimine formation.[161, 162] The fluorine substitution on the ortho 
position of an azide group sufficiently increases the lifetime of the highly reactive singlet 
nitrene to accomplish the desired intermolecular reactions. Cross-linking with nitrenes 
formally produces nitrogen-carbon bonds or more labile nitrogen heteroatom bonds, whereas 
carbenes produce the formation of more stable carbon-carbon bonds. The search for replacing 
the azide photophore led to the discovery of 3-aryl-3-trifluoromethyldiazirines by Brunner et 
al.[163] Amongst diazirine derivatives, trifluoromethylaryl-diazirines meet most of the criteria 
required for an ideal photoreactive group. In addition to their excellent chemical stability prior 
to photolysis, diazirines can be rapidly photolyzed at wavelengths beyond the UV absorbance 
region of proteins. 
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Scheme 1.9: Typical compounds used as precursor of reactive species in photoaffinity labelling. 
 
1.5.2 Benzophenones as Photoractive Groups 
Benzophenone (BP) photochemistry has attracted the attention of biochemists for more than 
three decades. The expanding use of BP photoprobes can be attributed to three distinct 
chemical and biological advantages. 
 
1. They are chemically more stable than diazo esters, aryl azides and diazirines. 
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2. They can be manipulated at an ambient light and can be activated at 350-360 nm and 
thus avoid protein damaging wavelengths. 
3. They preferentially react with unreactive C–H bonds, even in the presence of solvent 
water or bulk nucleophiles. 
 
These three properties combine to produce highly efficient covalent modification of the 
macromolecules. These advantages outweigh the disadvantage of additional bulkiness and 
hydrophobicity resulting from the introduction of BP group. 
1.5.2.1 Photochemistry of benzophenones 
Absorption of a proton at ~350 nm results in the promotion of one electron of nonbonding  
sp2-like n-orbital on oxygen to an antibonding ?* orbital of carbonyl group. In the 
diradicaloid triplet state 49, the electron-deficient oxygen n–orbital is electrophonic and thus 
interacts with weak C–H ? bonds resulting in hydrogen abstraction to complete its half-filled 
n-orbital.  
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Scheme 1.10: Photochemistry of benzophenone chromophore. 
 
When amines or similar heteroatoms are located near to the excited state carbonyl, an electron 
transfer step may be followed by proton abstraction from an adjacent alkyl group and a radical 
1,2-shift. The ketyl 50 and alkyl radicals 51 that are formed recombine readily to generate a 
new C–C bond thus produces benzpinacol type compounds such as 52 (Scheme 1.10). This 
basic process, which is also used for remote site functionalization, is based on the observation 
that the diradicaloid species can only attack geometrically accessible C-H bonds.  
There are various factors which controls the activity of BP photoprobe. 
1.5.1.2.1. Lifetime 
The lifetime of the excited state containing two unpaired electrons is much longer than the 
singlet state. Therefore, the triplet state may last up to 80-120 ?s in the absence of an 
abstractable H. But, it may be 100 times shorter in the presence of a suitably oriented C–H 
bond. Increasing concentrations of an H-donor decrease the lifetime proportionally according 
to the Stern-Volmer equation,  
 
1
? =
1
?? + k2 [RH]  
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where ?0 is t he excited-state lifetime in the absence of RH (H-donor), ? is the excited-state 
lifetime in the presence of RH (H-donor) and k2 is the second-order rate coefficient. The 
triplet state readily relaxes to the ground state if it does not find an H-donor with the required 
geometry. This relaxation process does not require a scavenger and this constitutes one of the 
major advantages of this photophore. BP probes relax electronically, maintain their binding 
and photoactivatable properties and then undergo many excitation- relaxation cycles until a 
favorable geometry for covalent modification is accomplished. The probability of achieving 
an optimal geometry for covalent attachment can be further improved by using a flexible 
linker, although more rigid linkers should give superior data in the topographic mapping of an 
active site.  
1.5.1.2.2. Flexibility and proximity 
Intramolecular BP photochemistry with long flexible chains grants multiple sites for 
attack.[164] Intermolecular reactions are very sluggish, are completely diffusion-controlled and 
lack the regio-selectivity. In the excited state, the BP ring system is required to be nearly 
planar, showing significant rigidity. This rigid system can be extended with rigid linkers to 
relocate the photophore and thus modify the efficiency and site of the resulting attachment. 
For biochemical experiments, linker size and orientation is critical, since the primary goal is 
to label the binding site for the ligand while minimizing nonspecific modifications. Typically, 
the BP photophore in biochemical probes are coupled with active ligands via linkers bearing 
either moderately flexible (1-3 CH2 units, O, NH) or moderately rigid (C=O, COO) 
functionalities. In short, BP photochemistry in biochemical systems is most regioselective 
when the flexibility is limited to what which is necessary to achieve efficient H-abstraction. 
1.5.1.2.3. Reactivity and effects of substituents  
Besides the geometric factors, the reactivity and the efficiency of covalent attachment 
strongly depend on the chemical and electronic environment of the photophore and the H-
donor moiety. The two major determining factors are: the strength of the bond being broken 
in the H-donor and the relative stabilities of the resulting alkyl radicals. The homolytic 
cleavage of C–H bonds, induced by the triplet biradical, is favored over the O–H bonds. In the 
case of N–H bonds, the electrophilic excited state abstracts an electron first and this event is 
followed by the H-abstraction from the adjacent C–H group. The most effective H-donors in 
the biological systems are the backbone C–H bonds in amino acids, polypeptides and 
carbohydrates. Methylene groups of lipids and amino acid side chains also offer abstractable 
hydrogens. In the absence of any orientational preference, the reactivity order for C–H bonds 
is: >NCH, > –SCH, > methine > C=CCH2 > –CH2 > –CH3. The electron rich tertiary centers 
such as C?–H of leucine and C?–H of valine and the CH2 groups adjacent to heteroatoms in 
lysine, argenine and methionene are principally the reactive sites. In photoaffinity probes, BP 
is either connected to an active ligand or is used to replace a portion of the ligand, partially 
mimicking its geometry. The substituents on BP can affect the photochemistry dramatically. 
Electron-withdrawing groups increase the efficiency of H-abstraction. Electron donating 
groups and electron delocalization into aromatic and conjugated systems cause a partial shift 
of the electron transition from n–?* to ?–?*, and the latter triplet state becomes much less 
reactive toward H-abstraction. Therefore, substituents can affect the steric accessibility, and 
the introduction of alkyl groups in the ortho or meta positions of the BP increases the 
possibility of intramolecular interactions which may reduce the efficacy of the probe. 
1.5.1.2.4. Recombination products  
Analysis of the site of covalent ligand attachment gives information regarding the exact 
location of the binding domain. Therefore a stable cross-linked complex is desired. The 
radical recombination product is suppressed only if a ring is the target, due to the additional 
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steric hindrance (Scheme 1.11). Thus, when proline was found as a main cross-linking site, a 
dehydroproline moiety 55 arose from a second H-transfer to the ketyl radical, resulting in 
elimination. Proton abstraction from secondary alcohols can lead to a second ketyl radical, 
which may form a ketone by the removal of second hydrogen. After recombination, the 
adduct is generally stable. However, if a glycine residue has been modified, the resulting 
benzhydrol can undergo elimination (dehydration), giving a highly conjugated species 53. In 
general, benzpinacol formation accompanies the heteroradical recombination as a radical 
dimerization, although in low yield. With laser flash photolysis, the cross-linking can occur 
on the 2- or 4-position of the phenyl ring, forming highly colored species, referred to as light-
absorbing transients 54. 
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Scheme 1.11: Various radical recombination pathways of the benzophenone chromophore. 
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2. AIMS OF THIS STUDY 
 
The final and the decisive step in the release of A? is carried out by ?-secretase. It is believed 
that the devastating neurodegenerative process observed in the AD is triggered by the 
pathological effects of A? peptides. A?42 is the most toxic species of all the A? peptides 
secreted and forms the central core of the plaques. The work presented in this thesis aimed to 
synthesize novel chemical entities that modulate ?-secretase to secrete less A?42 and to 
synthesize affinity or photoaffinity labels to characterize the active ?-secretase complex. 
 
The specific aims in each of the studies were: 
1. Synthesis of ?-secretase modulators using the scaffold of selective and nonselective 
COX inhibitors. 
2. Synthesis of ?-secretase modulators using the scaffold of COX-2 selective inhibitors. 
3. Synthesis of N-substituted carbazolyloxyacetic acids as potential ?-secretase 
modulators. 
4. Synthesis of ?-secretase modulators using the scaffold of LXR-agonists via the 
structural modification. 
5. Synthesis of affinity labels derived from the non-selective and selective COX 
inhibitors for the identification of the binding site via immunoprecipitation 
experiments. 
6. Design and synthesis of flurbiprofen derived photoaffinity labels to identify the 
binding site on the active ?-secretase enzyme complex via covalent bond formation. 
7. Design and synthesis of DAPT derived photoaffinity labels to identify the binding site 
and mode of action via covalent bond formation with the active site. 
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3. RESULTS AND DISCUSSION 
 
3.1. Synthesis and Biological Evaluation of NSAIDs Derived ?-Secretase 
Inhibitors and Modulators. 
 
“The most fruitful basis for the discovery of a new drug is to start with an old drug.” 
Sir James Black 
 
The term A? comprises the peptides of 38-42 amino acids which are generated by the 
sequential cleavage of the APP by the secretases. A?42 is more prone to aggregate into fibrils 
and are critical for formation of plaques. Epidemiological studies have indicated a reduced 
prevalence of AD among patients using prolonged treatment of NSAIDs. These protective 
effects of NSAIDs appear  directly proportional to the length of treatment and depend on the 
specific chemical structure of the NSAIDs being used.[105] In spite of these encouraging 
results, negative results have been reported in all large, long-term, placebo controlled clinical 
trials which were aimed at reducing inflammation in the brain of AD patients since 
inflammation has a fundamental role in AD. More recently, it has been reported that some 
NSAIDs decrease the production of A?42 in vitro and in vivo,[111, 112, 114] and impede the 
progression of A?42 pathology in transgenic mouse models of AD.[165] The proposed 
mechanism for this activity is an allosteric modulation of PS1 which is the major component 
of the ?-secretase complex.[166] They seem to interfere with substrate recognition/cleavage and 
shift the precision of ?-secretase cleavage from the ?42 to the ?38 site to generate more of 
A?38 and less of A?42.[167, 168] Compounds with reverse shift were reported recently, they 
result in enhanced A?42 production.[113] The inhibition of A?42 is completely independent of 
their anti-cyclooxygenase activity,[125] and is related to the chemical structure of the NSAIDs 
but not to the class. Therefore some NSAIDs display modulatory activity (for e.g. ibuprofen, 
sulindac sulfide, flurbiprofen, indomethacin, diclofenac) where as others do not (naproxen, 
aspirin, celecoxib). Probably this might be the explanation for the negative outcomes of the 
large AD trials being carried out so far, since they were performed with compounds ( for e.g. 
naproxen, hydroxychloroquine, dapsone, prednisone, rofecoxib and celecoxib) which are not 
able to decrease A?42 production.[169] Unfortunately, the generic use of NSAIDs in AD is 
hampered by a significant gastrointestinal toxicity associated with COX inhibition. This 
prompted the identification of new NSAIDs analogues which are capable with potent and 
selective A?42 lowering activity but devoid of COX inhibitory activity which may be suitable 
for chronic use in AD patients.  
3.1.1. Flurbiprofen Derivatives as Potential ?-Secretase Modulators 
3.1.1.1. Synthesis of flurbiprofen derived amides 
Specifically, the initial efforts were concentrated on flurbiprofen since it is one of the most 
active and studied NSAID so far.[112] The R-enantiomer of flurbiprofen is much less active 
than the S-enantiomer on both COX-1 (IC50 ?M of 44 versus 0.03 ?M) and COX-2 (IC50 of 
123 ?M versus 0.91 ?M) activity.[121] The R-enantiomer (MPC-7869) is reported to be in 
Phase-III clinical trial for AD in the USA. The IC50 of R-flurbiprofen on A?42 (280 ?M) is 
still higher than that on both COX-1 (44 ?M) and COX-2 (123 ?M). Flurbiprofen 32 (10 and 
25 mg/kg/d) elicits non-selective reductions in both A?40 and A?42 plasma levels, but was 
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found to be toxic. It produced small reductions in A?40 in the cortex at 25 mg/kg/d, but did not 
affect A? levels in the hippocampus or CSF. 
Flurbiprofen derivatives were synthesized via structural modification of acid moiety in order 
to increase A?42 lowering properties and to reduce or lower COX inhibitory activity. Initially 
flurbiprofen derived amides were synthesized to investigate the impact of amides on the ?- 
and ?-secretase inhibitory activity as depicted in Scheme 3.1. The acid moiety of flurbiprofen 
32 was coupled with various amines using EDAC and HOBt as coupling reagents in CH2Cl2 
to afford the corresponding amides 56 (Table 3.1). All the compounds were purified by 
column chromatography. Only a few of them were characterized by NMR spectroscopy and 
rest of them were analysed by HPLC. 
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Scheme 3.1: Synthesis of flurbiprofen amides. 
 
The diastereomeric mixture was observed when serine t-butyl ester and tyrosine t-butyl ester 
were employed for coupling with racemic flurbiprofen. The diastereomers were separated by 
column chromatography using ethyl acetate:hexane (2:8) as eluents. (Scheme 3.2). The less 
polar and polar compounds in case of  S-serine t-butyl ester were 56m and 56n and in case of 
S-tyrosinol t-butyl ester were 56o and 56p respectively. The compounds were submitted for 
the biological experiments without further assignments of absolute stereochemistry. 
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Scheme 3.2: Flurbiprofen derived amides. 
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Table 3.1: Synthesis of flurbiprofen derived amides. 
Entry Compound Compound 
Code
R Yield % 
 
1 
 
56a 
 
BSc2171 
 
O
O
 
73 
 
2 
 
56b 
 
BSc2172 
 
O
 
77 
 
3 
 
56c 
 
BSc2222 
 
Ph
 
61 
 
4 
 
56d 
 
BSc2223 
 
N
 
55 
 
5 
 
56e 
 
BSc2224 
OMe
O
NH
 
67 
 
6 
 
56f 
 
BSc2226 
OMe
O
OtBu
O  
64 
 
7 
 
56g 
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N  
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56h 
 
 
 
BSc2229            
OMe
O
 
 
 
86 
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56i 
 
 
BSc2230 
 
OH
 
41 
 
10 
 
56j 
 
BSc2231 
 
Ph
 
68 
 
 
11 
 
 
56k 
 
 
 
BSc2232 OMe
O
 
55 
 
 
12 
 
 
56l 
 
 
BSc2233 
 
N
 
58 
 
Compounds 56a (BSc2171) and 56b (BSc2172) were tested for their ability to inhibit or 
modulate ?-secretase in the A? liquid phase electrochemiluminescence (LPECL) assay. 
Sulindac sulfide was used as the control. Surprisingly, compounds 56a and 56b turned out to 
be inverse modulators of ?-secretase. They affected the ?-secretase cleavage at different 
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extent. They particularly increased the formation of the most toxic and aggregation prone 
A?42 species while reducing the formation of A?38. The conversion of the acid moiety in to 
amides changed the mode from modulation to inverse modulation compared to parent 
compound.   
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Figure 3.1: Activity report of compounds 56a–b on ?-secretase. 
 
Compounds 56c–p (BSc2222–BSc2233 and BSc2303–BSc2306) were tested for their 
potential to inhibit the aspartic protease BACE-1 to rule out upstream cleavage inhibition in 
the fluorescence resonance energy transfer (FRET) based assay with full length BACE-1,[170]  
and results are shown in Table 3.2. This assay was carried out at Hoffmann-La Roche, 
Switzerland. FRET is a convenient method in which the fluorescence signal enhancement is 
observed after the substrate is cleaved by BACE-1, thus separating the quenching moiety 
(Dabsyl) from the fluorochrome (Lucifer yellow). All enzyme assays were carried out at 20 
°C on a FLUOstar (BMG Lab Technologies, D-77656 Offenburg) using 96-well microtiter 
plates (DYNEX Microfluor 2, Chantilly, VA). The volume of assay was 100 ?L. Usually, 
inhibitors dissolved in DMSO were added into a well followed by the buffer and the enzyme. 
The concentration of DMSO was kept below 4%. The enzymatic reaction was started by 
adding the substrate. The fluorescence enhancement was measured at ?emission = 520 nm with 
fluorescence excitation at ?excitation = 430 nm. At various inhibitor concentrations reaction 
kinetics was followed for 30 min. Assays were performed at enzyme concentrations that 
warranted a linear progression of product formation. A known peptidic inhibitor of the 
hydroxyl ethylamine class was always included in the experiment as a positive control for 
inhibition. The results are given as IC50 (?M). This assay was found to be very good with 
known BACE-1 inhibitors, however, only if the compound is water soluble at the assay pH of 
4.5. Depending on charge and poor solubility of the compound, this assay may show apparent 
inhibition that is not specific. To investigate the specificity and selectivity of the synthesized 
flurbiprofen amides, they were profiled in FRET based assay for BACE-1 and more distant 
aspartic proteases, cathepsin D (CatD). The activity report is displayed in Table 3.2. 
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None of the compound displayed inhibitory activity in the BACE-1 FRET-assay. 
Furthermore, the same set of compound was tested in the radioligand binding assay (RLBA) 
for the ability to inhibit BACE-1. Out of the tested compounds, only 56e, 56o and 56p 
displayed good inhibitory activity (Table 3.2), where as 56d, 56m and 56n displayed 
moderate inhibitory activity. Rest of the compounds displayed either marginal inhibitory 
activity or were found to be inactive. Introduction of amines bearing bulky lipophilic groups 
with polar end groups such as –NH and –OH, increased BACE-1 inhibitory activity (e.g. 56e, 
56m).  
 
Table 3.2: Activity data of flurbiprofen amides on BACE-1. 
Entry Compound Compound 
Code 
FRET 
(BACE-1) 
RLBA     
(Tween) 
RLBA 
(BSA) 
FRET 
(CatD)
 IC50 ?M IC50 ?M IC50 ?M IC50 ?M 
1 56c BSc2222 >200 Inactive Inactive >200 
2 56d BSc2223 Inactive 195 Inactive >200 
3 56e BSc2224 >200 46 Inactive 34 
4 56f BSc2226 >200 Inactive >200 >200 
5 56g BSc2228 >200 >200 Inactive Inactive 
6 56h BSc2229 >200 >200 Inactive >200 
7 56i BSc2230 Inactive 201 Inactive >200 
8 56j BSc2231 >200 >200 Inactive >200 
9 56k BSc2232 >200 >200 Inactive >200 
10 56l BSc2233 >200 >200 Inactive Inactive 
11 56m BSc2303 Inactive 126 Inactive 129 
12 56n BSc2304 Inactive 120 Inactive >200 
13 56o BSc2305 >200 35 Inactive 9 
14 56p BSc2306 >200 32 Inactive 11 
 
Moreover, none of the compound displayed inhibitory activity in the RLBA in the presence of 
bovine serum albumin (BSA). To investigate the specificity and selectivity, compounds 56c–p 
were tested in the CatD FRET-assay. Most of the compounds displayed no activity or 
marginal inhibitory activity in the CatD FRET-assay except the compounds 56e, 56m, 56o 
and 56p. The most active compounds were particularly 56o and 56p and they displayed the 
CatD inhibition in the FRET assay at low micromolar concentration.  
The Structure Activity Relationship (SAR) revealed that the most active compound in the 
RLBA (tween) assay were the compounds 56e, 56o and 56p bearing the polar, hydrogen bond 
donor moiety. But at the same time these compounds lacked selectivity and were found to be 
equipotent in the CatD FRET-assay. These multipotent aspartic protease inhibitors were 
abandoned because of the selectivity issue which is very crucial for the drug design. A 
potential ?-secretase inhibitor has to be very selective since aspartic proteases are widely 
distributed in the body and the treatment of AD will be a long term therapy. Therefore, 
BACE-1 selectivity is important as the target enzyme resides in the brain, where the closely 
related ubiquitous enzymes such as CatD are found. BACE-1 inhibitors with poor selectivity 
against these enzymes may cause undesired side effects.    
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3.1.1.2. Synthesis of flurbiprofen derived esters 
Initially, benzyl ester of flurbiprofen 57k (BSc2171) was synthesized in order to investigate 
the impact of an ester moiety on BACE-1 and ?-secretase inhibitory activity. In the A? liquid 
phase electrochemiluminescence (LPECL) assay, 57k was found to be an inverse modulator 
of ?-secretase (Figure 3.1). It reduced the formation of A?38 and increased the formation of 
A?42. The flurbiprofen benzyl ester 57k was tested for its potential to inhibit BACE-1 in the 
fluorometric BACE activity assay,[171] MDCK cells were used for the assay. Flurbiprofen 
benzyl ester 57k displayed good BACE-1 inhibitory activity (IC50 = 20 ?M). That prompted 
the synthesis of a series of flurbiprofen derived esters as depicted in Scheme 3.3. The acid 
moiety of flurbiprofen was coupled with various alcohols using EDAC and HOBt as coupling 
reagents in CH2Cl2 at an ambient temperature (Table 3.3). The purity of all the compounds 
was analysed by HPLC and were submitted to the assays for their biological evaluation 
without further characterization. 
 
F
O
OH EDAC, HOBt, 
Et3N, ROH
CH2Cl2, RT, 6-48 h, 
30-76% F
O
O
R
32, Flurbiprofen
57
 
Scheme 3.3: Synthesis of flurbiprofen derived esters. 
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Table 3.3: Synthesis of flurbiprofen derived esters. 
Entry Compound Compound Code R Yield % 
 
1 
 
57a 
 
BSc2292 
H2
C
O
 
35 
 
2 
 
57b 
 
BSc2293 CH
 
43 
 
3 
 
57c 
 
BSc2294 
 
H2
C
 
48 
 
4 
 
57d 
 
BSc2295 
 
O
 
55 
 
5 
 
57e 
 
BSc2297 
 
N
 
65 
 
6 
 
57f 
 
BSc2298 
  
57 
 
7 
 
57g 
 
BSc2300 
 
O
 
40 
 
8 
 
57h 
 
BSc2301 
 
O
O OH
 
34 
 
9 
 
57i 
 
BSc2302 
 
O
O
 
40 
 
10 
 
57j 
 
BSc2171 
 
 
70 
 
 
 
A set of compounds 57a–k (BSc2292–BSc2302) was tested for their potential to inhibit 
BACE-1 in the FRET assay (Table 3.4). The assays were performed at Hoffman La-Roche, 
Basel. Surprisingly, none of the flurbiprofen derived ester displayed significant activity in the 
FRET assay. The compounds were further analysed for their ability to inhibit BACE-1 in the 
RLBA (Tween) assay. Only three compounds, 57a (BSc2292), 57e (BSc2297) and 57i 
(BSc2302) displayed marginal activity in the RLBA (Tween) assay. Most of the compounds 
were found to be inactive in the RLBA (BSA) assay whereas, compounds 57c (BSc2294) and 
57e (BSc2297) displayed very weak inhibitory activity. CatD was used from human liver as 
obtained commercially (Calbiochem). CatD is a lysosomal aspartyl protease, which is 
homologous to BACE-1. The CatD assay provides an assessment of relative specificity of 
inhibitors for BACE-1. None of the flurbiprofen esters exhibited significant inhibitory activity 
in the CatD assay 
.  
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Table 3.4: Activity report of flurbiprofen esters. 
Entry Compound Compound 
Code 
FRET 
(BACE) 
RLBA     
(Tween) 
RLBA 
(BSA) 
FRET 
(CatD)
IC50  ?M IC50 ?M IC50 ?M IC50 ?M 
 
1 
 
57a 
 
BSc2292 
 
>200 
 
179 
 
Inactive 
 
Inactive 
2 57b BSc2293 >200 >200 Inactive Inactive 
3 57c BSc2294 >200 >200 200 Inactive 
4 57d BSc2295 >200 >200 Inactive Inactive 
5 57e BSc2297 >200 95 >200 Inactive 
6 57f BSc2298 >200 >200 Inactive Inactive 
7 57g BSc2300 >200 >200 Inactive Inactive 
8 57h BSc2301 >200 >200 Inactive Inactive 
9 57i BSc2302 >200 171 Inactive >200 
 
3.1.2. Synthesis of Sulindac Sulfoxide Derived Amides as ?-Secretase Modulators. 
Sulindac is a non-steroidal anti-inflammatory drug of the arylalkanoic acid class and useful in 
the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived 
from sulfinylindene that is converted in the body to an active NSAID. More specifically, the 
agent is converted by liver enzymes to a sulfide which is excreted in the bile and then 
reabsorbed from the intestine. The exact mechanism of its NSAID properties is unknown, but 
it is thought to act on enzymes COX-1 and COX-2, inhibiting prostaglandin synthesis. Unlike 
its active metabolite, sulindac sulfide, sulindac sulfoxide 58 does not inhibit COX-1 and 
COX-2. Sulindac sulfide 33 is a ?-secretase modulator and reduces A?42, the most toxic and 
fibrillogenic peptide at 40 ?M concentration. It was anticipated that transformation of the acid 
moiety of sulindac sulfoxide into its amide derivatives would turn it into ?-secretase 
modulator devoid of COX inhibitory activity. Therefore, a series of sulindac sulfoxide derived 
amides was synthesized as depicted in Scheme 3.4. 
 
EDAC, HOBt, 
Et3N, RNH2
CH2Cl2, RT, 6-28 h, 
41-86%
F
S
O
O
OH
F
S
O
O
HN R
58 59
 
 
Scheme 3.4: Synthesis of sulindac derived amides. 
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Table 3.5: Synthesis of sulindac derived amides. 
Entry Compound Compound Code R Yield % 
 
1 
 
59a 
 
BSc2234 
 
Ph
 
61 
 
2 
 
59b 
 
BSc2235 
 
N
 
55 
 
3 
 
59c 
 
BSc2236 
OMe
O
NH
 
67 
 
4 
 
59d 
 
BSc2237 OtBu
O
OH  
64 
 
5 
 
59e 
 
BSc2238 
OMe
O
OtBu
O  
72 
 
6 
 
59f 
 
BSc2239 
OtBu
O
OH  
86 
 
7 
 
59g 
 
BSc2240 N
N  
41 
 
8 
 
59h 
 
BSc2241 
OMe
O
 
68 
 
9 
 
59i 
 
BSc2242 OH
 
55 
 
10 
 
59j 
 
BSc2243 
 
Ph
 
58 
 
11 
 
59k 
 
BSc2244 
OMe
O
 
75 
 
12 
 
59l 
 
BSc2245 N
 
53 
 
The acid moiety of sulindac sulfoxide 58 was coupled with various amines using EDAC and 
HOBt as coupling reagents in CH2Cl2 at RT to afford amides 59 (Table 3.5). The reactions 
were monitored by TLC and the crude products were purified by column chromatography. 
The purity of all compounds was analyzed by HPLC and the compounds were submitted for 
their biological evaluation without further characterization.  
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A set of compounds 59a–l (BSc2234–BSc2245) was tested in the A? liquid phase 
electrochemiluminescence assay for their potential to modulate ?-secretase activity.  
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Figure 3.2: Activity data of compounds 59a–l (BSc2234–BSc2245) on ?-secretase. 
 
Sulindac sulfide, an active metabolite of sulindac sulfoxide which is a known modulator of ?-
secretase, was used as a standard along with S-DAPT. All the compounds were tested at 40 
?M concentration except S-DAPT, which was used at 20 ?M concentration. The displayed 
A? levels are the mean of four experiments (Figure 3.2). As anticipated, most of the tested 
compounds displayed ?-secretase modulatory activity. Interestingly, it was found to be an 
inverse modulatory activity except 59c and 59i. The remaining compounds affected the 
cleavage at the ?38, ?40 and ?42 sites to a different extent and particularly increased the 
formation of A?42, while reducing the formation of A?38. The most active compounds that 
displayed modulatory activity were particularly, 59d (BSc2237), 59k (BSc2344) and 59l 
(BSc2345). They significantly increased the formation of A?42 while reducing the formation 
of A?38 and displayed an inverse mode of action compared to typical NSAIDs. Surprisingly, 
two of the tested compounds, 59c (BSc2236) and 59e (BSc2238), turned out to be full 
inhibitors of ?-secretase.  
Conversion of the acid moiety of sulindac sulfoxide into its corresponding amides turned it 
into potent, but inverse modulators of ?-secretase. Introduction of amines with lipophilic 
substituents significantly increased the inverse modulatory activity (e.g. 59d, 59k–l).On the 
other hand, the introduction of chiral and bulky amines such as S-tryptophan methyl ester and 
S-aspartic acid t-butyl ester transformed the sulindac sulfoxide into potent inhibitors of ?-
secretase. Introduction of amines with additional polar groups turned it into mild inhibitors of 
?-secretase (e.g. 59g, 59i). But, none of these compounds displayed the desired straight 
modulatory activity. 
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3.1.3. Synthesis of Meclofenamic Acid Derivatives as ?-Secretase Inhibitors. 
Meclofenamic acid is a non-selective COX inhibitor. It belongs to the anthranlic class of 
NSAIDs. It was anticipated that the conversion of the acid moiety of meclofenamic into its 
amides using various bulky or chiral amines, would turn the nonselective-COX inhibitors 
meclofenmaic acid into potent ?-secretase inhibitors devoid of COX activity.  
Meclofenamic acid derived amide derivatives were synthesized as depicted in Scheme 3.5. 
Sulindac sulfoxide derived amides, 59c and 59e, bearing chiral and bulky amines were found 
to be potent inhibitors of ?-secretase. Therefore, bulky and chiral amines were employed to 
couple with meclofenamic acid. The acid moiety of meclofenamic acid 37 was converted to 
the corresponding amides using various amines and EDAC and HOBt as coupling reagents in 
CH2Cl2 at ambient temperature. The reaction was monitored by TLC.  
 
Cl
N
H
ONaO
EDAC, HOBt, 
RNH2, Et3N
CH2Cl2, RT, 3-18 h, 
70-90%
Cl
N
H
N
H
O
N
H
O
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O
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O
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H
N
H
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37
(BSc2399)
Cl Cl R
60
 60a (BSc2395) (75%)  R =  60b (BSc2396) (78%)  R =
 60c (BSc2397) (72%)  R =  60d (BSc2398) (60%)  R =
 
Scheme 3.5: Synthesis of meclofenamic acid derived amide derivatives 60. 
 
Compounds 60a–d were tested for their potential to inhibit ?-secretase inhibitors in the A? 
liquid phase electrochemiluminescence assay. All compounds were tested at 20 ?M 
concentration and meclofenamic acid and sulindac sulfide were used as standards (Figure 
3.3). Meclofenamic acid is known to be a modulator of ?-secretase. But, in the A? liquid 
phase electrochemiluminescence assay it was found to be an inhibitor of ?-secretase (Figure 
3.3). In contrast to the previous results, conversion of meclofenamic acid into their 
corresponding amides turned them into ?-secretase modulators except compound 60d. 
Compound 60a–c affected the cleavage at the ?38, ?40 and ?42 sites to a different extent and 
particularly enhanced the formation of A?42, while suppressing the formation of A?38. The 
most active ?-secretase modulator was compound 60b and it increased the formation of A?42 
significantly. In accordance with previous results, only compound 60d was found to be a 
potent inhibitor of ?-secretase. 
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Figure 3.3: ?-Secretase activity data for compounds (60a–d). 
 
In conclusion, the conversion of the acid moiety common to the COX inhibitors to the 
corresponding amides and esters turned them into either ?-secretase inverse modulators or full 
inhibitors. Derivatization of the acid moiety of flurbiprofen to amides dramatically changed 
the mode of action on ?-secretase from classical modulation to inverse modulation. 
Flurbiprofen derived esters 57 and amides 56 were tested for their ability to inhibit BACE-1 
but none of the tested compound displayed inhibitory activity on BACE-1 in FRET assay and 
very few compounds displayed inhibitory activity in the RLBA( Tween) assay (56o, 56p). 
But these two multipotent compounds lacked the selectivity and displayed the inhibitory 
activity on other aspartic proteases such as CatD at low micromolar concentration. A similar 
SAR trend was observed with the amide derivatives of sulindac sulfoxide 59 in the A? liquid 
phase electrochemiluminescence assay. Transformation of sulindac sulfoxide into its amide 
turned it into an inverse modulator of ?-secretrase. But, only compounds 59c and 59e were 
found to be potent inhibitors of ?-secretase. Based on the SAR of compounds 59a–l, 
meclofenamic acid derived amides 60a–d were synthesized. In contrast to the previous 
results, the conversion of meclofenamic acid into its amide resulted in potent inverse 
modulators of ?-secretase. Only compound 60d was found to be an inhibitor of ?-secretase in 
accordance with the previous results. It is apparent from the SAR that free acid is crucial for 
the modulatory activity and to preserve the typical NSAID like profile. Any derivatization of 
the acid moiety either resulted in the loss of modulatory activity or inversion of the 
modulatory activity. Inhibition was observed as the third mode of action. 
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3.2. The Scaffold of the COX-2 Inhibitor Carprofen Provides Alzheimer ?-
Secretase Modulators 
Promising results for the treatment of AD were obtained with some COX-1 inhibitors,[117, 167, 
172-174] both in vitro and in a prospective, population-based cohort study of 6989 patients.[175] 
This is not a class effect as the NSAIDs: diclofenac and naproxen do not lower A? in 
vitro,[167, 173] and neither naproxen nor rofecoxib (a COX-2 inhibitor) slow cognitive decline 
in patients with mild-to-moderate AD.[176, 177] The positive clinical results are still in need of a 
sound rational and an experimental validation.[178] The proof of concept is still missing. 
NSAIDs, that modulate ?-secretase cleavage of APP, affect the distance between APP and 
PS1, the catalytic subunit of ?-secretase.[168] Just a few NSAIDs were reported to modulate ?-
secretase and an even smaller number of NSAIDs display confirmed modulation at 
physiological feasible concentrations. Despite these vague, sometimes contradictory results 
reported for NSAID activity. That encouraged the investigation of NSAIDs as scaffolds for ?-
secretase inhibitors. The derivatization of the carboxylic acid common to the COX inhibitors 
was commenced initially. Although some of the esters and amides displayed moderate 
inhibition of the cleavage by ?-secretase (A?38, A?40, A?42) this approach was soon 
abandoned. Few of these initial derivatives displayed increased, unselective inhibition of ?-
secretase in comparison to their parent drugs. Most of the carboxylic acid derivatives such as 
esters and amides resulted in loss of activity. This indicated an important contribution of the 
carboxylic acid to target affinity. After a brief investigation of flurbiprofen, sulindac sulfoxide 
and meclofenamic acid analogues, the efforts were focussed on carprofen 53, which is a 
COX-2 inhibitor approved for the use in dogs, cows and horses as Imadyl? or Rimadyl?. The 
selectivity of carprofen versus COX-2canine and COX-1canine is greater than 100:1 (COX-2canine 
IC50: R/S-carprofen 102 nM, R-carprofen 5.97 ?M, S-carprofen 37 nM).[179] Original 
carprofen (as isolated from Rimadyl? tablets 500 mg) was found to be a weak inhibitor of ?-
secretase and reduced A????? A?????and A????at high concentration. This corresponds to the 
activity of ?-methylated carprofen, which was reported to inhibit A?42 production by 40% at 
100 ?M.[122] The readily accessible sulfonamides were inspired by the ?-secretase inhibitor 
BMS-299897 and supported by a recent series from Merck Sharp & Dohme.[88, 89] 
3.2.1. Synthesis of N-sulfonylated carprofen derivatives 
Initially N-sulfonylated derivatives of carprofen were synthesized as depicted in Scheme 3.6. 
The acid moiety of carprofen was protected as a benzyl ester 61. N-Sulfonylation of 61 was 
carried out using NaH, p-toluene sulfonyl chloride and 3,5-bis(trifluoromethyl) phenyl 
sulfonyl chloride in THF to afford esters 62. Subsequent benzyl deprotection of 62 by 
hydrogenation furnished the desired acids 63. N-tosylated carprofen 63a was further coupled 
with various heterocyclic amines in CH2Cl2 at RT using EDAC and HOBt as coupling 
reagents to afford amides 64. The crude compounds were purified by column chromatography 
to afford the amides.  
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N
N
H
N
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Scheme 3.6: Synthesis of N-sulfonylated carprofen amides. 
 
The compounds 62a–b, 63a–b and 64a–c were tested in the A? liquid phase 
electrochemiluminescence assay for their ability to inhibit ?-secretase enzyme activity. The ?-
secretase cellular assay was carried out under the supervision of Dr. Karlheinz Baumann at F. 
Hoffmann La Roche, Basel. Sulindac sulfide was used as standard and all the compounds 
were tested at 20 ?M concentration. These compounds were expected to be inhibitors of ?-
secretase activity due to their resemblance to the ?-secretase inhibitor 29 (BMS-299897). 
Serendipitously, N-sulfonylated carprofen derivatives, 63a and 63b, turned out to be 
modulators of ?-secretase activity, which control the cleavage pattern of???-secretase. They 
affected the cleavage at the ?38, ?40 and ?42 sites to a different extent and particularly 
suppressed the formation of A?42, while enhancing the formation of A?38 and thus showed the 
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typical profile of effective NSAIDs (Figure 3.4). Such modulators may preserve the cleavage 
of substrates like Notch[42, 180] Notch and a subset of cell-surface receptors and proteins 
involved in embryonic development, haematopoiesis, cell adhesion and cell/cell contacts.[181] 
In accordance with previous results, N-sulfonylated carprofen benzyl esters 62 and amides 
derivatives 64 turned out to be inverse modulators of ?-secretase and increased the formation 
of A?42 (Figure 3.4).  
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Figure 3.4: Activity data of N-substituted carprofen derivatives 62, 63 and 64. 
 
Thus, the initial objective was adapted from inhibition to modulation. The encouraging results 
obtained from lead compounds 63a (BSc2406) and 63b (BSc2411) prompted the synthesis of 
a series of N-sulfonylated carprofen derivatives. 
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O
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10% Pd-C, MeOH:EtOAc 
(1:1), H2, 3-18 h, 70-94%
NaOH, THF:MeOH:H2O 
(1:1:1), RT, 3-12 h,
 80-92%  
Scheme 3.7: Synthesis of N-sulfonylated carprofen derivatives 63. 
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A series of N-sulfonylated carprofen derivatives was synthesized using the same methodology 
as depicted in Scheme 3.6. The benzyl group of 62 was removed by either by hydrogenation 
(62a–62m, 62p–62r) or base hydrolysis in case of 62n–62o, 62s due to the presence of the 
hydrogenation sensitive functionalities (Scheme 3.7) to give the acid 63. 
Table 3.6:  Activity of carprofen N-sulfonamide derivatives. 
[a] EC50 values are displayed for A?38 except compound 41. The EC50 is based on the maximum level with a 
slope approximating 0. 
[b] Maximum effect on A?38 not observed at 40 ?M (except for 41: 160 ?M, 63a: 200 ?M, 63b:200 ?M) 
 
3.2.1. Synthesis of N-alkylated carprofen derivatives 
N-Alkylated carprofen derivatives were prepared to evaluate the contribution of the 
sulfonamide moiety in 63r and the most active derivate 63p, where the sulfonamide is 
shielded by isopropyl substituents. The carprofen benzyl ester 61 was alkylated using NaH 
and RX in THF to yield the ester 65 (Scheme 3.8). Subsequent benzyl deprotection by 
hydrogenation gave the desired N-alkylated carprofen 66. The benzyl deprotection of 65c was 
carried out by base hydrolysis due to the presence of hydrogenation sensitive moiety. 
 
Entry Comp. 
Code 
Comp. R IC50 [?M] 
 A?38a A?40 A?42 
1 Carprofen 41 H 78 133 76 
2 BSc2406 63a 4-Methylphenyl 43 > 100 56 
3 BSc2411 63b 3,5-Bis(trifluoromethyl)phenyl  NDb > 30 11 
4 BSc2826 63c 4,5-Dibromothiophen-2-yl NDb ND > 40 
5 BSc2827 63d 3,5-Difluorophenyl NDb ND > 40 
6 BSc2829 63e 4-Biphenyl  NDb ND 37 
7 BSc2830 63f 2-Fluorophenyl NDb ND > 40 
8 BSc2831 63g 3-Fluorophenyl NDb ND > 40 
9 BSc2832 63h 4-Fluorophenyl NDb ND > 40 
10 BSc2833 63i 2-Bromophenyl NDb ND 40 
11 BSc2835 63j 4-Bromophenyl NDb ND > 40 
12 BSc2836 63k Phenyl NDb ND > 40 
13 BSc2837 63l 4-Chlorophenyl NDb ND > 40 
14 BSc2838 63m 3-Chlorophenyl NDb ND > 40 
15 BSc2840 63n 3-Nitrophenyl NDb ND 39 
16 BSc2841 63o 4-Nitrophenyl NDb ND > 40 
17 BSc2842 63p 2,4,6-Tri-iso-propylphenyl 0.3 > 20 8.5 
18 BSc3036 63q 4-n-Propylphenyl NDb > 40 > 40 
19 BSc3037 63r Octyl NDb > 40 25 
20 BSc3044 63s 4-Cyanophenyl NDb ND > 40 
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Scheme 3.8: Synthesis of N-alkylated carprofen derivatives 66. 
 
 
Table 3.7:  Activity of N-alkylated carprofen derivatives. 
 [a] Maximum effect on A?38 not observed at 40 ?M. 
 
The compounds 63a–63s and 66a–66f turned out to be effective modulators of ?-secretase. 
They affected the cleavage at the ?38, ?40 and ?42 sites to a different extent and particularly 
suppressed the formation of A?42, while enhancing the formation of A?38 and thus showed the 
typical profile of effective NSAIDs (see Tables 3.6 and 3.7).  
 
Detailed results and discussion of these experiments are described in the article attached at the 
end as Appendix I. i.e. 
“Rajeshwar Narlawar, Blanca Perez Revauelta, Christian  Haass, Harald Steiner, Boris 
Schmidt, Karlheinz Baumann, The Scaffold of the COX-2 Inhibitor Carprofen Provides 
Alzheimer ?-Secretase Modulators, Journal of Medicinal Chemistry, 2006, 49 (26), 7588-
7591.” 
 
 
 
Entry 
 
Comp. 
 
R 
 
Code 
Activity in ?M 
EC50 
A?38 
IC50 
A?40 
IC50 
A?42 
 
1 66a 
 
3-(Trifluoromethoxy)benzyl 
 
BSc2901 
 
NDa 
 
> 40 
 
7.5 
2 66b 3-Methoxybenzyl BSc2902 NDa > 40 39 
3 66c 3-Nitrobenzyl BSc2903 NDa > 40 22 
4 66d Octyl BSc3039 NDa > 40 6.9 
5 66e Nonyl BSc3040 8.1 > 40 3.0 
6 66f Decyl BSc3041 5.8 > 40 2.9 
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3.3. N-Substituted Carbazolyloxyacetic Acids Modulate Alzheimer 
Associated ?–Secretase 
Knowing about the relevance of the carboxylic acid and N-substitution of carprofen, the 
scaffolds not included in the patent applications and publications by E. Koo et al. or Stock, or 
Imbibo, and others were investigated.[182] Carprofen’s similarity to the ?-secretase inhibitor 29 
(BMS-299897) prompted the investigation of N-sulfonylated and N-alkylated 2-hydroxy 
carbazolyloxyacetic acids. The corresponding sulfonamides 70a–k were readily accessible by 
straightforward synthesis. 
3.3.1. Synthesis of N-sulfonalyted carbazolyloxyacetic acids 
A series of 2-hydroxy carbazole N-sulfonamide derivatives was prepared as outlined in 
Scheme 3.9. 2-Hydroxycarbazole 67 was alkylated using anhydrous K2CO3 and 
ClCH2CO2tBu in acetone at 60–70 °C to give compound 68. N-sulfonylation of 68 was carried 
out using NaH, various sulfonyl chlorides in THF to afford N-sulfonylated ester 69 (Table 
3.8). The t-butyl deprotection of 69 was accomplished by 20% trifluoroacetic acid in CH2Cl2 
furnished the desired compounds 70. 
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Scheme 3.9: Synthesis of N-sulfonylated carbazolyloxyacetic acid derivatives. 
 
Table 3.8: Synthesis of N-sulfonylated carbazolyloxyacetic acid derivatives. 
Entry Compound R 
1 70a 4-Methylphenyl 
2 70b 3,5-Bis(trifluoromethyl)Phenyl  
3 70c 4-Biphenyl 
4 70d 2,4,6-Tri-iso-Propylphenyl 
5 70e 4-N-Propylphenyl 
6 70f Octyl 
7 70g (1S)-1-(Methyl)-7,7-dimethylbicyclo[2.2.1]heptan-2-one 
8 70h 4-Chlorophenyl 
9 70i 3,5-Difluorophenyl 
10 70j 2-Bromophenyl 
11 70k 3-Nitrophenyl 
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3.3.2. Synthesis of N-alkylated carbazolyloxyacetic acids 
N-alkylated carbazolyloxyacetic acids were prepared to evaluate the contribution of the 
sulfonamide moiety in 70g and the most active derivative 70d, where the sulfonamide is 
shielded by isopropyl substituents. The N-alkylated carbazolyloxyacetic acids were 
synthesized as shown in Scheme 3.10. Compound 68 was alkylated using KOBut and alkyl 
halide in dry THF to give N-alkylated ester 71. The t-butyl ester hydrolysis was achieved by 
base hydrolysis to obtain desired N-alkylated carbazolyloxyacetic acids as colorless solids 72.  
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Scheme 3.10: Synthesis of N-alkylated carbazolyloxyacetic acids. 
 
It was speculated that the lipophilic substituent anchors the N-substituted carbazolyloxyacetic 
acid in the required orientation within the membrane, thus the maximum tolerated length 
should be similar to natural phospholipids. To explore this hypothesis, N-alkylated 
carbazolyloxy acetic acids were synthesized using the alkyl halides of length equivalent to the 
phospholipids such as undecyl, dodecyl, tetradecyl, hexadecyl. 
3.3.3. Synthesis of 6-methoxy and 8-methoxy carbazolyloxyacetic acids 
The 2-hydroxy-6-methoxy and 2-hydroxy-8-methoxy N-sulfonylated carbazolyloxyacetic 
acids were synthesized in order to investigate the impact of an electron donating substituent 
on the activity. The synthesis of 6-methoxy and 8-methoxy-2-hydroxy carbazoles was 
commenced from the commercially available 4-chloro-3-nitrophenol 73 as outlined in 
Scheme 3.11. The phenolic –OH of 73 was protected as a p-methoxybenzyl (PMB) ether 74. 
Suzuki-Miyaura coupling of 74 with 3-methoxybenzeneboronic acid using the catalyst 
[(PPh3)4]Pd gave biphenyl 75, which was then cyclized to its corresponding carbazole by 
refluxing it in o-dichlorobenzene with PPh3. The PPh3 mediated cyclization resulted in two 
regioisomers, 6-methoxy carbazole, 76a and 8-methoxy carbazole, 76b which were separated 
by flash column chromatography.  
N-sulfonylated derivatives of 2-hydroxy-6-methoxy and 2-hydroxy-8-methoxy 
carbazolyloxyacetic acids were synthesized as depicted in Scheme 3.12. 
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Scheme 3.11: Synthesis of 6-methoxy and 8-methoxy carbazoles. 
 
The PMB group of 76 was deprotected by hydrogenation at 60 psi to get phenol 77. The free 
–OH was alkylated using anhydrous K2CO3 and ClCH2CO2tBu in acetone at 60–70 °C to 
yield alkylated 78.  
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Scheme 3.12: Synthesis of 6-methoxy and 8-methoxy N-sulfonylated carbazolyloxyacetic acids. 
 
Table 3.9: Synthesis of 6-methoxy and 8-methoxy N-sulfonylated carbazolyloxyacetic acids. 
Compound R1 R2 R3
 
80a 
 
OMe 
 
H 
 
3,5-(bis-trifluoro)phenyl 
80b OMe H 4-chlorophenyl 
80c OMe H 4-biphenyl 
80d OMe H 2-bromophenyl 
80e H OMe 4-chlorophenyl 
80f H OMe 4-biphenyl 
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N-sulfonylation of 78 was carried out using NaH and R3SO2Cl in dry THF to afford N-
sulfonylated 79 (Table 3.9). The t-butyl group removal was carried out by 20% TFA in 
CH2Cl2 to furnish the desired compound acids 80. 
Compounds 70a–k and 72a–g were tested for their ability to modulate ?-secretase in the A? 
liquid phase electrochemiluminescence assay and turned out to be effective modulators of ?-
secretase. They affected the cleavage at the ?38, ?40 and ?42 sites to a different extent and 
particularly reduced the formation of A?42, while increasing the formation of A?38 (see Table 
3.10 and Table 3.11). 
 
Table 3.10: Activity report of N-sulfonylated carbazolyloxyacetic acids. 
Entry  Compound   
    Code 
Compound Cell Toxicityc 
[?M] 
IC50 [?M] 
A?38a A?40 A?42 
 1 BSc2913 70a 20 13 >40 39 
2  BSc2915 70b 20 >40 >40 >40 
3 BSc2914 70c 20 13 40 24 
4 BSc2912 70d 20 7.8 19 7.5 
5 BSc3034 70e >40 NDb >40 38 
6 BSc3033 70f >40 NDb >100 37 
7 BSc3035 70g 40 14 >40 20 
8 BSc3624 70h 40 32 >40 32 
9 BSc3626 70i 40 13 >40 >40 
10 BSc3627 70j 40 >40 >40 >40 
11 BSc3625 70k 40 16 >40 >40 
[a] EC50 values are displayed for A?38. 
[b] Maximum effect on A?38 not observed at 200 ?M. 
[d] Significant cellular toxicity observed at this concentration. Viability reduction > 20%. 
 
 
Table 3.11: Activity report of N-alkylated carbazolyloxyacetic acids. 
Entry  Code Rc Compound CLogP Cell toxicityc
[?M] 
IC50 [?M] 
A?38a A?40 A?42
  
1 
 
BSc2916 
 
H 72a 
 
2.82 
 
>40 
 
>40 
 
>40 
 
>40 
2  BSc3030 Octyl 72b 7.03 >40 24 >100 19 
3 BSc3031 Nonyl 72c 7.55 >40 30 >100 17 
4 BSc3032 Decyl 72d 8.08 >40 ND >40 11 
5 BSc3770 Undecyl 72e 8.61 >40 14.6 >40 17.3 
6 BSc3771 Dodecyl 72f 9.14 >40 10.4 >40 15 
7 BSc3772 Tetradecyl 72g 10.2 >40 6.5 >40 8.2 
8 BSc3773 Hexadecyl 72h 11.2 >40 7.3 >40 14.6 
[a] EC50 values are displayed for A?38. 
[b] Maximum effect on A?38 not observed at 200 ?M.  
[c] tPSA for all compounds 72a-h is 62.9. 
 
The most potent inhibitors of A?42 were compounds 70d, 70g, 72c and 72g. Compounds 80a–
c showed modulatory activity but required very high concentrations. The compounds 80d–f 
turned out to be inverse modulators; they increased A?42 formation and reduced A?38 
formation at very high concentrations. Introduction of long alkyl chains such as undecyl, 
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dodecyl, tetradecyl and hexadecyl showed no siginificant improvement in the modulatory 
activity compared to 72c, but affected the CLogP dramatically. Compound 72g was found to 
be the most active compound amongst the N-alkylated carbazolyloxy acetic acids 72, but the 
increased CLogP due to the lipophilic substituent tetradecyl makes the blood brain penetration 
unlikely. The necessary levels for IC50/EC50 determination were not reached at 40 ?M. The 
effect of the most potent compounds on ?-secretase cleavage at the ?-site was assessed using 
an in vitro assay that monitors the de novo generation of AICD.[183, 184] The formation of 
AICD was affected by the compounds to various extend. 
 
Detailed results and discussion of these experiments are described in the article attached at the 
end as Appendix II. i.e. 
“Rajeshwar Narlawar, Blanca Perez Revauelta, Karlheinz Baumann, Robert Schubenel, 
Christian  Haass, Harald Steiner, Boris Schmidt, N-Substituted Carbazolyloxyacetic Acids 
Modulate Alzheimer Associated ?-Secretase, Bioorganic and  Medicinal Chemistry Letters, 
2007, 17, 176-182.” 
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3.4. The LXR-Agonist TO-901317 Can Be Tuned From Inverse to Normal 
Modulation of ?-Secretase 
Most of the reported and confirmed ?-secretase inhibitors are not substrate specific and 
interfere with Notch processing and signalling. A long term treatment with ?-secretase 
inhibitors may cause severe gastrointestinal toxicity and interferes with the maturation of B- 
and T-lymphocytes in mice effects due to inhibition of Notch processing and signalling.[185, 
186] But, compounds capable of modulating the active ?-secretase complex by interference 
with substrate recognition may alter or block A? production with little or no effect on Notch 
cleavage will be ideal candidates for AD therapeutics. The allosteric modulation is 
particularly attractive target for drug development since it may control the ratio of A? 
fragments while retaining the cleavage of other substrates being processed by ?-secretase. 
Recent studies suggest that the protease complex contains allosteric binding sites that can 
alter substrate selectivity and the sites of substrate proteolysis.[187, 188] Epidemiological studies 
have indicated an association between prolonged use of NSAIDs and reduced risk for AD. 
Certain NSAIDs (e.g., ibuprofen, indomethacin and sulindac sulfide) can reduce the 
production of the highly aggregation prone A?42 peptide and increase the level of A?38 
peptide, independent of their COX inhibitory activity.[167, 173, 189] Enzyme kinetic studies and 
displacement experiments revealed that the selective NSAIDs can be non-competitive with 
respective to APP substrate and to a transition-state analogue inhibitor. This indicates that 
they might be interacting with a site distinct from the active site.[117] N-Sulfonylated and N-
alkylated carprofen and carbazolyloxyacetic acid derivatives that modulate ?-secretase 
independent of their COX inhibitory activity have been discussed previously.[120, 182]  
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Scheme 3.13: Chemical structures of 72d (BSc3032), 66f (BSc3041), 63p (BSc2842) and  
TO-901317. 
 
The most active compounds 63p (BSc2842), 66f (BSc3041) and 72d (BSc3032), affected the 
cleavage at the ?38, ?40 and ?42 sites to a different extent and particularly suppressed the 
formation of A?42, while enhancing the formation of A?38 and thus showed the typical profile 
of effective NSAIDs (Scheme 3.13). Modification of the acid moiety into its amide or ester 
derivatives resulted in the complete loss of modulatory activity. This indicated an important 
contribution of the carboxylic acid to target affinity. Recently Czech et al. demonstrated that 
TO-901317,[190] a LXR agonist, interacts directly with the ?-secretase complex to alter the 
production of different A? peptides.[191] Moreover, TO-901317 directly modulates the site of 
Results and discussion 
 
 54
cleavage of APP by ?-secretase in vitro and displays cholesterol-independent effect on APP 
processing. It was found to be an inverse modulator of ?-secretase and displayed activity at 
low micromolar concentration. It selectively increased the formation of A?42 and reduced the 
formation of A?38. Riddell et al. reported that LXR agonist, TO901317, increased 
hippocampal ABCA1 and apoE and decreased A?42 levels in APP transgenic mice. 
TO901317 had no significant effects on levels of A?40, full length APP, or the APP 
processing products. These observations indicate that LXR agonists do not directly inhibit 
APP processing but rather facilitate the clearance of A?42 and may represent a novel 
therapeutic approach to AD.[190] 
In the search for non-peptidic ?-secretase modulators, LXR agonist TO-901317 analogous 
compound was synthesized, but the hexafluorocarbinol moiety was replaced by an oxyacetic 
acid moiety. It was hypothesized that, the replacement of hexafluorocarbinol moiety by an 
acid moiety would change the mode of action from inverse modulation to normal modulation. 
Therefore, the LXR agonist TO-901317 analogous compound 87 was synthesized as depicted 
in Scheme 3.14. Alkylation of the phenolic –OH of 82 using anhydrous K2CO3 and t-butyl 
chloroacetate in acetone at 60–70 °C to afford nitro ester 83. Subsequent nitro group 
reduction by hydrogenation using 10% Pd-C in ethyl acetate gave amine 84.  
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Scheme 3.14: Synthesis of LXR agonist analogous ?-secretase modulator. 
N-sulfonylation of amine 84 was carried out using triethyl amine, catalytic DMAP and 3,5-
bis-(trifluoromethyl) benzene sulfonyl chloride in CH2Cl2 to afford sulfonamide 85. N-
alkylation of sulfonamide 85 was accomplished using KOBut and n-octyl iodide in DMF 
provided alkylated product 86 and subsequent acidic cleavage of t-butyl ester gave acid 87 as 
colourless solid. 
Compounds 85-87 were tested for their ability to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay. As anticipated compounds 85 and 86 turned out to be 
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inverse modulators of ?-secretase and displayed the inverse modulatory activity in the low 
micromolar concentration (see Table 3.12, Figure 3.5).  
 
Table 3.12: Activity report of compounds 85-87. 
 
Entry 
 
Compound 
 
Compound
Code 
 
Cell viabilitya
[?M] 
Activity in ?M 
IC50
A?38
EC50
A?38 
IC50 
A?40 
IC50 
A?42 
EC50
A?42 
1 81 TO901317 – 4.5 – >40 – 3.6 
2 85 BSc3850 >40 >40 – >40 – 10.6 
3 86 BSc3851 >40 13.3 – >40 – 6.2 
4 87 BSc3769 40 – 23.7 >40 19.6 – 
 [a] Significant cellular toxicity observed at this concentration. Viability reduction > 20%. 
 
In accordance with previous results,[120, 182] the ester 85 and 86 affected the cleavage at the 
?38, ?40 and ?42 sites to a different extent and suppressed the formation of A?38, while 
enhancing the formation of A?42. N-alkylation of sulfonamide 86 dramatically enhanced the ?-
secretase modulatory activity (Table 3.7). However, compound 87 turned out to be effective 
modulator of ?-secretase. It reduced particularly the formation of A?42 and enhanced the 
formation of less toxic A?38. The transformation of ester 86 into its free acid 87 changed the 
mode of action from inverse modulation to normal modulation and displayed a typical 
NSAID like profile. Moreover, it showed toxicity at 40 ?M concentration (Figure 3.6). 
Compound 87 is believed to have no or little effect on the ?-secretase cleavage at ?-site. This 
confirms the hypothesis that the free acid moiety is crucial for the modulatory activity and for 
uptake. It is speculated that the lipophilic substituent anchors the N-substituted phenoxyacetic 
acid in the required orientation within the membrane, thus the maximum tolerated length 
should be similar to natural phospholipids. 
In conclusion, replacement of the hexafluorocarbinol moiety of LXR agonist, TO-901317 by 
an oxyacetic acid group dramatically changed the mode of action from inverse modulation to 
modulation. In accordance with previous results, the modification of acid into its derivatives 
such as ester turned the compounds 85 and 86 into inverse modulators. Introduction of n-
octyl, a lipophilic substituent on the sulfonamide 85 increased the inverse modulatory activity. 
Compound 87 with the free acid moiety was found to be a classical modulator of ?-secretase.  
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Figure 3.5: Dose response curves; A? (% of control). (A) Compound 78. (B) Compound 79. (C) 
Compound 80.  
 
Again, it is evident from the structure activity relationship data that the free acid moiety is 
crucial for the PS modulatory activity. This significant modification can be applied to several 
reported ?-secretase inverse modulators such as celecoxib and rofecoxib and thus applied 
structural modification may change the mode of action from inverse modulation to 
modulation.   
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3.5. Curcumin Derived Pyrazoles and Oxazoles – Swiss Knives or Dirty 
Tools for AD? 
 
This chapter is removed due to the IP reasons. 
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3.6. Synthesis and Biological Evaluation of NSAIDs Derived Affinity Labels 
?-Secretase has been an attractive target in many ways for AD therapeutics. But, the 
interference of most of the reported and confirmed ?-secretase inhibitors with Notch 
processing and signalling leads to toxicities that rule out their clinical use. Long term 
treatment with ?-secretase inhibitors causes severe gastrointestinal toxicity and interferes with 
the maturation of B- and T-lymphocytes in mice. These observed effects are indeed due to 
inhibition of Notch processing and signalling.[195] Recent studies indicate that the active ?-
secretase complex contains allosteric binding sites which may alter the substrate selectivity 
and the sites of proteolysis. Certain NSAIDs such as ibuprofen, indomethacin and sulindac 
sulfide can reduce the production of the highly aggregation prone A?42 peptide and increase 
the level of A?38, a pharmacological property that is independent of COX inhibition.[111] The 
alteration of the proteolytic cleavage site is observed with isolated or purified ?-secretase. 
This indicates that the compounds interact directly with the ?-secretase complex to exert these 
effects.[118, 196] Enzyme kinetic studies and displacement experiments suggest that selective 
NSAIDs can be non-competitive with respect to APP substrate and a transition-state analogue 
inhibitor, suggesting interaction with a site distinct from the active site. The site of cleavage 
within the Notch TMD is equally affected, but this slight change does not inhibit the release 
of the intracellular domain (ICD) and therefore the signalling Notch is not affected.[42] For 
this reason, these agents may be safer as AD therapeutics compared to the ?-secretase 
inhibitors that block the active site or the docking site. Surprisingly, the site of proteolytic 
cleavage by signal peptide peptidase (SPP) can also be modulated by the same NSAIDs that 
affect ?-secretase. These observations suggest that PS is the site where NSAIDs bind within 
the ?-secretase complex and that SPP and PS share a conserved binding site for allosteric 
modulation of substrate cleavage sites. Most of the NSAIDs interfere with the APP 
mechanism via allosteric modulation, but this is not a class effect. Negative results were 
obtained with some NSAIDs such as aspirin, naproxen. 
 
1. Addition of streptavidin
sepharose
2. Elution with 2% SDS
Purification and 
identification of ?-
secretase complex
NSAID Biotin
?-Secretase
 
 
Figure 3.6: Approach to capture the active ?-secretase complex and identify the binding site of 
NSAID. 
It is apparent that certain A?42-modulating compounds such as NSAIDs target the ?-secretase 
complex, but the molecular details are still mysterious. One important concern is to identify 
the interaction partner of A?42-modulating compounds within the ?-secretase complex. 
Results and discussion 
 
 62
Although PS seems to be the crucial candidate, but at the same time interaction with any of 
the components in the ?-secretase complex or with the substrate APP is quiet possible. Even 
more mysterious issue is how the conformational changes are being persuaded by A?42-
modulating compounds which lead to the observed shift in cleavage specificity from A?42 to 
A?38. One potential explanation is that these compounds induce subtle changes in the 
presentation of the substrate i.e. APP to the catalytic center in the ?-secretase complex.  
To shed light on the binding site of NSAIDs and understand the actual mechanism of 
modulation, biotinylated NSAIDs were synthesized. Biotin was used to facilitate the isolation 
and identification of the reversibly labelled adducts via their streptavidin-enzyme linked 
conjugates. It was anticipated that the NSAIDs would bind to the allosteric site on ?-secretase 
and the biotin tag would help to identify the binding partner via immunoprecipitation. 
Ethylene diamine was used as the spacer to maintain the distance between affinity label and 
the ligand (Figure 3.6).  
3.6.1. Synthesis of Biotinylated NSAIDs via Structural Modification of Acid Moiety 
3.6.1.1. Synthesis of biotinylated flurbiprofen 
Initially, biotinylated flurbiprofen was synthesized by the derivatization of acid moiety of 
flurbiprofen which is common to the COX inhibitors as depicted in Scheme 3.17. 
Flurbiprofen 32 is a classical modulator of ?-secretase and displays the modulatory activity 
independent to its COX-1 inhibitory activity.[111, 112, 117]  
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Scheme 3.17: Synthesis of flurbiprofen-biotin 94 (BSc2174). 
 
The acid moiety of flurbiprofen was coupled with N-Boc ethylene diamine using EDAC and 
HOBt as coupling reagent to afford the coupled product 92. N-Boc deprotection of compound 
by 20% TFA in CH2Cl2 gave amine 93 as a trifluoroacetic acid salt. The free amine 93 was 
then subjected for the condensation with D-biotin using EDAC and HOBt as coupling reagent 
in CH2Cl2. The reaction exhibited poor conversion and yield. It was attributed to the traces of 
the TFA in amine which remained even after flushing several times with n-hexane and drying 
in vacuo. Therefore, the N-Boc of 92 deprotected using 16% HCl in dioxane. The reaction 
displayed 100% conversion on TLC and, yielded the amine as a hydrochloride salt 93. The 
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coupling of amine hydrochloride 93 with D-biotin using EDAC and HOBt as coupling 
reagents in DMF went smoothly and gave biotinylated flurbiprofen 94.   
Flurbiprofen-biotin 94 was tested for its ability to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay. The assay was performed at Hoffman-La Roche, Basel, by 
Dr. Karlheinz Baumann. The dose response curve of 94 revealed that it acts as an inverse 
modulator in the cellular assay (Figure 3.8). A classical NSAID suppresses the formation of 
the most toxic species A?42 and increase the formation of less toxic A?38. 
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Figure 3.7: Dose response curve for flurbiprofen-biotin 94 (BSc2174). 
 
But surprisingly, the conversion of the acid moiety of flurbiprofen into its amide turned it into 
an inverse modulator of ?-secretase and resulted in an elevation of A?42 and reduction of A?38 
(Figure 3.7). Next, the biotinylated flurbiprofen 94 was tested for its ability to bind and pull 
down the active ?-secretase complex. The immunoprecitipation experiments were performed 
at the LMU Munich by Blanca I. Perez Revaulta. It was anticipated that, 94 would bind to the 
allosteric sites on the active ?-secretase complex and the biotin tag would allow the isolation, 
since biotin has a very strong affinity with streptavidin. Flurbiprofen-biotin 94 binding was 
expected to be optimal under solubilization conditions where the enzyme remains in a 
catalytically active conformation. CHAPSO-solubilized ?-secretase was incubated with the 
biotinylated affinity ligand for 2 h at 4 °C followed by precipitation of enzyme-inhibitor 
complexes with streptavidin-coupled magnetic beads. Polypeptides present in the precipitates 
were characterized by western blotting. Flurbiprofen-biotin was tested for its ability to capture 
?-secretase complex at three different concentrations, 100 ?M, 250 ?M and 500 ?M. Further 
analysis revealed that by combining an incubation of solubilized ?-secretase at an affinity 
ligand concentration of 500 ?M followed by capture using streptavidin beads (Figure 3.9) an 
optimal specific precipitation of the members of active ?-secretase complex, PS1, nicastrin, 
Aph-1 and pen-2 was observed. Omission of the affinity ligand (Figure 3.8) abolished the 
precipitation of all these polypeptides. The western blots revealed that regardless of having 
lost its NSAIDs like activity, flurbiprofen-biotin 94 indeed captured the ?-secretase complex 
in a dose dependant fashion. 
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Figure 3.8: F-B 94 captures the ?-secretase complex in dose dependant manner. 
 
One of the crucial issues related to the ?-secretase inhibitors is the interference with other ?-
secretase substrates such as Notch and others. Therefore, the effect of flurbiprofen-biotin 94 
on ?-secretase cleavage at the ?-site was assessed using an in vitro assay that monitors the de 
novo generation of ?-amyloid precursor protein intracellular domain (AICD) (Figure 3.9). 
The ?-cleavage of ?-secretase was not inhibited by 94 at low compound concentrations that 
determined to be modulatory at the ?-secretase site. However, at concentrations where most 
efficient binding occurred (500 µM), the compound acted as an inhibitor, as monitored by an 
in vitro ?-secretase assay that assessed AICD generation (i.e. ?-secretase cleavage at the ?-
site) (Figure 3.10).   
AICD
 
Figure 3.9: Effect of F-biotin 94 and flurbiprofen 32 on ?-secretase cleavage at ?-site. 
 
3.6.1.2. Synthesis of biotinylated flurbiprofen via Curtis rearrangement 
Biotinylated flurbiprofen was synthesized via a Curtis rearrangement. The acid moiety of 
flurbiprofen was converted to its corresponding urea in order to investigate the impact of urea 
moiety on the capture efficiency of ?-secretase active complex.  
The synthesis commenced from commercially available flurbiprofen 32. The acid moiety of 
flurbiprofen 32 was converted to the mixed anhydride using ethyl chloroformate and 
nucleophilic substitution by azide gave the acyl azide 95. The acyl azide underwent the Curtis 
rearrangement to give the isocynate which was trapped in situ using N-Boc ethylene diamine 
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to give the urea 96. N-Boc of 96 was deprotected using 16% HCl in dioxane to give the free 
amine 97 as the hydrochloride salt which was used in the next step without further 
purification. The coupling reaction of the amine hydrochloride 97 with (D)-biotin underwent 
smoothly using EDAC and HOBt as coupling reagents in DMF to afford the desired 
biotinylated flurbiprofen 98 as colorless solid (Scheme 3.18).   
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Scheme 3.18: Synthesis of flurbiprofen biotin 98 (BSc2454) via Curtis rearrangement.  
 
The biotinylated flurbiprofen 98 was tested in the A? liquid phase electrochemiluminescence 
assay for its ability to modulate ?-secretase (Figure 3.12). The assay results revealed that 
compound 98 is an inverse modulator of ?-secretase and displayed activity at 40 ?M 
concentration. The immunoprecipitation experiments carried out with 98 illustrated that 
compound does not capture the ?-secretase active complex even at very high concentrations.   
Introduction of the biotin via functional group transformation into amide or urea resulted in 
the loss of classical modulation. Instead, the biotinylated probes were found to be inverse 
modulators of ?-secretase. Even then, the affinity label 98 captured ?-secretase active 
complex. These results encouraged the synthesis of biotinylated NSAIDs which are known to 
inhibit or modulate APP metabolism via interference with ?-secretase and investigation using 
immunoprecipitation assay for the identification of a binding partner. Therefore, sulindac 
sulfone, meclofenamic acid, ketoprofen and carprofen were shortlisted due to their ability to 
modulate or inhibit ?-secretase.   
3.6.1.3. Synthesis of biotinylated meclofenamic acid derivative 
Meclofenamic acid is a nonselective COX inhibitor and belongs to N-arylanthranilic acid 
derivative which are commonly known as fenamtes. Meclofenamic acid exhibits 
pharmacologic actions similar to those of aspirin but is 150 times potent that aspirin. It is a 
potent inhibitor of COX, thereby inhibits the release of prostaglandins. It was found to be an 
inverse modulator at very high concentration.[112] As discussed previously, meclofenamic acid 
derived amides were found to be either potent inhibitors or inverse modulators of ?-secretase. 
Biotinylated meclofenamic acid was synthesized in order to identify the binding partner via 
immunoprecipitation. Biotin was introduced via the transformation of meclofenamic acid as 
depicted in Scheme 3.19. 
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Synthesis of biotinylated meclofenamic acid commenced from the commercially available 
meclofenamic acid sodium salt 37. The acid of 37 was coupled with N-Boc ethylene diamine 
using EDAC and HOBt in CH2Cl2 to get coupled product 99. N-Boc deprotection was 
accomplished using 16% HCl in dioxane to afford free amine 100 as hydrochloride salt which 
was used in the next step without further purification. Amine 100 underwent amidation 
reaction with D-biotin using EDAC and HOBt as coupling reagent in DMF. The crude 
compound was purified by column chromatography using eluents MeOH:CH2Cl2 (1:9) to 
obtain biotinylated meclofenamic acid derivative 101 as pale brown solid.  
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Scheme 3.19: Synthesis of biotinylated meclofenamic acid 101 (BSc2403). 
 
The probe 101 was tested for its potential to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay. 101 was found to be an inverse modulator of ?-secretase at 
40 ?M concentration (Figure 3.10).  
The conversion of meclofenamic acid into its 101 amide turned it into an inverse modulator of 
?-secretase. The immunoprecipitation assay of affinity label was carried out to investigate its 
potential to find a binding partner in immunoprecipitation assay and capture the active ?-
secretae complex. Affinity label 101 did not find the binding partner in the 
immunoprecipitation assay and thus failed to capture the active ?-secretase complex.  
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Figure 3.10: Activity report of biotinylated NSAIDs on ?-secretase at 10 ?M and 40 ?M 
concentration. 
 
3.6.1.4. Synthesis biotinylated sulindac sulfoxide derivative 
Sulindac sulfoxide 102 is a non-selective COX inhibitor. It is a prodrug and its active form, 
sulindac sulfide 33 displays potent COX inhibitory activity. Sulindac sulfide 33 is a classical 
modulator of ?-secretase: selectively reduces the formation of A?42 and increases the 
formation of A?38.[111, 112, 116, 117] Sulindac sulfoxide derived affinity label was synthesized as 
outlined in Scheme 3.20. The synthesis began from the commercially available sulindac 
sulfoxide 102. The acid 102 underwent coupling with N-Boc ethylene diamine using EDAC 
and HOBt as coupling reagent in CH2Cl2 to achieve compound 103.  
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Scheme 3.20: Synthesis of biotinylated sulindac sulfoxide 105 (BSc2452). 
 
Initially, the N-Boc of 103 was deprotected using 16% HCl in dioxane to obtain the free 
amine 104 as hydrochloride salt which was used in the next step without further purification. 
The amine hydrochloride salt 104 was coupled with D-biotin in DMF using EDAC and HOBt 
as coupling reagent. The TLC of the reaction indicated several spots and it made the 
separation by column chromatography difficult. The formation of impurities was credited to 
the highly acidic reaction condition used for the cleavage of N-Boc. Consequently, N-Boc of 
103 was deprotected using 20% TFA in CH2Cl2 to give amine 104 as TFA salt which was 
used in the next step without further purification. Amine 104 was coupled with D-biotin in 
DMF using PyBrop as coupling reagent. The TLC indicated complete consumption of starting 
material and the reaction was much cleaner. The purification by column chromatography gave 
the sulindac sulfoxide derived affinity label 105 as yellow solid.  
The affinity label 105 was tested for its ability to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay. Compound 105 was found to be an inverse modulator of ?-
secretase and displayed activity at 40 ?M concentration. It particularly increased the 
formation of A?42, the most toxic species which is prone to aggregate (Figure 3.10). 
Subsequently, the affinity label 105 was tested in immunoprecipitation assay for its ability to 
find the binding partner and capture the active ?-secretase complex. The assay results 
indicated that 105 do not capture the ?-secretase active complex even at very high 
concentrations.    
3.6.1.5. Synthesis of biotinylated ketoprofen 
Ketoprofen is a COX inhibitor and was found to be an inverse modulator of ?-secretase at 
high concentration.[112]  The chemical strucutre of ketoprofen reveals a photoreactive 
benzophenone group which can be used directly for the photoaffinity labelling experiment. 
The biotinylated ketoprofen 109 can be used for the photolabelling experiment, where the 
benzophenone serves as the photoreactive group and biotin as an affinity tag. 
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Scheme 3.21: Synthesis of biotinylated ketoprofen 109 (BSc2394). 
 
The biotinylated derivative of ketoprofen was synthesized as illustrated in Scheme 3.21. The 
acid moiety of ketoprofen 106 underwent amidation with N-Boc ethylene diamine using 
EDAC and HOBt as coupling regent in CH2Cl2 to afford the coupled product 107. Subsequent 
N-Boc deprotection using 20% TFA in CH2Cl2 gave free the amine 108 as trifluoroacetic acid 
salt which was used in the next step without further purification. Biotinylation of amine 108 
was carried out using D-biotin and PyBrop as coupling reagents in DMF to give 109 as a 
cream colored solid. 
Affinity label 109 was for its capability to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay. It was found to be an inverse modulator of ?-secretase and 
displayed the activity at 40 ?M concentration. (Figure 3.10). The ability of affinity label 109 
to bind and capture ?-secrease active complex was tested in immunoprecipitaton assay. Again 
the experiment did not meet with success. 
3.6.1.6. Synthesis of biotinylated carprofen 
Carprofen 41 is a COX-2 inhibitor approved for the use in dogs, cows and horses. The 
selectivity of carprofen versus COX-2canine and COX-1canine is greater than 100:1 (COX-
2canine IC50: R/S-carprofen 102 nM, R-carprofen 5.97 ?M, S-carprofen 37 nM). Original 
carprofen (as isolated from 500 mg tablets) was found to be a weak inhibitor of ?-secretase 
and reduced A?38, A?40 and A?42 at high concentration.[120] Biotinylated carprofen derivative 
was synthesized as depicted in Scheme 3.22.  
The acid moiety of carprofen 41 was coupled with N-Boc ethylene diamine using EDAC and 
HOBt as coupling reagents to afford coupled product 110. N-Boc of 110 was deprotected 
using 20% TFA in CH2Cl2 to afford the free amine 111 which was used in the next step 
without further purification. Subsequently, the amine 111 was coupled with D-biotin using 
EDAC and HOBt as coupling reagents in DMF to afford the affinity label 112 as a cream 
colored solid.  
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Scheme 3.22: Synthesis of biotinylated carprofen derivative 112 (BSc2392). 
 
Affinity label 112 was tested for its ability to inhibit ?-secretase in the A? liquid phase 
electrochemiluminescence assay. Surprisingly, it was found to be an inverse modulator of ?-
secretase (Figure 3.10). The transformation of the acid moiety of carprofen into amide 
changed the mode of action from full blown inhibition to inverse modulation. Furthermore, 
affinity label 112 was tested in immunoprecipitation assay for its potential to capture active ?-
secretase complex. Eventually the affinity label 112 did not reveal any binding in the 
immunoprecipitation assay.  
To summarize, the structure analysis relationship (SAR) of NSAIDs derived affinity labels 
94, 98, 101, 105, 109, 112 demonstrated that the incorporation of biotin via the structural 
modification of the acid moiety dramatically changed the mode of action from modulation or 
inhibition to inverse modulation. All the affinity labels selectively increased the formation of 
A?42 and reduced the less toxic A?38 formation. These results confirmed the requirement of 
the free acid moiety of the NSAIDs which is crucial for the classical modulatory activity and 
to maintain the typical NSAID like profile. It is presumed that, the free acid might be vital for 
the uptake. Interestingly, out of all tested affinity labels, only 94 (BSc2174) found a binding 
partner in the immunoprecipitation assay and captured the ?-secretase in the dose dependant 
fashion despite being an inverse modulator. The optimal concentration required for the ?-
secretase capture was 500 ?M. Moreover, it did not inhibit the formation of AICD, a typical 
property exhibited by ?-secretase modulating NSAIDs, even at a very high concentration.  
SAR advocated the synthesis of NSAIDs derived affinity labels keeping intact the free acid. 
As a result, flurbiprofen and carprofen were selected initially.  
3.6.2. Synthesis of Biotinylated NSAIDs without perturbing the Acid Moiety  
3.6.2.1. Synthesis of biotinylated flurbiprofen with free acid moiety 
The synthesis of biotin-flurbiprofen commenced from the commercially available flurbiprofen 
as outlined in Scheme 3.23. Flurbiprofen 32 was nitrated using 70% nitric acid at room 
temperature for 48 h. The nitration reaction resulted in two regio isomers: o-nitrated 113 and 
p-nitrated 114 products.  
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Scheme 3.23: Synthesis of biotinylated flurbiprofen 117 (BSc2805). 
 
The purification of the regio isomers at this step was difficult due to an almost similar Rf 
value on TLC. Therefore, the acid moiety of the nitrated flurbiprofen mixture was protected 
and the regio isomers 113, 114 were separated by column chromatography. The nitro group of 
113 was chemoselectively reduced to its corresponding amine 115 using anhydrous SnCl2 in 
ethanol at 80-90 °C. Amine 115 was coupled with D-biotin using EDAC and HOBt in DMF 
to afford biotinylated flurbiprofen benzyl ester 116. The cleavage of the benzyl group was 
achieved by hydrogenation at 60 psi in MeOH to afford 117.  
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Figure 3.11: Dose response curve of compound 117 (BSc2805). 
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The probe 117 was tested for its ability to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay. As anticipated, the probe 117 (BSc2805) turned out to be an 
effective modulator of ?-seretase. It affected the cleavage of ?38, ?40 and ?42 to a different 
extent and particularly reduced the formation of A?42 (Figure 3.11).  
Affinity label 117 was tested in immunoprecipitation assay for its potential to capture active 
?-secretase active complex. The assay revealed the probe 117 did not capture the active ?-
secretase complex.  
3.6.2.1. Synthesis of biotinylated carprofen via N-substitution with free acid moiety 
Carprofen is a selective COX-2 inhibitor and displays inhibitory activity on ?-secretase. As 
mentioned in the previous chapter, N-substitution of carprofen changed the mode of action 
from full inhibition to modulation. It was evident from the SAR of N-substituted carprofen 
derivatives that the free acid is crucial for the modulatory activity. Therefore, N-substituted 
carprofen derived labels were designed in order to keep the modulatory activity intact. The 
synthesis of N-sulfonylated carprofen derived affinity label commenced from the previously 
synthesized intermediate N-(4-nitrophenyl sulfonyl) carprofen benzyl ester 62o as outlined in 
Scheme 3.24. The nitro group of 62o was chemoselectively reduced to its free amine 118 
using anhydrous SnCl2 in ethanol at 80-90 °C. Different methods were employed for the 
coupling of amine 118 with D-biotin. The reaction did not show any indication of product 
formation even after using various coupling reagents (see Scheme 3.24). This was attributed 
to the low nucleophilicity of aniline 118 which bears an electron withdrawing group at its 
para position. 
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Scheme 3.24: Synthesis of carprofen derived affinity label 120. 
 
To overcome this problem, previously synthesized intermediate N-(3-nitrophenly sulfonyl) 
carprofen benzyl ester 62n was inducted in the synthesis of affinity label 123 as depicted in 
Scheme 3.25.  
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Scheme 3.25: Synthesis of carprofen derived affinity label 116. 
 
It was presumed that an electon withdrawing group at the meta position of amine 121 would 
not affect the nucleophilicity and thus would facilitate the coupling reaction with D-biotin. 
The chemoselective nitro reduction of intermediate 62n was carried out using anhydrous 
SnCl2 to give amine 121. Amine 121 underwent coupling reaction with D-biotin using EDAC 
and HOBt as coupling reagents in DMF. The reaction did not show any sign of progression 
even after 96 h. Therefore, other coupling reagents were employed such as DCC and PyBrop. 
Both of them failed to couple amine 121 with D-biotin. It was assumed that sulfonyl group 
either at meta or at para position of aniline 121 affects the nucleophilicty dramatically and 
impedes the amidation reaction with D-biotin.  
To overcome the nucleophilicity problem of anilines 118 and 121, previously synthesized 
intermediate, N-(3-nitrobenzyl) carprofen benzyl ester 66c was opted as a starting material for 
the synthesis. The synthesis commenced from the intermediate 66c as illustrated in Scheme 
3.26. Chemoselective nitro group reduction of N-(3-nitrobenzyl) carprofen benzyl ester 66c 
was achieved using anhydrous SnCl2 in ethanol to afford amine 124 as pale brown gummy 
mass. The coupling reaction of amine 124 with D-biotin using EDAC and HOBt as coupling 
reagents in DMF went smoothly and gave the biotinylated ester 125 as colorless solid. The 
benzyl group cleavage of benzyl ester 125 was achieved by hydrogenation using 10% Pd-C in 
MeOH at 60 psi to obtain biotinylated carprofen 126.  
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Scheme 3.26: Synthesis of biotinylated carprofen derivative 126. 
 
Affinity label 126 was tested for its ability to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay (Figure 3.12). As anticipated, compound 126 was found to 
be a modulator of ?-secretase and affected the cleavage of ?38, ?40 and ?42 to a different 
extent. It particularly reduced the formation of A?42 and increased the formation of A?38. 
Introduction of a polar end group such as biotin was well tolerated and did not affect the 
activity yet changed the mode of action from full inhibition to classical modulation. 126 
displayed typical NSAID like profile:  reduced formation of A?42, increased formation of 
A?38 and no inhibition of ?-secretase cleavage at ?-site. Probe 126 was tested in the 
immunoprecipitation assay for its ability to capture ?-secretase complex. The 
immunoprecipitation experiments revealed that 126 did not capture the ?-secretase complex. 
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Figure 3.12: Dose response curve for compound 126 (BSc2912). 
 
To conclude, a series of NSAIDs derived affinity labels (94, 98, 101, 105, 109 and 112) was 
synthesized via structural modification of the common acid moiety. The SAR indicated the 
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necessity of acid moiety which is believed to be critical for the modulatory activity. The 
affinity labels (94, 98, 101, 105, 109 and 112) which were synthesized via the modification of 
the acid moiety of NSAIDs resulted in the complete loss of NSAID like profile and turned out 
to be inverse modulators of ?-secretase. They selectively increased the formation A?42 and 
reduced the formation of less toxic A?38. Out of all tested affinity probes, only 94 captured ?-
secretase active complex in dose dependant manner in the immunoprecipitation assay. Despite 
being an inverse modulator, probe 94 did not inhibit the ?-secretase cleavage at ?-site. Rest of 
the affinity probes did not capture the ?-secretase complex. Considering the key role of free 
acid moiety for the ?-secretase modulation, affinity labels 117, 126 were synthesized without 
disturbing the free acid moiety of NSAIDs. As anticipated, the incorporation of biotin keeping 
the free acid moiety intact resulted in the classical modulation of ?-secretase by the affinity 
probes 117 and 126. Interestingly, the introduction of biotin in 117 was well tolerated and did 
not hamper the modulatory activity. However, 117 turned out to be unsuitable bait for the ?-
secretase complex although it displayed significant modulation of ?-secretase activity. 
Carprofen derived affinity probe 126 was found to be a modulator of ?-secretase. The 
introduction biotin did not hamper the modulatory activity and was well tolerated. Affinity 
probe 126 did not capture ?-secretase in the immunoprecipitation assay. Robust bait for the 
successful pull-down of the binding domain within ?-secretase is still unknown. 
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3.7. Design, Synthesis and Biological Evaluation of Flurbiprofen Derived 
Photoaffinity Label 
?-Secretase is a multiprotein complex that is assembled from at least four obligatory proteins, 
PS, nicastrin, Aph-1 and Pen-2 and the PS contains the active site of this enzymatic 
activity.[197] Flurbiprofen is a COX-1 and COX-2 inhibitor, but displays 30-fold more 
selectivity towards COX-1. Apart from its COX inhibitory activity it modulates ?-secretase 
and selectively reduces A?42 (IC50 305 ?M). Cell based studies with A?42-lowering 
compounds have demonstrated that ?-secretase modulators do not induce the same molecular 
side effects as ?-secretase inhibitors in regard to APP processing and effects on other 
substrates of ?-secretase such as Notch.[111, 115, 117, 118] In contrast, it now seems likely that 
A?42-lowering compounds act by direct modulation of ?-secretase activity. This suggested a 
rather subtle shift in the ?-secretase cleavage pattern with increased production of the shorter 
A?38 species at the expense of the longer A?42 species. Since then, the most convincing 
evidence for direct ?-secretase modulation was provided by the fact that A?42-lowering 
compounds are active in cell-free ?-secretase assays.[112, 116, 117] Compounds that exert activity 
in these assays are presumed to modulate A? production either by direct interaction with the 
?-secretase enzyme complex or the substrate APP. One credible explanation for the selective 
A?42-lowering activity of NSAIDs is that these compounds change ?-secretase conformation 
in a similar yet opposite way to PS mutations. 
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Figure 3.13: Approach to identify the binding site of flurbiprofen on active ?-secretase complex via 
photoaffinity labelling 
 
The elucidation of interacting partners is an immediate entrance into the discovery of 
medicinal leads. The method of photoaffinity labelling enables the direct probing of target 
protein through a covalent bond which is photochemically introduced between a ligand and its 
specific receptor. Thus, photoaffinity labelling enables to identify protein ligand contacts. If 
the binding site analysis of a target protein is important for defining a particular 
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pharmacophore, the photoaffinity labelling will give the structural information of the receptor 
binding domain at micro-level. 
It is well known that flurbiprofen binds to an allosteric site on the active ?-secretase active 
complex and exerts modulatory activity. It was presumed that flurbiprofen derived 
photoaffinity label would reversibly bind to the active ?-secretase complex and form a 
covalent bond formation with the active ?-secretase complex upon photoactivation. Then, 
addition of streptavidin sepharose followed by the elution with 2% SDS would provide the 
information regarding the binding partners in detail (Figure 3.13).    
Flurbiprofen derived probe was synthesized in order to identify the binding site via 
photoaffnity labelling followed by the detection using immunoprecipitation assay (Figure 
3.14). Benzophenone was used as a photoreactive group since it has certain advantages such 
as: stability, selectivity, allows manipulation at ambient light and activation at 350-360 nm 
which avoids protein damage. Biotin was used as a non-radioactive tag since it has great 
affinity with avidin and streptavidin. Thus, the labelled protein fragments can be isolated by 
means of their interaction with avidin or streptavidin and isolated them by affinity 
chromatography. Ethylene diamine was used as spacer to maintain the distance between 
affinity label and the photoreactive group.   
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Figure 3.14: Design of flurbiprofen derived photoaffinity probe. 
 
The synthesis of flurbiprofen derived photoaffinity label commenced from the previously 
synthesized intermediate 113 as illustrated in Scheme 3.27. The nitro group of 113 was 
reduced chemoselectively to amine 115 using anhydrous SnCl2. Amine 115 was converted to 
?-chloro acetamide 128 using chloroacetyl chloride in CH2Cl2. Benzophenone 128 was 
alkylated using anhydrous K2CO3 and ?-chloroacetamide 127 in acetone at 60–70 °C to give 
compound 129 which was purified by crystallization as colorless solid. The deprotection of 
the t-butyl group 129 was accomplished using 20% trifluoroacetic acid in CH2Cl2. The 
deprotection reaction went smoothly and the product 131 was purified by crystallization to 
afford the acid. Different coupling reagents were employed for coupling of acid 130 with N-
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Boc ethylene diamine such as: PyBrop, DCC and EDAC. The best results were obtained when 
EDAC and HOBt were used as coupling reagents in CH2Cl2 and gave product 131 as 
colorless solid. N-Boc deprotection of compound 131 resulted in the multiple products as 
indicated by TLC when 16% HCl in dioxane was used. Therefore, N-Boc was deprotected 
using 20% TFA in CH2Cl2 to give amine 131 as a trifluoroacetic acid salt (Scheme 3.28). 
Amine 132 was coupled with D-biotin in DMF using PyBrop as coupling reagent to afford 
biotinylated 133 as pale yellow solid. The benzyl ester cleavage of compound 133 was carried 
out by hydrogenation at 60 psi in MeOH to obtain the acid 134 as pale yellow solid.  
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Scheme 3.27: Synthesis of intermediate 131. 
 
Probe 134 was tested for its potential to modulate ?-secretase in the A? liquid phase 
electrochemiluminescence assay. It was found to be a modulator of ?-secretase and selectively 
reduced the formation of A?42 and increased the formation of A?38. The introduction of 
benzophenone and biotin neither affected the activity significantly nor changed the mode of 
action (Figure 3.15). Photoaffinity labelling experiments with 134 are being carried out by 
Dr. Thomas Kukar, Mayo Clinic, Florida, USA. The preliminary data with the flurbiprofen 
photoaffinity probe revealed that 134 is able to crosslink to the APP-CTF substrate 
(recombinant C100).  
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Scheme 3.28: Synthesis of photoaffinity label 134. 
 
 
This labelling can be competed away with NSAIDs that lower A?42 levels. The identification 
of the binding site of flurbiprofen on active ?-secretase complex via photoaffinity labelling 
with photoaffinity probe 134 is ongoing.  
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Figure 3.15: Dose response curve of compound 134 (BSc3583). 
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3.8. Design, Synthesis and Biological Evaluation of DAPT Derived 
Photoaffinity Label. 
PS is a membrane protein which undergoes endo-proteolytic processing within its putative 
loop region generating N-terminal and C-terminal fragments (PS-NTF and PS-CTF). It is 
believed to consist of six and two to four TMDs such as PS1 and PS2. PS expression is 
absolutely required for ?-secretase activity. Inactivation of PS1 in neurons obtained from PS1 
knock-out mice leads to a dramatic reduction of ?-secretase activity and an accumulation of 
the corresponding substrates, ?-APP CTFs. PS alone can not mediate ?-secretase activity. Its 
overexpression in cell culture systems and transgenic mice did not lead to an increase in A? 
production. In order to achieve this, co-expression of PS1 together with other transmembrane 
proteins nicastrin, Aph-1 and Pen-2 is required, allowing reconstitution of ?-secretase activity 
in yeast or other eukaryotic cells.[42] Combined biochemical evidence suggests that all these 
membrane proteins assemble into the enzymatically active ?-secretase complex with PS at its 
catalytic center. As a result of complex assembly, PS undergoes endoproteolysis into the 
active form of the enzyme. It is still unknown how exactly the substrate is hydrolyzed within 
the membranous hydrophobic environment which requires the presence of water molecule 
bound to the enzyme.  
Despite tremendous research efforts, much is not known about how ?-secretase carries out 
proteolytic activities in the hydrophobic environment. Various photoaffinity probes were 
employed using the known and confirmed ?-secretase inhibitors to investigate the mode of 
action and to identify the binding site of ?-secretase inhibitors. Peptidic PS1 inhibitors, like 
Merck’s L-685,458 (135, IC50 = 17 nM) is a potent inhibitor of ?-secretase. It was proposed 
that compound 135 acts as a direct transition-state analogue of the A?40 and A?42 cleavage 
sites (Scheme 3.29). The basic structure of 135 was linked to biotin and photoreactive 
fragments N- or C-terminally leading to L-852,505 (136) and L-852,646 (137), which were 
suitable for labelling studies. In spite of the attachment of photoreactive benzophenones, 136 
and 137 preserved inhibitory activity (IC50 < 1 nM). Biotin was used to facilitate the isolation 
and identification of the reversibly labelled adducts via their streptavidin-enzyme linked 
conjugates. Photolysis in the presence of solubilised ?-secretase and isolation on a biotin-
specific streptavidin-agarose gel provided a protein of 20 kD linked to L-852,505 (136). This 
fragment was shown to be the C-terminal fragment of PS1 (PS1-CTF) by specific antibodies. 
In a control experiment, the binding of 136 to wild type PS1 was negative. However, the 
binding to the deletion construct PS1?E9, which lacks the cytosolic E9 loop, was positive.[198] 
Useful information resulted from the photolysis of L-852,646 (137) in the presence of 
solubilised ?-secretase. This resulted in the isolation of a 34 kD fragment, which was assigned 
to be an N-terminal fragment of PS1. Elan’s semi-peptidic ?-secretase inhibitor DAPT (4, 
IC50=20 nM) was developed from N-dichlorophenylalanine lead. The SAR showed that the 
phenylglycine and the difluoro phenylacetic acid moieties are crucial for the activity.[199, 200] 
DAPT has displayed very good activity in vivo at relatively high doses. The subcutaneous 
application to mice in a dosage of 100 mg/kg, resulted in a 50% reduction of cortical A? 
levels within 3 hours. 40% A? reduction was observed at the dosage of 100 mg/kg orally, 
again after 3 hours, but no brain levels of DAPT were reported for the latter study.[201] Several 
preclinical studies carried out with DAPT found that it displays in vivo toxicity since DAPT 
affects the Notch pathway at higher levels (100 to1000-fold).[202, 203]  Kan et al. reported the 
solid phase supported synthesis of DAPT derived photoaffinity label 138.[204] The synthesis of 
138 took more than 18 steps. 
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Scheme 3.29:  ?-Secretase inhibitors derived photoaffinity probes. 
 
The binding mode of DAPT to ?-secretase is not fully known. DAPT and its analogues do not 
differentiate between the substrates such as APP and Notch. Therefore it is important to 
understand the mechanism of action and identify the binding modes of Notch selective 
inhibitors. 
3.8.1. Design and retrosynthetic analysis of DAPT derived photoaffinity label 
The DAPT derived photoaffinity label 139 was designed to elucidate the binding mode at 
more detail as depicted in Figure 3.16. The photoreactive group and the affinity label were 
introduced at C-terminal of DAPT since the difluoroacetic acid and phenyl glycine moieties 
are crucial for the ?-secretase inhibitory activity. Benzophenone was selected as a 
photoreactive group due to its chemical stability and reactivity. A biotin moiety was 
incorporated in the photoaffinity probe to facilitate isolation and identification of the adducts.   
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Figure 3.16: Design of DAPT derived photoaffinity label. 
 
The retrosynthetic analysis of DAPT derived photoaffinity label 140 is depicted in Scheme 
3.30.  
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Scheme 3.30: Retrosynthetic analysis of DAPT derived probe 139. 
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The amide bond of 140 can be constructed by peptide coupling of amine 141 and acid 142. 
The ester bond of 141 can be formed by esterification of acid DAPA 142 and alcohol 143. 
The amine 141 can be synthesized by two step synthesis from commercially available D-
biotin and N-Boc ethylene diamine. The acid 143 can be derived from DAPT. The alcohol 
144 can be synthesized from commercially available 4,4´-hydroxy benzophenone 148 by 
sequential alkylation of phenolic –OH using t-butyl chloroacetate and 2-chloro ethanol 
respectively. 
3.8.2. Synthesis of photoaffinity probe 139. 
The synthesis of probe 139 was commenced with the synthesis of DAPA 143 as illustrated in 
Scheme 3.31. The peptide coupling of Z-Ala 148 and Phg-tBu 149 was achieved using EDAC 
and HOBt as coupling reagents in CH2Cl2 to give the coupled product 150. Z-deprotection of 
150 was achieved by hydrogenation in MeOH at 60 psi to afford amine 151. Amine 151 was 
coupled with 3,5-difluorophenyl acetic acid using EDAC and HOBt as coupling reagents in 
CH2Cl2 to obtain DAPT 145 as colorless solid. The t-butyl cleavage of DAPT was 
accomplished using 20% trifluoroacetic acid in CH2Cl2 to give DAPA 142 as colorless solid. 
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Scheme 3.31: Synthesis of DAPA 142. 
 
The synthesis of building block 143 commenced from the commercially available 4,4´-
hydroxy benzophenone 147 as depicted in Scheme 3.32. One of the phenolic –OH of 147 was 
alkylated using t-butyl chloroacetate and anhydrous K2CO3 in dry acetone at 60–70 °C. The 
reaction yielded a mixture of mono- and di-alkylated product along with the unreacted 
starting material. This mixture was separated by column chromatography to afford the mono-
alkylated product 146. The phenolic –OH 146 of was alkylated using 2-chloroethanol and 
anhydrous K2CO3 in acetone at 60–70 °C to give the primary alcohol 143 in 60% yield.  
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Scheme 3.32: Synthesis of building block 143. 
 
The synthesis of amine 141 commenced from the commercially available D-biotin 144. N-
Boc ethylene diamine was coupled with D-biotin using EDAC and HOBt as coupling reagents 
in DMF to afford the product 152. The isolation of 152 from the reaction mixture and the 
purification by column chromatography was tedious due to its high polarity and poor 
solubility in CHCl3, CH2Cl2 and EtOAc. N-Boc deprotection 152 was achieved using 20% 
TFA in CH2Cl2 to obtain amine 141 as trifluoroacetic acid salt which was used in the next 
step without further purification (Scheme 3.33). 
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Scheme 3.33: Synthesis of amine 141. 
 
Different methods were employed for the synthesis of ester 153 as depicted in Scheme 3.34. 
EDAC and HOBt were used initially for the esterification of DAPA 142 with alcohol 143 in 
CH2Cl2 at room temperature. The TLC did not indicate the formation of any new spot apart 
from the starting material even after 120 h. This prompted the use of different coupling 
reagent such as DCC and PyBrop. But they helped little as TLC indicated no formation of 
product even after 120 h. Yamaguchi lactonization is a classical method for the synthesis of 
macrolactones and esters. This methodology was employed for the esterification of DAPA 
142 using the alcohol 143 and 2,4,6-trichlorobenzoyl chloride. The TLC indicated no 
formation of a product. This advocated the conversion of the acid into mixed anhydride using 
solid phase supported p-toluene sulfonyl chloride and solid phase supported DIEA as base. 
Nucleophilic attack of alcohol 143 at the carbonyl group of mixed anhydride was anticipated 
to afford the desired ester. But, even after 7 days, the TCL indicated no formation of product 
153.   
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Scheme 3.34: Different methods employed for the synthesis of ester 153. 
 
The unusual un-reactivity of alcohol 143 to undergo esterification impelled to convert it into a 
good leaving group such as –Br or Tos. Therefore, the primary alcohol 143 was tosylated 
using p-toluene sulfonyl chloride, pyridine and catalytic DMAP in DMF to afford 154 as 
outlined in Scheme 3.35. The reaction was very sluggish and TLC indicated 50% conversion 
even after 7 days. 
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Scheme 3.35: Synthesis of compound 154. 
 
The ester 153 was synthesized by nucleophilic substitution using DAPA 142, tosylated 
alcohol 154 and anhydrous K2CO3 in DMF as illustrated in Scheme 3.36. The reaction went 
smoothly and the desired ester 153 was purified by column chromatography as a colorless 
gummy mass. The t-butyl ester of 153 was cleaved using 20% TFA in CH2Cl2 to get acid 140 
as colorless solid. The acid 140 was coupled with amine 141 using EDAC and HOBt as 
coupling reagents  in DMF to afford the photoaffinity label 139 as cream colored solid.  
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Scheme 3.36: Synthesis of photoaffinity label 139. 
 
The final step in the synthesis of photoaffinity label 139 gave very poor yield. In order to 
improve the yield, the synthetic strategy was modified as outlined in Scheme 3.37. Acid 140 
was coupled with N-Boc ethylene diamine using EDAC and HOBt as coupling reagents in 
CH2Cl2 to afford 155. N-Boc deprotection of 155 was performed using 16% HCl in dioxane to 
get amine 156 as hydrochloride salt which was used in the next step without further 
purification. Amine 156 was coupled with D-biotin using EDAC and HOBt as coupling 
reagents in DMF to afford the photoaffinity label 139 as pale brown solid. As anticipated, the 
modification in the synthetic strategy improved the yield significantly in the final step. The 
introduction of biotin affected the solubility and the polarity dramatically of 139 . The low 
solubility of photoaffinity label in CHCl3 and CH2Cl2 made the isolation of the crude 
compound difficult from the reaction mixture. The isolated crude compound was purified by 
column chromatography using CHCl3:MeOH (4:1) as eluents to afford the desired 
photoaffinity label as pale brown solid. 
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Scheme 3.37: Modified synthesis of photoaffinity label 139. 
 
3.8.3. Synthesis of biotinylated benzophenone. 
The biotinylated benzophenone 162 was synthesized to use as a standard for the photoaffinity 
labelling experiment. The synthesis started from the commercially available 4-hydroxy 
benzophenone 157 as depicted in Scheme 3.38. The phenolic –OH of 157 was alkylated using 
t-butyl chloroacetate and anhydrous K2CO3 in acetone at 60–70 °C. The crude product was 
purified by crystallization to afford the t-butyl ester 158 as colorless solid. The t-butyl ester 
cleavage of 158 was achieved using 20% TFA in CH2Cl2 at room temperature and the crude 
product was purified by crystallization to get the acid 159 as colorless solid. The acid 159 was 
coupled with N-Boc ethylene diamine using EDAC and HOBt as coupling reagents in CH2Cl2 
at room temperature and further purification by column chromatography gave the coupled 
product 160 as colorless solid. N-Boc cleavage of 160 was accomplished using 16% HCl in 
dioxane to obtain amine hydrochloride 161 which was used in the next step without further 
purification. The amine 161 was coupled with D-biotin using EDAC and HOBt as coupling 
reagents in DMF at ambient temperature. Further purification by column chromatography 
using MeOH:CHCl3 (1:9) gave the biotinylated benzophenone 162 as cream colored solid. 
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Scheme 3.38: Synthesis of biotinylated benzophenone 162. 
 
3.8.4. Biological activity report 
The photoaffinity labelling experiment was carried out in collaboration with Dr. Harald 
Steiner, LMU Munich, Germany and Dr. Takeshi Iwatsubo, Japan. The interaction of the 
photoaffinity probes with ?-secretase was studied using solubilized ?-secretase to circumvent 
complications arising from limited uptake by cells of the biotinylated photoreactive 
compounds.  
 
 
 
Figure 3.17: Schematic representation of the typical photoaffinity labelling experiment carried out 
with 139. 
The photoaffinity probe 139 was photoactivated in the presence of solubilized ?-secretase to 
covalently label the active site of their aspartyl protease targets (Figure 3.17). Following 
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photoactivation, the reaction mixture was treated with CHAPSO buffer to increase the 
accessibility of the biotin group in the photolabelled proteins to streptavidin. The biotin-
linked photolabelled proteins were isolated from the reaction mixture by absorption on 
streptavidin-agarose beads. The covalently labelled proteins were then eluted from the beads, 
subjected to SDS±polyacrylamide gel electrophoresis (SDS±PAGE) and visualized by 
immunoblotting using an anti-biotin antibody. In the immunoblot analysis covalently labelled 
biotinylated species was obtained. The photoaffinity labelling experiment were performed in 
comparison with previously reported DAPTBpB 138.[204]  
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Figure 3.18: Dose response curve for 139 (BSc2170). 
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Figure 3.19: Dose response curve for DAPT. 
 
The photoaffinity probe 139 indeed labelled the active site of the PS, but it was very weak 
binding compared to the DAPTBpB 138. The photoaffinity probe DAPTBpB 138 labelled the 
PS-CTF and displayed strong binding.  
It was presumed that the introduction of the photoreactive group and an affinity label might 
have affected the ability to bind dramatically. Therefore, 139 was tested for its potential to 
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inhibit ?-secretase in the A? liquid phase electrochemiluminescence assay. Photoaffinity 
probe 139 was found to be a potent inhibitor of ?-secretase and displayed the inhibitory 
activity at nanomolar concentration. The introduction of benzophenone and biotin indeed 
reduced the inhibitory activity by 20-fold compared to DAPT (Figure 3.18, 3.19).  
The resemblance of compound 162 with the ketoprofen derived affinity probe 109 and 
biotinylated fenofibrate, advocated investigating the ability of 162 to modulate ?-secretase in 
the A? liquid phase electrochemiluminescence assay. As anticipated, the biotinylated 
benzophenone 162 was found to be an inverse modulator of ?-secretase (Figure 3.20). It 
affected the cleavage of ?38, ?40 and ?42 to a different extent and particularly increased the 
formation of A?42.  
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Figure 3.20: Dose response curve for 162 (BSc2253). 
 
In conclusion, DAPT derived photoaffinity label 139 was synthesized in solution phase by a 
straight forward synthesis compared to the simultaneously reported photoaffinity label 139. 
Photoreactive group, benzophenone and an affinity label, biotin were introduced at the C-
terminal of DAPT since the 3,5-difluoro phenyl and phenyl glycine moieties were crucial for 
the inhibitory activity. As anticipated, the photoaffinity label 139 preserved the ?-secretase 
inhibitory activity, but introduction of benzophenone and biotin moieties reduced the ?-
secretase inhibitory activity 20-fold compared to parent DAPT. To test the ability of 139 to 
label the active site of ?-secretase via covalent bond formation, the photoaffinity labelling 
experiment was performed. A very weak covalent bond formation with the PS, the active site 
of ?-secretase was observed when the photoaffinity labelling experiment was performed using 
139.  
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4. SUMMARY 
The final and critical cleavage in the APP processing which generates A? is carried out by ?-
secretase. ?-Secretase activity can be controlled either by the inhibition of the active site of 
PS1 or by interference with complex assembly or substrate recognition, the latter resulting 
from allosteric modulation or inhibition. Most of the reported and confirmed ?-secretase 
inhibitors are not substrate specific and inhibit the processing of other ?-secretase substrates 
equally. Long term treatment with ?-secretase inhibitors causes severe gastrointestinal toxicity 
and interferes with the maturation of B- and T-lymphocytes in mice. These effects are due to 
inhibition of Notch processing and signalling.[195] But, compounds which are capable of 
modulating the active ?-secretase and no effect on Notch would be ideal candidates for AD 
therapeutics. The allosteric mechanisms are particularly attractive targets for drug 
development, since they may control the ratio of the A? fragments: A?38, A?40 and A?42, 
while retaining the cleavage of other substrates.  
4.1. Synthesis of NSAIDs Derived ?-Secretase Inhibitors and Modulators 
NSAIDs offer the best solution to the substrate selectivity problem which is the major 
obstacle in development of AD therapeutics. NSAIDs derived secretase inhibitors were 
synthesized in order to reduce the COX inhibitory activity and increase the ?-secretase 
modulatory activity. Flurbiprofen, sulindac sulfoxide and meclofenamic acid were short listed 
and derivatization of the carboxylic acid common to these COX-1 inhibitors to its esters and 
amides was carried out. Flurbiprofen amides were found to be inverse modulators of ?-
secretase (56a–b) in the A? liquid phase electrochemiluminescence assay. Flurbiprofen 
amides (56c–p) did not display inhibitory activity on BACE-1 in FRET and in RLBA assay. 
A series of flurbiprofen derived esters was synthesized and tested for their ability to inhibit 
BACE-1 in FRET and RLBA assay. The conversion of the acid moiety of sulindac sulfoxide 
into its various amides (59a–l) resulted in either full inhibition (59c, 59e) or inverse 
modulation (59d, 59k, 59l). The classical modulatory activity was abolished due to the 
derivatization of the acid moiety. Meclofenamic acid derived amides (60a–d) were 
synthesized and tested for their potential to inhibit ?-secretase in A? liquid phase 
electrochemiluminescence assay. But, most of the compounds (60a-c) turned out to be inverse 
modulators of ?-secretase. They affected the ?-secretase cleavage at different extent and 
particularly increased the formation of most toxic and aggregation prone A?42 species while 
reducing the formation A?38. Only compound 60d was found to be inhibitor of ?-secretase. 
Thus, few of these initial derivatives displayed increased, unselective inhibition of ?-secretase 
in comparison to their parent drugs. Most of NSAID carboxylic acid derivatives resulted in 
loss of activity. This indicated an important contribution of the carboxylic acid to target 
affinity.  
4.2. Synthesis of N-Substituted Carprofen Derivatives as ?-Secretase Modulators 
After a brief investigation of sulindac analogues, the efforts were focused on carprofen, which 
is a COX-2 inhibitor approved for the use in dogs, cows and horses. N-sulfonylated carprofen 
derived amides and ester were synthesized and were expected inhibit ?-secretase due to their 
similarity with BMS-299897. But serendipitously, the N-substitution of carprofen turned it 
into a potent ?-secretase modulator and thus initial objective was adapted from inhibition to 
modulation. In accordance with previous results, N-substituted carprofen amides 64 and esters 
62 were found to be inverse modulators of ?-secretase. A series of N-sulfonylated carprofen 
derivatives was synthesized to optimize the lead compound 63b. N-Alkylated carprofen 
derivatives 66 were prepared to evaluate the contribution of the sulfonamide moiety in 63r 
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and the most active derivative 63p, where the sulfonamide is shielded by isopropyl 
substituents. 
The compounds 63a–63s and 66a–66f turned out to be effective modulators of ?-secretase. 
They affected the cleavage at the ?38, ?40 and ?42 sites to a different extent and particularly 
suppressed the formation of A?42, while enhancing the formation of A?38 and thus showed the 
typical profile of effective NSAIDs. The most active compounds were particularly 63p (A?42 
IC50 = 8.5 ?M), 66a (A?42 IC50 = 7.5 ?M) and 66f (A?42 IC50 = 2.9 ?M). The introduction of 
a single lipophilic substituent, which may vary from arylsulfone to alkyl substituents, 
transformed the COX-2 inhibitor carprofen into a ?-secretase modulator and improved 
potency 10-fold or more. Thus, several compounds caused the selective reduction of A?42 and 
an increase of the less aggregatory A?38. The most active compounds (63p, 66a and 66f) are 
more potent than the best reported NSAIDs and they are devoid of COX-1 and COX-2 
activity at the critical concentration; thus, they do not interfere with the delicate COX-1/COX-
2 balance. If affected at all, the ?-cleavage of ?-secretase was inhibited at much higher 
compound concentrations than those determined to be modulatory at the ?-site. The 
compounds are therefore expected to have little or no impact on ?-secretase mediated 
signalling via the AICD or via ICDs of other ?-secretase substrates. The most active 
compounds 63p, 66a and 66f are the potential lead candidates for the further optimization. 
4.2. Synthesis N-Substituted Carbazolyloxyacetic Acids as Substrate Specific ?-Secretase 
Modulators 
Knowing about the relevance of carprofen’s similarity with BMS-299897 and N-substitution 
of carprofen, N-Sulfonylated and N-alkylated carbazolyloxyacetic acids were synthesized. It 
was speculated that the lipophilic substituent anchors the N-substituted carbazolyloxyacetic 
acid in the required orientation within the membrane, thus the maximum tolerated length 
should be similar to natural phospholipids. To explore this hypothesis, N-alkylated 
carbazolyloxy acetic acids were synthesized using the alkyl halides of length equivalent to 
membrane phospholipids such as undecyl, dodecyl, tetradecyl and hexadecyl. As anticipated, 
N-sulfonylated compounds 70a–k and N-alkylated compounds 72a–g turned out to be 
effective modulators of ?-secretase. They affected the cleavage at the ?38, ?40 and ?42 sites to 
a different extent and particularly reduced the formation of A?42, while increasing the 
formation of A?38. The most active compounds were 70d (A?42 IC50 = 7.5 ?M), 72d (A?42 
IC50 = 11 ?M), 72e (A?42 IC50 = 8.2 ?M) and displayed activity at low micromolar 
concentration. The introduction of a lipophilic substituent, which may vary from arylsulfone 
to alkyl, turned 2-carbazolyloxyacetic acids into potent ?-secretase modulators. This resulted 
in the selective reduction of A?42 and an increase of the less aggregatory A?38 fragment by 
several compounds (e.g. 70d, 72d, 72e). Some in silico parameters of these lead candidates 
are close to the range of drug-like compounds, but the lipophilic substituents cause a dramatic 
increase of the CLogP. Introduction of an electron donating group such as methoxy, at 
position 6 and 8 of N-sulfonylated carbazolyloxyacetic acids either decreased or inversed the 
modulatory activity. The most active compounds displayed activity on APP overexpressing 
cell lines in the low micromolar range and little or no effect on the ?-secretase cleavage at the 
?-site. If affected at all, the ?-cleavage of ?-secretase was inhibited at much higher compound 
concentrations than those determined to be modulatory at the ?-site. Therefore, these lead 
compounds are ideal ones for further optimization since they fulfil the criteria for an ideal 
compound for AD therapy: reduction of toxic A?42 levels, no effect on the other cleavages 
such as AICD and no COX inhibitory activity. 
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4.3. Structurally Modified Analog of LXR-Agonist TO-901317 as Modulator of ?-
Secretase 
It was very much evident from the SAR of N-substituted carprofen derivatives[120] and N-
substituted carbazolyloxyacetic acids[182] that the free acid is crucial for the modulatory 
activity. LXR-agonist 81 (TO-901317) was found to be an inverse modulator of ?-secretase. It 
increased selectively the formation of A?42 and reduced the formation of less aggregatory 
A?38 in cellular assay. Knowing about the relevance of free acid moiety and modulation of ?-
secretase, an analog of 81 was synthesized, but the hexafluorocarbinol moiety was replaced 
by an oxyacetic acid  moiety. As anticipated, the replacement of the hexafluorocarbinol 
moiety by an oxyacetic acid group dramatically changed the mode of action from inverse 
modulation to normal modulation of ?-secretase. Compound 81 (A?42 IC50 = 19.6 ?M) was 
found to be a modulator of ?-secretase and reduced selectively the formation of A?42, while 
increasing the formation of A?38 in A? liquid phase electrochemiluminescence assay. In 
consistence with previous results, the ester derivative of 87 was found to be an inverse 
modulator of ?-secretase. This confirms the hypothesis that the free acid moiety is mandatory 
for the modulatory activity for ?-secretase. This significant structural modification can be 
applied to the known inverse modulators of ?-secretase such as celecoxib and rofecoxib. That 
might change their mode of action from inverse modulation to normal modulation of ?-
secretase. 
4.4. Curcumin derived heterocycles: Swiss knives for AD 
 
4.5. Synthesis and Biological Evaluation of NSAIDs Derived Affinity Probes 
A set of biotinylated NSAIDs was synthesized to identify the binding identify the binding 
partner via immunoprecipitation. The synthesis of biotinylated NSAIDs was commenced with 
the commercially available COX and COX-2 inhibitors such as flurbiprofen, ketoprofen, 
meclofenamic acid, sulindac sulfoxide and carprofen. Initially the carboxylic acid common 
with NSAIDs was derivatized for biotin incorporation which resulted in the loss of activity or 
inversion in modulation. They affected the cleavage at the ?38, ?40 and ?42 sites to a different 
extent and particularly increased the formation of A?42, while increasing the formation of 
A?38. Amongst the tested affinity labels (94, 98, 101, 105, 109 and 112), only 94 was able to 
capture ?-secretase complex in dose dependant manner but failed to pull down the active 
complex. The SAR advocated the synthesis of the affinity probes without disturbing acid 
moiety of the NSAIDs to conserve the modulatory activity. Therefore, the biotinylated 
flurbiprofen 117 and N-substituted carprofen 126 were synthesized keeping the acid moiety 
intact. As anticipated, the introduction of biotin in the presence of the acid moiety resulted in 
the modulation of ?-secretase. An immunoprecipitation assay carried out with affinity probe 
117 indicated that the biotin bound unspecifically. 117 turned out to be unsuitable bait for the 
pull down of ?-secretase active complex. 
4.6. Synthesis and Biological Evaluation of Flurbiprofen and DAPT derived 
Photoaffinity Probes 
Flurbiprofen and DAPT derived photoaffinity probes (134 and 139) were synthesized in order 
to identify the binding site on ?-secretase and their mode of action. Photoaffinity labelling 
experiments carried out with the photoaffinity probe 139 revealed that it binds covalently to 
PS, but the observed binding was very weak. Moreover, the introduction of a photoreactive 
group and the affinity tag did not reduce the ?-secretase inhibitory activity significantly. But, 
the photoaffinity labelling experiment carried out with flurbiprofen derived photoaffinity 
probe 134 disclosed that it binds to the C-terminal fragment of PS, on the enzyme of the 
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active ?-secretase complex. The identification of the binding site of flurbiprofen on active ?-
secretase complex via photoaffinity labelling with photoaffinity probe 134 is ongoing.  
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5. EXPERIMENTAL 
 
5.1 Instrumentation and General Experimental Considerations 
5.1.1. Thin layer chromatography (TLC) 
Thin-layer chromatography (TLC) was carried out using aluminum sheets precoated with 
silica gel 60 F254 (0.2 mm; E. Merck). Chromatographic spots were visualized by UV and/or 
spraying with an acidic, ethanolic solution of p-anisaldehyde or an ethanolic solution of 
ninhydrin followed by heating. For preparative TLC plates precoated with silica gel 60 F254 
(2.0 mm; E. Merck) were used.  
5.1.2. Column chromatography 
Flash column chromatography was carried out using Merck silica gel 60 (40-63 and 15-40 
?m) and 60G (5-40 ?m). 
5.1.3. Melting points 
Measurements below 200 °C were determined on a Büchi 510 melting point apparatus and 
above 200 °C were carried out on a Kofler-Heiztischmikroskop apparatus and are 
uncorrected. 
5.1.4. NMR spectroscopy 
The 1H spectra were recorded on a Bruker AC 300 and AC 500 spectrometer at 300 and 500 
MHz. The 13C spectra was recorded on Bruker AC 300 and AC 500 spectrometer at 75 and 
125 MHz. Chemical shifts are reported as % values (ppm) downfield from Me4Si. 
5.1.5. Mass spectrometry 
Mass spectrometry was performed on a Bruker-Franzen Esquire LC mass spectrometer. 
5.1.6. Drying of solvents 
THF was dried and distilled from sodium and benzophenone under nitrogen prior to use. 
DMF was stored over 3 Å molecular sieves. All other commercial chemicals were used 
without further purification. CH2Cl2 and Et3N were distilled from CaH2 under nitrogen prior 
to use. Amino acid derivatives were bought from Fluka Chemie (Switzerland), NovaBiochem 
(Switzerland), or Bachem (Switzerland). All other chemicals were of reagent quality and used 
as obtained from the manufacturers. Reactions were carried out in Ar when necessary. 
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5.2. Synthesis of NSAID Derivatives as Potential ?-Secretase Inhibitors and 
Modulators. 
5.2.1. General procedure for peptide coupling using EDAC as coupling reagent 
1.0 equiv. Et3N was added to a solution of 1.0 equiv. of acid in CH2Cl2 which was followed 
by the addition of 1.0 equiv. ethyl-3-(3´-dimethylaminopropyl) carbodiimide hydrochloride 
(EDAC) and 1.2 equiv. HOBt (N-hydroxybenzotriazole hydrate) and stirred at RT until it 
became clear. 1.2 equiv. Et3N and 1.2 equiv. amine were added to it simultaneously. The 
reaction mixture was kept on stirring at RT for 2-24 h and monitored by TLC. The reaction 
mixture was diluted with CH2Cl2. The organic phase was washed sequentially with NaHCO3, 
(0.1 N) HCl and brine simultaneously. The organic phase was dried over anhydrous Na2SO4 
and the solvent was evaporated in vacuo to afford the crude product which was further 
purified by column chromatography to obtain the pure product. 
5.2.2. General procedure for esterification using EDAC as coupling reagent 
1.0 equiv. Et3N was added to a solution of 1.0 equiv. of acid in CH2Cl2 which was followed 
by the addition of 1.0 equiv. ethyl-3-(3´-dimethylaminopropyl) carbodiimide hydrochloride 
(EDAC, 1.2 equiv. HOBt (N-hydroxybenzotriazole hydrate) and stirred at RT until it became 
clear. 1.2 equiv. Et3N and 1.2 equiv. alcohol was added to it simultaneously. The reaction 
mixture was kept on stirring at RT for 6–48 h and monitored by TLC. The reaction mixture 
was diluted with CH2Cl2. The organic phase was washed sequentially with NaHCO3, (0.1 N) 
HCl and brine simultaneously. The organic phase was dried over anhydrous Na2SO4 and the 
solvent was evaporated in vacuo to afford the crude product which was further purified by 
column chromatography to obtain the pure product. 
5.2.3. Synthesis of Flurbiprofen Derivatives 
5.2.3.1. Synthesis of flurbiprofen derived amides. 
5.2.3.1.1 N-(Benzo[d][1,3]dioxol-5-ylmethyl)-2-(2-fluorobiphenyl-4-yl)propanamide (56a) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2-fluoro-4-biphenyl)propanoic acid (100 mg, 0.4 mmol), EDAC (94 mg, 0.5 
mmol), HOBt (69 mg, 0.5 mmol), Et3N (125 ?L, 0.9 mmol), (benzo[d][1,3]dioxol-6-
yl)methanamine (75 mg, 0.5 mmol). 
Yield: 115 mg, 75%. 
1H NMR (300 MHz, CDCl3): ? = 7.45 (dd, J = 6.6 Hz, J = 1.5 Hz, 2H; H-3), 7.40-7.27 (m, 
5H; H-1, H-2, H-6, H-7), 7.07 (m, 1H; H-9), 6.65-6.55 (m, 3H; H-15, H-16, H-20), 5.84 (s, 
2H; H-18), 5.69 (brs, 1H; NH), 4.26 (dd, J = 14.7 Hz, J = 5.8 Hz, 1H; H-13), 4.21 (dd, J = 
14.7 Hz, J = 5.8 Hz, 1H; H-13´), 3.53 (q, J = 7.2 Hz, 1H; H-11), 1.49 (d, J = 7.2 Hz, 3H; H-
12) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 173.3 (C-11), 159.1 (C-10), 148.0 (C-17, C-19), 142.7 (C-
8), 142.6 (C-4), 135.4 (C-14), 131.1 (C-5), 130.1 (C-6), 129.0 (C-2), 128.5 (C-3), 127.8 (C-1), 
123.6 (C-7), 121.0 (C-15), 115.5 (C-9), 115.2 (C-16), 108.3 (C-20), 101.1 (C-18), 46.7 (C-
11), 43.6 (C-13), 18.7 (C-12) ppm. 
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5.2.3.1.2 2-(2-Fluorobiphenyl-4-yl)-N-(4-methoxybenzyl)propanamide (56b) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2-fluoro-4-biphenyl)propanoic acid (100 mg, 0.4 mmol), EDAC (94 mg, 0.5 
mmol), HOBt (69mg, 0.5 mmol), Et3N (125 ?L, 0.9 mmol), 4-methoxybenzyl amine (67 mg, 
0.5 mmol). 
Yield: 119 mg, 80%. 
1H NMR (300 MHz, CDCl3): ? = 7.45 (dd, J = 7.0 Hz, J = 1.4 Hz, 2H; H-3), 7.38-7.25 (m, 
4H; H-1, H-2, H-6), 7.08-7.02 (m, 4H; H-H-7, H-9, H-15), 6.75 (dd, J = 8.8 Hz, J = 2.4 Hz, 
2H; H-16), 5.66 (brs, 1H; NH), 4.32 (dd, J = 14.6 Hz, J = 5.6 Hz, 1H; H-13), 4.26 (dd, J = 
14.6 Hz, J = 5.6 Hz, 1H; H-13´), 3.70 (s, 3H; H-18), 3.49 (q, J = 7.6 Hz, 1H; H-11), 1.49 (d, J 
= 7.6 Hz, 3H; H-12) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 173.3 (C-11), 159.1 (C-10), 158.2 (C-17), 142.8 (C-8), 
142.7 (C-4), 135.4 (C-14), 131.1 (C-5), 130.3 (C-6), 129.5 (C-2), 129.0 (C-15), 128.5 (C-3), 
127.8 (C-1), 123.7 (C-7), 115.5 (C-9), 114.1 (C-16), 55.3 (C-18), 46.7 (C-11), 43.3 (C-13), 
18.7 (C-12) ppm. 
MS (EI): m/z = 363 (M+, 23% ), 199 (20%), 121 (100%) 
5.2.3.1.3 Compound 56c–56p 
Compounds 56c–56p were synthesized using the general procedure mentioned in 5.2.1.  
Reactants: 2-(2-fluoro-4-biphenyl)propanoic acid (40 mg, 0.16 mmol), EDAC (38 mg, 0.2 
mmol), HOBt (27 mg, 0.2 mmol), Et3N (125 ?L, 0.36 mmol), Amine (0.2 mmol). The amount 
of various amines used and the yield is depicted in the Table 5.1. 
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Table 5.1: Structure and amount of various amines used in the synthesis of compounds 56c–
p. 
 
Compound Amount Amine Yield  
 
56c 
 
25 ?L 
 
H2N Ph  
 
37 mg  
(61%) 
 
56d 
 
20 ?L 
 
N
H2N
 
30 mg 
(55%) 
 
56e 
 
50 mg 
ClH.H2N
OMe
O
NH
 
48 mg 
(67%) 
 
56f 
 
49 mg 
ClH.H2N
OMe
O
OtBu
O  
49 mg 
(64%) 
 
56g 
 
22 ?L N
N
H
38 mg  
(72%) 
 
56h 
 
36 mg 
      
ClH.H2N
OMe
O
 
57 mg 
(86%) 
 
56i 
 
16 ?L 
 
OH
H2N
 
20 mg  
(41%) 
 
56j 
 
25 ?L 
 
H2N
Ph
 
 
38 mg  
(68%) 
 
56k 
 
 
29 mg 
ClH.H2N
OMe
O
 
33 mg 
(55%) 
 
56l 
 
27 ?L 
 
HN
 
31 mg  
(58%) 
56m & 
56n 
24 mg 
ClH.H2N
OMe
O
OH 20 mg (48m) 
18 mg (48n) 
60% combine 
 
56o & 
56p 
 
47 mg 
ClH.H2N
O
O
OH  
28 mg (48o) 
25 mg (48p) 
70% combine  
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5.2.3.2. Synthesis of flurbiprofen derived esters. 
5.2.3.2.1. Flurbiprofen derived esters 57a–57i 
Compound 57a–57i were synthesized by following the general procedure mentioned in 5.2.2. 
Reactants: 2-(2-fluoro-4-biphenyl)propanoic acid (40 mg, 0.16 mmol), EDAC (38 mg, 0.2 
mmol), HOBt (27 mg, 0.2 mmol), Et3N (125 ?L, 0.36 mmol), Alcohol (0.2 mmol).  
The amount of various alcohols used and the yield is depicted in the Table 5.2. 
 
Table 5.2: Structure and amount of various alcohols used in the synthesis of compounds 57a–
i.  
Entry Compound Amount Alcohol Yield 
 
1 
 
57a 
 
16 ?L 
H2
C
O
HO
16 mg 
(35%) 
 
2 
 
57b 
 
17 ?L CH
OH
 
26 mg 
(43%) 
 
3 
 
57c 
 
16 ?L 
 
 
C
H
HO
 
24 mg 
(48%) 
 
4 
 
57d 
 
15 ?L 
 
O
HO
 
30 mg 
(55%) 
 
5 
 
57e 
 
16 ?L 
 
N
HO
 
35 mg 
(65%) 
 
6 
 
57f 
 
20 ?L 
 
HO
 
32 mg 
(57%) 
 
7 
 
57g 
 
21 ?L 
 
O
HO
 
22 mg 
(40%) 
 
8 
 
57h 
 
25 ?L 
 
 
O
O OH
 
20 mg 
(34%) 
 
9 
 
57i 
 
21 ?L 
 
O
O
HO
 
23 mg 
(40%) 
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5.2.3.2.1. Benzyl 2-(2-fluorobiphenyl-4-yl)propanoate (57j) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.2. 
Reactants: 2-(2-fluoro-4-biphenyl)propanoic acid (100 mg, 0.4 mmol), EDAC (94 mg, 0.5 
mmol), HOBt (69 mg, 0.5 mmol), Et3N (125 ?L, 0.9 mmol), benzyl alcohol (53 mg, 0.5 
mmol). 
1H NMR (300 MHz, CDCl3): ? = 7.46-7.41 (m, 2H; H-3), 7.37-7.18 (m, 9H; H-1, H-2, H-5, 
H-15, H-16, H17), 7.07-7.01 (m, 2H; H-7, H-9), 5.08 (d, J = 6.4 Hz, 1H; H-13), 5.04 (d, J = 
6.4 Hz, 1H; H-13´), 3.72 (q, J = 7.2 Hz, 1H; H-11), 1.47 (d, J = 7.2 Hz, 3H; H-12) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 173.9 (C-11), 161.4 (C-10), 141.8 (C-14), 141.7 (C-8), 
135.9 (C-4), 130.9 (C-5), 130.8 (C-6), 129.5 (C-2), 129.0 (C-16), 128.6 (C-3), 128.3 (C-15), 
128.1 (C-1), 127.7 (C-17), 126.4 (C-7), 115.5 (C-9), 66.8 (C-13), 45.1 (C-11), 18.4 (C-12) 
ppm. 
MS (EI): m/z = 334 (M+, 38%), 199 (100%), 91 (28%). 
5.2.4. Synthesis of Sulindac Sulfoxide Derived Amides. 
Compounds 59a–59l were synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-((1Z)-1-(4-(Methylsulfinyl)benzylidene)-5-fluoro-2-methyl-1H-inden-3-
yl)acetic acid (60 mg, 0.17 mmol), EDAC (36 mg, 0.19 mmol), HOBt (27 mg, 0.2 mmol), 
Et3N (52 ?L, 0.45 mmol), Amine (0.2 mmol). 
The amount of various amines used and the yield is depicted in the Table 5.3. 
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Table 5.3: Structure and amount of various amines used in the synthesis of compounds 59a–
59l. 
 
Entry Compound Amount Amines Yield 
 
1 
 
59a 
 
26 ?L 
 
H2N Ph  
 
47 mg 
(61%) 
 
2 
 
59b 
 
21 ?L 
 
N
H2N
 
41 mg 
(55%) 
 
3 
 
59c 
 
52 mg 
 
 ClH.H2N OMe
O
NH
 
67 mg 
(67%) 
 
4 
 
59d 
 
33 mg 
ClH.H2N
OMe
O
OH 49 mg 
(64%) 
 
5 
 
59e 
 
50 mg 
 ClH.H2N OMe
O
OtBu
O  
70 mg 
(72%) 
 
6 
 
59f 
 
48 mg 
ClH.H2N
O
O
OH  
83 mg 
(86%) 
 
7 
 
59g 
 
21 mg N
N
H  
30 mg 
(41%) 
 
 
8 
 
59h 
 
37 mg 
      
ClH.H2N
OMe
O
 
59 mg 
(68%) 
 
9 
 
59i 
 
16 ?L 
 
OH
H2N
 
38 mg 
(55%) 
 
10 
 
59j 
 
26 ?L 
 
H2N
Ph
 
 
44 mg 
(58%) 
 
11 
 
59k 
 
30 mg 
ClH.H2N
OMe
O
 
61 mg 
(75%) 
 
12 
 
59l 
 
28 ?L 
 
HN
 
39 mg 
(53%) 
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5.2.4. Synthesis of Meclofenamic Acid Derived Amides. 
5.2.4.1. (S)-Methyl 2-(2-(2,6-dichloro-3-methylphenylamino)benzamido)-3-(1H-indol-3-
yl)propanoate (60a) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2,6-dichloro-3-methylphenylamino)benzoic acid (60 mg, 0.18 mmol), EDAC 
(94 mg, 0.22 mmol), HOBt (69 mg, 0.22 mmol), Et3N (62 ?L, 0.45 mmol), Tryptophan 
methyl ester hydrochloride (58 mg, 0.22 mmol). 
Yield: 75 mg, 75%. 
1H NMR (300 MHz, CDCl3): ? = 9.11 (brs, 1H; NH), 8.09 (brs, 1H; NH), 7.47 (d, J = 7.8 
Hz, 1H; H-11), 7.21-7.17 (m, 2H; H-1, H-9), 7.11-7.06 (m, 2H; H-21, H-24), 7.03-6.93 (m, 
3H, H-19, H-22/23), 6.69 (d, J = 7.5 Hz, 1H; H-8), 6.61 (t, J = 7.0 Hz, 1H; H-10), 6.29 (d, J = 
8.4 Hz, 1H; H-2), 5.08-5.03 (m, 1H; H-14), 3.64 (s, 3H; H-17), 3.46-3.41 (m, 2H; H-15), 2.31 
(s, 3H; H-26) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 172.5 (C-16), 169.0 (C-13), 145.5 (C-7), 136.4 (C-20), 
136.2 (C-5), 135.7 (C-3), 135.0 (C-4), 133.3 (C-9), 130.2 (C-11), 127.8 (C-1), 127.7 (C-25), 
126.8 (C-6), 123.0 (C-19), 122.3 (C-23), 121.3 (C-2), 121.2 (C-22), 119.8 (C-8), 119.4 (C-
24), 118.4 (C-10), 114.8 (C-21), 111.0 (C-18), 53.4 (C-14), 52.6 (C-17), 30.7 (C-15), 20.7 (C-
26) ppm. 
5.2.4.2. (S)-Di-tert-butyl 2-(2-(2,6-dichloro-3-methylphenylamino)benzamido)succinate 
(60b) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2,6-dichloro-3-methylphenylamino)benzoic acid (60 mg, 0.18 mmol), EDAC 
(94 mg, 0.22 mmol), HOBt (69 mg, 0.22 mmol), Et3N (62 ?L, 0.45 mmol), 
Asp(OtBu)tBu.HCl (56 mg, 0.22 mmol). 
Yield: 83 mg, 78%. 
1H NMR (300 MHz, CDCl3): ? = 9.27 (brs, 1H; NH), 7.45 (dd, J = 7.8 Hz, J = 1.4 Hz, 1H; 
H-11), 7.17-7.12 (m, 2H; H-8/9), 6.98 (d, J = 8.0 Hz, 1H; H-1), 6.71 (t, J = 7.0 Hz, 1H; H-
10), 6.32 (d, J = 8.4 Hz, 1H; H-2),4.84-4.79 (m, 1H; H-14), 2.92 (dd, J = 7.0 Hz, J = 4.4 Hz, 
1H; H-18), 2.82 (dd, J = 7.0 Hz, J = 4.4 Hz, 1H; H-18´), 2.31 (s, 3H; H-22), 1.41 (s, 9H; H-
21), 1.38 (s, 9H; H-17) ppm.  
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13C NMR (75 MHz, CDCl3):? ? = 170.5 (C-19), 170.1 (C-15), 168.5 (C-13), 145.7 (C-7), 
136.4 (C-5), 135.8 (C-3), 133.4 (C-4), 132.3 (C-9), 130.3 (C-11), 127.7 (C-1), 127.2 (C-6), 
122.0 (C-2), 120.1 (C-12), 118.0 (C-8), 114.7 (C-10), 82.5 (C-20), 81.7 (C-16), 49.4 (C-14), 
37.6 (C-18), 28.1 (C-21), 28.0 (C-17), 20.7 (C-22) ppm. 
5.2.4.3. N-(2-(1H-Indol-3-yl)ethyl)-2-(2,6-dichloro-3-methylphenylamino)benzamide 
(60c) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2,6-dichloro-3-methylphenylamino)benzoic acid (60 mg, 0.18 mmol), EDAC 
(94 mg, 0.22 mmol), HOBt (69 mg, 0.22 mmol), Et3N (62 ?L, 0.45 mmol), tryptamine (37 
mg, 0.22 mmol). 
Yield: 64 mg, 72%. 
1H NMR (300 MHz, CDCl3): ? = 9.21 (brs, 1H; NH), 8.04 (brs, 1H, NH), 7.57 (d, J = 7.8 
Hz, 1H; H-11), 7.28 (d, J = 7.8 Hz, 1H; H-1), 7.22-6.95 (m, 7H; H-8/9, H-17, H-19/20/21/22), 
6.62 (t, J = 7.8 Hz, 1H; H-10), 6.29 (dd, J = 8.2 Hz, 1H; H-2), 6.13 (brs, 1H, NH), 3.72 (q, J = 
6.4 Hz, 2H; H-14), 3.03 (t, J = 6.4 Hz, 2H; H-15), 2.31 (s, 3H; H-24) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 169.6 (C-13), 145.2 (C-7), 136.4 (C-18), 135.8 (C-5), 135.1 
(C-3), 135.0 (C-4), 133.2 (C-9), 131.9 (C-11), 130.1 (C-23), 127.8 (C-1), 126.6 (C-6), 122.4 
(C-17), 122.3 (C-21), 121.4 (C-2), 120.8 (C-12), 120.4 (C-20), 119.6 (C-8), 118.8 (C-22), 
118.0 (C-10), 114.8 (C-19), 111.4 (C-16), 42.3 (C-14), 25.3 (C-15), 20.7 (C-24) ppm. 
5.2.4.4. 2-(2,6-Dichloro-3-methylphenylamino)-N-(2-(5-hydroxy-1H-indol-3-
yl)ethyl)benzamide (60d) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2,6-dichloro-3-methylphenylamino)benzoic acid (60 mg, 0.18 mmol), EDAC 
(94 mg, 0.22 mmol), HOBt (69 mg, 0.22 mmol), Et3N (62 ?L, 0.45 mmol), seritonin 
hydrochloride (48 mg, 0.22 mmol). 
Yield: 55 mg, 60%. 
1H NMR (300 MHz, CDCl3): ? = 8.78 (brs, 1H; NH), 7.25 (dd, J = 7.8 Hz, J = 1.2 Hz, 1H; 
H-11), 7.22 (d, J = 8.2 Hz, 1H; H-1), 7.13-7.07 (m, 3H; H-9, H-17, H-19), 6.99-6.93 (m, 2H; 
H-8, H-22), 6.81 (brs, 1H; NH), 6.69 (d, J = 8.8 Hz, 1H; H-20), 6.64 (t, J = 7.0 Hz, 1H; H-
10), 6.27 (dd, J = 8.4 Hz, 1H; H-2), 3.65 (q, J = 6.9 Hz, 2H; H-14), 2.97 (t, J = 6.9 Hz, 2H; H-
15), 2.31 (s, 3H H-24) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 169.9 (C-13), 150.1 (C-21), 144.8 (C-7), 136.4 (C-5), 135.6 
(C-3), 135.2 (C-4), 133.0 (C-9), 131.8 (C-18), 131.4 (C-23), 129.9 (C-11), 126.6 (C-1), 125.8 
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(C-6), 123.2 (C-17), 122.3 (C-2), 121.4 (C-12), 120.8 (C-8), 119.6 (C-10), 118.0 (C-19), 
114.7 (C-20), 113.0 (C-16), 113.7 (C-22), 39.9 (C-14), 25.2 (C-15), 20.5 (C-24) ppm 
5.3. Synthesis of Carprofen Derived ?-Secretase Modulators 
5.3.1. Synthesis of compound 61, 62, 63, 65 and 66 
The synthetic procedures and spectral data of compounds 61, 62, 63, 65 and 66 is published in 
the supplementary material of the article “The Scaffold of the COX-2 Inhibitor Carprofen 
Provides Alzheimer ?-Secretase Modulators, Journal of Medicinal Chemistry, 2006, 49 (26), 
7588-7591.” The material is available free of charge via the Internet at http://pubs.acs.org. 
5.3.2. Synthesis of 2-(6-Chloro-9-tosyl-9H-carbazol-2-yl)propanoic acid amides (64) 
5.3.2.1. (2S)-Methyl 2-(2-(6-chloro-9-tosyl-9H-carbazol-2-yl)propanamido)-3-(1H-
imidazol-4-yl)propanoate (64a) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(6-Chloro-9-tosyl-9H-carbazol-2-yl)propanoic acid  (63a) (25 mg, 0.06 mmol), 
EDAC (14 mg, 0.07 mmol), HOBt (9.5 mg, 0.7 mmol), Et3N (15 ?L, 0.13 mmol), His-
OMe.HCl (12 mg, 0.07 mmol). 
Yield: 23 mg, 70%. 
1H NMR (300 MHz, CDCl3): ? = 8.22 (d, J = 1.2 Hz, 1H; H-5), 8.17 (d, J = 8.9 Hz, 1H; H-
4), 7.74 (d, J = 2.1 Hz, 1H; H-1), 7.71 (d, J = 8.0 Hz, 1H; H-8), 7.58 (dd, J = 8.6, J = 1.9 Hz, 
2H; H-17), 7.48 (s, 1H; H-24), 7.37 (dd, J = 8.8, J = 2.1 Hz, 1H; H-3), 7.27 (dd, J = 8.3, J = 
1.4 Hz, 1H; H-7), 7.03 (d, J = 8.0 Hz, 2H; H-18), 6.80 (s, 1H; H-26), 4.72-4.64 (m, 1H; H-
21), 3.84 (q, J = 7.2 Hz, 1H; H-13), 3.71 (s, 3H; H-28), 3.06-2.94 (m, 2H; H-22), 2.19 (s, 3H; 
H-20), 1.53 (d, J = 7.2 Hz, 3H; H-14) ppm.  
13C NMR (75 MHz, CDCl3): ? = 172.7 (C-15), 172.3 (C-20), 145.3 (C-16), 139.1 (C-12), 
137.0 (C-10), 135.6 (C-24), 135.1 (C-19), 134.3 (C-18), 129.7 (C-17), 127.7 (C-6), 126.5 (C-
11), 122.5 (C-5), 121.9 (C-3), 120.2 (C-4), 119.8 (C-7), 119.4 (C-26), 116.3 (C-8), 114.6 (C-
1), 104.6 (C-9), 54.5 (C-26), 45.9 (C-13), 30.1 (C-22), 21.4 (C-20), 18.7 (C-14) ppm.  
MS (ESI): m/z = 601.2 (M + Na)+. 
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5.3.4.2. 2-(6-Chloro-9-tosyl-9H-carbazol-2-yl)-N-(3-methylisothiazol-5-yl)propanamide 
(64b) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(6-Chloro-9-tosyl-9H-carbazol-2-yl)propanoic acid (63a) (25 mg, 0.06 mmol), 
EDAC (14 mg, 0.07 mmol), HOBt (9.5 mg, 0.07 mmol), Et3N (15 ?L, 0.13 mmol), 3-
methylisothiazol-5-amine (10.6 mg, 0.07 mmol). 
Yield: 13 mg, 40%. 
1H NMR (300 MHz, CD3OD): ? = 8.21(d, J = 1.2 Hz, 1H; H-5), 8.14 (d, J = 8.9 Hz, 1H; H-
4), 7.71 (d, J = 2.1 Hz, 1H; H-1), 7.67 (d, J = 8.0 Hz, 1H; H-8), 7.54 (dd, J = 8.6, J = 1.9 Hz, 
2H; H-17), 7.34 (dd, J = 8.8, J = 2.1 Hz, 1H; H-3), 7.29 (s, 1H, H-22), 7.23 (dd, J = 8.3, J = 
1.4 Hz, 1H; H-7), 7.03 (d, J = 8.0 Hz, 2H; H-18), 3.84 (q, J = 7.2 Hz, 1H; H-13), 2.41 (s, 3H; 
H-24), 2.19 (s, 3H; H-20), 1.53 (d, J = 7.2 Hz, 3H; H-14) ppm.  
13C NMR (75 MHz, CD3OD): ? = 172.7 (C-15), 166.5 (C-23), 148.1 (C-21), 145.1 (C-16), 
139.3 (C-12), 137.2 (C-10), 134.5 (C-18), 130.7 (C-17), 127.9 (C-6), 126.4 (C-11), 122.1 (C-
5), 121.0 (C-3), 120.1 (C-4), 119.3 (C-7), 116.1 (C-8), 114.0 (C-1), 107.2 (C-22), 104.1 (C-9), 
45.9 (C-13), 24.4 (C-20), 19.1 (C-24), 18.3 (C-14) ppm.  
MS (ESI): m/z = 549.9 (M + Na)+. 
5.3.4.3. 2-(6-Chloro-9-tosyl-9H-carbazol-2-yl)-N-(1H-1,2,4-triazol-3-yl)propanamide 
(64c) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(6-Chloro-9-tosyl-9H-carbazol-2-yl)propanoic acid  (63a) (25 mg, 0.06 mmol), 
EDAC (14 mg, 0.07 mmol), HOBt (9.5 mg, 0.07 mmol), Et3N (15 ?L, 0.13 mmol), 1H-1,2,4-
triazol-3-amine (10.6 mg, 0.07 mmol). 
Yield: 9 mg, 32%. 
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1H NMR (300 MHz, CD3OD): ? = 8.31 (s, 1H; H-22), 8.19 (d, J = 1.2 Hz, 1H; H-5), 8.14 (d, 
J = 8.9 Hz, 1H; H-4), 7.70 (d, J = 2.1 Hz, 1H; H-1), 7.68 (d, J = 8.0 Hz, 1H; H-8), 7.49 (dd, J 
= 8.6, 1.9 Hz, 2H; H-17), 7.31 (dd, J = 8.8, J = 2.1 Hz, 1H; H-3), 7.25 (dd, J = 8.3, J = 1.4 Hz, 
1H; H-7), 7.06 (d, J = 8.0 Hz, 2H; H-18), 3.79 (q, J = 7.2 Hz, 1H; H-13), 2.16 (s, 3H; H-20), 
1.55 (d, J = 7.2 Hz, 3H; H-14) ppm.  
13C NMR (75 MHz, CD3OD): ? = 172.7 (C-15), 155.6 (C-21), 154.9 (C-22), 145.1 (C-16), 
139.7 (C-12), 137.6 (C-10), 134.5 (C-18), 130.4 (C-17), 127.9 (C-6), 126.1 (C-11), 122.8 (C-
5), 121.2 (C-3), 120.1 (C-4), 119.2 (C-7), 116.8 (C-8), 114.5 (C-1), 104.8 (C-9), 46.2 (C-13), 
22.4 (C-20), 18.6 (C-14) ppm.  
MS (ESI): m/z = 516.1 (M + Na)+. 
5.4. Synthesis of N-Substituted Carbazolyloxyacetic Acids 
5.4.1. Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) 
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Anhydrous K2CO3 (2.26 g, 16.38 mmol) was added to a stirred solution of 4-hydroxy 
carbazole (1 g, 5.46 mmol) in acetone (15 mL) and stirred at ambient temperature for 30 min. 
T-butyl chloroacetate (0.94 mL, 6.55 mmol) was added to it and heated to 60–70 °C for 12 h. 
Reaction was cooled to room temperature and filtered. The residue was washed with acetone 
(3×). Combined organic extract was evaporated in vacuo and purified by crystallization 
(EtOAc:hexane) to yield the title compound as a colorless solid (1.6 g, 95%)  
1H NMR (300 MHz, CDCl3): ? = 7.99 (brs, 1H; NH), 7.96-7.93 (m, 2H; H-4/5), 7.38-7.35 
(m, 2H; H-7/8), 7.24-7.21 (m, 1H; H-6), 6.92 (d, J = 3.0 Hz, 1H; H-1), 6.87 (dd, J = 9.0, J = 
1.5 Hz, 1H; H-3), 4.61 (s, 2H; H-13), 1.51 (s, 9H; H-16) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 168.3 (C-14), 157.3 (C-2), 139.6 (C-12), 124.7 (C-9), 123.7 
(C-11), 122.7 (C-6), 121.0 (C-7), 120.5 (C-4), 119.7 (C-5), 110.8 (C-3), 108.3 (C-10), 96.2 
(C-1), 82.3 (C-15), 66.4 (C-13), 28.0 (C-16) ppm. 
5.4.2. Synthesis of N-sulfonylated of tert-butyl 2-(9H-carbazol-2-yloxy)acetate 
derivatives (69) 
5.4.2.1. General procedure for N-sulfonylation of carbazole derivatives 
NaH (60% dispersion, 1.2 eq.) was combined with THF (5 mL/mmol) and cooled to 0 °C. 
Tert-butyl 2-(9H-carbazol-6-yloxy)acetate (68) (1 eq.) was added to the stirring slurry in 
portions. After 30 minutes R-sulfonyl chloride (1.2 eq.) dissolved in THF was added and the 
reaction was stirred at ambient temperature for 6–24 h. The heterogeneous reaction mixture 
was quenched with NH4Cl (sat. aq.), diluted with EtOAc and then washed sequentially with 
H2O and brine (×2). The organic extract was dried over anhydrous Na2SO4 and evaporated in 
vacuo to give crude compound. The crude compound was purified by flash column 
chromatography using (EtOAc:hexane, 1:9) to afford the desired product. 
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5.4.2.2. Tert-butyl 2-(9-tosyl-9H-carbazol-2-yloxy)acetate (69a) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), toluene sulfonyl chloride (167 mg, 0.88 mmol), NaH (36 mg, 0.88 mmol). 
Yield: 210 mg, 55%. 
1H NMR (300 MHz, CDCl3): ? = 8.18 (d, J = 8.2 Hz, 1H; H-5), 7.80 (d, J = 2.2 Hz, 1H; H-
1), 7.72-7.68 (m, 2H; H-4, H-8), 7.59 (d, J = 8.3 Hz, 2H; H-14), 7.32 (dt, J = 7.3, J = 1.3 Hz, 
1H; H-7), 7.24 (dt, J = 7.6, J = 1.0 Hz, 1H; H-6), 7.02 (d, J = 8.2 Hz, 2H; H-15), 6.92 (dd, J = 
8.5 Hz, J = 2.3 Hz, 2H; H-3), 4.58 (s, 2H; H-18), 1.52 (s, 9H; H-21) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 168.1 (C-19), 158.2 (C-2), 145.0 (C-16), 139.7 (C-12), 
135.1 (C-13), 129.8 (C-15), 127.7 (C-14), 126.6 (C-9), 126.4 (C-11), 124.1 (C-6), 120.7 (C-
4/7), 119.4 (C-5), 115.3 (C-3), 113.1 (C-8), 105.9 (C-10), 97.9 (C-1), 82.8 (C-20), 66.4 (C-
18), 28.3 (C-21), 21.6 (C-17) ppm.  
5.4.2.3. Tert-butyl 2-(9-(3,5-bis(trifluoromethyl)phenylsulfonyl)-9H-carbazol-2-
yloxy)acetate (69b) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 3,5-bis(trifluoromethyl)benzene sulfonyl chloride (280 mg, 0.88 mmol), NaH (36 
mg, 0.88 mmol). 
Yield: 260 mg, 61%. 
1H NMR (300 MHz, CDCl3): ? = 8.18 (d, J = 8.2 Hz, 1H; H-5), 8.07 (s, 2H; H-14, H-18), 
7.82 (s, 1H; H-16), 7.74 (s, 1H; H-1), 7.64-7.65 (m, 2H; H-4, H-8), 7.38 (t, J = 7.7 Hz, 1H; H-
7), 7.21 (t, J = 7.6 Hz, 1H; H-6), 6.96 (d, J = 8.6 Hz, 1H; H-3), 4.58 (s, 2H; H-21), 1.52 (s, 
9H; H-23) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.8 (C-22), 158.7 (C-2), 139.9 (C-13), 138.1 (C-12), 
133.2 (C-15), 132.8 (C-17), 127.4 (C-14), 127.2 (C-18), 126.8 (C-16), 125.3 (C-9), 124.0 (C-
19/20), 123.7 (C-11), 121.2 (C-6), 120.4 (C-4/7), 119.8 (C-5), 115.4 (C-3), 114.1 (C-8), 109.3 
(C-10), 101.3 (C-1), 82.8 (C-23), 66.4 (C-21), 28.3 (C-24) pm. 
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5.4.2.4. Tert-butyl 2-(9-(biphenyl-4-ylsulfonyl)-9H-carbazol-2-yloxy)acetate (69c) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 4-biphenyl sulfonyl chloride (222 mg, 0.88 mmol), NaH (36 mg, 0.88 mmol). 
Yield: 205 mg, 55%. 
1H NMR (500 MHz, CDCl3): ? = 8.21 (d, J = 8.3 Hz, 1H; H-5), 7.85 (d, J = 2.3 Hz, 1H; H-
1), 7.76 (td, J = 8.6 Hz, J = 2.0 Hz, 2H; H-14), 7.72 (d, J = 8.6 Hz, 2H; H-18), 7.37 (td, J = 
8.7 Hz, J = 2.0 Hz, 2H; H-15), 7.40-7.25 (m, 7H; H-4, H-6/7/8, H-19/20), 6.95 (dd, J = 8.6 
Hz, J = 2.3 Hz, 1H; H-3), 4.60 (s, 2H; H-21), 1.46 (s, 9H; H-24) ppm.  
13C NMR (125 MHz, CDCl3): ? ?= 168.1 (C-22), 158.2 (C-2), 145.0 (C-16), 139.7 (C-12), 
138.6 (C-13), 135.1 (C-17), 129.8 (C-19), 128.9 (C-15), 128.8 (C-14), 127.8 (C-20), 127.6 
(C-18), 126.7 (C-9), 126.6, 124.4 (C-11), 122.1 (C-6), 120.7 (C-4/7), 119.4 (C-5), 115.3 (C-
3), 113.1 (C-8), 105.1 (C-10), 100.9 (C-1), 82.8 (C-23), 66.4 (C-21), 28.3 (C-24) ppm.  
5.4.2.5. Tert-butyl 2-(9-(2,4,6-triisopropylphenylsulfonyl)-9H-carbazol-2-yloxy)acetate 
(69d) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 2,4,6-triisppropylbenzene sulfonyl chloride (266 mg, 0.88 mmol), NaH (36 mg, 
0.88 mmol). 
Yield: 130 mg, 31%. 
1H NMR (500 MHz, CDCl3): ? = 7.80-7.75 (m, 2H; H-4/5), 7.59 (m, 1H; H-8), 7.31 (d, J = 
2.2, 1H; H-1), 7.23-7.18 (m, 2H; H-6/7), 7.06 (s, 2H; H-15, H-17), 6.90 (dd, J = 8.6 Hz, J = 
2.2 Hz, 1H; H-3), 4.39 (s, 2H; H-29), 4.11- 4.06.(m, 2H; H-19, H-27), 2.85-2.76 (m, 1H; H-
23), 1.42 (s, 9H; H-32), 1.15 (d, J = 6.9 Hz, 6H; H-24/25), 0.94 (d, J = 6.7 Hz, 12H; H-20/22, 
H-26/28) ppm.  
13C NMR (125 MHz, CDCl3): ? ?= 165.5 (C-30), 156.6 (C-16), 153.1 (C-2), 150.1 (C-14/18), 
138.5 (C-12), 137.5 (C-13), 125.0 (C-9), 124.7 (C-11), 124.0 (C-15/17), 123.0 (C-6), 121.8 
(C-7), 119.6 (C-4), 118.2 (C-5), 113.5 (C-3), 113.1 (C-8), 110.9 (C-10), 98.4 (C-1), 81.4 (C-
Experimental 
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31), 65.2 (C-29), 33.1 (C-23), 28.4 (C-32), 27.0 (C-21/27), 23.2 (C-20/22/26/28), 22.4 (C-
24/25) ppm.  
5.4.2.6. Tert-butyl 2-(9-(4-propylphenylsulfonyl)-9H-carbazol-2-yloxy)acetate (69e) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 4-n-propylbenzene sulfonyl chloride (157 ?L, 0.88 mmol), NaH (36 mg, 0.88 
mmol). 
Yield: 197 mg, 56%. 
1H NMR (300 MHz, CDCl3): ? = 8.18 (d, J = 9.0 Hz, 1H; H-5), 7.81 (d, J = 3.0 Hz, 1H; H-
1), 7.72-7.69 (m, 2H; H-4, H-8), 7.63 (d, J = 9.0 Hz, 2H; H-14), 7.36-7.24 (m, 2H; H-6/7), 
7.03 (d, J = 9.0 Hz, 2H; H-15), 6.93 (dd, J = 9.0 Hz, J = 3.0 Hz, 1H; H-3), 4.59 (s, 2H; H-20), 
2.42 (t, J = 9.0 Hz, 2H; H-17),1.53-1.40 (m, 11H; H-18, H-23), 0.77 (t, J = 7.5 Hz, 3H; H-19) 
ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.9 (C-21), 158.1 (C-2), 149.4 (C-16), 139.5 (C-12), 
135.1 (C-13), 129.0 (C-15), 128.5 (C-14), 126.4 (C-9), 124.2 (C-11), 122.9 (C-6), 120.7 (C-
4/7), 119.2 (C-5), 115.1 (C-3), 113.9 (C-8), 109.7 (C-10), 100.7 (C-1), 82.6 (C-22), 66.2 (C-
20), 37.8 (C-17), 28.1 (C-23), 23.8 (C-18), 13.7 (C-19) ppm.  
5.4.2.7. Tert-butyl 2-(9-(octylsulfonyl)-9H-carbazol-2-yloxy)acetate (69f)  
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), octane sulfonyl chloride (225 mg, 0.88 mmol), NaH (36 mg, 0.88 mmol). 
Yield: 185 mg, 52%. 
1H NMR (300 MHz, CDCl3): ? = 8.02 (dd, J = 9.0 Hz, J = 1.5 Hz, 1H; H-), 7.82-7.72 (m, 
2H; H-4, H-8), 7.61 (d, J = 3.0 Hz, 1H; H-1), 7.34-7.29 (m, 2H; H-6/7), 6.97 (dd, J = 9.0 Hz, 
J = 3.0 Hz, 1H; H-1), 4.56 (s, 2H; H-21), 3.07 (t, J = 9.0 Hz, 2H; H-13), 1.56-1.52 (m, 2H; H-
14), 1.45 (s, 9H; H-24), 1.21-1.02 (m, 10H; H-15/16/17/18/19), 0.75 (t, J = 9.0 Hz, 3H; H-20) 
ppm.  
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13C NMR (75 MHz, CDCl3):? ? = 167.7 (C-22), 158.0 (C-2), 139.7 (C-12), 126.3 (C-9), 125.8 
(C-11), 123.9 (C-6), 120.8 (C-7), 119.9 (C-4), 119.4 (C-5), 114.4 (C-3), 113.7 (C-8), 110.0 
(C-10), 94.5 (C-1), 82.5 (C-23), 66.0 (C-21), 52.5 (C-13), 31.5 (C-18), 28.9 (C-24), 28.8 (C-
16), 28.0 (C-17), 27.9 (C-15), 22.7 (C-14), 22.4 (C-19), 13.9 (C-20) ppm. 
5.4.2.8. Tert-butyl 2-(9-(((1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-
yl)methylsulfonyl)-9H-carbazol-2-yloxy)acetate (69g)  
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), camphor sulfonyl chloride (220 mg, 0.88 mmol), NaH (36 mg, 0.88 mmol). 
Yield: 220 mg, 58%. 
1H NMR (300 MHz, CDCl3): ? = 8.17 (d, J = 9.0 Hz, 1H; H-5), 7.92 (dd, J = 9.0 Hz, J = 3.0 
Hz, 1H; H-4), 7.79 (d, J = 9.0 Hz, 1H; H-8), 7.45-7.39 (m, 2H; H-6/7), 7.07 (dd, J = 7.5 Hz, J 
= 1.5 Hz, 1H; H-1), 4.67 (s, 2H; H-23), 3.53 (d, J = 15 Hz, 1H; H-13), 3.01 (d, J = 15 Hz, 1H; 
H-13´), 2.63-2.59 (m, 1H; H-16), 2.52-2.41 (m, 1H; H-16´), 2.17-2.10 (m, 2H; H-19), 1.94 (d, 
(d, J = 18 Hz, 1H; H-17), 1.88-1.70 (m, 2H; H-18), 1.50 (s, 9H; H-26), 1.17 (s, 3H; H-21), 
0.82 (s, 3H; H-22) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 213.8 (C-15), 167.8 (C-24), 158.1 (C-2), 139.4 (C-12), 
128.4 (C-9), 127.4 (C-11), 123.9 (C-6), 120.8 (C-7), 120.0 (C-4), 119.4 (C-5), 114.4 (C-3), 
113.8 (C-8), 100.7 (C-10), 95.2 (C-1), 82.4 (C-25), 66.2 (C-23), 58.2 (C-14), 48.7 (C-13), 
42.9 (C-16), 37.4 (C-20), 32.6 (C-17), 29.7 (C-18), 28.5 (C-26), 26.9 (C-19), 19.9 (C-21), 
19.7 (C-22) ppm. 
5.4.2.9. Tert-butyl 2-(9-(4-chlorophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (69h) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 4-chlorobenzene sulfonyl chloride (185 mg, 0.88 mmol), NaH (36 mg, 0.88 
mmol). 
Yield: 205 mg, 60%. 
1H NMR (300 MHz, CDCl3): ? = 8.14 (d, J = 9.0 Hz, 1H; H-5), 7.78 (d, J = 3.0 Hz, 1H; H-
1), 7.73-7.69 (m, 2H; H-4, H-8), 7.63 (dd, J = 7.5 Hz, J = 1.5 Hz, 2H; H-14), 7.36-7.26 (m, 
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2H; H-6/7), 7.21 (dd, J = 9.0 Hz, J = 1.5 Hz, 2H; H-15), 6.92 (dd, J = 9.0 Hz, J =3.0 Hz, 1H; 
H-3), 4.59 (s, 2H; H-17), 1.47 (s, 9H; H-20) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.8 (C-18), 158.1 (C-2), 140.5 (C-16), 139.7 (C-12), 
138.4 (C-13), 130.9 (C-15), 129.3 (C-14), 125.8 (C-9), 124.6 (C-11), 122.4 (C-6), 120.4 (C-
7), 120.1 (C-4), 119.4 (C-5), 115.1 (C-8), 113.8 (C-3), 107.8 (C-10), 100.9 (C-1), 82.7 (C-19), 
66.1 (C-17), 28.1 (C-20) ppm.  
5.4.2.10. Tert-butyl 2-(9-(3,5-difluorophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (69i) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 3,5-difluorobenzene sulfonyl chloride (187 mg, 0.88 mmol), NaH (36 mg, 0.88 
mmol). 
Yield: 190 mg, 55%. 
1H NMR (300 MHz, CDCl3): ? = 8.12 (d, J = 9.0 Hz, 1H; H-5), 7.76-7-71 (m, 3H; H-1, H-4, 
H-8), 7.37-7.22 (m, 4H; H-6/7, H-14), 6.97 (dd, J = 9.0 Hz, J = 1.5 Hz, 1H; H-3), 6.85-6.80 
(m, 1H; H-16), 4.59 (s, 2H; H-17), 1.48 (s, 9H; H-20) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.7 (C-18), 164.2 (C-15), 158.2 (C-2), 140.4 (C-13), 
139.2 (C-12), 126.6 (C-9), 124.7 (C-11), 122.7 (C-6), 120.9 (C-7), 120.7 (C-4), 119.5 (C-5), 
115.0 (C-3), 113.4 (C-8), 109.9 (C-10), 100.8 (C-1), 82.7 (C-19), 66.2 (C-17), 28.1 (C-20) 
ppm.  
5.4.2.11. Tert-butyl 2-(9-(2-bromophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (69j) 
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The title compound was synthesized by following the general procedure mentioned in 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 2-bromobenzene sulfonyl chloride (225 mg, 0.88 mmol), NaH (36 mg, 0.88 
mmol). 
Yield: 205 mg, 55%. 
1H NMR (300 MHz, CDCl3): ? = 7.83-7.77 (m, 4H; H-5, H-1, H-16, H-18), 7.56-7.53 (m, 
2H; H-4, H-17), 7.36-7.23 (m, 4H; H-6/7/8, H-16), 6.95 (dd, J = 7.5 Hz, 1.5 Hz, 1H; H-3), 
4.50 (s, 2H; H-19), 1.49 (s, 9H; H-22) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.8 (C-20), 157.1 (C-2), 140.1 (C-13), 138.7 (C-12), 
135.9 (C-16), 134.3 (C-14), 131.2 (C-18), 127.6 (C-17), 125.9 (C-9), 125.5 (C-11), 123.7 (C-
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6), 120.9 (C-15), 120.8 (C-7), 119.5 (C-4), 119.4 (C-5), 114.7 (C-3), 113.7 (C-8), 100.7 (C-
10), 96.5 (C-1), 82.5 (C-21), 66.1 (C-19), 28.1 (C-22) ppm. 
5.4.2.6. Tert-butyl 2-(9-(3-nitrophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (69k) 
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The title compound was synthesized by following the general procedure mentioned in 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 3-nitrobenzene sulfonyl chloride (195 mg, 0.88 mmol), NaH (36 mg, 0.88 
mmol). 
Yield: 215 mg, 60%. 
1H NMR (300 MHz, CDCl3): ? = 8.70 (s, 1H; H-14), 8.43-8.25 (m, 2H; H-16, H-18), 8.04 
(d, J = 9.0 Hz, 1H; H-5), 7.87 (d, J = 3.0 Hz, 1H; H-1), 7.81-7.76 (m, 2H; H-4, H-8), 7.55-
7.34 (m, 3H; H-6/7, H-17), 7.04 (dd, J = 9.0 Hz, J = 3.0 Hz, 1H; H-3), 4.68 (s, 2H; H-19), 
1.62 (s, 9H; H-22) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.8 (C-20), 158.3 (C-2), 147.8 (C-15), 139.1 (C-13), 
137.9 (C-12), 135.5 (C-18), 131.7 (C-17), 128.5 (C-16), 125.2 (C-9), 124.7 (C-11), 122.8 (C-
6), 121.8 (C-14), 120.8 (C-4/7), 119.5 (C-5), 115.1 (C-3), 113.6 (C-8), 108.8 (C-10), 100.9 
(C-1), 82.7 (C-21), 66.1 (C-19), 28.1 (C-22) ppm.  
5.4.3. Synthesis of N-sulfonylated 2-(9H-carbazol-2-yloxy)acetic acids (70) 
5.4.3.1. General procedure for t-butyl ester cleavage of N-substituted tert-butyl 2-(9H-
carbazol-2-yloxy)acetates 
A solution of t-butyl ester in 20% trifluoroacetic acid in CH2Cl2 (5 mL/mmol) was stirred at 
ambient temperature for 4 to 12 h. After completion of reaction (TLC), solvent was 
evaporated in vacuo to get crude product. The crude acid was purified by crystallization 
(EtOAc:hexane) to afford the desired product. 
5.4.3.2. 2-(9-Tosyl-9H-carbazol-2-yloxy)acetic acid (70a) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-Tosyl-9H-carbazol-2-yloxy)acetate (100 mg, 0.22 mmol), 20% 
trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 78 mg, 90%. 
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1H NMR (300 MHz, CDCl3): ? = 8.15 (d, J = 8.2 Hz, 1H; H-5), 7.80 (d, J = 7.0 Hz, 1H; H-
4), 7.73-7.68 (m, 2H; H-6/7), 7.58 (d, J = 8.5 Hz, 2H; H-14), 7.32 (dt, J = 7.8, 1.2 Hz, 1H; H-
8), 7.26 (d, J = 8.5 Hz, 2H; H-15), 7.14 (d, J = 1.3 Hz, 1H; H-1), 6.93 (dd, J = 8.6 Hz, 1.3 Hz, 
1H; H-3), 4.62 (s, 2H; H-18) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 172.6 (C-19), 159.4 (C-2), 146.7 (C-16), 139.8 (C-12), 
135.8 (C-13), 131.0 (C-15), 127.8 (C-14), 127.6 (C-9), 125.5 (C-11), 122.1 (C-6), 120.7 (C-
7), 119.8 (C-4), 116.3 (C-5), 113.9 (C-3), 111.2 (C-8), 102.3 (C-10), 97.2 (C-1), 66.8 (C-18), 
22.3 (C-17) ppm.  
MS (ESI): m/z = 418.1 (M+Na)+. 
5.4.3.3. 2-(9-(3,5-Bis(trifluoromethyl)phenylsulfonyl)-9H-carbazol-2-yloxy)acetic acid 
(70b) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(3,5-bis(trifluoromethyl)phenylsulfonyl)-9H-carbazol-2-
yloxy)acetate (100 mg, 0.174 mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 85 mg, 95%. 
1H NMR (500 MHz, CDCl3): ? = 8.99 (s, 2H; H-14), 8.95 (s, 1H; H-16), 8.75 (d, J = 6.7 Hz, 
1H; H-5), 8.63 (d, J = 8.4 Hz, 1H; H-4), 8.5 (m, 2H; H-6/7),  8.23 (d, J = 7.6 Hz, 1H; H-8), 
8.15 (d, J = 1.4 Hz, 1H; H-1), 7.82 (dd, J = 8.8 Hz, J = 1.4 Hz, 1H; H-3), 4.68 (s, 2H; H-19) 
ppm.  
13C NMR (125 MHz, CDCl3): ? ?= 171.8 (C-20), 158.7 (C-2), 139.9 (C-13), 139.2 (C-12), 
135.4 (C-15), 131.0 (C-16), 127.4 (C-14), 127.2 (C-17/18), 126.8 (C-9), 125.3 (C-11), 124.0 
(C-6), 121.2 (C-7), 120.4 (C-4), 119.8 (C-5), 115.4 (C-3), 114.1 (C-8), 105.8 (C-10), 96.8 (C-
1), 72.4 (C-19) ppm. 
5.4.3.4. 2-(9-(Biphenyl-4-ylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70c) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(biphenyl-4-ylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 mg, 
0.194 mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
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Yield: 82 mg, 93%. 
1H NMR (500 MHz, CDCl3): ? = 8.20 (d, J = 8.4 Hz, 1H; H-5), 7.82-7.82 (m, 5H; H-4, H-
14/15), 7.52 (dd, J = 6.8 Hz, J = 1.8 Hz, 2H; H-18), 7.41-7.37(m, 3H; H-6/7/8), 7.32-7.26 (m, 
4H; H-1, H-19/20), 6.96 (dd, J = 8.6 Hz, J = 1.2 Hz, 1H; H-3), 4.73 (s, 2H; H-21) ppm.  
13C NMR (125 MHz, CDCl3): ? ?= 172 (C-22), 158.2 (C-2), 145.0 (C-16), 139.7 (C-12), 
138.6 (C-13), 135.1 (C-17), 129.8 (C-19), 129.1 (C-15), 128.8 (C-14), 128.1 (C-18), 127.9 
(C-20), 126.7 (C-9), 126.4 (C-11), 124.1 (C-6), 120.7 (C-7), 119.4 (C-4), 118.2 (C-5), 115.3 
(C-3), 113.1 (C-8), 107.2 (C-10), 95.7 (C-1), 60.3 (C-21) ppm.  
MS (ESI): m/z = 480.1 (M+Na)+. 
5.4.3.5. 2-(9-(2,4,6-Triisopropylphenylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70d) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(2,4,6-triisopropylphenylsulfonyl)-9H-carbazol-2-yloxy)acetate 
(100 mg, 0.177 mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 86 mg, 95%. 
1H NMR (300 MHz, CDCl3): ? = 7.80-7.75 (m, 2H; H-15, H-17), 7.62-7.57 (m, 1H; H-5), 
7.23-7.18 (m, 2H; H-4, H-8), 7.15-7.09 (m, 2H; H-6/7), 6.92-6.87 (m, 2H; H-1, H-3), 4.45 (s, 
2H; H-29), 4.05- 3.95.(m, 2H; H-21, H-27), 2.86-2.76 (m, 1H; H-23), 1.15 (d, J = 6.9 Hz, 6H; 
H-24/25), 0.93 (d, J = 6.7 Hz, 12H; H-20/21, H-26/28) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 169.5 (C-30), 159.1 (C-2), 156.0 (C-16), 152.6 (C-14/18), 
139.9 (C-12), 130.2 (C-13), 127.2 (C-9), 126.4 (C-11), 125.5 (C-15/17), 122.4 (C-6), 122.1 
(C-7), 120.7 (C-4), 117.5  (C-5), 114.7 (C-3), 113.2 (C-8), 100.7 (C-10), 93.2 (C-1), 67.0 (C-
29), 35.8 (C-23), 30.9 (C-21/27), 25.2 (C-20/22/26/28), 24.5 (C-24/25) ppm. 
MS (ESI): m/z = 430.2 (M+Na)+. 
5.4.3.6. 2-(9-(4-Propylphenylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70e) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
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Reactants: Tert-butyl 2-(9-(biphenyl-4-ylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 mg, 0.2 
mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 85 mg, 97%. 
1H NMR (300 MHz, CDCl3): ? = 8.17 (d, J = 8.0 Hz, 1H; H-5), 7.81 (d, J = 8.4 Hz, 1H; H-
4), 7.69 (d, J = 8.4 Hz, 2H; H-14), 7.62 (d, J = 8.4 Hz, 1H; H-8), 7.34-7.23 (m, 2H; H-6/7), 
7.12 (d, J = 2.4 Hz, 1H; H-1), 7.04 (d, J = 8.7 Hz, 2H; H-15), 6.93 (dd, J = 8.7 Hz, 2.4 Hz, 
1H; H-1), 4.66 (s, 2H; H-20), 2.41 (t, J = 7.8 Hz, 2H; H-17),1.51-1.34 (m, 2H; H-18), 0.76 (t, 
J = 7.5 Hz, 3H; H-19) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 175.2 (C-21), 153.5 (C-2), 143.3 (C-16), 138.8 (C-12), 
135.8 (C-13), 129.9 (C-15), 128.9 (C-14), 125.8 (C-9), 124.5 (C-11), 123.1 (C-6), 120.1 (C-
7), 119.7 (C-4), 118.8 (C-5), 113.4 (C-3), 111.4 (C-8), 104.8 (C-10), 95.8 (C-1), 69.7 (C-20), 
41.6 (C-17), 27.6 (C-18), 17.4 (C-19) ppm 
MS (ESI): m/z = 446.2 (M+Na+). 
5.4.3.7. 2-(9-(Octylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70f)  
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(octylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 mg, 0.21 
mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 82 mg, 90%. 
1H NMR (300 MHz, CDCl3): ? = 8.01 (dd, J = 9.0 Hz, 1.5 Hz, 1H; H-5), 7.51-7.22 (m, 4H; 
H-4, H-6/7/8), 6.95 (d, J = 1.5 Hz, 1H; H-1), 6.86 (dd, J = 7.5 Hz,  J =  1.5 Hz, 1H; H-3), 4.82 
(s, 2H), 4.23 (t, J = 7.5 Hz, 2H; H-13), 1.91-1.82 (m, 2H; H-14), 1.40-1.21 (m, 10H; H-
15/16/17/18/19), 0.87 (t, J = 6.0 Hz, 3H; H-20) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 172.8 (C-22), 156.8 (C-2), 140.8 (C-12), 129.0 (C-9), 124.8 
(C-11), 122.7 (C-7), 121.2 (C-4), 119.9 (C-5), 113.7 (C-3), 113.1 (C-8), 106.6 (C-10), 95.0 
(C-1), 65.5 (C-21), 43.1 (C-13), 31.7 (C-18), 29.3 (C-16), 29.1 (C-17), 28.8 (C-15), 24.5 (C-
19), 22.6 (C-14), 14.0 (C-20) ppm. 
MS (ESI): m/z = 440.2 (M+Na)+. 
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5.4.3.8. 2-(9-(((1S)-7,7-Dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methylsulfonyl)-9H-
carbazol-2-yloxy)acetic acid (70g)  
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1 
Reactants: Tert-butyl 2-(9-(((1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-
yl)methylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 mg, 0.19 mmol), 20% trifluoroacetic 
acid in CH2Cl2 (5 mL). 
Yield: 79 mg, 89%. 
1H NMR (300 MHz, CDCl3): ? = 8.07 (d, J = 7.5 Hz, 1H; H-5), 7.83-7-77 (m, 2H; H-4, H-
8), 7.73 (d, J = 2.1 Hz, 1H; H-1), 7.39-7.30 (m, 2H; H-6/7), 7.01 (dd, J = 8.5 Hz, 2.2 Hz, 1H; 
H-3), 4.67 (s, 2H; H-23), 3.42 (d, J = 15 Hz, 1H; H-13), 2.91 (d, J = 15 Hz, 1H; H-13´), 2.52-
2.41 (m, 1H; H-16), 2.33-2.22 (m, 1H; H-16´), 2.09-1.95 (m, 2H; H-17/19), 1.87 (m, 1H; H-
19´), 1.78-1.66 (m, 1H; H-18), 1.48-1.33 (m, 1H; H-18´), 1.07 (s, 3H; H-21), 0.72 (s, 3H; H-
22) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 214.8 (C-15), 175.3 (C-24), 161.9 (C-2), 142.3 (C-12), 
128.3 (C-9), 127.9 (C-11), 124.8 (C-6), 121.0 (C-7), 120.3 (C-4), 118.2 (C-5), 116.6 (C-3), 
113.2 (C-8), 104.1 (C-10), 95.5 (C-1), 69.7 (C-23), 62.2 (C-14), 46.7 (C-13), 42.3 (C-16), 
37.5 (C-20), 33.7 (C-17), 29.3 (C-18), 27.5 (C-19), 23.6 (C-21), 23.5 (C-22) ppm. 
MS (ESI): m/z = 478.2 (M+Na)+. 
5.4.3.9. 2-(9-(4-Chlorophenylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70h) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(4-chlorophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 mg, 
0.21 mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 86 mg, 97%. 
1H NMR (300 MHz, CDCl3): ? = 8.15 (d, J = 7.8 Hz, 1H; H-5), 7.78 (d, J = 8.1 Hz, 1H; H-
4), 7.72-7.69 (m, 2H; H-14), 7.65-7.62 (m, 2H; H-15), 7.29-7.20 (m, 4H; H-1, H-6/7/8), 6.95 
(dd, J = 8.1 Hz, 2.3 Hz, 1H; H-3), 4.69 (s, 2H; H-17) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 174.8 (C-18), 161.8 (C-2), 144.8 (C-16), 141.1 (C-12), 
137.6 (C-13), 131.9 (C-15), 131.1 (C-14), 126.3 (C-9), 125.3 (C-11), 122.7 (C-6), 120.3 (C-
7), 118.9 (C-4), 116.8 (C-3), 113.1 (C-8), 104.9 (C-10), 97.3 (C-1), 64.5 (C-17) ppm. 
Experimental 
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5.4.3.10. 2-(9-(3,5-Difluorophenylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70i) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(3,5-difluorophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 
mg, 0.21 mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 79 mg, 90%. 
1H NMR (300 MHz, CDCl3): ? = 8.12 (d, J = 8.1 Hz, 1H; H-5), 7.77-7-72 (m, 3H; H-4, H-
14), 7.37-7.27 (m, 5H; H-1, H-6/7/8), 6.97 (dd, J = 8.6 Hz, 2.2 Hz, 1H; H-3), 6.91-6.81 (m, 
1H; H-16), 4.68 (s, 2H; H-17) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 174.7 (C-18), 164.7 (C-16), 161.9 (C-2), 144.1 (C-13), 
141.9 (C-12), 128.6 (C-9), 124.8 (C-11), 123.4 (C-6), 120.1 (C-7), 119.5 (C-4), 118.8 (C-5), 
116.9 (C-3), 114.2 (C-8), 105.9 (C-10), 94.4 (C-1), 69.5 (C-17) ppm.  
5.4.3.11. 2-(9-(2-Bromophenylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70j) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(2-bromophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 mg, 
0.19 mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 71 mg, 80%. 
1H NMR (300 MHz, CDCl3): ? = 7.97 (d, J = 8.1 Hz, 1H; H-18), 7.80-7.51 (m, 3H; H-4, H-
5, H-15), 7.58-7.50 (m, 2H; H-8, H-17), 7.38-7.23 (m, 4H; H1, H-6, H-7, H-16 ), 6.95 (dd, J = 
8.5 Hz, J = 2.2 Hz, 1H; H-3), 4.59 (s, 2H; H-19) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 174.7 (C-20), 161.4 (C-2), 143.7 (C-13), 139.8 (C-12), 
135.2 (C-16), 131.5 (C-15), 129.9 (C-18), 128.7 (C-17), 127.6 (C-9), 124.8 (C-15), 123.6 (C-
6), 120.3  (C-7), 119.6 (C-4), 118.6 (C-5), 116.3 (C-3), 111.5 (C-8), 104.7 (C-10), 97.2 (C-1), 
69.6 (C-19) ppm.  
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5.4.3.6. 2-(9-(3-Nitrophenylsulfonyl)-9H-carbazol-2-yloxy)acetic acid (70k) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(3-nitrophenylsulfonyl)-9H-carbazol-2-yloxy)acetate (100 mg, 0.2 
mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 81 mg, 92%. 
1H NMR (300 MHz, CDCl3): ? = 8.55  (d, J = 1.9 Hz, 1H; H-14), 8.19-8.12 (m, 2H; H-5, H-
18), 8.01-7.86 (m, 1H; H-16), 7.81 (d, J = 2.28 Hz, 1H; H-1), 7.73-7.70 (m, 2H; H-4, H-17), 
7.50 (t, J = 8.0 Hz, 1H; H-8), 7.39-7.25 (m 2H; H-6/7), 6.97 (dd, J = 8.6 Hz, 2.3 Hz, 1H; H-
3), 4.71 (s, 2H; H-19) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 174.7 (C-20), 162.0 (C-2), 151.8 (C-15), 142.9 (C-13), 
141.8 (C-12), 135.7 (C-18), 132.1 (C-17), 128.6 (C-16), 127.9 (C-16), 127.5 (C-9), 124.8 (C-
11), 122.1 (C-6), 121.2 (C-14), 120.1 (C-7), 119.5 (C-4), 118.1 (C-5), 115.1 (C-3), 113.6 (C-
8), 104.5 (C-10), 99.3 (C-1), 69.5 (C-19) ppm. 
MS (ESI): m/z = 446.2 (M+Na+). 
5.4.4. Synthesis of N-alkylated tert-butyl 2-(9H-carbazol-2-yloxy)acetate derivatives (71) 
5.4.4.1. General procedure for N-alkylation of tert-butyl 2-(9H-carbazol-2-yloxy)acetate 
derivatives 
KOBut (1.1 eq.) was added to a stirred solution of THF (5 mL/mmol) tert-butyl 2-(9H-
carbazol-6-yloxy)acetate (68) (1 eq.) at 0 °C. After 30 minutes alkyl halide (1.2 eq.) dissolved 
in THF was added. The reaction mixture was stirred at ambient temperature for 6–24 h. The 
heterogeneous reaction mixture was quenched with NH4Cl (sat. aq), diluted with EtOAc and 
then washed sequentially with H2O and brine. The organic extract was dried over anhydrous 
Na2SO4 and evaporated in vacuo to give crude compound. The crude compound was purified 
by flash column chromatography (EtOAc:hexane, 1:9). 
5.4.4.2. Tert-butyl 2-(9-octyl-9H-carbazol-2-yloxy)acetate (71a)  
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The title compound was synthesized by following the general procedure mentioned in 5.4.4.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 1-iodooctane (160 ?L, 0.88 mmol), KOBut (98 mg, 0.88 mmol). 
Experimental 
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Yield: 260 mg, 90%. 
1H NMR (300 MHz, CDCl3): ? = 7.93 (d, J = 9.0 Hz, 1H; H-5), 7.88 (d, J = 9.0 Hz, 1H; H-
4), 7.32-7.28 (m, 2H; H-6/7), 7.14-7.10 (m, 1H; H-8), 6.82 (d, J = 3.0 Hz, 1H; H-1), 6.75 (dd, 
J = 9.0 Hz, J = 1.5 Hz, 1H; H-3), 4.56 (s, 2H; H-21), 4.14 (t, J = 7.5 Hz, 2H; H-13), 1.81-1.72 
(m, 2H; H-14), 1.43 (s, 9H; H-24), 1.32-1.12 (m, 10 H; H-15/16/17/18/19), 0.79 (t, J = 7.5 
Hz, 3H; H-20) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 167.2 (C-22), 156.2 (C-2), 139.7 (C-12), 126.9 (C-9), 125.5 
(C-11), 123.5 (C-6), 121.8 (C-7), 120.2 (C-4) 118.6 (C-5), 117.9 (C-3), 116.6 (C-8), 107.4 (C-
10), 93.7 (C-1), 81.2 (C-23), 65.4 (C-21), 52.1 (C-13), 30.8 (C-18), 28.4 (C-24), 28.1 (C-14), 
27.8 (C-16), 27.0 (C-17), 26.3 (C-15), 21.5 (C-19), 13.0 (C-20) ppm. 
5.4.4.3. Tert-butyl 2-(9-nonyl-9H-carbazol-2-yloxy)acetate (71b)  
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The title compound was synthesized by following the general procedure mentioned in 5.4.4.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 1-bromononane (168 ?L, 0.88 mmol), KOBut (98 mg, 0.88 mmol). 
Yield: 248 mg, 80%. 
1H NMR (300 MHz, CDCl3): ? = 7.93 (d, J = 9.0 Hz, 1H; H-5), 7.89 (d, J = 9.0 Hz, 1H; H-
4), 7.32-7.28 (m, 2H; H-6/7), 7.14-7.10 (m, 1H; H-8), 6.83 (d, J = 3.0 Hz, 1H; H-1), 6.75 (dd, 
J = 9.0 Hz, J = 1.5 Hz, 1H, H-3), 4.56 (s, 2H; H-21), 4.14 (t, J = 7.5 Hz, 2H; H-13), 1.82-1.71 
(m, 2H; H-14), 1.43 (s, 9H; H-25), 1.36-1.13 (m, 12H; H-15/16/17/18/19/20), 0.80 (t, J = 7.5 
Hz, 3H; H-21) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 168.2 (C-23), 157.2 (C-2), 141.6 (C-12), 127.5 (C-9), 125.8 
(C-11), 124.5 (C-6), 122.8 (C-7), 121.0 (C-4), 119.6 (C-5), 118.9 (C-3), 117.6 (C-8), 108.4 
(C-10), 94.7 (C-1), 82.2 (C-24), 66.4 (C-22), 53.1 (C-13), 31.8 (C-19), 29.4 (C-24), 29.2 (C-
17), 28.8 (C-25), 27.3 (C-16/18), 26.8 (C-15), 22.6 (C-20), 14.0 (C-21) ppm. 
5.4.4.4. Tert-butyl 2-(9-decyl-9H-carbazol-2-yloxy)acetate (71c) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.4.1 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 1-bromodecane (183 ?L, 0.88 mmol), KOBut (98 mg, 0.88 mmol). 
Yield: 272 mg, 85%. 
1H NMR (300 MHz, CDCl3): ? = 7.93 (d, J = 9.0 Hz, 1H; H-5), 7.89 (d, J = 9.0 Hz, 1H; H-
4), 7.31-7.28 (m, 2H; H-6/7), 7.14-7.10 (m, 1H; H-8), 6.83 (d, J = 1.5 Hz, 1H; H-1), 6.75 (dd, 
J = 9.0 Hz, J = 1.5 Hz, 1H; H-3), 4.56 (s, 2H; H-21), 4.14 (t, J = 7.5 Hz, 2H; H-13), 1.82-1.71 
(m, 2H; H-14), 1.43 (s, 9H; H-26), 1.37-1.12 (m, 14H; H-15/16/17/18/19/20/21), 0.80 (t, J = 
6.0 Hz, 3H; H-22) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 168.2 (C-23), 157.2 (C-2), 141.6 (C-12), 127.8 (C-9), 125.7 
(C-11), 124.5 (C-6), 122.9 (C-7), 121.3 (C-4), 119.4 (C-5), 118.6 (C-3), 117.4 (C-8), 108.1 
(C-10), 94.7 (C-1), 82.2 (C-25), 66.4 (C-23), 53.1 (C-13), 31.8 (C-10), 29.5 (C-14), 29.4 (C-
17), 29.2 (C-18), 28.8 (C-26), 28.0 (C-16/19), 27.3 (C-15), 22.6 (C-21), 14.0 (C-22) ppm. 
5.4.4.5. Tert-butyl 2-(9-undecyl-9H-carbazol-2-yloxy)acetate (71d) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.4.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 1-bromoundecane (196 ?L, 0.88 mmol), KOBut (98 mg, 0.88 mmol). 
Yield: 210 mg, 65%. 
1H NMR (300 MHz, CDCl3): ? = 7.91 (d, J = 7.7 Hz, 1H; H-5), 7.88 (d, J = 8.5 Hz, 1H; H-
4), 7.33-7.27 (m, 2H; H-6/7), 7.14-7.09 (m, 1H; H-8), 6.82 (d, J = 2.1 Hz, 1H; H-1), 6.75 (dd, 
J = 8.6 Hz, J = 2.1 Hz, 1H; H-3), 4.56 (s, 2H; H-21), 4.13 (t, J = 7.5 Hz, 2H; H-13), 1.82-1.72 
(m, 2H; H-14), 1.43 (s, 9H; H-27), 1.34-1.11 (m, 16H; H-15/16/17/18/19/20/21/22), 0.80 (t, J 
= 6.0 Hz, 3H; H-23) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 168.2 (C-25), 157.2 (C-2), 141.6 (C-12), 127.7 (C-9), 125.7 
(C-11), 124.5 (C-6), 122.8 (C-7), 121.0 (C-4), 119.6 (C-5), 118.8 (C-3), 117.6 (C-8), 108.4 
(C-10), 94.7 (C-1), 82.2 (C-26), 66.4 (C-24), 53.1 (C-13), 31.8 (C-21), 29.5 (C-14), 29.4 (C-
17/19), 29.2 (C-18), 28.8 (C-16), 28.3 (C-27), 28.0 (C-20), 27.3 (C-15), 22.6 (C-22), 14.0 (C-
23) ppm. 
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5.4.4.6. Tert-butyl 2-(9-dodecyl-9H-carbazol-2-yloxy)acetate (71e) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.4.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 1-bromododecane (211 ?L, 0.88 mmol), KOBut (98 mg, 0.88 mmol). 
Yield: 207 mg, 61%. 
1H NMR (300 MHz, CDCl3): ? = 7.92 (d, J = 7.8 Hz, 1H; H-5), 7.89 (d, J = 8.6 Hz, 1H; H-
4), 7.32-7.26 (m, 2H; H-6/7), 7.14-7.09 (m, 1H; H-8), 6.83 (d, J = 2.0 Hz, 1H; H-1), 6.76 (dd, 
J = 8.4 Hz, J = 2.2 Hz, 1H; H-3), 4.56 (s, 2H; H-21), 4.13 (t, J = 7.5 Hz, 2H; H-13), 1.81-1.71 
(m, 2H; H-14), 1.43 (s, 9H; H-28), 1.41-1.12 (m, 18H; H-15/16/17/18/19/20/21/22/23), 0.80 
(t, J = 6.0 Hz, 3H; H-24) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 168.2 (C-26), 157.2 (C-2), 141.6 (C-12), 127.7 (C-9), 125.7 
(C-11), 124.5 (C-6), 122.8 (C-7), 121.0 (C-4), 119.6 (C-5), 118.8 (C-3), 117.6 (C-8), 108.4 
(C-10), 94.7 (C-1), 82.2 (C-27), 66.4 (C-25), 53.1 (C-13), 31.9 (C-22), 29.5 (C-14), 29.4 (C-
17/19), 29.3 (C-18/20), 28.8 (C-16), 28.3 (C-28), 28.0 (C-21), 27.3 (C-15), 22.6 (C-23), 14.1 
(C-24) ppm. 
5.4.4.7. Tert-butyl 2-(9-tetradecyl-9H-carbazol-2-yloxy)acetate (71f) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.4.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 1-bromotetradecane (239 ?L, 0.88 mmol), KOBut (98 mg, 0.88 mmol). 
Experimental 
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Yield: 227 mg, 63%. 
1H NMR (300 MHz, CDCl3): ? = 7.91 (d, J = 7.8 Hz, 1H; H-5), 7.88 (d, J = 8.5 Hz, 1H; H-
4), 7.34-7.26 (m, 2H; H-6/7), 7.13-7.08 (m, 1H; H-8), 6.82 (d, J = 2.2 Hz, 1H; H-1), 6.74 (dd, 
J = 8.5 Hz, J = 2.2 Hz, 1H; H-3), 4.56 (s, 2H; H-21), 4.13 (t, J = 7.5 Hz, 2H; H-13), 1.81-1.71 
(m, 2H; H-14), 1.43 (s, 9H; H-30), 1.41-1.12 (m, 22H; H-15/16/17/18/19/20/21/22/23/24/25), 
0.80 (t, J = 6.0 Hz, 3H; H-26) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 168.2 (C-28), 157.2 (C-2), 141.6 (C-12), 127.7 (C-9), 125.7 
(C-11), 124.5 (C-6), 122.8 (C-7), 121.0 (C-4), 119.6 (C-5), 118.8 (C-3), 117.6 (C-8), 108.4 
(C-10), 94.7 (C-1), 82.2 (C-29), 66.4 (C-27), 53.1 (C-13), 31.9 (C-24), 29.7 (C-14), 29.6 (C-
23), 29.5 (C-22), 29.4 (C-17/19), 29.3 (C-18/20), 28.8 (C-16), 28.5 (C-30), 28.0 (C-21), 27.3 
(C-15), 22.6 (C-25), 14.1 (C-26) ppm. 
5.4.4.8. Tert-butyl 2-(9-hexadecyl-9H-carbazol-2-yloxy)acetate (71g) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.4.1. 
Reactants: Tert-butyl 2-(9H-carbazol-2-yloxy)acetate (68) (200 mg, 0.74 mmol), (200 mg, 
0.73 mmol), 1-bromohexadecane (268 ?L, 0.88 mmol), KOBut (98 mg, 0.88 mmol). 
Yield: 204 mg, 53%. 
1H NMR (300 MHz, CDCl3): ? = 7.91 (d, J = 7.6 Hz, 1H; H-5), 7.88 (d, J = 8.4 Hz, 1H; H-
4), 7.31-7.27 (m, 2H; H-6/7), 7.14-7.09 (m, 1H; H-8), 6.82 (d, J = 2.0 Hz, 1H; H-1), 6.75 (dd, 
J = 8.5 Hz, J = 2.2 Hz, 1H; H-3), 4.56 (s, 2H; H-21), 4.13 (t, J = 7.5 Hz, 2H; H-13), 1.81-1.71 
(m, 2H; H-14), 1.43 (s, 9H; H-30), 1.40-1.12 (m, 26H; H-
15/16/17/18/19/20/21/22/23/24/25/26/27), 0.80 (t, J = 6.0 Hz, 3H; H-28) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 167.2 (C-30), 156.2 (C-2), 140.6 (C-12), 127.7 (C-9), 125.7 
(C-11), 123.5 (C-6), 121.8 (C-7), 120.0 (C-4), 118.6 (C-5), 117.8 (C-3), 116.6 (C-8), 107.4 
(C-10), 93.7 (C-1), 81.2 (C-31), 65.4 (C-29), 52.1 (C-13), 30.9 (C-26), 28.7 (C-14), 28.6 (C-
23/25), 28.5 (C-22/24), 28.4 (C-17/19), 28.3 (C-32), 28.3 (C-18/20), 27.8 (C-16), 27.0 (C-21), 
26.3 (C-15), 21.6 (C-27), 13.1 (C-28) ppm. 
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5.4.5. Synthesis of N-alkylated 2-(9H-carbazol-2-yloxy)acetic acids (72) 
5.4.5.1. 2-(9-Octyl-9H-carbazol-2-yloxy)acetic acid (72a)  
N
O
OH
O
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2
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-octyl-9H-carbazol-2-yloxy)acetate (71a) (100 mg, 0.24 mmol), 
20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 82 mg, 95%. 
1H NMR (300 MHz, CDCl3): ? = 8.02 (d, J = 6.8 Hz, 1H; H-5), 7.83-7.80 (m, 2H; H-4, H-8), 
7.65 (d, J = 2.1 Hz, 1H; H-1), 7.35-7.30 (m, 2H; H-6/7), 6.98 (dd, J = 8.6 Hz, 2.1 Hz, 1H; H-
3), 4.65 (s, 2H; H-21), 3.09 (t, J = 8.0 Hz, 2H; H-13), 1.62-1.51 (m, 2H; H-14), 1.21-1.11 (m, 
10H; H-15/16/17/18/19), 0.75 (t, J = 7.0 Hz, 3H; H-20) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 174.6 (C-22), 161.7 (C-2), 142.5 (C-12), 130.2 (C-8), 127.8 
(C-11), 124.7 (C-6), 124.0 (C-7), 123.3 (C-4), 118.2 (C-5), 116.1 (C-3), 113.2 (C-8), 104.4 
(C-10), 97.2 (C-1), 69.4 (C-21), 56.4 (C-13), 35.3 (C-18), 32.5 (C-14), 32.4 (C-16), 31.7 (C-
17), 26.6 (C-15), 22.3 (C-19), 17.7 (C-20) ppm. 
5.4.5.2. 2-(9-Nonyl-9H-carbazol-2-yloxy)acetic acid (72b) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-nonyl-9H-carbazol-2-yloxy)acetate (71b) (100 mg, 0.23 mmol), 
20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 74 mg, 86%. 
1H NMR (300 MHz, CDCl3): ? = 7.92 (d, J = 7.7 Hz, 1H; H-5), 7.87 (d, J = 8.8 Hz, 1H; H-
4), 7.32-7.29 (m, 2H; H-1, H-8), 7.11 (t, J = 7.8 Hz, 1H; H-6), 6.86-6.84 (m, 1H; H-7), 6.75 
(dd, J = 8.0 Hz, J = 2.3 Hz, 1H; H-3), 4.67 (s, 2H; H-21), 4.14 (t, J = 7.2 Hz, 2H; H-13), 1.91-
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1.80 (m, 2H; H-14), 1.36-1.02 (m, 12H; H-15/16/17/18/19/20), 0.78 (t, J = 7.0 Hz, 3H; H-21) 
ppm.  
13C NMR (75 MHz, CDCl3):? ? = 175.1 (C-23), 160.9 (C-2), 144.6 (C-12), 128.5 (C-9), 126.6 
(C-11), 124.9 (C-6), 123.4 (C-7), 122.7 (C-4), 121.5 (C-5), 113.3 (C-3), 110.7 (C-8), 105.5 
(C-10), 98.8 (C-1), 69.9 (C-22), 60.4 (C-13), 35.6 (C-19), 33.2 (C-14), 32.1 (C-17), 31.0 (C-
16), 30.6 (C-18), 29.5 (C-15), 26.5 (C-20), 17.8 (C-21) ppm. 
MS (ESI): m/z = 390.2 (M+Na)+. 
5.4.5.3. 2-(9-Decyl-9H-carbazol-2-yloxy)acetic acid (72c)  
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-decyl-9H-carbazol-2-yloxy)acetate (71c) (100 mg, 0.22 mmol), 
20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 77 mg, 89%. 
1H NMR (300 MHz, CDCl3): ? = 8.03-7.98 (m, 2H; H-4/5), 7.44-7.38 (m, 2H; H-1, H-8), 
7.24-7.20 (m, 2H; H-6/7), 6.94 (d, J = 1.5 Hz, 1H; H-1), 6.85 (dd, J = 7.5 Hz, J = 1.5 Hz, 1H; 
H-3), 4.82 (s, 2H; H-23), 4.23 (t, J = 7.5 Hz, 2H; H-13), 1.91-1.80 (m, 2H; H-14), 1.46-1.19 
(m, 14H; H-15/16/17/18/19/20/21), 0.88 (t, J = 7.5 Hz, 3H; H-22) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 172.7 (C-24), 156.4 (C-2), 141.5 (C-12), 128.8 (C-9), 124.8 
(C-11), 122.7 (C-6), 121.2 (C-7), 119.7 (C-5), 119.5 (C-3), 118.2 (C-8), 108.5 (C-10), 95.0 
(C-1), 65.6 (C-23), 53.1 (C-13), 31.8 (C-28), 29.5 (C-17/18), 29.2 (C-16), 28.8 (C-19), 27.3 
(C-15), 22.6 (C-21), 14.8 (C-22) ppm. 
MS (ESI): m/z = 404.3 (M+Na)+. 
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5.4.5.4. 2-(9-Undecyl-9H-carbazol-2-yloxy)acetic acid (72d) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-undecyl-9H-carbazol-2-yloxy)acetate (71d) (100 mg, 0.22 mmol), 
20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 75 mg, 86%. 
1H NMR (300 MHz, CDCl3): ? = 7.91 (d, J = 7.0 Hz, 1H; H-5), 7.86 (d, J = 8.5 Hz, 1H; H-
4), 7.33-7.27 (m, 2H; H-6/7), 7.14-7.09 (m, 1H; H-8), 6.82 (d, J = 2.0 Hz, 1H; H-1), 6.78 (dd, 
J = 8.5 Hz, J = 2.0 Hz, 1H; H-3), 4.59 (s, 2H; H-21), 4.15 (t, J = 7.5 Hz, 2H; H-13), 1.81-1.72 
(m, 2H; H-14), 1.32-1.11 (m, 16H; H-15/16/17/18/19/20/21/22), 0.79 (t, J = 6.0 Hz, 3H; H-
23) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 177.9 (C-25), 157.2 (C-2), 141.6 (C-12), 127.7 (C-9), 125.7 
(C-11), 124.8 (C-6), 122.8 (C-7), 121.3 (C-4), 119.8 (C-5), 119.1 (C-3), 117.6 (C-8), 108.8 
(C-10), 95.0 (C-1), 66.4 (C-24), 53.1 (C-13), 31.8 (C-21), 29.5 (C-14), 29.4 (C-17/19), 29.2 
(C-18), 28.8 (C-16), 28.0 (C-20), 27.3 (C-15), 22.6 (C-22), 14.0 (C-23) ppm. 
5.4.5.5. 2-(9-Dodecyl-9H-carbazol-2-yloxy)acetic acid (72e) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-dodecyl-9H-carbazol-2-yloxy)acetate (71e) (100 mg, 0.21 mmol), 
20% trifluoroacetic acid in CH2Cl2 (5 mL). 
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Yield: 79 mg, 90%. 
1H NMR (300 MHz, CDCl3): ? = 7.92 (d, J = 7.2 Hz, 1H; H-5), 7.85 (d, J = 8.4 Hz, 1H; H-
4), 7.32-7.28 (m, 2H; H-6/7), 7.13-7.09 (m, 1H; H-8), 6.81 (d, J = 2.1 Hz, 1H; H-1), 6.77 (dd, 
J = 8.6 Hz, J = 2.1 Hz, 1H; H-3), 4.60 (s, 2H; H-21), 4.14 (t, J = 7.5 Hz, 2H; H-13), 1.80-1.71 
(m, 2H; H-14), 1.31-1.11 (m, 18H; H-15/16/17/18/19/20/21/22/23), 0.79 (t, J = 6.0 Hz, 3H; 
H-24) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 178.2 (C-26), 156.2 (C-2), 140.6 (C-12), 127.9 (C-9), 126.4 
(C-11), 125.4 (C-6), 123.4 (C-7), 121.9 (C-4), 119.8 (C-5), 119.3 (C-3), 118.6 (C-8), 109.3 
(C-10), 96.1 (C-1), 66.4 (C-25), 54.1 (C-13), 32.1 (C-22), 29.9 (C-14), 29.6 (C-17/19), 29.5 
(C-18/20), 29.0 (C-16), 28.7 (C-28), 28.3 (C-21), 27.8 (C-15), 22.8 (C-23), 13.7 (C-24) ppm. 
5.4.5.6. 2-(9-Tetradecyl-9H-carbazol-2-yloxy)acetic acid (72f) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-tetradecyl-9H-carbazol-2-yloxy)acetate (71f) (100 mg, 0.2 mmol), 
20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 81 mg, 92%. 
1H NMR (300 MHz, CDCl3): ? = 7.92 (d, J = 7.0 Hz, 1H; H-5), 7.84 (d, J = 8.5 Hz, 1H; H-
4), 7.32-7.28 (m, 2H; H-6/7), 7.13-7.08 (m, 1H; H-8), 6.82 (d, J = 2.2 Hz, 1H; H-1), 6.77 (dd, 
J = 8.6 Hz, J = 2.2 Hz, 1H; H-3), 4.60 (s, 2H; H-21), 4.14 (t, J = 7.6 Hz, 2H; H-13), 1.82-1.70 
(m, 2H; H-14), 1.33-1.11 (m, 22H; H-15/16/17/18/19/20/21/22/23/24/25), 0.79 (t, J = 6.0 Hz, 
3H; H-26) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 178.2 (C-28), 157.5 (C-2), 141.1 (C-12), 128.5 (C-9), 126.7 
(C-11), 125.5 (C-6), 123.5 (C-7), 122.0 (C-4), 120.1 (C-5), 119.3 (C-3), 118.3 (C-8), 108.1 
(C-10), 96.7 (C-1), 66.4 (C-27), 54.1 (C-13), 31.6 (C-24), 29.8 (C-14), 29.7 (C-23), 29.6 (C-
22), 29.5 (C-17/19), 29.4 (C-18/20), 28.9 (C-16), 28.6 (C-30), 28.3 (C-21), 27.8 (C-15), 22.8 
(C-25), 13.6 (C-26) ppm. 
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5.4.5.7. 2-(9-Hexadecyl-9H-carbazol-2-yloxy)acetic acid (72g) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-hexadecyl-9H-carbazol-2-yloxy)acetate (71g) (100 mg, 0.19 
mmol), 20% trifluoroacetic acid in CH2Cl2 (5 mL). 
Yield: 84 mg, 95%. 
1H NMR (300 MHz, CDCl3): ? = 7.91 (d, J = 7.2 Hz, 1H; H-5), 7.85 (d, J = 8.6 Hz, 1H; H-
4), 7.32-7.28 (m, 2H; H-6/7), 7.13-7.09 (m, 1H; H-8), 6.81 (d, J = 2.1 Hz, 1H; H-1), 6.76 (dd, 
J = 8.6 Hz, J = 2.1 Hz, 1H; H-3), 4.61 (s, 2H; H-21), 4.15 (t, J = 7.6 Hz, 2H; H-13), 1.81-1.70 
(m, 2H; H-14), 1.35-1.10 (m, 26H; H-15/16/17/18/19/20/21/22/23/24/25/26/27), 0.80 (t, J = 
6.4 Hz, 3H; H-28) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 178.2 (C-30), 156.4 (C-2), 141.4 (C-12), 127.5 (C-9), 125.5 
(C-11), 123.6 (C-6), 121.9 (C-7), 120.6 (C-4), 119.2 (C-5), 117.9 (C-3), 116.5 (C-8), 107.8 
(C-10), 95.5 (C-1), 65.4 (C-29), 52.1 (C-13), 31.5 (C-26), 29.7 (C-14), 29.6 (C-23/25), 29.5 
(C-22/24), 29.4 (C-17/19), 29.3 (C-18/20), 28.8 (C-16), 28.0 (C-21), 27.3 (C-15), 22.6 (C-27), 
13.8 (C-28) ppm. 
5.4.6. Synthesis of 6-methoxy and 8-methoxy N-sulfonylated carbazolyloxyacetic acids. 
5.4.6.1. 1-((4-Chloro-3-nitrophenoxy)methyl)-4-methoxybenzene (74) 
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Anhydrous K2CO3 (9.56 g, 69 mmol) was added to a stirred solution of 4-chloro-3-nitro 
phenol (4 g, 23 mmol) in acetone (50 mL) and stirred at ambient temperature for 30 min. p-
Methoxy benzyl chloride (3.3 mL, 24.2 mmol) was added to it and heated to 60–70 °C for 12 
h. The reaction mixture was cooled to RT and filtered. The residue was washed with acetone 
(3×). Combined organic extract was evaporated in vacuo and purified by crystallization 
(EtOAc:hexane) to yield the title compound as a pale yellow solid (6.3 g, 93%)  
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1H NMR (300 MHz, CDCl3): ? = 7.64 (d, J = 3.0 Hz, 1H; H-5), 7.33 (d, J = 8.9 Hz, 1H; H-
2), 7.26 (td, J = 8.8 Hz, 2.5 Hz, 2H; H-9), 7.03 (dd, J = 8.9 Hz, 3.0 Hz, 1H; H-3), 6.86 (td, J = 
8.8 Hz, 2.5 Hz, 2H; H-10), 4.95 (s, 2H; H-7), 3.81 (s, 3H; H-12) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 159.9 (C-11), 159.7 (C-4), 149.6 (C-6), 132.4 (C-8), 129.3 
(C-2), 127.2 (C-9), 120.6 (C-3), 118.3 (C-1), 114.2 (C-10), 111.5 (C-5), 70.7 (C-7), 55.3 (C-
12) ppm. 
5.4.6.2. 3'-Methoxy-4-(4-methoxybenzyloxy)-2-nitrobiphenyl (75) 
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A mixture of the 1-((4-chloro-3-nitrophenoxy)methyl)-4-methoxybenzene (67) (1 g, 3.41 
mmol), 3-methoxy phenylboronic acid (0.623 g, 4.09 mmol) and 2 M (aq.) K2CO3 (0.95 g, 
6.83 mmol) was taken up in toluene (10 mL) and sparged with bubbling N2 for 5 min. At that 
time, Pd(PPh3)4 (0.08 g, 0.07 mmol) was added and sparging continued for an additional 10 
min before the flask was closed and the contents heated to reflux. Upon complete 
consumption of the halogen starting material (24 h), the reaction was cooled, filtered and 
washed with EtOAc (~ 400 mL). The organic mixture was washed with H2O (2 × 50 mL) and 
brine, dried over anhydrous Na2SO4 and evaporated in vacuo. Chromatography of the residue 
gave the pure product as colorless solid (0.75 g, 56%). 
1H NMR (300 MHz, CDCl3): ? = 7.35 (d, J = 3.3 Hz, 1H; H-5), 7.30-7.18 (m, 4H; H-2/3, H-
8/9), 7.10 (dd, J = 8.5 Hz, J = 2.6 Hz, 1H; H-10), 6.88-6.73 (m, 5H; H-12, H-16/17), 4.99 (s, 
2H; H-14), 4.06 (s, 3H; H-13), 4.03 (s, 3H; H-19) ppm. 
13C NMR (75 MHz, CDCl3):? ? = 159.8 (C-11), 159.6 (C-4), 158.2 (C-18), 149.6 (C-6), 138.5 
(C-7), 132.6 (C-15), 130.1 (C-9), 129.7 (C-3), 129.3 (C-16), 127.7 (C-1), 120.4 (C-3), 119.1 
(C-8), 114.3 (C-17), 113.7 (C-10), 113.3 (C-12), 110.0 (C-5), 69.9 (C-14), 55.3 (C-13), 55.2 
(C-19) ppm. 
MS (EI): m/z = 365 (16%, M+), 335 (7%), 265 (31%), 263 (100%), 244 (22%), 198 (16%). 
5.4.6.3. 2-(4-Methoxybenzyloxy)-6-methoxy-9H-carbazole & 7-(4-Methoxybenzyloxy)-1-
methoxy-9H-carbazole (76) 
2-Nitrobiphenyl derivative (0.74 g, 2 mmol) and PPh3 (1.33 g, 5 mmol) was taken up in 1,2- 
dichlorobenzene (o-DCB) (6 mL) under N2 and heated to reflux, with vigorous stirring. The 
reaction was stopped upon complete consumption of the nitrobiphenyl starting material (6 h), 
at which point the reaction was cooled and the solvent stripped in vacuo. The residue was 
chromatographed (EtOAc:hexane, 1:9) directly to separate the two regio isomers formed i.e. 
6-methoxy carbazole as colorless solid (0.3 g, 44%) and 8-methoxy carbazole as colorless 
solid (0.2 g, 30%). 
5.4.6.3.1. 6-Methoxy-2-(4-methoxybenzyloxy)-9H-carbazole  (76a) 
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1H NMR (300 MHz, CDCl3): ? = 8.09 (brs, 1H; NH), 7.83 (d, J = 6.0 Hz, 1H; H-1), 7.51 (d, 
J = 9.0 Hz, 1H; H-8), 7.35-7.21 (m, 3H; H-5, H-16), 7.03 (d,  J = 7.5 Hz, 1H; H-7), 6.91 (d, J 
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= 1.5 Hz, 1H; H-4), 6.88-6.82 (m 2H; H-17), 6.76 (dd, J = 7.5 Hz, J = 1.5 Hz, 1H; H-2), 4.99 
(s, 2H; H-14), 3.92 (s, 3H; H-13), 3.73 (s, 3H; H-19) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 158.4 (C-18), 157.1 (C-6), 156.3 (C-3), 134.4 (C-15), 132.5 
(C-12), 128.5 (C-11), 128.2 (C-16), 127.5 (C-9), 123.4 (C-1), 118.3 (C-17), 116.7 (C-8), 
113.9 (C-2), 111.1 (C-7), 108.5 (C-10), 104.2 (C-5), 95.0 (C-4), 69.2 (C-14), 54.4 (C-13), 
54.2 (C-19) ppm. 
 5.4.6.3.2. 1-Methoxy-7-(4-methoxybenzyloxy)-9H-carbazole (76b) 
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1H NMR (300 MHz, CDCl3): ? = 7.81 (d, J = 9.0 Hz, 1H; H-1), 7.40 (d, J = 1.5 Hz, 1H; H-
4), 7.32-7.29 (m, J = 9.0 Hz, 1.5 Hz, 2H; H-16), 7.27-7.18 (m, 2H; H-5/6), 6.89 (dd, J = 7.5 
Hz, J = 1.5 Hz, 1H; H-3), 6.85 (dd, J = 9.0 Hz, J = 1.5 Hz, 2H; H-17), 6.81 (d, J = 9.0 Hz, 
17), 4.99 (s, 2H; H-14), 3.84 (s, 3H; H-13), 3.73 (s, 3H; H-19) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 158.4 (C-18), 157.1 (C-3), 144.4 (C-8), 139.3 (C-15), 134.4 
(C-12), 128.4 (C-16), 128.2 (C-11), 127.5 (C-9), 123.8 (C-6), 121.7 (C-1), 118.3 (C-17), 
116.7 (C-2), 113.0 (C-5), 109.9 (C-7), 107.5 (C-10), 101.7 (C-4), 69.3 (C-14), 55.1 (C-13), 
54.3 (C-19) ppm. 
5.4.6.4. 6-Methoxy-9H-carbazol-2-ol (77a) 
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10% Pd-C (20% w/w, 60 mg) was added to the solution of 6-methoxy-2-(4-
methoxybenzyloxy)-9H-carbazole (76a), (300 mg, 0.9 mmol) in MeOH (5 mL) and the 
resulting suspension was kept under H2 at 60 psi, at ambient temperature for 24 h. The 
reaction mixture was filtered through the celite bed and the celite bed was washed several 
times with warm MeOH. The combined organic extract was evaporated in vacuo to yield the 
crude product. The crude compound was purified by flash column chromatography 
(EtOAc:hexane, 3:7) to obtain the title compound as a cream colored (165 mg, 86%). 
1H NMR (300 MHz, CDCl3): ? = 7.79 (d, J = 8.0 Hz, 1H; H-1), 7.55 (brs, 1H; NH), 7.50 (dd, 
J = 1.8 Hz, J = 7.8 Hz, 1H; H-8), 7.04 (d, J = 1.8 Hz, 1H; H-5), 6.88 (d, J = 1.7 Hz, 1H; H-4), 
6.80 (dd, J = 7.6 Hz, J = 1.6 Hz, 1H; H-2), 6.69 (dd, J = 8.4 Hz, J = 2.2 Hz, 1H; H-7), 3.97 (s, 
3H; H-13) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 157.1 (C-6), 148.9 (C-3), 134.3 (C-12), 130.2 (C-11), 125.9 
(C-9), 122.0 (C-1), 118.8 (C-2), 113.0 (C-8), 109.6 (C-7), 106.1 (C-10), 102.3 (C-5), 97.9 (C-
4), 56.5 (C-13) ppm. 
MS (EI): m/z = 213 (68%, M+), 198 (49%), 170 (71%), 144 (9%), 119 (18%), 43 (100%). 
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5.4.6.5. 8-Methoxy-9H-carbazol-2-ol (77b) 
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10% Pd-C (20% w/w, 40 mg) was added to the solution of 1-methoxy-7-(4-
methoxybenzyloxy)-9H-carbazole (76b), (200 mg, 0.6 mmol) in MeOH (5 mL) and the 
resulting suspension was kept under H2 at 60 psi, at ambient temperature for 24 h. The 
reaction mixture was filtered through the celite bed and the celite bed was washed several 
times with warm MeOH. The combined organic extract was evaporated in vacuo to yield the 
crude product. The crude compound was purified by flash column chromatography 
(EtOAc:hexane, 3:7) to obtain the title compound as a cream colored (115 mg, 90%). 
MS (EI): m/z = 213 (71%, M+), 198 (44%), 170 (67%), 144 (12%), 43 (100%). 
5.4.6.6. Tert-butyl 2-(3-methoxy-9H-carbazol-7-yloxy)acetate (78a) 
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Anhydrous K2CO3 (242 mg, 1.8 mmol) was added to a stirred solution of 6-methoxy-9H-
carbazol-2-ol (77a) (130 mg, 0.6 mmol) in acetone (5 mL) and stirred at ambient temperature 
for 30 min. T-butyl chloroacetate (105 ?L, 0.75 mmol) was added to it and heated to 60–70 
°C for 12 h. Reaction was cooled to room temperature and filtered. The residue was washed 
with acetone (×3). Combined organic extract was evaporated in vacuo and purified by 
crystallization to yield the title compound as a colorless solid (190 mg, 95%)  
1H NMR (300 MHz, CDCl3): ? = 8.09 (brs, 1H; NH), 7.84 (d, J = 8.6 Hz, 1H; H-1), 7.51 (d, 
7.8 Hz, 1H; H-8), 7.07 (d, J = 1.8 Hz, 1H; H-5), 6.87 (d, J = 2.2 Hz, 1H; H-4), 6.80-6.76 (m, 
2H; H-2, H-7), 4.53 (s, 2H; H-14), 3.93 (s, 3H; H-13), 1.42 (s, 9H; H-17) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 168.2 (C-15), 157.2 (C-6), 155.4 (C-3), 140.2 (C-12), 129.7 
(C-11), 124.3 (C-9), 121.2 (C-1), 113.9 (C-8), 111.4 (C-2), 110.2 (C-7), 108.4 (C-10), 105.2 
(C-5), 96.3 (C-4), 82.3 (C-16), 66.4 (C-14), 55.5 (C-13), 28.0 (C-17) ppm. 
5.4.6.7. Tert-butyl 2-(1-methoxy-9H-carbazol-7-yloxy)acetate (78b) 
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Anhydrous K2CO3 (148 mg, 1 mmol) was added to a stirred solution of 8-methoxy-9H-
carbazol-2-ol (77b) (75 mg, 0.35 mmol) in acetone (5 mL) and stirred at ambient temperature 
for 30 min. T-butyl chloroacetate (62 ?L, 0.42 mmol) was added to it and heated to 60–70 °C 
for 12 h. Reaction was cooled to room temperature and filtered. The residue was washed with 
acetone (×3). Combined organic extract was evaporated in vacuo and purified by 
crystallization to yield the title compound as a colorless solid (115 mg, 90%)  
Experimental 
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1H NMR (300 MHz, CDCl3): ? = 7.90 (brs, 1H; NH), 7.81 (d, J = 8.5 Hz, 1H; H-1), 7.38 (d, 
8.5 Hz, 1H; H-5), 7.19 (d, J = 1.5 Hz, 1H; H-4), 6.90 (t, J = 8.7 Hz, 1H; H-6), 6.81 (d, J = 8.5 
Hz, 1H; H-7), 6.76 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H; H-3), 4.52 (s, 2H; H-14), 3.74 (s, 3H; H-
13), 1.42 (s, 9H; H-17) ppm.  
13C NMR (75 MHz, CDCl3):? ? = 167.2 (C-15), 156.3 (C-3), 147.4 (C-8), 138.4 (C-12), 130.5 
(C-11), 124.3 (C-9), 123.2 (C-6), 119.9 (C-1), 114.0 (C-2), 113.6 (C-5), 109.9 (C-7), 107.0 
(C-10), 95.1 (C-4), 81.3 (C-16), 65.3 (C-14), 55.0 (C-13), 28.2 (C-17) ppm. 
MS (EI): m/z = 327 (22%, M+), 271 (68%), 212 (26%), 94 (48), 59 (51%), 43 (100%). 
5.4.6.8. Tert-butyl 2-(9-(3,5-bis(trifluoromethyl)phenylsulfonyl)-6-methoxy-9H-carbazol-
2-yloxy)acetate (79a) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(3-methoxy-9H-carbazol-7-yloxy)acetate (78a) (40 mg, 0.12 mmol), 
3,5-bis(trifluoromethyl)phenyl sulfonyl chloride (46 mg, 0.14 mmol), KOBut (17 mg, 0.13 
mmol). 
Yield: 44 mg, 60%. 
1H NMR (300 MHz, CDCl3): ? = 8.23 (s, 2H; H-14), 7.97 (s, 1H; H-16), 7.79 (d, J = 8.4 Hz, 
1H; H-4), 7.73 (d, J = 8.7 Hz, 1H; H-8), 7.37 (d, J = 1.0 Hz, 1H; H-6), 7.22 (d, J = 1.1 Hz, 
1H; H-1), 7.00 (dd, J = 8.5 Hz, 1.5 Hz, 1H; H-7), 6.77 (dd, J = 7.2 Hz, J = 1.2 Hz, 1H; H-3), 
4.59 (s, 2H; H-19), 1.43 (s, 9H; H-22) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.7 (C-20), 158.2 (C-6), 155.5 (C-2), 142.2 (C-13), 140.5 
(C-12), 133.1 (C-16), 129.1 (C-5), 128.7 (C-14), 127.7 (C-9), 125.6 (C-17/18), 123.5 (C-11), 
121.0 (C-4), 113.3 (C-8), 111.0 (C-3), 109.8 (C-7), 107.7 (C-10), 102.7 (C-1), 82.6 (C-21), 
66.1 (C-19), 55.2 (C-23), 28.0 (C-22) pm.  
MS (ESI): m/z = 626.1 (M+Na)+. 
5.4.6.9. Tert-butyl 2-(9-(4-chlorophenylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetate 
(79b) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(3-methoxy-9H-carbazol-7-yloxy)acetate (78a) (40 mg, 0.12 mmol), 
4-chlorophenyl sulfonyl chloride (31 mg, 0.14 mmol), KOBut (17 mg, 0.13 mmol). 
Experimental 
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Yield: 42 mg, 70%. 
1H NMR (300 MHz, CDCl3): ? = 7.81 (d, J = 8.4 Hz, 1H; H-4), 7.72-7.64 (m, 3H; H-8; H-
14), 7.37-7.30 (m, 3H; H-5, H-15), 7.20-7.14 (m, 1H; H-1), 6.97 (dd, J = 8.7 Hz, J = 2.4 Hz, 
1H; H-7), 6.76 (dd, J = 8.7 Hz, J = 1.0 Hz, 1H; H-3), 4.58 (s, 2H; H-17), 1.44 (s, 9H; H-20) 
ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 166.8 (C-18), 156.9 (C-6), 154.2 (C-2), 140.7 (C-16), 138.3 
(C-12), 138.2 (C-13), 130.1 (C-15), 129.5 (C-14), 126.3 (C-9), 125.8 (C-11), 121.9 (C-4), 
116.4 (C-8), 114.4 (C-3), 109.8 (C-7), 104.6 (C-10), 96.1 (C-1), 81.5 (C-19), 65.0 (C-17), 
54.7 (C-21), 28.1 (C-20) ppm.  
5.4.6.10. Tert-butyl 2-(9-(biphenyl-4-ylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetate 
(79c) 
N
O
O
O
1
2
34
5
6
7
8
9
10 11
12
13
14
15
16 17 18
S
O
O
19
20
21 22
24
23
27
O
 
The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(3-methoxy-9H-carbazol-7-yloxy)acetate (78a) (40 mg, 0.12 mmol), 
4-biphenyl sulfonyl chloride (37 mg, 0.14 mmol), KOBut (17 mg, 0.13 mmol). 
Yield: 46 mg, 70%. 
1H NMR (300 MHz, CDCl3): ? = 7.88 (d, J = 2.2 Hz, 1H; H-5), 7.80 (d, J = 8.8 Hz, 2H; H-
14), 7.72 (d, J = 8.7 Hz, 1H; H-4), 7.55 (td, J = 6.6 Hz, J = 1.9 Hz, 2H; H-15), 7.48 (dd, J = 
6.6 Hz, J = 1.8 Hz, 2H; H-18), 7.40-7.31 (m, 4H; H-8, H-19/20), 7.19-7.14 (m, 1H; H-1), 6.97 
(dd, J = 8.6 Hz, J = 2.2 Hz, 1H; H-7), 6.76 (d, J = 7.2 Hz, 1H; H-3), 4.59 (s, 2H; H-21), 3.65 
(s, 3H; H-27), 1.41 (s, 9H; H-24) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 166.8 (C-22), 156.9 (C-6), 154.3 (C-2), 143.3 (C-16), 141.7 
(C-12), 139.8 (C-13), 138.5 (C-17), 130.1 (C-19), 129.3 (C-15), 128.9 (C-14), 128.2 (C-18), 
127.5 (C-20), 127.1 (C-9), 126.2 (C-11), 125.9 (C-4), 1139 (C-8), 111.2 (C-3), 110.8 (C-7), 
104.2 (C-10), 95.2 (C-1), 81.5 (C-23), 65.4 (C-21), 54.7 (C-27), 28.6 (C-24) ppm.  
5.4.6.11. Tert-butyl 2-(9-(2-bromophenylsulfonyl)-6-methoxy-9H-carbazol-2-
yloxy)acetate (79d) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(3-methoxy-9H-carbazol-7-yloxy)acetate (78a) (40 mg, 0.12 mmol), 
2-bromophenyl sulfonyl chloride (38 mg, 0.14 mmol), KOBut (17 mg, 0.13 mmol). 
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Yield: 34 mg, 52%. 
1H NMR (300 MHz, CDCl3): ? = 8.25 (dd, J = 8.0 Hz, J = 1.7 Hz, 1H; H-18), 7.89 (d, J = 
2.2 Hz, 1H; H-5), 7.76 (d, J = 8.5 Hz, 1H; H-15), 7.60 (dd, J = 7.9 Hz, 1H; H-4), 7.49-7.31 
(m, 3H; H-8, H-16/17), 7.24-7.14 (s, 1H; H-1), 6.98 (dd, J = 8.6 Hz, J = 2.3 Hz, 1H; H-7), 
6.69 (d, J = 6.8 Hz, 1H; H-3), 4.58 (s, 2H; H-19), 3.45 (s, 3H; H-21), 1.43 (s, 9H; H-23) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 167.9 (C-20), 157.6 (C-6), 155.3 (C-2), 144.6 (C-13), 141.8 
(C-12), 138.2 (C-16), 135.1 (C-15), 133.6 (C-18), 131.4 (C-17), 128.9 (C-9), 126.7 (C-11), 
125.0 (C-14), 122.1 (C-4), 115.5 (C-8), 113.3 (C-3), 110.8 (C-7), 107.8 (C-10), 103.2 (C-5), 
95.2 (C-1), 82.4 (C-22), 66.1 (C-19), 55.0 (C-21), 28.1 (C-23) ppm.  
5.4.6.6. Tert-butyl 2-(9-(4-chlorophenylsulfonyl)-8-methoxy-9H-carbazol-2-yloxy)acetate 
(79e) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(1-methoxy-9H-carbazol-7-yloxy)acetate (78b) (18 mg, 0.055 
mmol), 4-chlorophenyl sulfonyl chloride (14 mg, 0.066 mmol), KOBut (7.5 mg, 0.06 mmol). 
Yield: 19 mg, 70%. 
1H NMR (300 MHz, CDCl3): ? = 8.07-8.04 (m, 1H; H-4), 7.79-7.72 (m, 1H; H-5), 7.63-7.52 
(m, 2H; H-15), 7.41-7.29 (m, 2H; H-16), 7.16-7.09 (m, 1H; H-1), 6.96-6.87 (m, 3H; H-3, H-
6/7), 4.59 (s, 3H; H-17), 3.80 (s, 3H; H-21), 1.47 (s, 9H; H-20) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 168.8 (C-18), 154.9 (C-2), 148.2 (C-8), 140.7 (C-16), 137.3 
(C-12), 136.2 (C-13), 130.4 (C-15), 129.7 (C-14), 125.3 (C-9), 125.2 (C-11), 123.7 (C-6), 
121.9 (C-4), 114.4 (C-3), 113.4 (C-5), 109.8 (C-7), 107.6 (C-10), 95.1 (C-1), 80.5 (C-19), 
66.1 (C-17), 55.2 (C-21), 28.4 (C-20) ppm.  
5.4.6.13. Tert-butyl 2-(9-(biphenyl-4-ylsulfonyl)-8-methoxy-9H-carbazol-2-yloxy)acetate 
(79f) 
N
O
O
O
1
2
34
5
6
7
8
9
10 11
12
13
14
15
16 17 18
S
O
O
19
20
21 22
24
23
27
O
 
The title compound was synthesized by following the general procedure mentioned in 5.4.2.1. 
Reactants: Tert-butyl 2-(1-methoxy-9H-carbazol-7-yloxy)acetate (78b) (18 mg, 0.055 
mmol), 4-biphenyl sulfonyl chloride (17 mg, 0.066 mmol), KOBut (7.5 mg, 0.06 mmol). 
Yield: 23 mg, 80%. 
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1H NMR (300 MHz, CDCl3): ? = 8.10 (d, J = 9.0 Hz, 1H; H-4), 7.81 (d, J = 1.8 Hz, 1H; H-
1), 7.73-7.63 (m, 3H; H-5, H-14), 7.42-7.28 (m, 7H; H-15, H-18/19/20), 7.17-7-12 (m, 1H; H-
6), 6.97-6.91 (m, 2H; H-3, H-7), 4.60 (s, 2H; H-21), 3.80 (s, 3H; H-27), 1.42 (s, 9H; H-24) 
ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 168.8 (C-22), 155.3 (C-2), 147.3 (C-8), 142.3 (C-16), 140.7 
(C-12), 139.1 (C-13), 137.9 (C-17), 129.7 (C-19), 129.1 (C-15), 128.6 (C-14), 128.1 (C-18), 
127.8 (C-20), 127.6 (C-9), 127.1 (C-11), 125.9 (C-4), 124.1 (C-6), 113.9 (C-3), 111.6 (C-5), 
109.8 (C-7), 106.2 (C-10), 96.2 (C-1), 81.8 (C-23), 66.4 (C-21), 55.4 (C-27), 28.3 (C-24) 
ppm.  
5.4.6.14. 2-(9-(3,5-Bis(trifluoromethyl)phenylsulfonyl)-6-methoxy-9H-carbazol-2-
yloxy)acetic acid (80a) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(3,5-bis(trifluoromethyl)phenylsulfonyl)-6-methoxy-9H-carbazol-
2-yloxy)acetate (79a) (25 mg, 0.04 mmol), 20% trifluoroacetic acid in CH2Cl2 (2 mL). 
Yield: 19 mg, 90%. 
1H NMR (300 MHz, CDCl3): ? = 8.25 (s, 2H; H-14), 8.01 (s, 1H; H-16), 7.81 (d, J = 8.6 Hz, 
1H; H-4), 7.75 (d, J = 8.8 Hz, 1H; H-8), 7.41 (d, J = 1.5 Hz, 1H; H-6), 7.24 (d, J = 1.6 Hz, 
1H; H-1), 7.05 (dd, J = 8.8 Hz, J = 1.8 Hz, 1H; H-7), 6.81 (dd, J = 8.2 Hz, J = 1.5 Hz, 1H; H-
3), 4.65 (s, 2H; H-19), 3.54 (s, 3H; H-23) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 174.7 (C-20), 157.2 (C-6), 156.5 (C-2), 143.2 (C-13), 140.1 
(C-12), 133.6 (C-16), 129.7 (C-5), 128.9 (C-14), 128.1 (C-9), 125.8 (C-17/18), 123.9 (C-11), 
121.6 (C-4), 113.7 (C-8), 111.9 (C-3), 110.5 (C-7), 108.3 (C-10), 104.7 (C-1), 96.6 (C-1), 
66.9 (C-19), 56.6 (C-23) pm.  
MS (ESI): m/z = 626.1 (M+Na)+. 
5.4.6.15. 2-(9-(4-Chlorophenylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetic acid (80b) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(4-chlorophenylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetate 
(79b) (25 mg, 0.05 mmol), 20% trifluoroacetic acid in CH2Cl2 (2 mL). 
Experimental 
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Yield: 20 mg, 94%. 
1H NMR (300 MHz, CDCl3): ? = 7.91 (s, 1H; H-5), 7.80 (d, J = 1.5 Hz, 1H; H-1), 7.59 (d, J 
= 8.7 Hz, 2H; H-14), 7.44 (d, J = 9.0 Hz, 1H; H-4), 7.21 (d, J = 8.7 Hz, 2H; H-15), 7.10-6.84 
(m, 3H; H-3, H-7, H-8), 6.66 (dd, J = 8.7 Hz, J = 1.5 Hz, 1H; H-3), 4.54 (s, 2H; H-17) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 173.8 (C-18), 157.1 (C-6), 155.1 (C-2), 141.4 (C-16), 138.3 
(C-12), 138.1 (C-13), 130.3 (C-15), 129.6 (C-14), 126.4 (C-9), 125.9 (C-11), 122.2 (C-4), 
117.1 (C-8), 115.1 (C-3), 109.9 (C-7), 105.1 (C-10), 97.5 (C-1), 66.5 (C-17), 55.2 (C-21) 
ppm.  
 5.4.6.16. 2-(9-(Biphenyl-4-ylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetic acid (80c) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(biphenyl-4-ylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetate 
(79c) (25 mg, 0.045 mmol), 20% trifluoroacetic acid in CH2Cl2 (2 mL). 
Yield: 21 mg, 95%. 
1H NMR (300 MHz, CDCl3): ? = 7.89 (d, J = 2.2 Hz, 1H; H-5), 7.74 (d, J = 8.6 Hz, 2H; H-
14), 7.57 (d, J = 8.6 Hz, 1H; H-4), 7.50 (d, J = 8.6 Hz, 2H; H-15), 7.41 (dd, J = 7.8 Hz, J = 
2.2 Hz, 2H; H-18), 7.32-7.20 (m, 4H; H-8, H-19/20), 7.11-7.08 (s, 1H; H-1), 6.91 (dd, J = 8.8 
Hz, J = 2.1 Hz, 1H; H-7), 6.69 (d, J = 7.6 Hz, 1H; H-3), 4.57 (s, 2H; H-21), 3.59 (s, 3H; H-
27) ppm. 
13C NMR (75 MHz, CDCl3): ? ?= 174.8 (C-22), 156.3 (C-6), 155.1 (C-2), 142.6 (C-16), 141.1 
(C-12), 139.3 (C-13), 138.1 (C-17), 130.4 (C-19), 129.4 (C-15), 128.3 (C-14), 127.8 (C-18), 
127.2 (C-20), 126.9 (C-9), 126.1 (C-11), 125.4 (C-4), 113.2 (C-8), 111.1 (C-3), 109.2 (C-7), 
106.1 (C-10), 96.5 (C-1), 66.2 (C-21), 56.1 (C-27) ppm.  
5.4.6.17. 2-(9-(2-Bromophenylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetic acid (80d) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(2-bromophenylsulfonyl)-6-methoxy-9H-carbazol-2-yloxy)acetate 
(79d) (20 mg, 0.036 mmol), 20% trifluoroacetic acid in CH2Cl2 (2 mL). 
Yield: 14 mg, 80%. 
Experimental 
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1H NMR (300 MHz, CDCl3): ? = 8.25 (dd, J = 8.0 Hz, J = 1.7 Hz, 1H; H-18), 7.91 (d, J = 
2.2 Hz, 1H; H-5), 7.77 (d, J = 8.6 Hz, 1H; H-15), 7.61 (d, J = 7.9 Hz, 1H; H-4), 7.51-7.29 (m, 
3H; H-8, H-16/17), 7.24-7.14 (s, 1H; H-1), 6.98 (dd, J = 8.6 Hz, J = 2.3 Hz, 1H; H-7), 6.69 
(d, J = 6.8 Hz, 1H; H-3), 4.69 (s, 2H; H-19), 3.45 (s, 3H; H-21) ppm. 
13C NMR (75 MHz, CDCl3): ? ?= 175.9 (C-20), 156.2 (C-6), 155.5 (C-2), 145.1 (C-13), 140.2 
(C-12), 137.5 (C-16), 134.8 (C-15), 132.8 (C-18), 131.1 (C-17), 129.4 (C-9), 127.1 (C-11), 
125.6 (C-14), 122.3 (C-4), 115.6 (C-8), 113.1 (C-3), 110.1 (C-7), 106.1 (C-10), 101.3 (C-5), 
97.1 (C-1), 66.5 (C-19), 56.1 (C-21) ppm.  
5.4.6.18. 2-(9-(4-Chlorophenylsulfonyl)-8-methoxy-9H-carbazol-2-yloxy)acetic acid (80e) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(4-chlorophenylsulfonyl)-8-methoxy-9H-carbazol-2-yloxy)acetate 
(79e) (15 mg, 0.03 mmol), 20% trifluoroacetic acid in CH2Cl2 (2 mL). 
Yield: 12 mg, 93%. 
1H NMR (300 MHz, CDCl3): ? = 8.08-8.05 (m, 2H; H-4/5), 7.81 (m, 1H; H-1), 7.70-7.52 (m, 
3H; H-6, H-14), 7.41-7.30 (m, 2H; H-15), 7.15-7.10 (s, 1H; H-1), 6.97-6.84 (m, 2H; H-3, H-
7), 4.59 (s, 3H; H-17), 3.80 (s, 3H; H-21) ppm.  
13C NMR (75 MHz, CDCl3): ? ?= 174.5 (C-18), 156.1 (C-2), 148.5 (C-8), 140.5 (C-16), 136.9 
(C-12), 136.1 (C-13), 130.1 (C-15), 129.2 (C-14), 125.1 (C-9), 124.8 (C-11), 122.9 (C-6), 
122.1 (C-4), 113.9 (C-3), 111.9 (C-5), 110.1 (C-7), 106.9 (C-10), 96.3 (C-1), 66.5 (C-17), 
56.3 (C-21) ppm.  
5.4.6.19. 2-(9-(Biphenyl-4-ylsulfonyl)-8-methoxy-9H-carbazol-2-yloxy)acetic acid (80f) 
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The title compound was synthesized by following the general procedure mentioned in 5.4.3.1. 
Reactants: Tert-butyl 2-(9-(biphenyl-4-ylsulfonyl)-8-methoxy-9H-carbazol-2-yloxy)acetate 
(79f) (15 mg, 0.027 mmol), 20% trifluoroacetic acid in CH2Cl2 (2 mL). 
Yield: 12 mg, 90%. 
1H NMR (300 MHz, CDCl3): ? = 8.13 (d, J = 9.0 Hz, 1H; H-4), 7.85 (d, J = 1.5 Hz, 1H; H-
1), 7.71 (d, J = 9.0 Hz, 2H; H-14), 7.67 (d, J = 9.0 Hz, 1H; H-5), 7.42 (d, J = 9.0 Hz, 2H; H-
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15), 7.41-7.30 (m, 6H; H-6, H-18/19/20), 6.98 (d, J = 9.0 Hz, 1H; H-7), 6.94 (d, J = 9.0 Hz, J 
= 1.5 Hz, 1H; H-3), 4.76 (s, 2H; H-21), 3.81 (s, 3H; H-27) ppm.  
13C NMR (75 MHz, CDCl3): į ̓= 176.8 (C-22), 156.1 (C-2), 148.1 (C-8), 141.3 (C-16), 140.1 
(C-12), 138.8 (C-13), 137.6 (C-17), 129.3 (C-19), 128.4 (C-15), 128.1 (C-14), 127.6 (C-18), 
127.1 (C-20), 126.9 (C-9), 126.4 (C-11), 125.5 (C-4), 125.1 (C-6), 113.5 (C-3), 111.2 (C-5), 
108.3 (C-7), 105.2 (C-10), 97.2 (C-1), 66.8 (C-21), 56.1 (C-27) ppm. 
5.5. Synthesis of LXR Agonist TO-901317 Analogous ?-Secretase Modulator 
5.5.1. Tert-butyl 2-(4-nitrophenoxy)acetate (83) 
1
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Anhydrous K2CO3 (2.26 g, 16.38 mmol) was added to a stirred solution of 4-nitro phenol (1 g, 
7.19 mmol) in acetone (15 mL) and stirred for 30 min. at ambient temperature. T-butyl 
chloroacetate (1.13 mL, 7.91 mmol) was added to it and heated to 60–70 °C for 16 h. 
Reaction was monitored by TLC. Reaction was cooled to room temperature and filtered. The 
residue was washed with acetone (×3). Combined organic extract was evaporated in vacuo 
and purified by crystallization to yield the title compound as a yellowish solid (1.73 g, 95%). 
1H NMR (300 MHz, CDCl3): į = 8.02 (d, J = 9.0, 2H; H-3), 6.90 (d, J = 9.0, 2H; H-2), 4.41 
(s, 2H; H-5), 1.42 (s, 9H; H-8) ppm.  
5.5.2. Tert-butyl 2-(4-aminophenoxy)acetate (84) 
O
O
O
H2N  
10% Pd-C (300 mg, 20% w/w) was added to a stirred solution of tert-butyl 2-(4-
nitrophenoxy)acetate (83) methanol (20 mL) and the suspension was kept under H2 at 60 psi 
at room temperature for 6 h. The reaction was monitored by TLC and the ninhydrin was used 
for the visualisation. The reaction mixture was filtered through the celite bed. The celite bed 
was washed with warm methanol (3×). Combined organic extracts were evaporated in vacuo 
to yield the title compound as pale brown solid. The crude product was used for the next step 
without further purification. 
5.5.3. Tert-butyl 2-(4-(3,5-bis(trifluoromethyl)phenylsulfonamido)phenoxy)acetate (85) 
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Triethyl amine (150 ?L, 1.08 mmol) and catalytic DMAP (22 mg, 0.18 mmol) were added to 
a stirred solution of tert-butyl 2-(4-aminophenoxy)acetate (84) (200 mg, 0.89 mmol) in 
CH2Cl2 and stirred at an ambient temperature for 30 min. 3,5-Bis-(trifluoromethyl) phenyl 
sulfonyl chloride (342 mg, 1.08 mmol) was then added to it and stirred for another 18 h. 
Reaction was monitored by TLC. The reaction mixture was diluted with CH2Cl2, washed with 
H2O, dried over anhydrous Na2SO4 and evaporated in vacuo to afford the crude compound. 
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The crude compound was purified by column chromatography (EtOAc:hexane, 2:8) to afford 
the title compound as cream colored solid (150 mg, 35%).  
1H NMR (300 MHz, CDCl3): į = 8.03 (s, 2H; H-10), 7.95 (s, 1H; H-12), 6.88 (dd, J = 9.0 
Hz, J = 3.0 Hz, 2H; H-3), 6.70 (dd, J = 9.0 Hz, J = 3.0 Hz, 2H; H-2), 4.40 (s, 2H; H-5), 1.41 
(s, 3H; H-8) ppm.  
13C NMR (75 MHz, CDCl3): į ̓= 167.8 (C-6), 157.0 (C-1), 141.7 (C-9), 132.9 (C-11), 132.4 
(C-4), 127.5 (C-12), 126.3 (C-10), 124.1 (C-13), 120.5 (C-3), 115.5 (C-2), 82.8 (C-7), 65.8 
(C-5), 27.9 (C-8) pm.  
5.5.4. Tert-butyl 2-(4-(N-octyl-3,5-
bis(trifluoromethyl)phenylsulfonamido)phenoxy)acetate (86) 
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KOBut (27 mg, 0.22 mmol) was added to a stirred solution of tert-butyl 2-(4-(3,5-
bis(trifluoromethyl)phenylsulfonamido)phenoxy)acetate (85) (100 mg, 0.2 mmol) and stirred 
at room temperature for 30 min. To it octyl iodide (44 ?L, 0.24 mmol) was added and stirred 
for another 48 h at an ambient temperature. Reaction was monitored by TLC. The reaction 
mixture was diluted with EtOAc (50 mL) and washed with water. The aqueous phase was 
extracted with EtOAc (3×). The combined organic extract was washed with water, brine, 
dried over anhydrous Na2SO4 and rotary evaporated to afford the crude product. The product 
was purified by column chromatography (EtOAc:hexane, 0.5:9.5) to obtain the title 
compound as colorless gummy mass (40 mg, 33%). 
1H NMR (300 MHz, CDCl3): į = 7.98 (s, 2H; H-10), 7.93 (s, 1H; H-12), 6.84 (d, J = 9.0 Hz, 
2H; H-3), 6.77 (d, J = 9.0 Hz, 2H; H-2), 4.43 (s, 2H; H-5), 3.43 (t, J = 7.5 Hz, 2H; H-14), 
1.52-1.49 (m, 2H; H-15), 1.42 (s, 9H; H-8), 1.34-1.12 (m, 10H; H-16/17/18/19/20), 0.80 (t, J 
= 7.5 Hz, 3H; H-21) ppm.  
13C NMR (75 MHz, CDCl3): į ̓= 167.5 (C-6), 157.9 (C-1), 141.2 (C-9), 132.8 (C-11), 132.4 
(C-4), 127.8 (C-12), 126.5 (C-10), 124.4 (C-13), 120.8 (C-3), 115.4 (C-2), 82.6 (C-7), 65.8 
(C-5), 51.3 (C-14), 30.8 (C-19), 28.9 (C-8), 28.5 (C-15), 28.1 (C-17), 28.0 (C-18), 26.2 (C-
16), 22.5 (C-20), 14.0 (C-21) ppm. 
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5.5.5. 2-(4-(N-Octyl-3,5-bis(trifluoromethyl)phenylsulfonamido)phenoxy)acetic acid (87) 
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Tert-butyl 2-(4-(N-octyl-3,5-bis(trifluoromethyl)phenylsulfonamido)phenoxy)acetate (86) (30 
mg, 0.05 mmol) was added to a solution of 20% TFA in CH2Cl2 and stirred at room 
temperature for 4 h. Reaction was monitored by TLC. Solvent was evaporated in vacuo and 
flushed with hexane several times. The crude compound was purified by crystallization 
(EtOAc) to afford the title compound as cream colored solid (21 mg, 77%). 
1H NMR (300 MHz, CDCl3): į = 7.97 (s, 1H; H-10), 7.91 (s, 2H; H-8), 6.90-6.76 (m, 4H; H-
2, H-3), 4.40 (s, 2H; H-5), 3.40 (t, J = 7.5 Hz, 2H; H-12), 1.37-1.28 (m, 2H; H-13), 1.24-1.11 
(m, 10H; H-14/15/16/17/18), 0.78 (t, J = 7.0 Hz, 3H; H-19) ppm.  
13C NMR (75 MHz, CDCl3): į ̓= 173.5 (C-6), 155.9 (C-1), 140.2 (C-7), 131.7 (C-9), 132.4 
(C-4), 124.8 (C-8), 123.4 (C-11), 122.5 (C-3), 114.5 (C-2), 64.3 (C-5), 50.1 (C-12), 30.6 (C-
17), 28.7 (C-6), 28.0 (C-13), 27.1 (C-15), 25.2 (C-16), 22.8 (C-14), 21.5 (C-18), 13.0 (C-19) 
ppm. 
5.6 Synthesis of Curcumin Derived Oxazole and Pyrazoles Derivatives 
 
The synthetic procedures and spectral data of curcumin derived oxazoles and pyrazoles are 
removed due to the IP reasons. 
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5.7. Synthesis of NSAIDs Derived Affinity Labels. 
5.7.1. Tert-butyl 2-(2-(2-fluorobiphenyl-4-yl)propanamido)ethylcarbamate (92) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2-fluoro-4-biphenyl)propanoic acid (150 mg, 0.61 mmol), EDAC (118 mg, 
0.74 mmol), HOBt (83 mg, 0.74 mmol), Et3N (189 ?L, 0.14 mmol), N-Boc ethylene diamine 
(116 ?L, 0.5 mmol). 
Yield: 213 mg, 90%. 
1H NMR (300 MHz, CDCl3): į = 7.44 (dd, J = 7.0 Hz, J = 1.4 Hz, 2H; H-3), 7.37-7.25 (m, 
4H; H-1, H-2, H-6), 7.09-7.01 (m, 2H; H-7, H-9), 6.45 (brs, 1H; NH), 4.93 (brs, 1H; NH), 
3.49 (q, J = 7.0 Hz, 1H; H-11), 3.24-3.05 (m, 4H; 13-H, 14-H), 1.47 (p, J = 7.0 Hz, 3H; H-
12), 1.33 (s, 9H; H-17) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 174.3 (C-18), 158.2 (C-10), 157.1 (C-15), 142.9 (C-8), 
135.5 (C-4), 131.1 (C-5), 130.0 (C-6), 129.0 (C-2), 128.5 (C-3), 127.9 (C-1), 123.6 (C-7), 
115.5 (C-9), 79.8 (C-16), 46.6 (C-11), 41.3 (C-13), 40.0 (C-14), 28.4 (C-16), 18.6 (C-17) 
ppm. 
5.7.2. N-(2-Aminoethyl)-2-(2-fluorobiphenyl-4-yl)propanamide (93) 
F
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A solution of compound tert-butyl 2-(2-(2-fluorobiphenyl-4-yl)propanamido)ethylcarbamate 
(92)  (120 mg, 0.3 mmol) in 16% HCl in dioxane (1 mL) was stirred at room temperature for 
1 h. Reaction was monitored by TLC and then the reaction mixture was evaporated in vacuo 
and lyophilized to afford the title compound as hydrochloride salt which was used in the next 
step without any purification. 
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5.7.3. N-(2-(2-(2-Fluorobiphenyl-4-yl)propanamido)ethyl)-5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (94) 
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Et3N (54 ?L, 0.38 mmol) was added to a stirred solution of D-biotin (94 mg, 0.38 mmol) in 
anhydrous DMF (3 mL) and stirred at ambient temperature for 10 min. To it ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (88 mg, 0.46 mmol) and N-
hydroxybenzotriazole hydrate (52 mg, 0.46 mmol) were added and the resulting solution was 
stirred at ambient temperature for 30 min. until it became clear. A solution of N-(2-
aminoethyl)-2-(2-fluorobiphenyl-4-yl)propanamide (93) as hydrochloride salt (100 mg, 0.3 
mmol) in DMF (1 mL) was added to the reaction mixture followed by Et3N (129 ?L, 0.9 
mmol) and stirred at ambient temperature for 16 h. The reaction mixture was diluted with 
CHCl3 (100 mL), washed sequentially with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine 
and dried over anhydrous Na2SO4 and evaporated in vacuo to yield the crude product. The 
crude product was purified by flash column chromatography (CHCl2:MeOH, 95:5) to afford 
the title compound as colorless solid (55 mg, 35%). 
1H NMR (500 MHz, CDCl3): į = 8.09 (brs, 1H; NH), 7.81 (brs, 1H; NH), 7.56-7.36 (m, 6H; 
H-1, H-2, H-3, H-6), 7.27-7.19 (m, 2H; H-7, H-9), 6.41 (brs, 1H; NH), 6.38 (brs, 1H; NH), 
4.37-4.28 (m, 1H; H-24), 4.16-4.08 (m, 1H; H-23), 3.64 (q, J = 7.2 Hz, 1H; H-11), 3.18-3.02 
(m, 5H; H-14, H-15, H-21), 2.80 (dd, J = 6.8 Hz, J = 5.0 Hz, 1H; H-22), 2.58 (d, J = 6.8 Hz, 
1H; H-22´), 2.20 (t, J = 7.2 Hz, 2H; H-17), 1.68-1.42 (m, 6H; H-18, H-19, H-20), 1.38 (d, J = 
7.0 Hz, 3H; H-12) ppm.  
13C NMR (125 MHz, CDCl3): ̓ į = 172.8 (C-16), 171.2 (C-13), 162.7 (C-25), 160.3 (C-10), 
136.9 (C-8), 136.4 (C-4), 130.4 (C-5), 130.1 (C-6), 129.8 (C-2), 128.6 (C-3), 128.1 (C-1), 
123.7 (C-7), 114.9 (C-9), 60.9 (C-24), 59.1 (C-23), 55.2 (C-21), 44.6 (C-11), 41.8 (C-22), 
39.5 (C-14), 39.3 (C-15), 35.1 (C-17), 28.1 (C-20), 27.9 (C-18), 25.1 (C-19), 18.5 (C-12) 
ppm. 
MS (EI): m/z = 56.5 (M+, 64%), 452.5 (71%), 270 (40%), 227.2 (84%), 199.2 (100%) 
5.7.4. 2-(2-Fluorobiphenyl-4-yl)propanoyl azide (95) 
F
N3
O
 
Flurbiprofen (200 mg, 0.82 mmol) was dissolved in THF (5 mL) under N2 and cooled to –20 
°C. After addition of EtOCOCl (86 ?L, 1.14 mmol) and Et3N (125 ?L, 0.9 mmol), the 
reaction mixture was stirred at –20 °C for 20 min. The resulting white suspension was 
allowed to warm to –10 °C and treated with aq. NaN3 solution (133 mg, 2.05 mmol). The 
mixture was stirred for 15 min, diluted with AcOEt, washed with brine, dried over anhydrous 
NaSO4 and evaporated in vacuo to give the expected acyl azide as colorless solid, which was 
used in the next step without further purification. 
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5.7.5. Tert-butyl 2-(3-(1-(2-fluorobiphenyl-4-yl)ethyl)ureido)ethylcarbamate (96) 
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Toluene was added under Ar to a flask containing 2-(2-Fluorobiphenyl-4-yl)propanoyl azide 
(95) and the resulting solution was heated to 65 °C under stirring. After the N2 gas evolution 
had stopped (15 min.), N-Boc ethylene diamine (128 ?L, 0.9 mmol) and pyridine (Et3N (125 
?L, 0.9 mmol)) were added. The mixture was stirred for 30 min at 65 °C and then cooled to 
room temperature. Tolune was removed in vacuo and the crude compound was purified by 
column chromatography (EtOAc:hexane, 2:8) to afford the title compound as colorless solid 
(280 mg, 85%).  
1H NMR (300 MHz, CDCl3): į = 7.42 (td, J = 8.3 Hz, J = 1.2 Hz, 2H; H-3), 7.37-7.24 (m, 
4H; H-1, H-2, H-6), 7.09-7.02 (m, 2H; H-7, H-9), 5.40 (brs, 2H, NH), 5.05 (brs, 1H, NH), 
4.82 (p, J = 7.0 Hz, 1H; H-11), 3.24-3.09 (m, 4H; H-14, H-15), 1.41 (d, J = 7.0 Hz, 3H; H-
12), 1.34 (s, 9H; H-18) ppm. 
13C NMR (75 MHz, CDCl3):̓ į = 161.5 (C-13), 158.1 (C-10), 157.0 (C-16), 146.5 (C-8), 
135.6 (C-4), 129.1 (C-6), 129.0 (C-2), 128.2 (C-3), 127.6 (C-1), 122.0 (C-7), 113.7 (C-9), 
79.7 (C-17), 49.4 (C-11), 41.2 (C-14), 40.8 (C-15), 28.4 (C-17), 23.1 (C-18) ppm. 
5.7.6. 1-(2-Aminoethyl)-3-(1-(2-fluorobiphenyl-4-yl)ethyl)urea (97) 
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A solution of compound tert-butyl 2-(3-(1-(2-fluorobiphenyl-4-
yl)ethyl)ureido)ethylcarbamate (96) (100 mg, 0.25 mmol) in 16% HCl in dioxane (1 mL) was 
stirred at room temperature for 1 h. Reaction was monitored by TLC The reaction mixture 
was evaporated in vacuuo and lyophilized to afford the title compound as hydrochloride salt 
which was used in the next step without any purification. 
5.7.7. N-(2-(3-(1-(2-Fluorobiphenyl-4-yl)ethyl)ureido)ethyl)-5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (98) 
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Et3N (43 ?L, 0.32 mmol) was added to a stirred solution of D-biotin (76 mg, 0.32 mmol) in 
anhydrous DMF (3 mL) and stirred at ambient temperature for 10 min. To it ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (72 mg, 0.38 mmol) and N-
hydroxybenzotriazole hydrate (51 mg, 0.38 mmol) were added and the resulting solution was 
stirred at ambient temperature for 30 min. until it became clear. A solution of 1-(2-
aminoethyl)-3-(1-(2-fluorobiphenyl-4-yl)ethyl)urea hydrochloride (97)  (85 mg, 0.25 mmol) 
in DMF (1 mL) was added to the reaction mixture followed by Et3N (217 ?L, 1.56 mmol) and 
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stirred at ambient temperature for 17 h. The reaction mixture was diluted with CHCl3 (100 
mL), washed with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine and dried over anhydrous 
Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was purified 
by flash column chromatography (CH2Cl2:MeOH, 95:5) to afford the title compound as 
colorless solid (46 mg, 35%). 
1H NMR (500 MHz, CDCl3): į = 7.42 (dd, J = 8.2 Hz, J = 1.6 Hz, 2H; H-3), 7.34 (tt, J = 7.2 
Hz, J = 1.6 Hz, 2H; H-2), 7.32-7.30 (m, 1H; H-6), 7.26 (t, J = 7.4 Hz, J = 1.6 Hz, 1H; H-1), 
7.08 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H; H-7), 7.03 (dd, J = 11.8 Hz, J = 1.6 Hz, 1H; H-9), 4.79-
4.71 (m, 1H; H-11), 4.41-4.36 (m, 1H; H-24), 4.20-4.15 (m, 1H; H-23), 3.20-3.13 (m, 1H; H-
21), 2.80 (dd, J = 6.8 Hz, J = 5.0 Hz, 1H; H-22), 2.64 (d, J = 6.8 Hz, 1H; H-22´), 2.04 (t, J = 
7.2 Hz, 2H; H-17), 1.65-1.54 (m, 4H; H-18, H-20), 1.37 (d, J = 7.0 Hz, 3H, 12-H) 1.36-1.28 
(m, 2H; H-19) ppm.  
13C NMR (125 MHz, CDCl3): ̓ į = 176.8 (C-16), 166.2 (C-13), 160.8 (C-24), 160.5 (C-10), 
148.8 (C-8), 137.4 (C-4), 130.5 (C-5), 130.0 (C-6), 129.2 (C-2), 128.5 (C-3), 128.2 (C-1), 
123.5 (C-7), 114.8 (C-9), 63.6 (C-25), 62.0 (C-23), 57.3 (C-21), 51.4 (C-11), 41.8 (C-22), 
41.1 (C-14), 39.1 (C-15), 37.1 (C-17), 29.7 (C-20), 27.1 (C-18), 26.8 (C-19), 24.2 (C-12) 
ppm. 
5.7.8. Tert-butyl 2-(2-(2,6-dichloro-3-methylphenylamino)benzamido)ethylcarbamate 
(99) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: 2-(2,6-dichloro-3-methylphenylamino)benzoic acid sodium salt (100 mg, 0.32 
mmol), EDAC (73 mg, 0.38 mmol), HOBt (51 mg, 0.38 mmol), Et3N (52 ?L, 0.45 mmol), N-
Boc ethylene diamine (60 ?L, 0.38 mmol). 
Yield: 128 mg, 90%. 
1H NMR (300 MHz, CDCl3): į = 9.43 (brs, 1H; NH), 7.49 (dd, J = 8.0 Hz, J = 1.4 Hz, 1H; 
H-11), 7.21 (d, J = 8.2 Hz, 1H; H-1), 7.19 (m, 1H; H-9), 6.97 (d, J = 8.2 Hz, 1H; H-8), 6.68 (t, 
J = 7.0 Hz, 1H; H-10), 6.29 (d, J = 8.2 Hz, 1H; H-2 ), 5.05 (t, J = 7.0 Hz, 1H; NH), 3.48 (q, J 
= 6.0 Hz, 2H; H-14), 3.32 (q, J = 6.0 Hz, 2H; H-15), 2.32 (s, 3H; H-19), 1.36 (s, 9H; H-18) 
ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 170.1 (C-13), 157.5 (C-16), 145.6 (C-7), 136.4 (C-5), 135.8 
(C-3), 133.3 (C-4), 132.0 (C-9), 128.1 (C-11), 127.7 (C-1), 127.1 (C-6), 122.0 (C-2), 120.1 
(C-12), 118.1 (C-18), 114.7 (C-10), 80.0 (C-17), 41.7 (C-15), 40.0 (C-14), 28.4 (C-18), 20.7 
(C-19) ppm. 
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5.7.9. N-(2-Aminoethyl)-2-(2,6-dichloro-3-methylphenylamino)benzamide (100) 
N
H
N
H
O
NH2Cl
Cl
 
A solution of compound tert-butyl 2-(2-(2,6-dichloro-3-
methylphenylamino)benzamido)ethylcarbamate (99) (100 mg, 0.3 mmol) in 16% HCl in 
dioxane (1 mL) was stirred at room temperature for 1 h. Reaction was monitored by TLC and 
then the reaction mixture was evaporated in vacuo and lyophilized to afford the title 
compound as hydrochloride salt which was used in the next step without any purification. 
5.7.10. 2-(2,6-Dichloro-3-methylphenylamino)-N-(2-(5-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl)benzamide (101) 
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Et3N (52 ?L, 0.38 mmol) was added to a stirred solution of biotin (91 mg, 0.38 mmol) in 
anhydrous DMF (3 mL) and stirred at ambient temperature for 10 min. To it ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (86 mg, 0.45 mmol) and N-
hydroxybenzotriazole hydrate (61 mg, 0.3 mmol) were added and the resulting solution was 
stirred at ambient temperature for 30 min. until it became clear. A solution of N-(2-
aminoethyl)-2-(2,6-dichloro-3-methylphenylamino)benzamide hydrochloride (100)  (101 mg, 
0.28 mmol) in DMF (1 mL) was added to the reaction mixture followed by Et3N (49 ?L, 0.35 
mmol) and stirred at ambient temperature for 16 h. The reaction mixture was diluted with 
CHCl3 (100 mL), washed with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine and dried over 
anhydrous Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was 
purified by flash column chromatography (DCM: MeOH, 95:5) to afford the title compound 
as colorless solid (106 mg, 63%). 
1H NMR (300 MHz, CDCl3): į = 7.49 (dd, J = 7.8 Hz, J = 1.4 Hz, 1H; H-11), 6.98 (d, J = 
8.2 Hz, 1H; H-1), 6.88 (t, J = 7.0 Hz, 1H; H-9), 6.78 (dd, J = 8.2 Hz, J = 1.0 Hz, 1H; H-8), 
6.48 (t, J = 7.0 Hz, 1H; H-10), 6.01 (d, J = 8.2 Hz, 1H; H-2), 4.08-4.04 (m, 1H; H-22), 3.88-
3.84 (m, 1H; H-23), 3.24-3.14 (m, 2H; H-15), 3.15-3.08 (m, 2H; H-14), 2.74-2.68 (m, 1H; H-
20), 2.52 (dd, J = 6.8 Hz, J = 5.0 Hz, 1H; H-21), 2.35 (d, J = 6.8 Hz, 1H; H-21´), 2.07 (s, 3H; 
H-25), 1.89 (t, J = 7.2 Hz, 2H; H-16), 1.60-1.39 (m, 4H; H-17/19); 1.10-1.03 (m, 2H; H-18) 
ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 175.1 (C-15), 170.5 (C-13), 164.7 (C-24), 144.9 (C-7), 
136.2 (C-5), 135.3 (C-3), 135.0 (C-4), 134.8 (C-9), 130.7 (C-11), 128.7 (C-1), 127.6 (C-6), 
121.5 (C-2), 120.5 (C-12), 117.7 (C-8), 114.9 (C-10), 61.6 (C-23), 59.9 (C-22), 55.2 (C-20), 
41.5 (C-21), 39.8 (C-14), 39.4 (C-15), 38.8 (C-26), 28.0 (C-19), 27.8 (C-18), 25.5 (C-17), 
19.8 (C-25) ppm. 
MS (ESI): m/z = 586.1 (M+Na)+, 562.1 (M–H)+ 
Experimental 
 
 155
5.7.11. (Z)-Tert-butyl 2-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetamido)ethylcarbamate (103) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: Sulindac sulfoxide (100 mg, 0.28 mmol), EDAC (65 mg, 0.34 mmol), HOBt (42 
mg, 0.3 mmol), Et3N (86 ?L, 0.62 mmol), N-Boc ethylene diamine (50 ?L, 0.3 mmol). 
Yield: 128 mg, 92%. 
1H NMR (300 MHz, CDCl3): į = 7.65 (d, J = 8.4 Hz, 2H; H-13), 7.59 (d, J = 8.4 Hz, 2H; H-
12), 7.10-7.16 (m, 2H; H-2, H-10), 6.82 (d, J = 8.8 Hz, 1H; H-5), 6.51 (d, J = 8.8 Hz, 1H; H-
6), 6.15 (brs, 1H; NH), 4.85 (brs, 1H; NH), 3.40 (s, 2H; H-16), 3.50-3.11 (m, 4H; H-18, H-
19), 2.73 (s, 3H; H-15), 2.14 (s, 3H; H-9), 1.32 (s, 9H; H-22) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 170.0 (C-17), 165.1 (C-1), 161.8 (C-20), 145.5 (C-3), 141.6 
(C-14), 139.6 (C-23), 138.8 (C-11), 135.5 (C-8), 132.5 (C-7), 130.3 (C-4), 128.9 (C-6), 128.4 
(C-12), 123.9 (C-13), 111.3 (C-6), 111.0 (C-2), 79.8 (C-21), 43.9 (C-16), 40.9 (C-19), 40.3 
(C-18), 33.7 (C-18), 28.4 (C-22), 10.6, (C-9) ppm. 
5.7.6. (Z)-N-(2-aminoethyl)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetamide (104) 
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A solution of compound (Z)-tert-butyl 2-(2-(5-fluoro-2-methyl-1-(4-
(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetamido)ethylcarbamate (103) (100 mg, 0.2 
mmol) in 20% TFA in CH2Cl2 (3 mL) was stirred at room temperature for 1 h. Reaction was 
monitored by TLC. The reaction mixture was then evaporated in vacuo and lyophilized to 
afford the title compound as trifluoroacetic acid salt which was used in the next step without 
further purification. 
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5.7.13. N-(2-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetamido)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide (105) 
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Et3N (16 ?L, 0.29 mmol) was added to a stirred solution of D-biotin (71 mg, 0.29 mmol) in 
anhydrous DMF (3 mL) and stirred at ambient temperature for 10 min. To it PyBrop (mg, 
0.32 mmol) was added and the resulting solution was stirred at ambient temperature for 30 
min. A solution of (Z)-N-(2-aminoethyl)-2-(5-fluoro-2-methyl-1-(4-
(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetamide (104)  (100 mg, 0.23 mmol) in DMF 
(1 mL) was added to the reaction mixure followed by Et3N (161 ?L, 1.16 mmol) and stirred at 
ambient temperature for 14 h. The reaction mixture was diluted with CHCl3 (100 mL), 
washed sequentially with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine and dried over 
anhydrous Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was 
purified by flash column chromatography (CHCl2:MeOH, 95:5) to afford the title compound 
as brownish solid (36 mg, 25%). 
1H NMR (500 MHz, CD3OD): į = 7.70 (d, J = 8.6 Hz, 2H; H-13), 7.63 (d, J = 8.6 Hz, 2H; 
H-12), 7.11-7.18 (m, 2H; H-2, H-10), 6.85 (d, J = 8.8 Hz, 1H; H-5), 6.55 (d, J = 8.8 Hz, 1H; 
H-6), 4.44-4.37 (m, 1H; H-27), 4.24-4.16 (m, 1H; H-28), 3.41 (s, 2H; H-16), 3.51-3.12 (m, 
4H; H-18, H-19), 2.85-2.79 (m, 1H; H-25), 2.75 (s, 3H; H-15), 2.72 (dd, J = 6.8 Hz, J = 5.0 
Hz, 1H; H-26), 2.48 (d, J = 6.8 Hz, 1H; H-26´), 2.16 (s, 3H; H-9), 1.66-1.42 (m, 4H; H-22, H-
24), 1.34-1.25 (m, 2H; H-23) ppm.  
13C NMR (125 MHz, CD3OD): ̓ į = 175.0 (C-20), 170.1 (C-17), 166.6 (C-29), 161.8 (C-1), 
145.6 (C-3), 141.8 (C-14), 139.5 (C-23), 138.8 (C-11), 135.4 (C-8), 132.7 (C-7), 130.4 (C-4), 
129.2 (C-6), 128.5 (C-12), 124.2 (C-13), 114.9 (C-6), 111.7 (C-2), 61.9 (C-28), 58.1 (C-27), 
57.3 (C-25), 45.3 (C-15), 41.8 (C-26), 40.7 (C-19), 40.1 (C-18), 37.4 (C-21), 27.0 (C-24), 
26.1 (C-22), 25.9 (C-23), 16.6 (C-9) ppm. 
5.7.14. Tert-butyl 2-(2-(3-benzoylphenyl)propanamido)ethylcarbamate (107) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: Ketoprofen (150 mg, 0.6 mmol), EDAC (136 mg, 0.7 mmol), HOBt (96 mg, 0.7 
mmol), Et3N (182 ?L, 0.13 mmol), N-Boc ethylene diamine (112 ?L, 0.7 mmol). 
Yield: 230 mg, 98%. 
Experimental 
 
 157
1H NMR (300 MHz, CDCl3): į = 7.72 (td, J = 7.0 Hz, J = 1.8 Hz, 2H; H-2), 7.67 (t, J = 1.8 
Hz, 1H; H-4), 7.57 (dt, J = 7.8 Hz, J = 1.4 Hz, 1H; H-8), 7.51 (d, J = 6.0 Hz, 2H; H-6, H-10), 
7.43-7.19 (m, 3H; H-3, H-7), 6.32 (brs, 1H; NH), 4.89 (brs, 1H; NH), 3.54 (q, J = 7.2 Hz, 1H; 
H-11), 3.31-3.15 (m, 4H; H-14, H-15), 1.45 (d, J = 7.2 Hz, 3H; H-12), 1.32 (s, 9H; H-18) 
ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 196.6 (C-19), 174.3 (C-13), 159.2 (C-18), 141.9 (C-5), 
138.0 (C-1), 137.5 (C-9), 132.6 (C-8), 132.1 (C-4), 131.6 (C-10), 130.1 (C-2), 129.2 (C-6), 
129.0 (C-7), 128.7 (C-3), 79.8 (C-17), 47.0 (C-11), 41.1 (C-14), 40.3 (C-15), 28.4 (C-18), 
18.8, (C-12) ppm. 
5.7.15. N-(2-Aminoethyl)-2-(3-benzoylphenyl)propanamide (108) 
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A solution of compound tert-butyl 2-(2-(3-benzoylphenyl)propanamido)ethylcarbamate (107) 
(110 mg, 0.28 mmol) in 20% TFA in CH2Cl2 (3 mL) was stirred at room temperature for 1 h. 
Reaction was monitored by TLC. The reaction mixture was then evaporated in vacuo and 
lyophilized to afford the title compound as trifluoroacetic acid salt which was used in the next 
step without purification. 
5.7.16. N-(2-(2-(3-Benzoylphenyl)propanamido)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamide (109) 
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Et3N (39 ?L, 0.28 mmol) was added to a stirred solution of D-biotin (85 mg, 0.28 mmol) in 
anhydrous DMF (3 mL) and stirred at ambient temperature for 10 min. To it ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (80 mg, 0.41 mmol), N-
hydroxybenzotriazole hydrate (56 mg, 0.41 mmol) were added and the resulting solution was 
stirred at ambient temperature for 30 min. until it became clear. A solution of N-(2-
aminoethyl)-2-(3-benzoylphenyl)propanamide (108) (92 mg, 0.28 mmol) in DMF (1 mL) was 
added to the reaction mixture followed by Et3N (49 ?L, 0.35 mmol) and stirred at ambient 
temperature for 16 h. The reaction mixture was diluted with CHCl3 (100 mL), washed 
sequentially with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine and dried over anhydrous 
Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was purified 
by flash column chromatography (CH2Cl2:MeOH, 95:5) to afford the title compound as 
brownish solid (65 mg, 45%). 
1H NMR (300 MHz, CDCl3): į = 7.91 (brs, 1H; NH), 7.86-7.81 (m, 3H; H-2/4), 7.72-7.65 
(m, 3H; H-6/8/10), 7.60-7.50 (m, 3H; H-3/7), 4.56-4.51 (m, 1H; H-22), 4.35 (m, 1H; H-23), 
3.77 (q, J = 7.6 Hz, 1H; H-11), 3.46-3.38 (m, 4H; H-14/15), 3.25-3.19 (m, 1H; H-21), 2.97 
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(dd, J = 6.8 Hz, J = 5.0 Hz, 1H; H-22), 2.78 (d, J = 6.8 Hz, 1H; H-22´), 2.17 (t, J = 7.4 Hz, 
2H; H-17), 1.82-1.62 (m, 4H; H-18/20), 1.57 (d, J = 7.6 Hz, 3H; H-12), 1.49-1.39 (m, 2H; H-
19)  ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 197.2 (C-26), 175.3 (C-16), 174.8 (C-13), 141.8 (C-5), 
141.6 (C-1), 137.4 (C-9), 132.5 (C-8), 132.1 (C-4), 131.4 (C-10), 130.2 (C-2), 129.7 (C-6), 
129.1 (C-7), 128.6 (C-3), 61.7 (C-24), 59.9 (C-23), 55.3 (C-21), 46.0 (C-11), 39.8 (C-22), 
39.1 (C-14), 39.0 (C-15), 35.3 (C-17), 28.1 (C-20), 27.8 (C-19), 25.1 (C-18), 18.5, (C-12) 
ppm. 
MS (ESI): m/z = 545.3 (M+Na)+ 
5.7.17. Tert-butyl 2-(2-(6-chloro-9H-carbazol-2-yl)propanamido)ethylcarbamate (110) 
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The title compound was synthesized by following the general procedure mentioned in 5.2.1. 
Reactants: Carprofen (100 mg, 0.38 mmol), EDAC (89 mg, 0.46 mmol), HOBt (63 mg, 0.46 
mmol), Et3N (118 ?L, 0.84 mmol), N-Boc ethylene diamine (73 ?L, 0.46 mmol). 
Yield: 75 mg, 50%. 
1H NMR (500 MHz, CD3OD): į = 7.88 (d, J = 1.9 Hz, 1H; H-2), 7.82 (d, J = 8.6 Hz, 1H; H-
8), 7.29 (d, J = 1.1 Hz, 1H; H-11), 7.20-7.16 (m, 2H; H-5/6), 7.07 (dd, J = 8.0 Hz, J = 1.5 Hz, 
1H; H-9), 3.60 (q, J = 7.0 Hz, 1H; H-13), 3.20-3.14 (m, 2H; H-16), 3.08-3.03 (m, 2H; H-17), 
1.47 (d, J = 7.5 Hz, 3H; H-14), 1.26 (s, 9H; H-20) ppm.  
13C NMR (125 MHz, CD3OD): ̓ į = 173.1 (C-15), 165.1 (C-18), 137.4 (C-12), 131.3 (C-7), 
127.1 (C-10), 127.1 (C-1), 125.6 (C-4), 124.1 (C-2), 120.7 (C-9), 119.1 (C-8), 118.1 (C-6), 
113.5 (C-5), 110.5 (C-11), 106.3 (C-3), 80.6 (C-19), 39.5 (C-17), 38.6 (C-16), 28.6 (C-20) 
ppm. 
5.7.18. N-(2-Aminoethyl)-2-(6-chloro-9H-carbazol-2-yl)propanamide (111) 
N
H
Cl
N
H
O
NH2
 
A solution of compound tert-butyl 2-(2-(6-chloro-9H-carbazol-2-
yl)propanamido)ethylcarbamate (110) (50 mg, 0.12 mmol) in 20% TFA in CHCl2 (1 mL) was 
stirred at room temperature for 1 h. Reaction was monitored by TLC. The reaction mixture 
was then evaporated in vacuo and lyophilized to afford the title compound as trifluoroacetic 
acid salt which was used in the next step without further purification. 
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5.7.19. N-(2-(2-(6-Chloro-9H-carbazol-2-yl)propanamido)ethyl)-5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (112) 
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To a stirred solution of (D)-biotin (37 mg, 0.15 mmol) in anhydrous DMF (2 mL), Et3N (21 
?L, 0.15 mmol) was added and stirred at ambient temperature for 10 min. To it, ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (35 mg, 0.18 mmol), N-
hydroxybenzotriazole hydrate (25 mg, 0.18 mmol) were added and the resulting solution was 
stirred at ambient temperature for 30 min. until it became clear. A solution of N-(2-
aminoethyl)-2-(6-chloro-9H-carbazol-2-yl)propanamide (111) (42 mg, 0.12 mmol) in DMF (1 
mL) was added to the reaction mixture followed by Et3N (17 ?L, 0.12 mmol) and stirred at 
ambient temperature for 18 h. The reaction mixture was diluted with CHCl3 (100 mL), 
washed sequentially with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine and dried over 
anhydrous Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was 
purified by flash column chromatography (CHCl2:MeOH, 95:5) to afford the title compound 
as brownish solid (25 mg, 40%). 
1H NMR (300 MHz, CD3OD): į = 7.63 (d, J = 1.9 Hz, 1H; H-2), 7.59 (d, J = 8.2 Hz, 1H; H-
8), 7.07 (d, J = 7.6 Hz, 1H; H-5), 7.03 (s, 1H; H-11), 6.97 (dd, J = 8.6 Hz, J = 1.9 Hz, 1H; H-
6), 6.80 (d, J = 8.0 Hz, 1H; H-9), 4.10-4.07 (m, 1H; H-25), 3.87-3.74 (m, 1H; H-26), 3.41 (q, 
J = 7.2 Hz, 1H; H-13), 3.32-3.92 (m, 4H; H-16, H-17), 2.66-2.56 (m, 1H; H-23), 2.52 (dd, J = 
6.8 Hz, J = 4.8 Hz, 1H; H-24), 2.37 (d, J = 6.8 Hz, 1H; H-24´), 1.87 (t, J = 7.2 Hz, 2H; H-19), 
1.22 (d, J = 7.2 Hz, 3H; H-14), 1.05-0.99 (m, 4H; H-20, H-22), 0.84-0.75 (m, 2H; H-21) ppm.  
13C NMR (75 MHz, CD3OD):̓ į = 176.3 (C-18), 173.1 (C-15), 165.1 (C-27), 139.5 (C-12), 
132.3 (C-7), 127.5 (C-10), 126.5 (C-1), 125.0 (C-4), 123.7 (C-2), 122.7 (C-9), 119.9 (C-8), 
119.1 (C-6), 113.5 (C-5), 111.5 (C-11), 109.3 (C-3), 61.6 (C-26), 59.9 (C-25), 55.3 (C-23), 
44.7 (C-13), 41.5 (C-24), 39.8 (C-17), 38.9 (C-16), 38.6 (C-19), 28.0 (C-22), 24.9 (C-21), 
24.1 (C-20), 17.9 (C-14) ppm. 
5.7.20. Benzyl 2-(2-fluoro-4'-nitrobiphenyl-4-yl)propanoate (113) 
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A mixture of 2-(2-fluoro-4-biphenyl)propanoic acid (500 g, 2.59 mmol) and 5 mL of 70% 
nitric acid was stirred with an efficient stirrer. The suspended solid gradually went into 
solution during the first 12 hours. The reaction was continued for another 48 h after which the 
TLC indicated complete consumption of starting material and formation of two products. The 
reaction mixture was poured on ice and extracted with CH2Cl2 (×3). The combined organic 
extracts were washed with water, brine, dried over anhydrous Na2SO4 and evaporated  in 
vacuo to yield the crude mixture of the ortho and para nitrated product as an orange gummy 
mass.  
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To a stirred solution of nitrated products (750 mg, 2.59 mmol) in anhydrous DMF (15 
mL), anhydrous K2CO3 (1075 mg, 7.88 mmol) was added and stirred for 30 minutes. Benzyl 
bromide (0.39 mL, 2.59 mmol) was added to it and stirred for another 3 h after which TLC 
indicated the complete consumption of starting material. The reaction mixture was then 
diluted with ethyl acetate and washed with water. The aqueous layer was extracted with ethyl 
acetate (×3). The combined organic extract was washed with water, brine, dried over 
anhydrous Na2SO4 and evaporated in vacuo to yield the crude mixture. The crude mixture of 
the ortho and para nitrated benzyl esters was purified by column chromatography 
(EtOAc:hexane, 2:8) to afford the title compound as brown gummy mass (250 mg, 32%). 
1H NMR (300 MHz, CDCl3): į = 8.30 (d, J = 9.0 Hz, 2H; H-2), 7.70 (dd, J = 7.2 Hz, J = 2.0 
Hz, 2H; H-4), 7.42-7.10 (m, 8H; H-6, ; H-7, ; H-9, ; H-15, ; H-16, ; H-17), 5.18 (d, J = 15.0 
Hz, 1H; H-13), 5.12 (d, J = 15.0 Hz, 1H; H-13´), 3.84 (q, J = 9.0 Hz, 1H; H-11), 1.57 (d, J = 
9.0 Hz, 3H; H-12) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 174.3 (C-18), 161.4 (C-10), 147.3 (C-1), 140.6 (C-4), 140.1 
(C-14), 137.6 (C-8), 130.6 (C-5), 130.5 (C-6), 129.9 (C-16), 129.8 (C-3), 127.7 (C-17), 127.5 
(C-15), 125.0 (C-7), 124.1 (C-2), 115.8 (C-9), 66.8 (C-13), 45.1 (C-11), 18.3 (C-12) ppm. 
5.7.21.  Benzyl 2-(4'-amino-2-fluorobiphenyl-4-yl)propanoate (115) 
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Anhydrous SnCl2 (556 mg, 0.59 mmol) was added to a stirred solution of benzyl 2-(2-fluoro-
4'-nitrobiphenyl-4-yl)propanoate (113) (225 mg, 0.59 mmol) in dry ethanol and refluxed for 6 
h. The reaction mixture was then cooled to room temperature and poured on ice. The solution 
was basified using saturated solution of NaHCO3 and extracted with ethyl acetate (3×). The 
combined organic extracts were washed with water, brine, dried over anhydrous and 
evaporated in vacuo to yield the crude product. The crude compound was purified by column 
chromatography (EtOAc:hexane, 2:8) to afford the pure product as pale brown gum (120 mg, 
57%).  
1H NMR (300 MHz, CDCl3): į = 7.42-7.10 (m, 8H; H-6; H-7; H-9; H-15; H-16; H-17), 
7.03.- 6.97 (m, 2H; H-3), 6.68 (dd, J = 6.5 Hz, J = 2.1 Hz, 2H; H-2), 5.08 (d, J = 15.0 Hz, 1H; 
H-13), 5.02 (d, J = 15.0 Hz, 1H; H-13´), 3.70 (q, J = 7.0 Hz, 1H; H-11), 1.46 (d, J = 7.0 Hz, 
3H; H-12) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 173.9 (C-18), 161.2 (C-10), 146.0 (C-1), 140.5 (C-8), 130.8 
(C-5), 130.2 (C-6), 129.9 (C-16), 129.2 (C-3), 127.8 (C-17), 127.3 (C-15), 126.5 (C-7), 126.4 
(C-4), 118.1 (C-9), 117.7 (C-2), 66.6 (C-13), 45.0 (C-11), 18.3 (C-12) ppm  
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5.7.22. Benzyl 2-(2-fluoro-4'-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamido)biphenyl-4-yl)propanoate (116) 
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Et3N (18 ?L, 0.1281 mmol) was added to a stirred solution of D-biotin (32 mg, 0.1281 mmol) 
in anhydrous DMF (2 mL) and stirred at ambient temperature for 10 min. To it ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (31 mg, 0.1602 mmol), N-
hydroxybenzotriazole hydrate (22 mg, 0.1602 mmol) were added and the resulting solution 
was stirred at ambient temperature for 30 min. until it became clear. A solution of benzyl 2-
(4'-amino-2-fluorobiphenyl-4-yl)propanoate (115) (75 mg, 0.1602 mmol) in DMF (1 mL) was 
added to the reaction mixture followed by Et3N (23 ?L, 0.1602 mmol) and stirred at ambient 
temperature for 36 h. The reaction mixture was diluted with CHCl3 (100 mL), washed 
sequentially with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine and dried over anhydrous 
Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was purified 
by flash column chromatography (CH2Cl2:MeOH, 95:5) to afford the title compound as 
brownish solid (72 mg, 65%). 
1H NMR (500 MHz, CD3OD): į = 7.56 (dd, J = 6.8 Hz, J = 1.8 Hz, 2H; H-2), 7.40 (dd, J = 
8.5 Hz, J = 1.2 Hz, 2H; H-3), 7.28 (t, J = 8.0 Hz, 1H; H-6), 7.25-7.15 (m, 5H; H-26, H-27, H-
28), 7.04 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H; H-7), 6.98 (dd, J = 6.0 Hz, J = 1.6 Hz, 1H; H-9), 
5.04 (s, 2H; H-24), 4.42 (q, J = 4.2 Hz, 1H; H-23), 4.24 (p, J = 4.1 Hz, 1H; H-21), 3.74 (q, J = 
7.2 Hz, 1H; H-11), 3.14-3.10 (m, 1H; H-19), 2.83 (dd, J = 6.8 Hz, J = 5.0 Hz, 1H; H-20), 2.65 
(d, J = 6.8 Hz, 1H; H-20´), 2.34 (t, J = 7.2 Hz, 2H, 15-C), 1.74-1.63 (m, 4H, 16-H, 18-H), 
1.62-1.54 (m, 2H, 17-H), 1.44 (d, J = 7.2 Hz, 3H, 12-H) ppm. 
13C NMR (125 MHz, CD3OD): ̓ į = 176.1 (C-13), 174.8 (C-14), 164.8 (C-22), 160.4 (C-10), 
143.2 (C-25), 139.8 (C-1), 137.5 (C-8), 132.8 (C-4), 130.9 (C-5), 130.1 (C-6), 129.8 (C-26), 
129.5 (C-27), 129.1 (C-3), 125.3 (C-7), 121.6 (C-2), 116.9 (C-9), 68.4 (C-24), 63.7 (C-23), 
62.0 (C-21), 57.3 (C-19), 46.7 (C-11), 41.8 (C-20), 38.2 (C-18), 30.2 (C-16), 29.9 (C-17), 
27.1 (C-16), 19.5 (C-12) ppm. 
5.7.23. 2-(2-fluoro-4'-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)biphenyl-4-yl)propanoic acid (117) 
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10% Pd-C (30% w/w, 21 mg) was added to a stirred solution of benzyl 2-(2-fluoro-4'-(5-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)biphenyl-4-
yl)propanoate (116), (70 mg, 0.1 mmol) in MeOH  (5 mL) and the resulting solution was kept 
under H2 at 60 psi for 18 h. Reaction was filtered through the celite bed and the celite bed was 
washed several times with warm MeOH. The combined organic extract was evaporated in 
vacuo to yield the crude product. The crude compound was purified by flash column 
chromatography (CH2Cl2:MeOH, 95:5) to afford the title compound as a cream colored solid 
(52 mg, 87%). 
1H NMR (300 MHz, CD3OD): į = 7.60 (d, J = 8.8 Hz, 2H; H-2), 7.40 (d, J = 7.2 Hz, 2H; H-
3), 7.30 (t, J = 8.0 Hz, 1H; H-6), 7.12-7.08 (m, 2H; H-7, H-9), 4.43-4.24 (m, 2H; H-23, H-21), 
3.78 (q, J = 7.2 Hz, 1H; H-11), 3.15-3.12 (m, 1H; H-19), 2.88 (dd, J = 6.8 Hz, J = 4.9 Hz, 1H; 
H-20), 2.66 (d, J = 6.8 Hz, 1H; H-20´), 2.36 (t, J = 7.2 Hz, 2H; H-15), 1.74-1.64 (m, 4H; H-
16, H-18), 1.63-1.54 (m, 2H; H-17), 1.44 (d, J = 7.2 Hz, 3H, 12-H) ppm. 
13C NMR (75 MHz, CD3OD):̓ į = 178.2 (C-13), 172.2 (C-14), 165.1 (C-22), 161.1 (C-10), 
137.9 (C-1), 136.4 (C-8), 132.4 (C-4), 130.1 (C-5), 129.8 (C-6), 128.8 (C-3), 123.4 (C-2), 
119.4 (C-9), 61.4 (C-23), 59.7 (C-21), 55.3 (C-19), 42.9 (C-11), 41.8 (C-20), 36.1 (C-15), 
28.1 (C-18), 25.3 (C-16), 25.0 (C-17), 18.0 (C-12) ppm. 
5.7.24. Benzyl 2-(9-(3-aminobenzyl)-3-chloro-9H-carbazol-7-yl)propanoate (125) 
N
Cl
O
O
NH2  
To a stirred solution of compound of benzyl 2-(9-(3-nitrobenzyl)-3-chloro-9H-carbazol-7-
yl)propanoate (66c) (80 mg, 0.16 mmol) in absolute ethanol (3 mL), was added anhydrous 
SnCl2 (152 mg, 0.8 mmol) and refluxed for 3 h. Reaction was monitored by TLC. The 
reaction mixture was then cooled to room temperature, basified up to pH:9 using 2N NaOH 
and extracted with EtOAc. The aqueous layer was extracted with EtOAc (3×). The combined 
organic extract was washed with H2O, brine, dried over anhydrous Na2SO4 and evaporated in 
vacuo to yield the crude product. The crude compound was used for the next step without 
further purification. 
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5.7.25. Benzyl 2-(9-(3-(5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-6-
yl)pentanamido)benzyl)-3-chloro-9H-carbazol-7-yl)propanoate (125) 
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To a stirred solution of D-biotin (32 mg, 0.13 mmol) in anhydrous DMF (2 mL), was added 
Et3N (18 ?L, 0.13 mmol) and stirred at ambient temperature for 10 min. To it ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (31 mg, 0.16 mmol), N-
hydroxybenzotriazole hydrate (22 mg, 0.16 mmol) were added and the resulting solution was 
stirred at ambient temperature for 30 min. until it became clear. A solution of benzyl 2-(9-(3-
aminobenzyl)-3-chloro-9H-carbazol-7-yl)propanoate, (66c) (75 mg, 0.16 mmol) in DMF (1 
mL) was added to the reaction mixture followed by Et3N (23 ?L, 0.16 mmol) and stirred at 
ambient temperature for 18 h. The reaction mixture was diluted with CHCl3 (100 mL), 
washed sequentially with water, 0.2 N HCl, H2O, 2 N NaOH, H2O, brine and dried over 
anhydrous Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was 
purified by flash column chromatography (CH2Cl2:MeOH, 95:5) to afford the title compound 
11 as brownish solid (72 mg, 65%). 
1H NMR (300 MHz, CDCl3): į = 7.93 (d, J = 1.2 Hz, 1H; H-5), 7.89 (d, J = 8.1 Hz, 1H; H-
4), 7.43 (d, J = 8.0 Hz, 1H; H-8), 7.29-7.04 (m, 11H; H-1, H-3, H-7, H-18, H-20/21, H-
34/35/36), 6.68 (d, J = 7.4 Hz, 1H; H-22), 5.32 (s, 2H; H-16), 5.05-4.94 (m, 2H; H-33), 4.38 - 
4.40 (m, 1H; H-32), 4.18 - 4.14 (m, 1H; H-30), 3.84 (q, J = 7.2 Hz, 1H; H-13), 3.06 - 2.97 (m, 
1H; H-28), 2.84 - 2.72 (m, 1H; H-29), 2.62 - 2.53 (m, 1H; H-29´), 2.19 (t, J = 7.3 Hz, 2H; H-
24), 1.66 - 1.42 (m, 4H; H-25/27), 1.54 (d, J = 7.2 Hz, 3H; H-14), 1.42 - 1.30 (m, 2H; H-26) 
ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 174.8 (C-23), 172.4 (C-13), 164.1 (C-31), 141.5 (C-34), 
139.3 (C-19), 139.0 (C-12), 137.6 (C-17), 135.9 (C-10), 129.5 (C-36), 128.5 (C-21), 128.2 
(C-6), 127.9 (C-37), 127.6 (C-2), 127.2 (C-35), 125.9 (C-22), 125.5 (C-11), 122.9 (C-5), 
122.0 (C-3), 121.9 (C-18), 121.3 (C-4), 120.7 (C-3), 120.0 (C-20), 119.4 (C-8), 117.6 (C-1), 
110.2 (C-9), 66.7 (C-33), 61.9 (C-32), 60.6 (C-30), 55.6 (C-28), 46.2 (C-13), 40.4 (C-29), 
36.7 (C-24), 28.4 (C-27), 25.4 (C-25/26), 18.8 (C-14) ppm 
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5.7.26. 2-(9-(3-(5-(Hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-6-
yl)pentanamido)benzyl)-3-chloro-9H-carbazol-7-yl)propanoic acid (126) 
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To a stirred solution of benzyl 2-(9-(3-(5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-6-
yl)pentanamido)benzyl)-3-chloro-9H-carbazol-7-yl)propanoate, (125) (70 mg, 0.1039 mmol) 
in MeOH  (5 mL) was added 10% Pd-C (30% w/w, 21 mg) and the resulting suspension was 
kept under H2 at 60 psi for 18 h. The reaction mixture was filtered through the celite bed and 
the celite bed was washed several times with warm MeOH. The combined organic extract was 
evaporated in vacuo to yield the crude product. The crude compound was further purified by 
flash column chromatography (CHCl3:MeOH, 95:5) to afford the title compound as a cream 
colored solid. (48 mg, 80%) 
mp: 186.6 °C 
1H NMR (500 MHz, CDCl3): į = 7.93 (s, 1H; H-5), 7.88 (d, J = 8.0 Hz, 1H; H-4), 7.52 (s, 
1H; H-1), 7.47 (d, J = 7.8 Hz, 1H; H-8), 7.34 (s, 1H; H-18), 7.24 – 7.18 (m, 2H; H-7, H-20), 
7.16 (d, J = 8.1 Hz, 1H; H-3), 7.12 (t, J = 7.9 Hz, 1H; H-21), 6.79 (d, J = 7.6 Hz, 1H; H-22), 
5.38 (s, 2H; H-16), 4.38 - 4.34 (m, 1H; H-32), 4.17 - 4.14 (m, 1H; H-30), 3.84 (q, J = 7.2 Hz, 
1H; H-13), 3.07 – 3.02 (m, 1H; H-28), 2.79 (dd, J = 6.7, 5.0 Hz, 1H; H-29), 2.62 (d, J = 5.0 
Hz, 1H; H-29´), 2.22 (t, J = 7.2 Hz, 2H; H-24), 1.64 - 1.55 (m, 4H; H-25, H-27), 1.42 (d, J = 
7.2 Hz, 3H; H-14), 1.37 - 1.31 (m, 2H; H-26) ppm.  
13C NMR (125 MHz, CDCl3): ̓ į = 177.6 (C-15), 174.6 (C-23), 167.6 (C-31), 141.1 (C-19), 
138.8 (C-12), 137.7 (C-17), 135.5 (C-10), 128.8 (C-21), 128.1 (C-2), 127.8 (C-6), 125.8 (C-
22), 125.6 (C-11), 122.1 (C-5) (C-3), 121.9 (C-18), 120.1 (C-4), 119.7 (C-7), 118.9 (C-20), 
116.3 (C-8), 115.2 (C-1), 107.8 (C-1), 61.6 (C-32), 59.9 (C-30), 55.2 (C-28), 46.0 (C-13), 
39.7 (C-29), 36.0 (C-24), 28.0 (C-27), 27.7 (C-25), 25.0 (C-26), 18.8 (C-14) ppm.  
MS (ESI): m/z = 627.2 (M+Na) +. 
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5.8. Synthesis of Flurbiprofen Derived Photoaffinity Label. 
5.8.1. Benzyl 2-(4'-(2-chloroacetamido)-2-fluorobiphenyl-4-yl)propanoate (127) 
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Triethlyl amine (0.098 mL, 0.7 mmol) was added to a stirred solution of benzyl 2-(4'-amino-
2-fluorobiphenyl-4-yl)propanoate (115) (205 mg, 0.58 mmol) in dry  CH2Cl2 at 0 °C and 
stirred for 30 minutes. Chloroacetyl chloride (0.056 ?L, 0.7 mmol) was added to it drop wise 
and stirred for another 30 minutes. The reaction mixture was then allowed to attain the room 
temperature and stirred for another 2.5 hours. It was then diluted with CH2Cl2 (100 mL), 
washed with water, brine, dried over anhydrous Na2SO4 and evaporated in vacuo to afford the 
crude product. The crude compound was purified by column chromatography (EtOAc:hexane, 
2:8) to obtain the title compound as colorless solid (240 mg, 95%). 
1H NMR (500 MHz, CDCl3): į = 7.55 (brs, 1H; NH), 7.55 (td, J = 8.5 Hz, J = 1.8 Hz, 2H; 
H-2), 7.47 (td, J = 7.2 Hz, J = 1.7 Hz, 2H; H-3), 7.31 (d, J = 8.0 Hz, 1H; H-9), 7.29-7.20 (m, 
5H; H-15, H-16, H-17), 7.08 (dd, J = 8.0 Hz, J = 1.8 Hz, 1H; H-7), 7.04 (dd, J = 11.0 Hz, J = 
1.8 Hz, 1H; H-9), 5.08 (d, J = 6.5 Hz, 1H; H-13), 5.04 (d, J = 6.5 Hz, 1H; H-13´), 4.14 (s, 2H; 
H-19), 3.72 (q, J = 7.2 Hz, 1H; H-11), 1.48 (d, J = 7.2 Hz, 3H; H-12) ppm.  
13C NMR (125 MHz, CDCl3): ̓ į = 175.3 (C-20), 165.4 (C-18), 158.0 (C-10), 141.5 (C-14), 
137.8 (C-1), 137.4 (C-8), 133.5 (C-4), 130.8 (C-5), 130.2 (C-6), 130.1 (C-16), 129.0, (C-3) 
127.9 (C-15), 126.1 (C-7), 121.6 (C-2), 117.3 (C-9), 68.3 (C-20), 46.6 (C-11), 44.5 (C-19), 
19.9 (C-12) ppm. 
5.8.2. Benzyl 2-(4'-(2-(4-(4-(2-tert-butoxy-2-oxoethoxy)benzoyl)phenoxy)acetamido)-2 
fluorobiphenyl-4-yl)propanoate (129) 
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Anhydrous K2CO3 (222 mg, 1.6 mmol) and benzyl 2-(4'-(2-chloroacetamido)-2-
fluorobiphenyl-4-yl)propanoate (128) (190 mg, 0.44 mmol) were added to a stirred solution of 
tert-butyl 2-(4-(4-hydroxybenzoyl)phenoxy)acetate (176 mg, 0.54 mmol) in dry acetone and 
heated to 60–70 °C for 12 hours. The reaction mixture was then cooled to room temperature 
and filtered. The residue was washed with acetone (×3). The combined organic layer was 
rotary evaporated to yield the crude product. The crude product was purified by column 
chromatography (EtOAc:hexane, 1:4) to afford the title compound as colorless solid (185 mg, 
57%). 
1H NMR (300 MHz, CDCl3): į = 8.30 (brs, 1H; NH), 7.84 (dd, J = 7.0 Hz, J = 1.9 Hz, 2H; 
H-23), 7.79 (dd, J = 9.2 Hz, J = 1.9 Hz, 2H; H-25), 7.70 (d, J = 8.7 Hz, 2H; H-1), 7.56 (dd, J 
= 8.5 Hz, J = 1.4 Hz, 2H; H-4), 7.39 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H; H-6), 7.37-7.28 (m, 5H; 
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H-15, H-16, H-17), 7.16 (dd, J = 8.5 Hz, J = 1.9 Hz, 2H; H-20), 7.11 (dd, J = 8.8 Hz, J = 1.9 
Hz, 2H; H-29), 7.07-6.95 (m, 2H; H-7, H-9), 5.17 (d, J = 6.5 Hz, 1H; H-13), 5.10 (d, J = 6.5 
Hz, 1H; H-13´), 4.75 (s, 2H; H-30), 4.63 (s, 2H; H-19), 3.83 (q, J = 7.2 Hz, 1H; H-11), 1.55 
(d, J = 7.2 Hz, 3H; H-12), 1.52 (s, 9H; H-33) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 194.2 (C-24), 173.8 (C-34), 167.5 (C-31), 161.4 (C-20, C-
29), 159.9 (C-10), 141.4 (C-14), 139.6 (C-1), 136.2 (C-8), 132.5 (C-26, C-28), 132.3 (C-4), 
131.5 (C-22, C-27), 131.7 (C-6), 130.6 (C-6), 129.7 (C-16), 128.6 (C-3), 128.3 (C-17), 128.1 
(C-15), 125.8 (C-7), 123.8 (C-2), 118.2 (C-9), 115.6 (C-21), 115.3 (C-28), 82.9 (C-32), 67.6 
(C-13), 66.8 (C-19), 65.6 (C-30), 45.1 (C-11), 28.1 (C-33), 18.4 (C-12) ppm. 
5.8.3. 2-(4-(4-(2-(4'-(1-(Benzyloxy)-1-oxopropan-2-yl)-2'-fluorobiphenyl-4-ylamino)-2-
oxoethoxy)benzoyl)phenoxy)acetic acid (130) 
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Trifluoroacetic acid (0.4 mL) was added to a stirred solution of benzyl 2-(4'-(2-(4-(4-(2-tert-
butoxy-2-oxoethoxy)benzoyl)phenoxy)acetamido)-2 fluorobiphenyl-4-yl)propanoate (129) 
(180 mg, 0.25 mmol) in CH2Cl2 (2 mL) at 0 °C and stirred for 6 hours. It was then evaporated 
in vacuo to afford the crude acid. The crude acid was purified by acid-base treatment to afford 
the titled compound as colorless solid (154 mg, 92%).  
MS (ESI): m/z = 684.3 (M+Na)+. 
5.8.4. Benzyl 2-(4'-(2-(4-(4-(2-(2-(tert-butoxycarbonylamino)ethylamino)-2-
oxoethoxy)benzoyl)phenoxy)acetamido)-2-fluorobiphenyl-4-yl)propanoate (131) 
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To a stirred solution of 2-(4-(4-(2-(4'-(1-(benzyloxy)-1-oxopropan-2-yl)-2'-fluorobiphenyl-4-
ylamino)-2-oxoethoxy)benzoyl)phenoxy)acetic acid (130) (150 mg, 0.22 mmol) in anhydrous 
CH2Cl2 (2 mL), was added Et3N (0.032 mL, 0.22 mmol) and stirred at ambient temperature 
for 10 min. Ethyl-3-(3´-dimethylaminopropyl)carbodiimide hydrochloride (48 mg, 0.25 
mmol), N-hydroxybenzotriazole hydrate (37 mg, 0.27 mmol) were added to it and the 
resulting solution was stirred at ambient temperature for 30 min. until it became clear. A 
solution of N-Boc ethylene diamine (43 ?L, 0.27 mmol) in CH2Cl2 (1 mL) was added to the 
reaction mixture followed by Et3N (0.038 mL, 0.27 mmol) and stirred at ambient temperature 
for 16 h. The reaction mixture was diluted with CHCl3 (100 mL), washed with water, brine, 
dried over anhydrous Na2SO4 and evaporated in vacuo to yield the crude product. The crude 
product was purified by flash column chromatography (EtOAc:hexane, 3:7) to yield the title 
compound as colorless solid (103 mg, 54%) 
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1H NMR (500 MHz, CDCl3): į = 8.21 (brs, 1H; NH), 7.88 (dd, J = 7.0 Hz, J = 2.0 Hz, 2H; 
H-22), 7.74 (dd, J = 7.0 Hz, J = 2.0 Hz, 2H; H-27), 7.61 (td, J = 8.5 Hz, J = 2.1 Hz, 2H; H-1), 
7.48 (dd, J = 8.5 Hz, J = 1.4 Hz, 2H; H-4), 7.32-7.19 (m, 6H; H-15, H-16, H-15, H-6), 7.08-
7.02 (m, 4H; H-7, H-9, H-21), 6.96 (dd, J = 7.0 Hz, J = 2.0 Hz, 2H; H-28), 5.08 (d, J = 6.5 
Hz, 1H; H-13), 5.04 (d, J = 6.5 Hz, 1H; H-13´), 4.98 (brs, 1H; NH), 4.67 (s, 2H; H-19), 4.65 
(s, 2H; H-30), 3.74 (q, J = 7.2 Hz, 1H; H-11), 3.40 (q, J = 6.4 Hz, 2H; H-32), 3.30-3.26 (m, 
2H; H-33), 1.48 (d, J = 7.2 Hz, 3H; H-12), 1.36 (s, 9H; H-37) ppm.  
13C NMR (125 MHz, CDCl3): ̓ į = 192.1 (C-24), 171.8 (C-36), 166.2 (C-18), 164.6 (C-29, C-
20), 163.6 (C-31), 158.8 (C-34), 158.6 (C-10), 141.1 (C-14), 137.8 (C-1), 136.9 (C-8), 132.8 
(C-4), 132.2 (C-23, C-25), 131.5 (C-27), 130.6 (C-5), 130.5 (C-6), 130.4 (C-16), 129.8 (C-3), 
128.7 (C-17), 128.6 (C-15), 127.8 (C-7), 121.8 (C-2), 118.2 (C-9), 113.6 (C-21), 113.4 (C-
29), 78.0 (C-35), 65.7 (C-13), 65.3 (C-19), 64.8 (C-30), 43.1 (C-12), 38.7 (C-32), 38.2 (C-33), 
26.4 (C-37), 16.4 (C-12) ppm. 
MS (ESI): m/z = 826.5 (M+Na)+. 
5.8.5. Benzyl 2-(4'-(2-(4-(4-(2-(2-aminoethylamino)-2-
oxoethoxy)benzoyl)phenoxy)acetamido)-2-fluorobiphenyl-4-yl)propanoate (132) 
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A solution of benzyl 2-(4'-(2-(4-(4-(2-(2-(tert-butoxycarbonylamino)ethylamino)-2-
oxoethoxy)benzoyl)phenoxy)acetamido)-2-fluorobiphenyl-4-yl)propanoate (131) (90 mg, 
0.11 mmol) in 16% HCl in dioxane (1 mL) was stirred at ambient temperature for 1 h. 
Dioxane was evaporated in vacuo and lyophilized to obtain the title compound as 
hydrochloride salt. The crude compound was used for next step without further purification. 
MS (ESI): m/z = 704.4 (M+H)+. 
5.8.6. Benzyl 2-(2-fluoro-4'-(2-(4-(4-(2-oxo-2-(2-(5-((3aR,4R,6aS)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamido)ethylamino)ethoxy)benzoyl)phenoxy)acetam-
ido)biphenyl-4-yl)propanoate (133) 
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To a stirred solution of D-biotin (33 mg, 0.13 mmol) in anhydrous DMF (2 mL), was added 
DIEA (0.024 mL, 0.13 mmol) and stirred at ambient temperature for 10 min. To it PyBrop (70 
mg, 0.15 mmol) was added and the resulting solution was stirred at ambient temperature for 
30 min. until it became clear. A solution of benzyl 2-(4'-(2-(4-(4-(2-(2-aminoethylamino)-2-
oxoethoxy)benzoyl)phenoxy)acetamido)-2-fluorobiphenyl-4-yl)propanoate (80 mg, 0.11 
mmol) (132) in DMF (1 mL) was added to the reaction mixure followed by di-isopropyl ethyl 
amine (0.071 mL, 0.4 mmol) and stirred at ambient temperature for 18 h. The reaction 
mixture was diluted with CHCl3 (100 mL), washed with water, brine, dried over anhydrous 
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Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was purified 
by flash column chromatography (CH2Cl2:MeOH, 95:5) to afford the title compound as 
brownish solid (22 mg, 25%). 
1H NMR (300 MHz, CDCl3): į = 9.90 (brs, 1H; NH), 8.05 (brs, 1H; NH), 7.80-7.71 (m, 6H; 
H-1, H-22, H-27), 7.65 (brs, 1H; NH), 7.50-7.36 (m, 5H; H-4, H-6, H-7, H-9), 7.16-7.07 (m, 
5H; H-15, H-16, H-17), 6.10 (brs, 1H; NH), 5.14 (d, J = 6.5 Hz, 1H; 13), 5.08 (d, J = 6.5 Hz, 
1H; 13´), 4.78 (s, 2H; H-19), 4.55 (s, 2H; H-30), 4.40-4.34 (m, 1H; H-41), 4.22-4.15 (m, 1H; 
H-42), 3.85 (q, J = 7.2 Hz, 1H; H-11), 3.24-3.12 (m, 4H; H-32, H-33), 3.10-3.01 (m, 1H; H-
38), 2.80 (dd, J = 6.6 Hz, J = 5.0 Hz, 1H; H-42), 2.65 (d, J = 6.6 Hz, 1H; H-42´), 2.13 (t, J = 
7.3 Hz, 2H; H-44), 1.76-1.55 (m, 4H; H-37, H-35), 1.52 (d, J = 7.2 Hz, 3H; H-12), 1.43-1.35 
(m, 2H; H-36) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 192.1 (C-24), 176.0 (C-43), 174.8 (C-34), 166.2 (C-18), 
164.2 (C-20), 163.9 (C-29), 162.4 (C-31), 159.5 (C-40), 158.4 (C-10), 142.4 (C-14), 137.6 
(C-1), 139.6 (C-8), 132.5 (C-23, C-25), 132.1 (C-4), 131.5 (C-22, C-27), 130.5 (C-5), 130.4 
(C-6), 130.3 (C-16), 129.6 (C-3), 128.5 (C-15), 128.4 (C-17), 127.5 (C-7), 121.6 (C-2), 118.6 
(C-9), 114.2 (C-21, C-28), 65.7 (C-13), 65.3 (C-30), 64.8 (C-19), 63.7 (C-39), 62.0 (C-41), 
57.7 (C-38), 43.1 (C-11), 41.8 (C-42), 38.7 (C-32), 38.2 (C-33), 37.1 (C-44), 29.8 (C-37), 
27.2 (C-36), 27.1 (C-35), 17.4 (C-12) ppm. 
MS (ESI): m/z = 952.4 (M+Na)+, 928.3 (M–H)+. 
5.8.7. 2-(2-Fluoro-4'-(2-(4-(4-(2-oxo-2-(2-(5-((3aR,4R,6aS)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-
yl)pentanamido)ethylamino)ethoxy)benzoyl)phenoxy)acetamido)biphenyl-4-
yl)propanoic acid (134) 
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To a stirred solution of benzyl 2-(2-fluoro-4'-(2-(4-(4-(2-oxo-2-(2-(5-(2-oxohexahydro-1H 
thieno[3,4-d]imidazol-4yl)pentanamido)ethylamino)ethoxy)benzoyl)phenoxy)acetamido) 
biphenyl-4yl)propanoate (133) (22 mg, 0.02 mmol) in MeOH (5 mL) was added 10% Pd-C 
(50% w/w, 11 mg) and the resulting suspension was kept under H2 at 60 psi at ambient 
temperature for 36 h. The reaction mixture was filtered through the celite bed and the celite 
bed was washed several times with warm MeOH. The combined organic extract was 
evaporated in vacuo to yield the crude product. The crude compound was purified by flash 
column chromatography (CH2Cl2:MeOH, 95:5) to obtain the title compound as a lemon 
colored solid. (12 mg, 60%) 
1H NMR (300 MHz, CDCl3): į = 7.76-7.58 (m, 6H; H-21, H-17, H-2), 7.45 (brs, 1H; NH), 
7.41 (brs, 1H; NH), 7.34-7.26 (m, 2H; H-3), 7.24-7.18 (m, 2H; H-6, H-7), 7.10-6.80 (m, 5H; 
H-9, H-16, H-22), 4.70 (s, 2H; H-14), 4.48 (s, 2H; H-24), 4.40-4.33 (m, 1H; H-36), 4.22-4.16 
(m, 1H; H-34), 4.05 (q, J = 7.2 Hz, 1H, H-11), 3.38-3.22 (m, 4H; H-26, H-27), 3.08-3.01 (m, 
1H; H-33), 2.78 (dd, J = 6.9 Hz, J = 4.8 Hz, 1H; H-37), 2.66 (d, J = 6.9 Hz, 1H; H-37´), 2.10 
(t, J = 7.2 Hz, 2H; H-29), 1.66-1.49 (m, 4H; H-30, H-32), 1.47 (d, J = 7.2 Hz, 3H; H-12), 
1.37-1.28 (m, 2H; H-31) ppm.  
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13C NMR (75 MHz, CDCl3):? į = 192.1 (C-19), 176.0 (C-11), 174.8 (C-28), 166.2 (C-13), 
164.2 (C-23, C-15), 159.5 (C-35), 158.4 (C-10), 139.6 (C-1), 137.5 (C-8), 134.0 (C-4), 132.7 
(C-20, C-18), 131.4 (C-17, C-21), 130.4 (C-5), 129.8 (C-6), 128.8 (C-3), 124.9 (C-7), 121.8 
(C-2), 117.8 (C-9), 115.6 (C-16, C-22), 65.3 (C-14), 64.8 (C-24), 63.3 (C-36), 61.0 (C-34), 
57.0 (C-33), 44.5 (C-11), 40.8 (C-37), 40.1 (C-27), 37.0 (C-26), 36.1 (C-29), 30.3, (C-32), 
27.2 (C-31), 27.1 (C-30), 15.1 (C-12) ppm. 
MS (ESI): m/z = 862.4 (M+Na)+, 838.3 (M–H)+ 
5.9. Synthesis of DAPT Derived Photoaffinity Label. 
5.9.1. Z-Ala-Phg-O(t-Bu) (150) 
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Et3N (0.46 mL, 3.33 mmol) was added to a solution of Z-alanine (0.75 g, 3.33 mmol) in 
CH2Cl2 (15 mL) followed by the addition EDAC (0.77 g, 4 mmol, HOBt (0.54 g, 4 mmol) 
and stirred at RT until it became clear. Et3N (0.46 mL, 3.33 mmol) and Phg-O(t-Bu).HCl 
(0.65 g, 2.67 mmol) was added to it simultaneously. The reaction mixture stirred at RT for 12 
h. The reaction mixture was then diluted with CH2Cl2 (300 mL). The organic phase was 
washed with NaHCO3, (0.1 N) HCl and brine simultaneously. The organic phase was dried 
over anhydrous Na2SO4 and the solvent was evaporated in vacuo to afford the crude product 
which was further purified by column chromatography (EtOAc:hexane, 3:7) to get the pure 
product as colorless solid (1.1 g, 80%). 
1H-NMR (300 MHz, DMSO- D6): ? = 8.52 (d, J = 7.4 Hz, 1H; NH,), 8.47 (d, J = 7.0 Hz, 1H; 
NH), 7.42–7.33 (m, 10H; H-1, H-2, H-3, H-12, H-13, H-14), 5.26 (d, 1H, J = 7.3 Hz, 1H; H-
10), 5.32 (s, 2H; H-5), 4.41–4-37 (m, 1H; H-7), 1.35 (s, 9H; H-17), 1.11 (d, J = 7.0 Hz; 3H, 
H-8) ppm. 
13C-NMR (75 MHz, DMSO- D6): ? = 175.0 (C-15), 169.3 (C-9), 164.7 (C-6), 138.7 (C-4), 
136.9 (C-8), 128.5 (C-9), 128.0 (C-11), 127.9 (C-2), 127.4 (C-1), 127.0 (C-3, C-10), 81.2 (C-
13), 65.8 (C-5), 56.5 (C-10), 52.2 (C-7), 27.6 (C-17), 19.5 (C-8) ppm. 
5.9.2. Ala-Phg-O(t-Bu) (151) 
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10% Pd-C (20% w/w, 0.6 g) was added to the solution of Z-Ala-Phg-O(t-Bu), (3 g, 7.3 mmol) 
in EtOH (50 mL) and the resulting suspension was kept under H2 at 60 psi, at ambient 
temperature for 24 h. The reaction mixture was filtered through the celite bed and the celite 
bed was washed several times with warm EtOH. The combined organic extract was 
evaporated in vacuo to yield the crude product. The crude compound was was used in the next 
step without further purification. 
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1H-NMR (300 MHz, DMSO- D6): ? = 8.50 (d, J = 7.3 Hz, 1H; NH), 7.41–7.37 (m, 5H; H-6, 
H-7, H-8), 5.22 (d, J = 7.3 Hz, 1H; H-4); 4.38–4-35 (m, 1H; H-2), 1.33 (s, 9H; H-11), 1.13 (d, 
J = 7.2 Hz, 3H, H-1) ppm. 
MS (EI): m/z = 278 (M+, 40%), 235 (100%), 215 (12%), 205 (78%). 
5.9.3. (S)-Tert-butyl 2-((S)-2-(2-(3,5-difluorophenyl)acetamido)propanamido)-2-
phenylacetate (DAPT) (145) 
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Et3N (1.18 mL, 8.55 mmol) was added to a solution of 3,5-difluoro phenylacetic acid (1.47 g, 
8.55 mmol) in CH2Cl2 (30 mL) followed by the addition EDAC (1.8 g, 9.4 mmol), HOBt 
(1.27 g, 9.4 mmol) and stirred at RT until it became clear. Et3N (1.18 mL, 8.55 mmol) and 
Ala-Phg-O(t-Bu) (1.9 g, 6.84 mmol) was added to it simultaneously. The reaction mixture 
stirred at RT for 12 h. The reaction mixture was then diluted with CH2Cl2 (500 mL). The 
organic phase was washed with NaHCO3, (0.1 N) HCl and brine. The organic phase was dried 
over anhydrous Na2SO4 and the solvent was evaporated in vacuo to afford the crude product 
which was further purified by column chromatography (CH2Cl2:MeOH, 9:1) to get the pure 
product as colorless solid (1.47 g, 50%). 
1H-NMR (300 MHz, DMSO- D6): ? = 8.48 (d, J = 7.0 Hz, 1H; NH), 8.32 (d, J = 7.1 Hz 1H; 
NH), 7.42–7.33 (m, 5H; H-12, H-13, H-14), 7.06 (m, 1H; H-1), 7.00-6.93 (m, 2H; H-3), 5.44 
(d, J = 7.0 Hz, 1H; H-10), 4.61–4-58 (m, 1H; H-7), 3.54 (s, 2H, H-5), 1.40 (s, 9H; H-17), 1.21 
(d, J = 7.0 Hz, 3H, H-8) ppm. 
13C-NMR (75 MHz, DMSO- D6): ? = 172.5 (C-15), 171.3 (C-9), 170.8 (C-6), 164.8 (C-2), 
138.1 (C-4), 136.9 (C-11), 129.0 (C-12), 128.8 (C-13), 127.4 (C-14), 113.1 (C-3), 103.4 (C-
1), 81.0 (C-16), 56.3 (C-10), 50.2 (C-7), 41.4 (C-5), 27.8 (C-17), 18.5 (C-8) ppm. 
5.9.4.  (S)-2-((S)-2-(2-(3,5-Difluorophenyl)acetamido)propanamido)-2-phenylacetic acid 
(DAPA) (142) 
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Trifluoroacetic acid (0.6 mL) was added to a stirred solution of DAPT (145) (100 mg, 0.23 
mmol) in CH2Cl2 (3 mL) at 0 °C and then allowed to warm at an ambient temperature. The 
reaction mixture was stirred for 6 h and evaporated in vacuo to afford the crude product. The 
crude product was purified by crystallization (CHCl3:MeOH) to obtain the title compound as 
colorless solid (82 mg, 95%). 
1H-NMR (300 MHz, DMSO- D6): ? = 8.60 (d, J = 7.4 Hz, 1H; NH), 8.36 (d, J = 7.6 Hz, 1H; 
NH), 7.39–7.32 (m, 5H; H-12, H-13, H-14), 7.08 (m, 1H; H-1), 7.01–6.95 (m, 2H; H-3), 5.31 
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(d, J = 7.4 Hz, 1H; H-10,), 4.44 (q, 1H, J = 7.2 Hz; H-7), 3.51 (s, 2H; H-5), 1.25 (d, J = 7.0 
Hz, 3H; H-8,) ppm. 
5.9.5. Tert-butyl 2-(4-(4-hydroxybenzoyl)phenoxy)acetate (146) 
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Anhydrous K2CO3 (1.3 g, 9.34 mmol) was added to a stirred solution of bis(4-
hydroxyphenyl)methanone (2 g, 9.33 mmol) in acetone (40 mL) and stirred at ambient 
temperature for 30 min. T-butyl chloroacetate (1.4 mL, 9.8 mmol) was added to it and heated 
to 60–70 °C for 24 h. Reaction was cooled to room temperature and filtered. The residue was 
washed with acetone (×3). Combined organic extract was evaporated in vacuo and purified by 
column chromatography (EtOAc:hexane, 2:8) to yield the title compound as a colorless solid 
(1.1 g, 37%)  
1H NMR (300 MHz, CDCl3): į = 7.70 (td, J = 8.8 Hz, J = 2.0 Hz, 2H; H-7), 7.64 (td, J = 8.8 
Hz, J = 2.0 Hz, 2H; H-3), 6.91 (td, J = 8.8 Hz, J = 2.4 Hz, 2H; H-8), 6.82 (td, J = 8.8 Hz, J = 
2.4 Hz, 2H; H-2), 4.52 (s, 2H; H-10), 2.97 (brs, 1H; NH), 1.42 (s, 9H; H-13) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 195.3 (C-5), 167.8 (C-11), 161.3 (C-9), 161.0 (C-1), 132.7 
(C-4), 132.2 (C-6), 131.6 (C-3), 131.2 (C-7), 115.1 (C-2), 114.1 (C-8), 83.0 (C-12), 65.5 (C-
10), 28.0 (C-13) ppm. 
6.9.6. Tert-butyl 2-(4-(4-(2-hydroxyethoxy)benzoyl)phenoxy)acetate (143) 
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Anhydrous K2CO3 (630 mg, 4.55 mmol) was added to a stirred solution of tert-butyl 2-(4-(4-
hydroxybenzoyl)phenoxy)acetate (146) (500 mg, 1.52 mmol) in acetone 15 mL) and stirred at 
ambient temperature for 30 min. 2-Chloro ethanol (507 ?L, 7.6 mmol) was added to it and 
heated to 60–70 °C for 48 h. The reaction was cooled to room temperature and filtered. The 
residue was washed with acetone (3×). Combined organic extract was evaporated in vacuo 
and purified by crystallization (EtOAc:hexane) to yield the title compound as a colorless solid 
(510 mg, 90%)  
1H NMR (300 MHz, CDCl3): į = 7.70 (td, J = 8.8 Hz, J = 2.4 Hz, 4H; H-3, H-7), 7.40 (brs, 
1H; OH), 6.91-6.84 (m, 4H; H-2, H-8), 4.51 (s, 2H; H-10), 4.11 (t, J = 4.5 Hz, 2H; H-14), 
3.94 (t, J = 4.5 Hz, 2H; H-15), 1.43 (s, 9H; H-13) ppm.  
13C NMR (75 MHz, CDCl3):? į = 194.5 (C-5), 167.5 (C-11), 162.1 (C-9), 161.1 (C-1), 132.3 
(C-4), 132.2 (C-6), 131.5 (C-7), 130.9 (C-3), 114.1 (C-2), 114.0 (C-9), 82.9 (C-12), 69.5 (C-
14), 65.5 (C-15), 61.3 (C-10), 28.1 (C-13) ppm. 
5.9.7. Tert-butyl 2-(5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)ethylcarbamate (151) 
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Et3N (28 ?L, 0.2 mmol) was added to a solution of D-biotin (50 mg, 0.2 mmol) in DMF (4 
mL) followed by the addition EDAC (48 g, 0.24 mmol) and HOBt (34 mg, 0.24 mmol) and 
stirred at RT until it became clear. Et3N (260 ?L, 1.8 mmol) and N-Boc ethylene diamine (40 
?L, 0.22 mmol) was added to it simultaneously. The reaction mixture stirred at RT for 3 h. 
The reaction mixture was then diluted with EtOAc (100 mL) and washed with brine. The 
organic phase was dried over anhydrous Na2SO4 and the solvent was evaporated in vacuo to 
afford the crude product which was further purified by column chromatography 
(EtOAc:hexane, 4:6) to get the title compound as colorless solid (35 mg, 45%). 
1H NMR (300 MHz, CDCl3): į = 4.50-4.40 (m, 1H; H-3), 4.30-4.20 (m, 1H; H-2), 3.80 (brs, 
4H; NH), 3.20 (q, J = 5.5 Hz, 2H; H-12), 3.11 (q, J = 5.5 Hz, 2H; H-11), 3.08-3.02 (m, 1H; 
H-5), 2.85 (dd, J = 6.8 Hz, J = 4.6 Hz, 1H; H-4), 2.68 (d, J = 6.8 Hz, 1H; H-4´), 2.13 (t, J = 
7.2 Hz, 2H; H-9), 1.68-1.54 (m, 4H; H-6- H-8), 1.42-1.11 (m, 11H; H-7, H-15) ppm 
13C NMR (75 MHz, CDCl3):̓ į = 172.1 (C-10), 165.2 (C-1), 156.9 (C-13), 62.0 (C-3), 60.4 
(C-2), 55.5 (C-5), 41.5 (C-4), 40.2 (C-12), 39.7 (C-11), 35.6 (C-9), 29.6 (C-6), 27.9 (C-15), 
25.4 (C-7), 25.2 (C-8) ppm. 
MS (ESI): m/z = 409.2 (M+Na)+. 
5.9.8. N-(2-Aminoethyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide (141) 
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A solution of tert-butyl 2-(5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)ethylcarbamate (151) (25 mg, 0.06 mmol) in 20% TFA in CH2Cl2 was stirred 
at room temperature for 3 h. The reaction mixture was then evaporated in vacuo and 
lyophilized to afford the title compound as trifluoroacetic acid salt which was used in the next 
step without purification. 
MS (ESI): m/z = 309.3 (M+Na)+. 
5.9.9. Tert-butyl 2-(4-(4-(2-(tosyloxy)ethoxy)benzoyl)phenoxy)acetate (154) 
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Pyridine (220 ?L, 2.7 mmol) and p-toluene sulfonyl chloride (385 mg, 2 mmol) were added to 
a stirred solution of tert-butyl 2-(4-(4-(2-hydroxyethoxy)benzoyl)phenoxy)acetate (143) (500 
mg, 1.35 mmol) in CH2Cl2 (10 mL) and stirred at ambient temperature for 7 days. Reaction 
was monitored by TLC. Upon completion of reaction, it was diluted with CH2Cl2 (100 mL). 
Organic phase was washed with water, 0.1 N HCl, dried over anhydrous Na2SO4, evaporated 
in vacuo and purified by column chromatography (EtOAc:hexane, 2.5:7.5) to afford the title 
compound as a colorless gummy mass (540 mg, 76%)  
1H NMR (300 MHz, CDCl3): į = 7.74 (d, J = 8.8 Hz, 2H; H-17), 7.71-7.64 (m, 4H; H-3, H-
7), 7.28 (d, J = 8.2 Hz, 2H; H-18), 6.88 (d, J = 8.8 Hz, 2H; H-8), 6.78 (d, J = 8.8 Hz, 2H; H-
2), 4.52 (s, 2H; H-10), 4.33 (t, J = 4.4 Hz, 2H; H-14), 4.15 (t, J = 4.4 Hz, 2H; H-15), 2.38 (s, 
3H; H-20), 1.42 (s, 9H; H-13) ppm. 
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13C NMR (75 MHz, CDCl3):̓ į = 195.5 (C-5), 167.5 (C-11), 161.2 (C-9, C-1), 145.2 (C-19), 
135.8 (C-16), 132.2 (C-6), 131.8 (C-4), 131.5 (C-7), 130.9 (C-3), 130.3 (C-18), 128.1 (C-17), 
114.2 (C-8), 114.1 (C-2), 82.9 (C-12), 67.9 (C-14), 65.6 (C-15), 60.5 (C-10), 28.1 (C-13), 
21.7 (C-20) ppm. 
5.9.10. (S)-2-(4-(4-(2-Tert-butoxy-2-oxoethoxy)benzoyl)phenoxy)ethyl 2-((S)-2-(2-(3,5-
difluorophenyl)acetamido)propanamido)-2-phenylacetate (153) 
O
O O
O
O
1
2
3
4
5
6
7
8 9
10
11 12
13
14
15
O
17
16
18
19
20
21
22
H
N
O
NH
O
O
F
F
23
24
25
26
27
28
29
30 31 32
33
34
 
Anhydrous K2CO3 was added (110 mg, 0.8 mmol) to a stirred solution of (S)-2-((S)-2-(2-(3,5-
difluorophenyl)acetamido)propanamido)-2-phenylacetic acid (142) (100 mg, 0.27 mmol) in 
anhydrous DMF (4 mL) and stirred for 30 min. at ambient temperature. A solution of tert-
butyl 2-(4-(4-(2 (tosyloxy)ethoxy)benzoyl)phenoxy)acetate (154) in dry DMF (1 mL) was 
added to it and the reaction mixture was stirred at ambient temperature for another 36 h. The 
reaction mixture was then diluted with ethyl acetate (100 mL). The aqueous layer was 
extracted with ethyl acetate (×3). The combined organic extract was washed with water, brine, 
dried over anhydrous Na2SO4 and evaporated in vacuo to afford the crude product. The crude 
product was purified by column chromatography (EtOAc:hexane, 1:4) to yield the title 
compound as colorless gummy mass (108 mg, 56%). 
1H NMR (500 MHz, CDCl3): į = 7.70 (d, J = 8.8 Hz, 2H; H-28), 7.67 (d, J = 8.8 Hz, 2H; H-
18), 7.26-7.22 (m, 5H; H-21, H-22, H-23, H-24, H-25), 6.89 (d, J = 8.8 Hz, 2H; H-29), 6.78 
(d, J = 8.8 Hz, 2H; H-17), 6.71-6.63 (m, 3H; H-2, H-4, H-6), 6.05 (d, J = 7.8 Hz, 1H; H-12), 
5.48 (q, J = 7.0 Hz, 1H; H-9), 4.52 (s, 2H; H-31), 4.52-4.22 (m, 4H; H-14, H-15), 4.12 (s, 2H; 
H-7), 3.47 (brs, 1H; NH), 3.41 (brs, 1H; NH), 1.42 (s, 9H; H-34), 1.26 (d, J = 7.0 Hz, 3H; H-
10) ppm.  
13C NMR (125 MHz, CDCl3): ̓ į = 197.5 (C-20), 172.5 (C-11), 172.4 (C-8), 169.4 (C-32), 
166.2 (C-3, C-5), 165.5 (C-30), 162.1 (C-16), 141.2 (C-1), 137.1 (C-26), 133.8 (C-27), 132.2 
(C-28), 131.9 (C-19), 131.5 (C-18), 130.9 (C-25, C-21), 129.9 (C-22, C-24), 127.6 (C-23), 
115.3 (C-29), 114.6 (C-17), 113.4 (C-2, C-6), 104.2 (C-4), 82.9 (C-33), 67.8 (C-15), 65.6 (C-
14), 64.5 (C-31), 57.1 (C-12), 50.1 (C-9), 39.8 (C-7),  28.9 (C-34), 16.4 (C-10) ppm. 
MS (ESI): m/z = 753.3 (M+Na)+, 729.2 (M–H)+ 
5.9.11. 2-(4-(4-(2-((S)-2-((S)-2-(2-(3,5-Difluorophenyl)acetamido)propanamido)-2-
phenylacetoxy)ethoxy)benzoyl)phenoxy)acetic acid (140) 
O
O O
OH
O
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O
NH
O
O
F
F  
Trifluoroacetic acid (0.2 mL) was added to a stirred solution of (S)-2-(4-(4-(2-tert-butoxy-2-
oxoethoxy)benzoyl)phenoxy)ethyl 2-((S)-2-(2-(3,5 difluorophenyl)acetamido)propanamido)-
2-phenylacetate (153) (100 mg, 0.137) in CH2Cl2 at 0 °C and then allowed to warm at an 
ambient temperature. The reaction was stirred for 6 h and then evaporated in vacuo to afford 
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the crude product. The crude product was purified by crystallization (EtOAc) to obtain the 
title compound as colorless solid (83 mg, 90%). 
MS (ESI): m/z = 697.2 (M+Na)+, 673.1 (M–H)+. 
5.9.6. (S)-2-(4-(4-(2-(2-(Tert-butoxycarbonylamino)ethylamino)-2-
oxoethoxy)benzoyl)phenoxy)ethyl 2-((S)-2-(2-(3,5-
difluorophenyl)acetamido)propanamido)-2-phenylacetate (155) 
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To a stirred solution of 2-(4-(4-(2-((S)-2-((S)-2-(2-(3,5-
difluorophenyl)acetamido)propanamido)-2 phenylacetoxy)ethoxy)benzoyl)phenoxy)acetic 
acid (140) (80 mg, 0.11 mmol) in anhydrous CH2Cl2 (4 mL), was added Et3N (16 ?L, 0.11 
mmol) and stirred at ambient temperature for 10 min. Ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (25 mg, 0.13 mmol) and N-
hydroxybenzotriazole hydrate (18 mg, 0.22 mmol) were added to it and the resulting solution 
was stirred at ambient temperature for 30 min. until it became clear. A solution of N-Boc 
ethylene diamine (21 ?L, 0.13 mmol) in CH2Cl2 (1 mL) was added to the reaction mixture 
followed by Et3N (19 ?L, 0.13 mmol) and stirred at ambient temperature for 10 h. The 
reaction mixture was diluted with CHCl3 (50 mL), washed with water, brine, dried over 
anhydrous Na2SO4 and evaporated in vacuo to yield the crude product. The crude product was 
purified by flash column chromatography (EtOAc:hexane, 3:7) to yield the title compound as 
colorless solid (90 mg, 87%). 
1H NMR (300 MHz, CDCl3): į = 7.74 (d, J = 8.8 Hz, 2H; H-28), 7.67 (d, J = 8.2 Hz, 2H; H-
18), 7.27-7.22 (m, 5H; H-21, H-22, H-23, H-24, H-25), 6.95 (d, J = 8.8 Hz, 2H; H-29), 6.78 
(d, J = 8.8 Hz, 2H; H-17), 6.69-6.61 (m, 3H; H-2, H-4, H-6), 6.18-6.12 (m, 1H; H-12), 5.45 
(m, 1H; H-9), 4.80 (brs, 1H; NH), 4.58 (s, 2H; H-31), 4.46-4.40 (m, 2H; H-15), 4.14-4.08 (m, 
2H; H-14), 3.48 (s, 2H; H-7), 3.43-3.38 (m, 2H; H-33), 3.31-3.24 (m, 2H; H-34), 1.70 (brs, 
2H; NH), 1.37 (s, 9H; H-37), 1.30 (d, J = 7.0 Hz, 3H; H-10) ppm.  
13C NMR (75 MHz, CDCl3):̓ į = 196.8 (C-20), 172.2 (C-11), 172.1 (C-13), 169.6 (C-32), 
165.9 (C-3, C-5), 165.2 (C-30), 162.2 (C-16), 156.6 (C-35), 141.4 (C-1), 137.5 (C-26), 133.3 
(C-27), 132.1 (C-19), 131.2 (C-28), 130.7 (C-18), 129.5 (C-21, C-25), 129.2 (C-22, C-24), 
127.8 (C-23), 115.6 (C-29), 114.9 (C-17), 113.3 (C-2, C-6), 105.1 (C-4), 80.2 (C-36), 69.1 
(C-15), 67.6 (C-14), 64.3 (C-31), 57.1 (C-12), 50.1 (C-9), 41.2 (C-7), 40.5 (C-34), 40.1 (C-
33), 28.4 (C-37), 17.4 (C-10) ppm. 
MS (ESI): m/z = 839.4 (M+Na)+, 815.2 (M–H)+ 
5.9.13. (S)-2-(4-(4-(2-(2-Aminoethylamino)-2-oxoethoxy)benzoyl)phenoxy)ethyl 2-((S)-2-
(2-(3,5-difluorophenyl)acetamido)propanamido)-2-phenylacetate (156) 
O
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A solution of compound (S)-2-(4-(4-(2-(2-(tert-butoxycarbonylamino)ethylamino)-2-
oxoethoxy)benzoyl)phenoxy)ethyl 2-((S)-2-(2-(3,5-difluorophenyl)acetamido)propanamido)-
2-phenylacetate (155)  (80 mg, 0.1 mmol) in 16% HCl in dioxane (1 mL) was stirred at room 
temperature for 1 h. The reaction was monitored by TLC. The reaction mixture was 
evaporated in vacuo and lyophilized to afford the title compound as hydrochloride salt which 
was used in the next step without purification. 
MS (ESI): m/z = 717.3 (M+H)+. 
5.9.14. (S)-2-(4-(4-(2-Oxo-2-(2-(5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)ethylamino)ethoxy)benzoyl)phenoxy)ethyl 2-((S)-2-(2-(3,5-
difluorophenyl)acetamido)propanamido)-2-phenylacetate (139) 
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To a stirred solution of D-biotin (30 mg, 0.12 mmol) in anhydrous DMF (2 mL), was added 
Et3N (17 ?L, 0.12 mmol) and stirred at ambient temperature for 10 min. Ethyl-3-(3´-
dimethylaminopropyl)carbodiimide hydrochloride (28 mg, 0.15 mmol), N-
hydroxybenzotriazole hydrate (20 mg, 0.15 mmol) were added to it and the resulting solution 
was stirred at ambient temperature for 30 min. until it became clear. A solution of (S)-2-(4-(4-
(2-(2-aminoethylamino)-2-oxoethoxy)benzoyl)phenoxy)ethyl 2-((S)-2-(2-(3,5-
difluorophenyl)acetamido)propanamido)-2-phenylacetate (156) (80 mg, 0.1 mmol) in DMF (1 
mL) was added to the reaction mixture followed by Et3N (68 ?L, 0.5 mmol) and stirred at 
ambient temperature for 18 h. The reaction mixture was diluted with CHCl3 (100 mL), 
washed with water, brine, dried over anhydrous Na2SO4 and evaporated in vacuo to yield the 
crude product. The crude product was purified by flash column chromatography 
(CH2Cl2:MeOH, 95:5) to obtain the title compound as a pale brown solid (20 mg, 20%). 
1H NMR (300 MHz, CD3OD): į = 7.68 (d, J = 8.0 Hz, 2H; H-28), 7.64 (dd, J = 8.2 Hz, J = 
1.6 Hz, 2H; H-18), 7.29-7.18 (m, 5H; H-21, H-22, H-23, H-24, H-25), 7.02 (d, J = 8.8 Hz, 
2H; H-29), 6.89-6.75 (m, 4H; H-2, H-6, H-17), 6.67 (m, 1H; H-4), 5.40 (d, J = 1.4 Hz, 1H; H-
12), 4.50 (s, 2H; H-31), 4.46-4.31 (m, 5H; H-9, H-14, H-15), 4.20-4.12 (m, 2H; H-40, H-42), 
3.43 (s, 2H; H-7), 3.34-3.26 (m, 4H; H-33, H-34), 3.08-3.02 (m, 1H; H-39), 2.78 (dd, J = 6.8 
Hz, J = 4.8 Hz, 1H; H-41), 2.58 (d, J = 6.8 Hz, 1H; H-41´), 2.10 (t, J = 7.2 Hz, 2H; H-28), 
1.66-1.39 (m, 4H; H,36, H-38), 1.36-1.17 (m, 5H; H-10, H-37) ppm.  
13C NMR (75 MHz, CD3OD):̓ į = 196.8 (C-20), 172.7 (C-44), 172.2 (C-11), 172.1 (C-13), 
171.9 (C-32), 169.6 (C-43), 165.9 (C-3, C-5), 163.7 (C-30), 162.5 (C-16), 141.2 (C-1), 138.1 
(C-26), 133.5 (C-27), 132.8 (C-19), 131.8 (C-28), 130.9 (C-18), 129.8 (C-21, C-25), 128.8 
(C-22, C-24), 128.7 (C-23), 115.8 (C-29), 115.5 (C-17), 113.1 (C-2, C-6), 105.2 (C-4), 69.2 
(C-15), 68.3 (C-31), 64.5 (C-14), 63.5 (C-40), 61.8 (C-42), 58.4 (C-39), 56.7 (C-12), 50.0 (C-
9), 41.2 (C-7), 41.0 (C-41), 40.6 (C-33), 39.9 (C-34), 36.9 (C-35), 29.8 (C-38), 26.8 (C-37), 
26.5 (C-36), 18.3 (C-10) ppm. 
MS (ESI): m/z = 943.4 (M)+, 965.4 (M+Na)+  
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Abstract: N-Sulfonylated and N-alkylated carprofen derivatives were
investigated for their inhibition and modulation of γ-secretase, which
is associated with Alzheimer’s disease. The introduction of a lipophilic
substituent transformed the COX-2 inhibitor carprofen into a potent
γ-secretase modulator. Several compounds (e.g., 9p, 11f) caused
selective reduction of A42 and an increase of A38. The most active
compounds displayed activities in the low micromolar range and no
effect on the γ-secretase cleavage at the -site.
Despite tremendous progress in understanding Alzheimer’s
disease (AD), there remains the challenge to develop agents
for its therapy. Approved drugs such as acetylcholinesterase
inhibitors and memantine hydrochloride offer symptomatic
treatment, but they do not address the basic pathology of the
disease: deposition of amyloid plaques and development of
neurofibrillary tangles. The metabolism of the -amyloid
precursor protein (APP), which is cleaved by the aspartic
proteases -secretase and γ-secretase, results in the generation
and pathological deposition of the 40 and 42 amino acid long
peptides A40 and A42 (Figure 1). These fragments are the
major components of amyloid fibrils.1,2
Promising results for the treatment of AD were obtained with
some cyclooxygenase-1 (COX-1) inhibitors,3-7 both in vitro and
in a prospective, population-based cohort study of 6989
patients.8 This is not a class effect because nonsteroidal anti-
inflammatory drugs (NSAIDs) (e.g., diclofenac (2-[2-(2,6-
dichlorophenyl)aminophenyl]ethanoic acid) and naproxen ((+)-
(S)-2-(6-methoxynaphthalen-2-yl)propanoic acid)) do not lower
A in vitro,3,5 and neither naproxen nor rofecoxib (4-(4-
methylsulfonylphenyl)-3-phenyl-5H-furan-2-one, a COX-2 in-
hibitor) slows cognitive decline in patients with mild-to-
moderate AD.9,10 The positive clinical results are still in need
of a sound rationale and experimental validation.11 The proof
of concept is still missing. NSAIDs that modulate γ-secretase
cleavage of APP affect the distance between APP and presenilin
1, the catalytic subunit of γ-secretase.12 They seem to interfere
with substrate recognition/cleavage and shift the precision of
γ-secretase cleavage from the γ42 to the γ38 site (Figure 1) to
generate more A38 and less A42.3,12 Compounds with reverse
shift were reported recently, and these enhanced A42 produc-
tion.13 Noncompetitive antagonism indicates an allosteric mech-
anism of action.7 Flurbiprofen ((()-2-(3-fluoro-4-phenylphenyl)-
propanoic acid, 1) (10 and 25 mg kg-1 d-1) elicits nonselective
reductions in A1-40 and A1-42 plasma levels but was found
to be toxic. It produced small reductions in A1-40 in the cortex
at 25 mg kg-1 d-1 but did not affect A levels in the
hippocampus or cerebrospinal fluid. Cyclopropylated flurbipro-
fen analogues without COX activity display improved potency
on γ-secretase inhibition.14 Contrary to previous reports, sulindac
sulfide (2-((5Z)-1-(4-(methylthio)benzylidene)-5-fluoro-2-meth-
yl-1H-inden-3-yl)acetic acid, 2) and ibuprofen (2-(4-isobutyl-
phenyl)propanoic acid, 4) were found to be neither toxic nor
efficacious at doses up to 50 mg kg-1 d-1.15 The kinetics of
A formation in the presence of the two NSAIDs and the
displacement of an active site directed inhibitor support allo-
steric, noncompetitive modes of action of sulindac sulfide (2)6
and R-flurbiprofen (1, Scheme 1) at low concentrations.7 This
resulted in selective inhibition of A42 production. However,
both NSAIDs shift their modes of action from modulation to
complete, nonselective inhibition of γ-secretase at high con-
centrations. Unfortunately, NSAID derivatives have escaped
photoaffinity labeling techniques so far, except for biotinylated
fenofibrate which labelled the C-terminal fragment of APP.16
* To whom correspondence should be addressed. Phone: (+49) 6151-
163075. Fax: (+49) 6151-163278. E-mail: schmidt_boris@t-online.de.
† Darmstadt University of Technology.
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Figure 1. Schematic representation of APP processing and the
modulation of γ-secretase cleavage by NSAIDs. (A) APP is first
processed by -secretase to generate the C-terminal fragment CTF,
which is subsequently cleaved within its transmembrane domain at two
principle sites, γ and , by γ-secretase to release A and AICD. (B)
Heterogeneous cleavage at the γ-site generates different A species
by cleavage at the γ38, γ40, and γ42 sites. A subset of NSAIDs
increases the cleavage at the γ38 site while reducing cleavage at the
γ42 site.
Scheme 1. Effect of NSAIDs (1-4) on A Levels as Reported
by Weggen3 and Beher7 and the Structure of BMS-299897 (5)
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In summary, just a few NSAIDs (1-4, Scheme 1) were
reported to modulate γ-secretase, and an even smaller number
of NSAIDs display confirmed modulation at physiological
concentrations. Despite these vague, sometimes contradictory
results reported for NSAID activity, we and others13,17 were
encouraged to investigate NSAIDs as scaffolds for γ-secretase
inhibitors. We commenced with the derivatization of the
carboxylic acid common to the COX-1 inhibitors. Furthermore,
we included COX-2 inhibitors that are different from the coxib
class such as carprofen ((()-2-(3-chloro-9H-carbazol-7-yl)-
propanoic acid, 6) and etodolac (2-(1,8-diethyl-1,3,4,9-tetra-
hydropyrano[3,4-b]indol-1-yl)acetic acid) because they are
structurally closer to COX-1 than to COX-2 inhibitors. Although
some of the esters and amides displayed moderate inhibition of
the cleavage by γ-secretase (A38, A40, A42), this approach
was soon abandoned. Few of these initial derivatives displayed
increased, unselective inhibition of γ-secretase in comparison
to their parent drugs. Most of the approximately 150 NSAID
carboxylic acid derivatives (e.g., 7) resulted in loss of activity.
This indicated an important contribution of the carboxylic acid
to target affinity. After a brief investigation of sulindac
analogues we focused on carprofen, which is a COX-2 inhibitor
approved for the use in dogs, cows, and horses. The selectivity
of carprofen versus COX-2canine and COX-1canine is greater than
100:1 (COX-2canine IC50: R/S-carprofen 102 nM, R-carprofen
5.97 µM, S-carprofen 37 nM).18 Original carprofen (as isolated
from 500 mg tablets) was found to be a weak inhibitor of
γ-secretase and reduced A38, A40, and A42 at high concen-
tration (Figure 2). This corresponds to the activity of R-methy-
lated carprofen, which was reported to inhibit A42 production
by 40% at 100 µM.17 This is in contrast to the inverse
modulation of the COX-2 inhibitors that was reported recently.13
The readily accessible sulfonamides were inspired by the
γ-secretase inhibitor 5 (BMS-299897) and supported by a recent
series from Merck Sharp & Dohme.19,20 An analogue series of
carprofen N-sulfonamides was prepared as outlined in Scheme
2. The acid functionality of carprofen was protected as a benzyl
ester 7. N-Sulfonylation of 7 was carried out using NaH and a
sulfonyl chloride in THF. The benzyl group of 8 was removed
by hydrogenation (8a-m,p-r) or base hydrolysis (8n-o,s) to
give the acid 9. We expected these compounds to be inhibitors
of γ-secretase activity because of their resemblance to the
γ-secretase inhibitor 5. Serendipitously, they turned out to be
modulators of γ-secretase activity, which control the cleavage
pattern of γ-secretase. Such modulators may preserve the
cleavage of substrates like Notch; thus, we adopted our initial
objectives from inhibition to modulation. Notch-ligand interac-
tion is a highly conserved mechanism that regulates specific
cell fate during development.21,22
N-Alkylated carprofen derivatives were prepared (Scheme 3)
to evaluate the contribution of the sulfonamide moiety in 9r
and the most active derivative 9p, where the sulfonamide is
shielded by isopropyl substituents. The carprofen benzyl ester
7 was alkylated using NaH and RX in THF to yield the ester
10. Subsequent benzyl deprotection by hydrogenation gave the
desired N-alkylated carprofen 11. The benzyl deprotection of
10c was carried out by base hydrolysis.
The biotinylated carprofen derivative 12 was synthesized as
depicted in Scheme 4 to identify the binding partner via
immunoprecipitation.
To evaluate the compounds for their potency in modulating
γ-secretase activity, we used the A liquid-phase electro-
chemiluminescence assay to measure A isoforms.27 γ-Secretase
cleavage activity at the -site was monitored by de novo
production of AICD in vitro using the previously reported
assay.25
Compounds 9a-s, 11a-f, and 12 turned out to be effective
modulators of γ-secretase. They affected the cleavage at the
γ38, γ40, and γ42 sites to a different extent and particularly
suppressed the formation of A42 while enhancing the formation
of A38 and thus showed the typical profile of effective NSAIDs
(see Tables 1and 2, Figures 3 and 4). Compounds 9b,p and
11a,e,f were the most potent inhibitors of A42. Interestingly,
the modulatory activity was preserved in the biotinylated 12,
which may therefore be used as an affinity reagent for
Figure 2. Dose response curve of carprofen (6).
Scheme 2a
a Reagents: (a) BnBr, K2CO3, DMF, room temp, 1.5 h, 97%; (b) NaH,
RSO2Cl, THF, 0 °C to room temp, 2-8 h, 22-84%; (c) 10% Pd-C, MeOH/
EtOAc (1:1), H2, 3-18 h, 70-94%; (d) NaOH, THF/MeOH/H2O (1:1:1),
room temp, 3-12 h, 80-92%.
Scheme 3a
a Reagents: (a) NaH, RX, THF, 0 °C to room temp, 2-8 h, 30-81%;
(b) 10% Pd-C, MeOH/EtOAc (1:1), H2, 3-18 h, 70-96%; (c) NaOH,
THF/MeOH/H2O (1:1:1), room temp, 3-12 h, 80-92%.
Scheme 4a
a Reagents: (a) SnCl2, EtOH, reflux, 3 h, 90%; (b) EDCl, HOBT, biotin,
Et3N, DMF, room temp, 16 h, 65%; (c) 10% Pd-C, MeOH, H2, room temp,
18 h, 90%.
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γ-secretase. We observed from another series that N-alkylation
of carbazole with shorter n-alkyl chains such as n-butyl and
n-hexyl diminishes the γ-secretase modulatory activity (unpub-
lished results). The observed differences for octyl, nonyl, or
decyl substitution are small and so is the difference for
alkylsulfone amides of equivalent length (see 11e versus 9r).
The sulfone amides display an increased topological polar
surface area (tPSA) from 49 to approximately 93 Å2, which
makes blood-brain barrier penetration less likely.23 The cal-
culated increase in tPSA is only partially compensated by a small
reduction of the clogP (- 0.5) in comparison to the analogue
alkyl derivatives. This favors the alkyl derivatives over the
sulfone amides for further investigation in animal models. The
N-benzylated or N-arylsulfonated derivatives benefit from
fluorinated substituents (9b, 11a) in the meta position. Ortho
fluorination as in (9f) did not alter the activity in comparison
to the parent sulfonamide (9k). The replacement of the methoxy
group in 11b by a trifluoromethoxy resulted in a 5-fold
improvement of the IC50 (A42). This fluorine-derived enhance-
ment may be due to lipophilicity or polar interactions. We
speculate that the lipophilic substituent anchors the N-substituted
carprofen in the required orientation within the membrane; thus,
the maximum tolerated length should be similar to those of
natural phospholipids. The effect of the most potent compounds
on γ-secretase cleavage at the -site was assessed by an in vitro
assay that monitors the de novo generation of the APP
intracellular domain (AICD).24,25 The generation of AICD was
affected by the compounds to various extent (Figure 4).
However, consistent with previous results,3,7 generally much
higher compound concentrations than those determined to be
modulatory were required to inhibit the -cleavage. One of the
most active carprofen derivatives 11f was selected for evaluation
in COX-1 and COX-2 assays to rule out COX-1 or COX-2
mediated effects at the necessary concentrations for γ-
secretase modulation. The assays were performed at CEREP
(www.cerep.com) using indomethacin as a standard for COX-1
and NS398 (N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfon-
amide) for COX-2. 11f displayed no activity on COX-1 and
only marginal activity on COX-2 at 10 µM. No toxicity was
observed at 40 µM in H4 cells except for 9p and 12, which
significantly decreased viability at 40 µM, respectively (data
not shown).
In conclusion, the introduction of a single lipophilic sub-
stituent, which may vary from arylsulfone to alkyl substituents,
turns the COX-2 inhibitor carprofen into a γ-secretase modulator
and improved potency 10-fold or more. Thus, several com-
pounds (e.g., 9p, 11f) caused the selective reduction of A42
and an increase of the less aggregatory A38. The most active
compounds are more potent than the best reported NSAIDs,
and they are devoid of COX-1 and COX-2 activity at the critical
concentration; thus, they do not interfere with the delicate COX-
1/COX-2 balance. Some of the sulfonamides are comparable
in potency to the best N-alkylated analogues (11b), but the 50%
increase of the tPSA (9p: 93.4 Å2) makes a penetration of the
blood-brain barrier less likely. Therefore, the N-alkylated
derivatives are favored over the sulfonamides for further
investigations. The properties of these N-alkylated lead candi-
dates are close to the range of approved drugs or preclinical
candidates except for their clogP.26 The carboxylic acid group
Table 1. Activity of Carprofen N-Sulfonamide Derivatives
IC50 (µM)
entry compd R A38a A40 A42
1 6 H 78 133 76
2 9a 4-methylphenyl 43 >100 56
3 9b 3,5-bis(trifluoromethyl)phenyl NDb >30 11
4 9c 4,5-dibromothiophen-2-yl NDb ND >40
5 9d 3,5-difluorophenyl NDb ND >40
6 9e 4-biphenyl NDb ND 37
7 9f 2-fluorophenyl NDb ND >40
8 9g 3-fluorophenyl NDb ND >40
9 9h 4-fluorophenyl NDb ND >40
10 9i 2-bromophenyl NDb ND 40
11 9j 4-bromophenyl NDb ND >40
12 9k phenyl NDb ND >40
13 9l 4-chlorophenyl NDb ND >40
14 9m 3-chlorophenyl NDb ND >40
15 9n 3-nitrophenyl NDb ND 39
16 9o 4-nitrophenyl NDb ND >40
17 9p 2,4,6-triisopropylphenyl 9.3 >20 8.5
18 9q 4-n-propylphenyl NDb >40 >40
19 9r octyl NDb >40 25
20 9s 4-cyanophenyl NDb ND >40
a EC50 values are displayed for A38 except 6. The EC50 is based on the
maximum level with a slope approximating 0. b Maximum effect on A38
not observed at 40 µM (except for 6, 160 µM; 9a, 200 µM; and 9b, 200
µM).
Table 2. Activity of N-Alkylated Carprofen Derivatives.
activity (µM)
entry compd R
EC50
A38
IC50
A40
IC50
A42
1 12 NDa >150 88
2 11a 3-(trifluoromethoxy)benzyl NDa >40 7.5
3 11b 3-methoxybenzyl NDa >40 39
4 11c 3-nitrobenzyl NDa >40 22
5 11d octyl NDa >40 6.9
6 11e nonyl 8.1 >40 3.0
7 11f decyl 5.8 >40 2.9
a Maximum effect on A38 not observed at 40 µM (except for 12, 150
µM).
Figure 3. Dose response curves for the most active carprofen
derivatives (A % of control): (A) 11f; (B) 9p; (C) 9b; (D) 12; (9)
A38; (2) A40; (b) A42).
Figure 4. Dose-response curves for carprofen derivatives (9b, 9p,
11a and 11f) on in vitro AICD generation. Results are the average of
three independent experiments. Error bars indicate the standard error
of the mean.
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may interfere with uptake, but the tPSA of 11b is just 62.9 Å2.
This compares favorably to lumiracoxib ({2-[(2-chloro-6-
fluorophenyl)amino]-5-methylphenyl}acetic acid, tPSA ) 58
Å2). The more polar 11c has similar properties (tPSA ) 96.1,
clogP ) 5.83) as the carboxylic acid 5 (clogP ) 5.92, tPSA )
93.4 Å2).19 The lipophilic substituents cause amphiphilic proper-
ties of the carboxylic acids, which may interact with membranes.
However, the placement of a polar end group, as in 12,
weakened but did not reverse the modulatory effect. Again, we
favor the N-alkylated derivatives for the investigation of
potential membrane interactions, as they allow the incorporation
of phospholipids analogues and membrane disrupting fragments.
If affected at all, the -cleavage of γ-secretase was inhibited
at much higher compound concentrations than those determined
to be modulatory at the γ-site (Figure 4). The compounds are
therefore expected to have little or no impact on γ-secretase-
mediated signaling via the AICD or via intracellular domains
of other γ-secretase substrates. However, the interaction site of
these compounds has not been identified yet. The improvement
of potency and the investigation of in vivo activity are subject
to further investigations.
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Abstract—N-Sulfonylated and N-alkylated carbazolyloxyacetic acids were investigated for the inhibition and modulation of the Alz-
heimer’s disease associated c-secretase. The introduction of a lipophilic substituent, which may vary from arylsulfone to alkyl,
turned 2-carbazolyloxyacetic acids into potent c-secretase modulators. This resulted in the selective reduction of Ab42 and an
increase of the less aggregatory Ab38 fragment by several compounds (e.g., 7d and 8c). Introduction of an electron donating group
at position 6 and 8 of N-substituted carbazolyloxyacetic acids either decreased the activity or inversed modulation. The most active
compounds displayed activity on amyloid precursor protein (APP) overexpressing cell lines in the low micromolar range and little or
no eﬀect on the c-secretase cleavage at the e-site.
 2006 Elsevier Ltd. All rights reserved.
Alzheimer’s disease (AD) is a devastating neurodegen-
erative disorder that causes the most common form of
dementia, aﬀecting approximately 5% of the popula-
tion over the age of 65 years in Europe. Short-term
memory impairment, disorientation, aphasia and a
general cognitive decline are common symptoms early
in disease development. As the disease progresses, spa-
tial and motor abilities are aﬀected and the patient be-
comes bedridden and completely dependent on the
caretaker. According to the World Health Organiza-
tion, an estimated 37 million people worldwide cur-
rently have dementia; AD aﬀects about 18 million of
them.1
Pathological lesions and plaques consisting of the amy-
loid b-peptide (Ab) are found in the brains of the AD
patients. Ab is heterogeneously produced by the
sequential cleavages of amyloid precursor protein
(APP) by the two aspartic proteases: b- and c-secre-
tase. Cleavage at the Ab N-terminus is executed by
the b-site cleaving enzyme (BACE).2,3 The following
intramembrane cleavage by c-secretase occurs with lit-
tle sequence speciﬁcity, resulting in Ab fragments of
diﬀerent length, predominantly Ab40, Ab42 and some
Ab38. Ab42 being the most aggregatory. The C-terminal
fragments generated by a- and b-secretase cleavage,
C83 and C99, are cleaved within their transmembrane
domains to produce the p3 peptide. The functional
c-secretase complex requires the correct assembly of
at least ﬁve components: presenilin-1 (PS1), nicastrin,
anterior pharynx defective-1 (Aph-1), presenilin
enhancer-2 (Pen-2) and the substrate.4–10 PS1, a cata-
lytic subunit of the c-secretase complex, harbours two
aspartates in the transmembrane domains 6 and 7 that
deﬁne a novel active site closely resembling that of
other recently identiﬁed aspartic proteases.11–14 PS1
acts as a heterodimer of N- and C-terminal fragments
(NTF, CTF) that derive from autoproteolysis. c-Secre-
tase activity can be controlled by the inhibition of the
active site of PS1 or by interference with complex
assembly or substrate recognition, the latter resulting
in allosteric modulation or inhibition. The allosteric
mechanisms are particularly attractive targets for drug
development as they may control the ratio of the Ab
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fragments: Ab38, Ab40, and Ab42, while retaining the
cleavage of other substrates. Most of the reported
and conﬁrmed c-secretase inhibitors are not substrate
speciﬁc and inhibit the processing of other c-secretase
substrates equally,15 for example, Notch and other.16
Epidemiological studies indicated an association be-
tween nonsteroidal anti-inﬂammatory drugs (NSAIDs)
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Scheme 2. Synthesis of N-sulfonylated carbazolyloxyacetic acid derivatives. Reagents and conditions: (a) ClCH2CO2
tBu, K2CO3, acetone, 60–70 C,
16 h, 100%; (b) NaH, RSO2Cl, THF, 0 C rt, 2–8 h, 80–100%; (c) 20% TFA in DCM, 1–4 h, 80–100%.
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Scheme 3. Synthesis of N-alkylated carbazolyloxyacetic acids and 8d.
Reagents and conditions: (a) KOtBu, RX, THF, 0 C rt, 2–8 h, 80–
91%; (b) NaOH, MeOH/H2O (1:1) rt, 2 h, 92–97%.
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use and a reduced risk for the development of
AD.17–20 Recently, we reported N-sulfonylated and N-
alkylated derivatives (2, 3) of carprofen (Scheme 1) that
modulate c-secretase and selectively reduce Ab42.21,22
This is accompanied by an increase of the less aggrega-
tory Ab38 species. Carprofen 1 is a COX-2 inhibitor
(COX = cyclooxygenase) approved for the use in dogs,
cows and horses as Imadyl or Rimadyl. The selectiv-
ity of carprofen versus COX-2canine and COX-1canine is
greater than 100:1 (COX-2canine IC50/R/S-carprofen
102 nM, R-carprofen 5.97 lM, S-carprofen 37 nM).23
Original carprofen (as isolated from Rimadyl tablets
500 mg) was found to be a weak inhibitor of c-secretase
and reduced Ab38, Ab40 and Ab42 at high concentra-
tions. Knowing about the relevance of the carboxylic
acid and N-substitution of carprofen, we decided to
investigate scaﬀolds not included in the patent applica-
tions and publications by Koo et al.24 or Stock,25 or
Imbimbo26 and others.27,28 Carprofen’s similarity to
the c-secretase inhibitor BMS-299897 (Scheme 1)
prompted us to investigate N-sulfonylated and N-alkyl-
ated 2-hydroxy carbazolyloxyacetic acids. The corre-
sponding sulfonamides 7a–k were readily accessible by
straightforward synthesis.
A series of 2-hydroxy carbazole N-sulfonamide deriv-
atives was prepared as outlined in Scheme 2. 2-
Hydroxycarbazole 5 was alkylated using anhydrous
K2CO3 and ClCH2CO2
tBu in acetone at 60–70 C to
give compound 6. N-Sulfonylation of 6 was carried
out using NaH, various sulfonyl chlorides in THF
and subsequent t-butyl deprotection by 20% triﬂuoro-
acetic acid in dichloromethane furnished the desired
compound 7.
N-Alkylated carbazolyloxyacetic acids were prepared to
evaluate the contribution of the sulfonamide moiety in
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Scheme 4. Synthesis of 6-methoxy and 8-methoxy carbazoles.
Reagents and conditions: (a) PMBCl, K2CO3, acetone, reﬂux, 16 h,
97%; (b) [(Ph3P)4Pd], 3-methoxybenzene-boronic acid, K2CO3, H2O,
toluene, reﬂux, 18 h, 67% (c) Ph3P, o-dichlorobenzene, reﬂux, 16 h,
60%.
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Scheme 5. Synthesis of 6-methoxy and 8-methoxy N-sulfonylated carbazolyloxyacetic acids. Reagents and conditions: (a) 10% Pd–C, H2, MeOH,
60 psi, rt, 12 h, 81%; (b) ClCH2CO2
tBu, K2CO3, acetone, reﬂux, 16–18 h, 82–88%; (c) R
3SO2Cl, NaH, THF, 0 C rt, 1–3 h, 55–71%; (d) 20% TFA in
DCM, rt, 2 h, 80–94%.
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7g and the most active derivate 7d, where the sulfon-
amide is shielded by isopropyl substituents. The N-alkyl-
ated carbazolyloxyacetic acids were synthesized as
shown in Scheme 3. Compound 6 was alkylated using
KOtBu and alkyl halide in dry THF. Subsequent depro-
tection of t-butyl group by base hydrolysis provided de-
sired N-alkylated carbazolyloxyacetic acid 8.
We synthesized the 2-hydroxy-6-methoxy and 2-hy-
droxy-8-methoxy N-sulfonylated carbazolyloxyacetic
acids to investigate the impact of an electron donating
substituent on the activity. We commenced the synthesis
of 6-methoxy and 8-methoxy-2-hydroxy carbazoles
from the commercially available 4-chloro-3-nitrophenol
9 as outlined in Scheme 4. The –OH functionality of 9
was protected as a para-methoxybenzyl (PMB) ether
10. Suzuki–Miyaura coupling of 10 with 3-methoxyben-
zeneboronic acid using the catalyst [(PPh3)4]Pd gave
biphenyl 11, which was then cyclized to its correspond-
ing carbazole by reﬂuxing it in o-dichlorobenzene with
PPh3. The PPh3 mediated cyclization resulted in two
regioisomers, 6-methoxy carbazole, 12a and 8-methoxy
carbazole, 12b which were separated by ﬂash column
chromatography.
N-Sulfonylated derivatives of 2-hydroxy-6-methoxy
and 2-hydroxy-8-methoxy carbazolyloxyacetic acids
were synthesized as depicted in Scheme 5. The
PMB group of 12 was deprotected by hydrogenation
at 60 psi and the free –OH was alkylated using
anhydrous K2CO3 and ClCH2CO2
tBu in acetone at
60–70 C to yield alkylated 13. N-Sulfonylation of
13 was carried out using NaH and R3SO2Cl in dry
THF and subsequent t-butyl group removal by
20% TFA in DCM furnished the desired compound
14.
Compounds 7a–k and 8a–c turned out to be eﬀective
modulators of c-secretase. They aﬀected the cleavage
at the c38, c40 and c42 sites to a diﬀerent extent,
and particularly reduced the formation of Ab42, while
increasing the formation of Ab38 (see Table 1 and
Fig. 1).33 The most potent inhibitors of Ab42 were
compounds 7d, 7g, and 8c. Compounds 14a–c showed
modulatory activity but required very high concentra-
tions. Compounds 14e and 14f showed some indica-
tions to be inverse modulators, they increased Ab42
formation and reduced Ab38 formation at very high
concentrations (see Fig. 2). The necessary levels for
IC50/EC50 determination were not reached at 40 lM.
The eﬀect of the most potent compounds on c-secre-
tase cleavage at the e-site was assessed using an in vi-
tro assay that monitors the de novo generation of
b-amyloid precursor protein intracellular domain
(AICD).29,30 The formation of AICD was aﬀected by
the compounds to various extent (Fig. 3). However,
much higher compound concentrations than those
determined to be modulatory were required to inhibit
the e-cleavage. One of the most active N-sulfonylated
carbazolyloxyacetic acids (7d) was selected for evalua-
tion in COX-1 and COX-2 assays to rule out COX-1
or COX-2 mediated eﬀects at the concentrations nec-
essary for c-secretase modulation. The assays were
performed at CEREP (www.cerep.com) using indo-
methacin as a standard for COX-1 and NS398 for
COX-2. The compound 7d displayed no activity on
COX-1 and COX-2 at 10 lM concentration. Only a
few compounds within this structural class displayed
cell toxicity in H4 cells at the highest concentration
tested (40 lM). It is very likely that this toxicity is
caused by unique structural properties of single
compounds.34,35
The introduction of a single lipophilic substituent,
which may vary from arylsulfone to alkyl, turns the
N-substituted carbazolyloxyacetic acids into a potent
c-secretase modulator. Some in silico parameters of
these lead candidates are close to the range of drug-like
compounds,31 but the lipophilic substituents cause a
dramatic increase of the c logP. The carboxylic
acid may interfere with uptake, but the total polar sur-
face area of 8c is just 62.9 A˚2, this compares to
COX189 (lumiracoxib, tPSA = 58 A˚2).The more polar
compound 7c displays similar properties (c logP =
6.426, tPSA = 107.5 A˚2) as the carboxylic acid BMS-
299897 (c logP = 5.92, tPSA = 93.4 A˚2).27 Further
increases in chain length will worsen this property,
but the determination of the maximum length may pro-
vide information on drug localisation or traﬃcking.
We speculate that the lipophilic substituent anchors
the N-substituted carbazolyloxyacetic acid in the re-
quired orientation within the membrane, thus the max-
imum tolerated length should be similar to natural
phospholipids. This hypothesis will be explored in the
next series. The desired selective reductions of Ab42
and the accompanying increases of the less aggregatory
Ab38 fragment are displayed by several compounds
Table 1. Activity report of N-alkylated and N-sulfonylated carbazol-
yloxyacetic acids
Entry Compound Cell toxicityd(lM) IC50 (lM)
Ab38
a Ab40 Ab42
1 7a 20 13 >40 39
2 7b 20 >40 >40 >40
3 7c 20 13 40 24
4 7d 20 7.8 19 7.5
5 7e >40 NDb >40 38
6 7f >40 NDb >40 37
7 7g 40 14 >40 20
8 7h 40 32 >40 32
9 7i 40 13 >40 >40
10 7j 40 >40 >40 >40
11 7k 40 16 >40 >40
12 8a >40 24 >40 19
13 8b >40 30 >40 17
14 8c >40 NDb >40 11
15 8d >40 >40 >40 >40
16 2 — 5.8 >40 2.9
17 3 — 9.3 >20 8.5
18 4c — — — 0.0071
a EC50 values are displayed for Ab38.
bMaximum eﬀect on Ab38 not observed at the highest concentration
tested.
c IC50 value is displayed for total Ab.
d Signiﬁcant cellular toxicity observed at this concentration. Viability
reduction > 20%.
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(e.g., 7d and 8c). The introduction of an electron
donating substituent at 6- and 8-position of
N-substituted carbazolyloxyacetic acids either de-
creased the modulatory activity (14a–14c) or inversed
modulatory activity (14d–14f). If aﬀected at all, the
e-cleavage of c-secretase was inhibited at much higher
compound concentrations than those determined to
be modulatory at the c-site (Fig. 3). The compounds
are thus expected to have little or no impact on
c-secretase-mediated signalling via the AICD or via
intracellular domains (ICDs) of other c-secretase
substrates.
The present data qualify the scaﬀold as a lead structure
for c-secretase modulation, but do not justify extensive
investigation of the current compounds in animals.
Improvements of potency, solubility and the investiga-
tion in neuronal cells are required prior to the investiga-
tion of in vivo activity.
Figure 1. Dose–response curves for the most active N-substituted
carbazolyloxyacetic acid derivatives; Ab (% of control). (A) Com-
pound 7d. (B) Compound 7g. (C) Compound 8c.
Figure 2. Activity of the compounds 14a–14f.
Figure 3. Dose–response curves for the most active N-substituted
carbazolyloxyacetic acids (7d, 7c, 8c, and 7g) on in vitro AICD
generation. Results are the average of three independent experiments.
Error bars indicate the standard error of the mean.
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